

2025

Prescription Drug Guide

NC State Health Plan Formulary

List of covered drugs or "Drug List"

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN.

42

Formulary 25800

This formulary was updated on 09/04/2024. For more recent information or other questions, please contact the NC State Health Plan Humana Customer Care Team with any questions at 1-888-700-2263 or for TTY users, 711, or visit your.humana.com/ncshp.

Humana[®]



Dale R. Folwell, CPA
STATE TREASURER OF NORTH CAROLINA
DALE R. FOLWELL, CPA

Welcome to Humana Group Medicare Plan!

Note to existing members: This Formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this Drug List (Formulary) refers to "we," "us", or "our," it means Humana. When it refers to "plan" or "our plan," it means Humana Group Medicare Plan.

This document includes a Drug List (formulary) for our plan which is current as of January 1, 2025. For an updated Drug List (formulary), please contact us. Our contact information, along with the date we last updated the Drug List (formulary), appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1 of each year, and from time to time during the year.

What is the Humana formulary?

In this document, we use the terms Drug List and formulary to mean the same thing. A formulary is the entire list of covered drugs or medications selected by Humana. The terms formulary and Drug List may be used interchangeably throughout communications regarding changes to your pharmacy benefits. Humana Group Medicare Plan worked with a team of doctors and pharmacists to make a formulary that represents the prescription drugs we think you need for a quality treatment program. Humana Group Medicare Plan will generally cover the drugs listed in the formulary as long as the drug is medically necessary, the prescription is filled at a Humana Group Medicare Plan network pharmacy, and other plan rules are followed. For more information on how to fill your medications, please review your Evidence of Coverage.

Can the formulary change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the formulary during the year, move them to different cost sharing tiers, or add new restrictions. We must follow Medicare rules in making these changes. Updates to the formulary are posted monthly to our website here: your.humana.com/ncshp.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **Immediate substitutions of certain new versions of brand name drugs and original biological products.** We may immediately remove a drug on our formulary if we are replacing it with a certain new version of that drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. When we add a new version of a drug to our formulary, we may decide to keep the brand name drug or biological product on our formulary, but immediately move it to a different cost-sharing tier or add new restrictions.

We can make these immediate changes only if we are adding a new generic version of a brand name drug, or adding certain new biosimilar versions of an original biological product, that was already on the formulary (for example, adding an interchangeable biosimilar that can be substituted for an original biological product by a pharmacy without a new prescription).

If you are currently taking the brand name drug or biological product, we may not tell you in advance before we make an immediate change, but we will later provide you with information about the specific change(s) we have made.

If we make such a change, you or your prescriber can ask us to make an exception and continue to cover for you the drug that is being changed. For more information, see the section below titled "How do I request an exception to the Humana Formulary?"

Some of these drug types may be new to you. For more information, see the section below titled "What are

original biological products and how are they related to biosimilars?”

- **Drugs removed from the market.** If a drug is withdrawn from sale by the manufacturer or the Food and Drug Administration (FDA) determines to be withdrawn for safety or effectiveness reasons, we may immediately remove the drug from our formulary and later provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may remove a brand name drug from the formulary when adding a generic equivalent or remove an original biological product when adding a biosimilar. We may also apply new restrictions to the brand name drug or original biological product, or move it to a different cost-sharing tier, or both. We may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective. Alternatively, when a member requests a refill of the drug, they may receive a 30-day supply of the drug and notice of the change.

We will notify members who are affected by the following changes to the formulary:

- When a drug is removed from the formulary.
- When prior authorization, quantity limits, or step-therapy restrictions are added to a drug or made more restrictive.
- When a drug is moved to a higher cost sharing tier.

If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the drug you have been taking. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below titled “How do I request an exception to the Humana Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2025 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2025 coverage year except as described above. This means these drugs will remain available at the same cost sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the formulary for the new benefit year for any changes to drugs.

What if you are affected by a Drug List change?

We will notify you by mail at least 30 days before one of these changes happens or we will provide a 30-day refill of the affected medicine with notice of the change.

The enclosed formulary is current as of January 1, 2025. To get updated information about the drugs covered by Humana please contact us. Our contact information appears on the front and back cover pages.

How do I use the Formulary?

There are two ways to find your drug in the formulary:

Medical condition

The formulary begins on page 11. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs that treat a heart condition are listed under the category “Cardiovascular Agents.” If you know what your drug is used for, look for the category name in the list that begins on page 11. Then look under the category name for your drug. The formulary also lists the Tier and Utilization Management Requirements for each drug (see page 6 for more information on Utilization Management Requirements).

Alphabetical listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 196. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to each drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of the drug in the first column of the list.

What are generic drugs?

Humana covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs work just as well as and usually cost less than brand name drugs. There are generic drug substitutes available for many brand name drugs. Generic drugs usually can be substituted for the brand name drug at the pharmacy without needing a new prescription, depending on state laws.

What are original biological products and how are they related to biosimilars?

On the formulary, when we refer to drugs, this could mean a drug or a biological product. Biological products are drugs that are more complex than typical drugs. Since biological products are more complex than typical drugs, instead of having a generic form, they have alternatives that are called biosimilars. Generally, biosimilars work just as well as the original biological product and may cost less. There are biosimilar alternatives for some original biological products. Some biosimilars are interchangeable biosimilars and, depending on state laws, may be substituted for the original biological product at the pharmacy without needing a new prescription, just like generic drugs can be substituted for brand name drugs.

- For discussion of drug types, please see the Evidence of Coverage, Chapter 5, Section 3.1, “The ‘Drug List’ tells which Part D drugs are covered.”

Prescription drugs are grouped into one of four tiers.

Humana Group Medicare Plan covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

- **Tier 1 - Generic or Preferred Generic:** Generic or brand drugs that are available at the lowest cost share for the plan
- **Tier 2 - Preferred Brand:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 1 Generic or Preferred Generic, and at a lower cost to you than Tier 3 Non-Preferred Drug
- **Tier 3 - Non-Preferred Drug:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 2 Preferred Brand drug
- **Tier 4 - Specialty Tier:** Some injectables and other high-cost drugs

How much will I pay for covered drugs?

The Humana Group Medicare Plan pays part of the costs for your covered drugs and you pay part of the costs, too.

The amount of money you pay depends on:

- Which tier your drug is on
- Whether you fill your prescription at a network pharmacy
- Your current drug payment stage - please read your Evidence of Coverage (EOC) for more information

If you qualified for extra help with your drug costs, your costs may be different from those described above. Please refer to your Evidence of Coverage (EOC) or call NC State Health Plan Humana Customer Care to find out what your costs are.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization (PA):** Humana Group Medicare Plan requires you to get prior authorization for certain drugs. This means that you will need to get approval from Humana Group Medicare Plan before you fill your prescriptions. If you do not get approval, Humana Group Medicare Plan may not cover the drug.
- **Quantity Limits (QL):** For certain drugs, the Humana Group Medicare Plan limits the amount of the drug that is covered. The Humana Group Medicare Plan might limit how many refills you can get or how much of a drug you can get each time you fill your prescription. For example, if it is normally considered safe to take only one pill per day for a certain drug, we may limit coverage for your prescription to no more than one pill per day. Some drugs are limited to a 30-day supply regardless of tier placement.
- **Step Therapy (ST):** In some cases, the Humana Group Medicare Plan requires that you first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, the Humana Group Medicare Plan may not cover Drug B unless you try Drug A first. If Drug A does not work for you, the Humana Group Medicare Plan will then cover Drug B.
- **Part B versus Part D (BvsD):** Some drugs may be covered under Medicare Part B or Part D, depending upon the circumstances. Information may need to be submitted to Humana that describes the use and the place where you receive and take the drug so a determination can be made.

For drugs that need prior authorization or step therapy, or drugs that fall outside of quantity limits, your health care provider can fax information about your condition and need for those drugs to Humana Group Medicare Plan at **1-877-486-2621**. Representatives are available Monday - Friday, 8 a.m. - 8 p.m. (EST).

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 11. You can also get more information about the restrictions applied to specific covered drugs by visiting your.humana.com/ncshp. We have posted online documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask Humana to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section "**How do I request an exception to the Humana Formulary?**" on page 7 for information about how to request an exception.

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact NC State Health Plan Humana Customer Care and ask if your drug is covered. For more information, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you learn that Humana Group Medicare Plan does not cover your drug, you have two options:

- You can ask NC State Health Plan Humana Customer Care for a list of similar drugs that are covered by Humana Group Medicare Plan. When you receive the list, show it to your doctor and ask them to prescribe a similar drug that is covered by Humana Group Medicare Plan.
- You can ask Humana Group Medicare Plan to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Humana Formulary?

You can ask the Humana Group Medicare Plan to make an exception to the coverage rules. There are several types of exceptions that you can ask us to make.

- **Formulary exception:** You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- **Utilization restriction exception:** You can ask us to waive a coverage restriction including prior authorization, step therapy, or a quantity limit on your drug. For example, for certain drugs, Humana Group Medicare Plan limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.
- **Tier exception:** You can ask us to cover a formulary drug at lower cost-sharing level unless the drug is on the specialty tier. If approved, this would lower the amount you must pay for your drug.

Generally, Humana Group Medicare Plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost sharing drug, or applying the restriction would not be as effective for you and/or would cause you to have adverse effects.

You or your prescriber should contact us to ask for a tiering, or formulary exception, including an exception to a coverage restriction. **When you request an exception, your prescriber will need to explain the medical reasons why you need the exception.**

Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can ask for an expedited (fast) decision if you believe, and we agree, that your health could be seriously harmed by waiting up to 72 hours for a decision. If we agree, or if your prescriber asks for a fast decision, we must give you a decision no later than 24 hours after we get your prescriber's supporting statement.

What can I do if my drug is not on the formulary or has a restriction?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but has a coverage restriction, such as prior authorization. You should talk to your prescriber about requesting a coverage decision to show that you meet the criteria for approval, switching to an alternative drug that we cover, or requesting a formulary exception so that we will cover the drug you take. While you and your doctor determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or has a coverage restriction, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30 day supply of

medication. If coverage is not approved, after your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug unless you have a prescription written for fewer days. (in which case we will allow multiple fills to provide up to a total of 31 days of a drug) while you pursue a formulary exception.

Throughout the plan year, your treatment setting (the place where you receive and take your medicine) may change. These changes include:

- Members who are discharged from a hospital or skilled-nursing facility to a home setting
- Members who are admitted to a hospital or skilled-nursing facility from a home setting
- Members who transfer from one skilled-nursing facility to another and use a different pharmacy
- Members who end their skilled-nursing facility Medicare Part A stay (where payments include all pharmacy charges) and who now need to use their Part D plan benefit
- Members who give up Hospice Status and go back to standard Medicare Part A and B coverage
- Members discharged from chronic psychiatric hospitals with highly individualized drug regimens

For these changes in treatment settings, Humana Group Medicare Plan will cover as much as a 31-day temporary supply of a Part D-covered drug when you fill your prescription at a pharmacy. If you change treatment settings multiple times within the same month, you may have to request an exception or prior authorization and receive approval for continued coverage of your drug. Humana Group Medicare Plan will review requests for continuation of therapy on a case-by-case basis understanding when you are on a stabilized drug regimen that, if changed, is known to have risks.

Transition extension

Humana Group Medicare Plan will consider on a case-by-case basis an extension of the transition period if your exception request or appeal has not been processed by the end of your initial transition period. We will continue to provide necessary drugs to you if your transition period is extended.

A Transition Policy is available on your.humana.com/ncshp, in the same area where the Prescription Drug Guides are displayed.

CenterWell Pharmacy™

You may fill your medicines at any network pharmacy. CenterWell Pharmacy – Humana's mail-delivery pharmacy is one option. To get started or learn more, visit CenterWellPharmacy.com. You can also call CenterWell Pharmacy at **1-844-222-2151 (TTY: 711)** Monday – Friday, 8 a.m. to 11 p.m. (EST), and Saturday, 8 a.m. to 6:30 p.m. (EST).

Other pharmacies are available in our network.

For More Information

For more detailed information about your Humana Group Medicare Plan prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about Humana Group Medicare Plan, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at **1-800-MEDICARE (1-800-633-4227)** 24 hours a day, seven days a week. **TTY** users should call **1-877-486-2048**. You can also visit **www.medicare.gov**.

Humana Group Medicare Plan Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by Humana Group Medicare Plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 196.

Your plan has additional coverage of some drugs. These drugs are not normally covered under Medicare Part D and are not subject to the Medicare appeals process. These drugs are listed separately on page 193.

How to read your formulary

The first column of the chart lists categories of medical conditions in alphabetical order. The drug names are then listed in alphabetical order within each category. Brand-name drugs are CAPITALIZED and generic drugs are listed in lower-case italics. Next to the drug name or Utilization Management column, you may see an indicator to tell you about additional coverage information for that drug. You might see the following indicators:

\$0 - Most vaccines and diabetic supplies covered 100% with no member cost.

DL - Dispensing Limit; Drugs that may be limited to a 30 day supply, regardless of tier placement.

MO - Drugs that are typically available through mail-order. Please contact your mail-order pharmacy to make sure your drug is available.

LA - Limited Access; The health plan has authorized certain pharmacies to dispense this medicine, as it requires extra handling, doctor coordination or patient education. Please call the number on the back of your ID card for additional information.

CI - Covered insulin products; Part D insulin products covered by your plan. For more information on cost sharing for your covered insulin products, please refer to your Evidence of Coverage.

PDS - Preferred Diabetic Supplies; BD and HTL-Droplet are the preferred diabetic syringe and pen needle brands for the plan.

The second column lists the tier of the drug. See page 5 for more details on the drug tiers in your plan.

The third column shows the Utilization Management Requirements for the drug. Humana Group Medicare Plan may have special requirements for covering that drug. If the column is blank, then there are no utilization requirements for that drug. The supply for each drug is based on benefits and whether your health care provider prescribes a supply for 30, 60, or 90 days. The amount of any quantity limits will also be in this column (Example: "QL - 30 for 30 days" means you can only get 30 doses every 30 days). See page 6 for more information about these requirements.

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ANALGESICS		
acetaminophen-caff-dihydrocod 320.5-30-16 mg CAPSULE DL	1	QL(300 per 30 days)
acetaminophen-codeine 120 mg-12 mg /5 ml (5 ml), 120-12 mg/5 ml, 300 mg-30 mg /12.5 ml SOLUTION DL	1	QL(2700 per 30 days)
acetaminophen-codeine 300-15 mg TABLET DL	1	QL(390 per 30 days)
acetaminophen-codeine 300-30 mg TABLET DL	1	QL(360 per 30 days)
acetaminophen-codeine 300-60 mg TABLET DL	1	QL(180 per 30 days)
ACTIQ 1,200 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG LOZENGE DL	4	PA,QL(120 per 30 days)
APADAZ 4.08-325 MG, 6.12-325 MG, 8.16-325 MG TABLET DL	3	
ARTHROTEC 50 50-200 MG-MCG TABLET, IR, DR, BIPHASIC MO	3	PA
ARTHROTEC 75 75-200 MG-MCG TABLET, IR, DR, BIPHASIC MO	3	PA
ascomp with codeine 30-50-325-40 mg CAPSULE DL	1	QL(360 per 30 days)
BELBUCA 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG, 750 MCG, 900 MCG FILM DL	3	ST,QL(60 per 30 days)
benzhydrocodone-acetaminophen 4.08-325 mg, 6.12-325 mg, 8.16-325 mg TABLET DL	3	
BUPRENEX 0.3 MG/ML SOLUTION DL	3	QL(240 per 30 days)
buprenorphine 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour PATCH, WEEKLY DL	1	PA,QL(4 per 28 days)
buprenorphine hcl 0.3 mg/ml SYRINGE DL	1	QL(240 per 30 days)
butalbital compound w/codeine 30-50-325-40 mg CAPSULE DL	1	QL(360 per 30 days)
butorphanol 1 mg/ml SOLUTION DL	1	QL(960 per 30 days)
butorphanol 10 mg/ml SPRAY, NON-AEROSOL DL	1	QL(5 per 28 days)
butorphanol 2 mg/ml SOLUTION DL	1	QL(480 per 30 days)
BUTRANS 10 MCG/HOUR, 15 MCG/HOUR, 20 MCG/HOUR, 5 MCG/HOUR, 7.5 MCG/HOUR PATCH, WEEKLY DL	3	PA,QL(4 per 28 days)
CALDOLOR 800 MG/200 ML (4 MG/ML) PIGGYBACK MO	3	
CALDOLOR 800 MG/8 ML (100 MG/ML) RECON SOLUTION MO	3	
CAMBIA 50 MG POWDER IN PACKET DL	4	ST,QL(9 per 30 days)
cataflam 50 mg TABLET MO	1	
CELEBREX 100 MG, 200 MG, 400 MG, 50 MG CAPSULE MO	3	PA,QL(60 per 30 days)
celecoxib 100 mg, 200 mg CAPSULE MO	1	QL(60 per 30 days)
celecoxib 400 mg, 50 mg CAPSULE MO	1	QL(60 per 30 days)
codeine sulfate 15 mg, 30 mg TABLET DL	1	QL(360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
codeine sulfate 60 mg TABLET DL	1	QL(180 per 30 days)
codeine-butalbital-asa-caff 30-50-325-40 mg CAPSULE DL	1	QL(360 per 30 days)
CONZIP 100 MG, 200 MG, 300 MG CAPSULE, ER, BIPHASIC DL	3	ST,QL(30 per 30 days)
DAYPRO 600 MG TABLET MO	3	
DEMEROL 50 MG/ML SOLUTION DL	3	QL(720 per 30 days)
DEMEROL (PF) 100 MG/ML SYRINGE DL	3	QL(360 per 30 days)
DEMEROL (PF) 25 MG/ML SYRINGE DL	3	QL(1440 per 30 days)
DEMEROL (PF) 50 MG/ML SYRINGE DL	3	QL(720 per 30 days)
DEMEROL (PF) 75 MG/ML SYRINGE DL	3	QL(480 per 30 days)
diclofenac epolamine 1.3 % PATCH, 12 HR. MO	1	PA,QL(60 per 30 days)
diclofenac potassium 25 mg CAPSULE MO	3	ST,QL(120 per 30 days)
diclofenac potassium 25 mg TABLET DL	4	
diclofenac potassium 50 mg POWDER IN PACKET MO	3	ST,QL(9 per 30 days)
diclofenac potassium 50 mg TABLET MO	1	
diclofenac sodium 1 % GEL MO	1	QL(1000 per 30 days)
diclofenac sodium 1.5 % DROPS MO	1	PA,QL(300 per 30 days)
diclofenac sodium 100 mg TABLET, ER 24 HR. MO	1	
diclofenac sodium 20 mg/gram /actuation(2 %) SOLUTION IN METERED DOSE PUMP DL	4	PA,QL(224 per 28 days)
diclofenac sodium 25 mg, 50 mg TABLET, DR/EC MO	1	
diclofenac sodium 75 mg TABLET, DR/EC MO	1	
diclofenac-misoprostol 50-200 mg-mcg, 75-200 mg-mcg TABLET, IR, DR, BIPHASIC MO	1	
diflunisal 500 mg TABLET MO	1	
DILAUDID 1 MG/ML LIQUID DL	3	PA,QL(2400 per 30 days)
DILAUDID 2 MG, 4 MG TABLET DL	3	PA,QL(360 per 30 days)
DILAUDID 8 MG TABLET DL	3	PA,QL(240 per 30 days)
DUEXIS 800-26.6 MG TABLET DL	4	PA,QL(90 per 30 days)
DURAMORPH (PF) 0.5 MG/ML SOLUTION DL	3	BvsD,QL(7200 per 30 days)
DURAMORPH (PF) 1 MG/ML SOLUTION DL	3	BvsD,QL(3600 per 30 days)
ec-naproxen 500 mg TABLET, DR/EC MO	3	
endocet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg TABLET DL	1	QL(360 per 30 days)
etodolac 200 mg, 300 mg CAPSULE MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
etodolac 400 mg, 500 mg TABLET MO	1	
etodolac 400 mg, 500 mg, 600 mg TABLET, ER 24 HR. MO	1	
FELDENE 10 MG, 20 MG CAPSULE MO	3	
fenoprofen 400 mg CAPSULE MO	1	ST
fenoprofen 600 mg TABLET MO	1	ST
fentanyl 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour PATCH. 72 HR. DL	1	QL(20 per 30 days)
fentanyl citrate 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg LOZENGE DL	4	PA,QL(120 per 30 days)
fentanyl citrate 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg TABLET, EFFERVESCENT DL	4	PA,QL(120 per 30 days)
fentanyl citrate 200 mcg LOZENGE DL	1	PA,QL(120 per 30 days)
fentanyl citrate (pf) 50 mcg/ml SOLUTION DL	1	BvsD,QL(720 per 30 days)
FENTORA 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG TABLET, EFFERVESCENT DL	4	PA,QL(120 per 30 days)
FLECTOR 1.3 % PATCH, 12 HR. MO	3	PA,QL(60 per 30 days)
flurbiprofen 100 mg TABLET MO	1	
hydrocodone bitartrate 10 mg, 15 mg, 20 mg, 30 mg, 40 mg CAPSULE, ER 12 HR. DL	1	ST,QL(90 per 30 days)
hydrocodone bitartrate 100 mg, 120 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg TABLET, ER 24 HR. DL	1	ST,QL(30 per 30 days)
hydrocodone bitartrate 50 mg CAPSULE, ER 12 HR. DL	1	ST,QL(120 per 30 days)
hydrocodone-acetaminophen 10-300 mg, 5-300 mg, 7.5-300 mg TABLET DL	1	QL(390 per 30 days)
hydrocodone-acetaminophen 10-325 mg, 5-325 mg, 7.5-325 mg TABLET DL	1	QL(360 per 30 days)
hydrocodone-acetaminophen 10-325 mg/15 ml(15 ml) SOLUTION DL	1	QL(2700 per 30 days)
hydrocodone-acetaminophen 2.5-325 mg TABLET DL	1	QL(360 per 30 days)
hydrocodone-acetaminophen 7.5-325 mg/15 ml SOLUTION DL	1	QL(5520 per 30 days)
hydrocodone-ibuprofen 10-200 mg, 5-200 mg, 7.5-200 mg TABLET DL	1	QL(150 per 30 days)
HYDROMORPHONE 0.25 MG/0.5 ML SYRINGE DL	1	BvsD
hydromorphone 0.5 mg/0.5 ml, 1 mg/ml SYRINGE DL	1	BvsD,QL(720 per 30 days)
hydromorphone 1 mg/ml LIQUID DL	1	QL(2400 per 30 days)
hydromorphone 1 mg/ml SOLUTION DL	1	BvsD,QL(720 per 30 days)
hydromorphone 12 mg TABLET, ER 24 HR. DL	1	ST,QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
hydromorphone 16 mg TABLET, ER 24 HR. DL	1	ST,QL(120 per 30 days)
hydromorphone 2 mg, 4 mg TABLET DL	1	QL(360 per 30 days)
hydromorphone 2 mg/ml SOLUTION DL	1	BvsD,QL(360 per 30 days)
hydromorphone 2 mg/ml SYRINGE DL	1	BvsD,QL(360 per 30 days)
hydromorphone 32 mg TABLET, ER 24 HR. DL	1	ST,QL(60 per 30 days)
hydromorphone 4 mg/ml SYRINGE DL	1	BvsD,QL(180 per 30 days)
hydromorphone 8 mg TABLET DL	1	QL(240 per 30 days)
hydromorphone 8 mg TABLET, ER 24 HR. DL	1	ST,QL(240 per 30 days)
hydromorphone (pf) 0.2 mg/ml, 1 mg/ml, 2 mg/ml SYRINGE DL	1	BvsD
hydromorphone (pf) 1 mg/ml SOLUTION DL	1	BvsD,QL(720 per 30 days)
hydromorphone (pf) 10 mg/ml SOLUTION DL	1	BvsD,QL(144 per 30 days)
hydromorphone (pf) 4 mg/ml SOLUTION DL	1	BvsD,QL(180 per 30 days)
HYSINGLA ER 100 MG, 120 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG TABLET, ER 24 HR. DL	3	ST,QL(30 per 30 days)
ibu 400 mg, 600 mg, 800 mg TABLET MO	1	
ibuprofen 100 mg/5 ml SUSPENSION MO	1	
ibuprofen 400 mg TABLET MO	1	
ibuprofen 600 mg, 800 mg TABLET MO	1	
ibuprofen-famotidine 800-26.6 mg TABLET MO	1	PA,QL(90 per 30 days)
INDOCIN 25 MG/5 ML SUSPENSION DL	4	
INDOCIN 50 MG SUPPOSITORY MO	3	
indomethacin 25 mg, 50 mg CAPSULE MO	1	
indomethacin 25 mg/5 ml SUSPENSION DL	4	
indomethacin 50 mg SUPPOSITORY MO	1	
indomethacin 75 mg CAPSULE, ER MO	1	
indomethacin sodium 1 mg RECON SOLUTION MO	1	
INFUMORPH P/F 10 MG/ML SOLUTION DL	3	BvsD,QL(360 per 30 days)
INFUMORPH P/F 25 MG/ML SOLUTION DL	3	BvsD,QL(150 per 30 days)
ketoprofen 200 mg CAPSULE ER PELLETS 24 HR. MO	1	
ketoprofen 25 mg, 50 mg, 75 mg CAPSULE MO	1	ST
ketorolac 10 mg TABLET MO	1	QL(20 per 30 days)
ketorolac 15 mg/ml, 30 mg/ml, 30 mg/ml (1 ml), 60 mg/2 ml SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ketorolac 15 mg/ml, 30 mg/ml, 60 mg/2 ml SYRINGE</i> MO	1	
<i>ketorolac 15.75 mg/spray SPRAY, NON-AEROSOL</i> DL	4	PA,QL(5 per 30 days)
<i>kiprofen 25 mg CAPSULE</i> MO	1	ST
<i>levorphanol tartrate 2 mg TABLET</i> DL	4	ST,QL(240 per 30 days)
<i>levorphanol tartrate 3 mg TABLET</i> DL	4	ST,QL(150 per 30 days)
<i>LICART 1.3 % PATCH, 24 HR.</i> MO	3	PA,QL(30 per 30 days)
<i>LODINE 400 MG TABLET</i> MO	3	PA
<i>lofena 25 mg TABLET</i> DL	4	
<i>lortab elixir 10-300 mg/15 ml SOLUTION</i> DL	1	QL(6000 per 30 days)
<i>meclofenamate 100 mg, 50 mg CAPSULE</i> MO	1	
<i>mefenamic acid 250 mg CAPSULE</i> MO	1	
<i>meloxicam 15 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>meloxicam 7.5 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>meloxicam submicronized 10 mg, 5 mg CAPSULE</i> MO	3	QL(30 per 30 days)
<i>meperidine 10 mg/ml CARTRIDGE</i> DL	1	QL(3600 per 30 days)
<i>meperidine 50 mg TABLET</i> DL	4	QL(480 per 30 days)
<i>meperidine 50 mg/5 ml SOLUTION</i> DL	1	QL(720 per 30 days)
<i>meperidine (pf) 100 mg/ml SOLUTION</i> DL	1	QL(360 per 30 days)
<i>meperidine (pf) 25 mg/ml SOLUTION</i> DL	1	QL(1440 per 30 days)
<i>meperidine (pf) 50 mg/ml SOLUTION</i> DL	1	QL(720 per 30 days)
<i>methadone 10 mg TABLET</i> DL	1	QL(240 per 30 days)
<i>methadone 10 mg/5 ml SOLUTION</i> DL	1	QL(1800 per 30 days)
<i>methadone 10 mg/ml CONCENTRATE</i> DL	1	QL(360 per 30 days)
<i>methadone 10 mg/ml SOLUTION</i> DL	1	QL(360 per 30 days)
<i>methadone 5 mg TABLET</i> DL	1	QL(480 per 30 days)
<i>methadone 5 mg/5 ml SOLUTION</i> DL	1	QL(3600 per 30 days)
<i>methadone intensol 10 mg/ml CONCENTRATE</i> DL	1	QL(360 per 30 days)
<i>METHADOSE 10 MG/ML CONCENTRATE</i> DL	3	QL(360 per 30 days)
<i>mitigo (pf) 10 mg/ml SOLUTION</i> DL	3	BvsD,QL(360 per 30 days)
<i>mitigo (pf) 25 mg/ml SOLUTION</i> DL	3	BvsD,QL(150 per 30 days)
<i>morphine 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg CAPSULE ER PELLETS</i> DL	1	ST,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>morphine 10 mg/5 ml SOLUTION</i> DL	1	QL(2700 per 30 days)
<i>morphine 10 mg/ml SOLUTION</i> DL	1	BvsD,QL(360 per 30 days)
<i>morphine 10 mg/ml SYRINGE</i> DL	1	BvsD,QL(360 per 30 days)
<i>morphine 100 mg TABLET ER</i> DL	1	QL(180 per 30 days)
<i>morphine 120 mg, 60 mg, 75 mg, 90 mg CAPSULE ER MULTIPHASE 24 HR.</i> DL	1	ST,QL(60 per 30 days)
<i>morphine 15 mg, 30 mg TABLET</i> DL	1	QL(180 per 30 days)
<i>morphine 15 mg, 30 mg, 60 mg TABLET ER</i> DL	1	QL(120 per 30 days)
<i>morphine 2 mg/ml SOLUTION</i> DL	1	BvsD,QL(1800 per 30 days)
<i>morphine 2 mg/ml SYRINGE</i> DL	1	BvsD,QL(1800 per 30 days)
<i>morphine 2 mg/ml, 4 mg/ml, 5 mg/ml SYRINGE</i> DL	1	BvsD
<i>morphine 20 mg/5 ml (4 mg/ml) SOLUTION</i> DL	1	QL(1350 per 30 days)
<i>morphine 200 mg TABLET ER</i> DL	1	QL(90 per 30 days)
<i>morphine 30 mg, 45 mg CAPSULE ER MULTIPHASE 24 HR.</i> DL	1	ST,QL(30 per 30 days)
<i>morphine 4 mg/ml SOLUTION</i> DL	1	BvsD,QL(900 per 30 days)
<i>morphine 4 mg/ml SYRINGE</i> DL	1	BvsD,QL(900 per 30 days)
<i>morphine 5 mg/ml SOLUTION</i> DL	1	BvsD,QL(720 per 30 days)
<i>morphine 8 mg/ml SOLUTION</i> DL	1	BvsD,QL(450 per 30 days)
<i>morphine 8 mg/ml SYRINGE</i> DL	1	BvsD,QL(450 per 30 days)
<i>morphine (pf) 0.5 mg/ml SOLUTION</i> DL	1	BvsD,QL(7200 per 30 days)
<i>morphine (pf) 1 mg/ml SOLUTION</i> DL	1	BvsD,QL(3600 per 30 days)
<i>morphine (pf) 30 mg/30 ml (1 mg/ml) PATIENT CONTROL ANALGESIA SOLN</i> DL	1	BvsD,QL(3600 per 30 days)
<i>morphine concentrate 100 mg/5 ml (20 mg/ml) SOLUTION</i> DL	1	QL(540 per 30 days)
<i>MS CONTIN 100 MG TABLET ER</i> DL	3	PA,QL(180 per 30 days)
<i>MS CONTIN 15 MG, 30 MG, 60 MG TABLET ER</i> DL	3	PA,QL(120 per 30 days)
<i>MS CONTIN 200 MG TABLET ER</i> DL	3	PA,QL(90 per 30 days)
<i>nabumetone 500 mg, 750 mg TABLET</i> MO	1	
<i>nalbuphine 10 mg/ml SOLUTION</i> DL	1	QL(240 per 30 days)
<i>nalbuphine 20 mg/ml SOLUTION</i> DL	1	QL(120 per 30 days)
<i>NALFON 400 MG CAPSULE</i> MO	3	ST
<i>NALFON 600 MG TABLET</i> MO	1	ST
<i>nalocet 2.5-300 mg TABLET</i> DL	4	PA,QL(360 per 30 days)
<i>NAPRELAN CR 375 MG TABLET, ER 24 HR., MULTIPHASE</i> MO	3	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NAPRELAN CR 500 MG TABLET, ER 24 HR., MULTIPHASE MO	3	QL(90 per 30 days)
NAPRELAN CR 750 MG TABLET, ER 24 HR., MULTIPHASE MO	3	QL(60 per 30 days)
NAPROSYN 125 MG/5 ML SUSPENSION DL	4	PA
<i>naproxen 125 mg/5 ml SUSPENSION</i> MO	1	
<i>naproxen 250 mg, 375 mg TABLET</i> MO	1	
<i>naproxen 375 mg, 500 mg TABLET, DR/EC</i> MO	1	
<i>naproxen 500 mg TABLET</i> MO	1	
<i>naproxen sodium 275 mg, 550 mg TABLET</i> MO	1	
<i>naproxen sodium 375 mg TABLET, ER 24 HR., MULTIPHASE</i> MO	1	ST,QL(120 per 30 days)
<i>naproxen sodium 500 mg TABLET, ER 24 HR., MULTIPHASE</i> MO	1	ST,QL(90 per 30 days)
<i>naproxen sodium 750 mg TABLET, ER 24 HR., MULTIPHASE</i> MO	1	ST,QL(60 per 30 days)
<i>naproxen-esomeprazole 375-20 mg, 500-20 mg TABLET, IR, DR, BIPHASIC</i> DL	4	PA,QL(60 per 30 days)
NUCYNTA 100 MG, 50 MG, 75 MG TABLET DL	4	ST,QL(180 per 30 days)
NUCYNTA ER 100 MG, 150 MG, 200 MG, 250 MG TABLET, ER 12 HR. DL	4	ST,QL(60 per 30 days)
NUCYNTA ER 50 MG TABLET, ER 12 HR. DL	3	ST,QL(60 per 30 days)
OLINVYK 1 MG/ML SOLUTION DL	4	PA
OLINVYK 30 MG/30 ML (1 MG/ML) PATIENT CONTROL ANALGESIA SOLN DL	4	PA
<i>oxaprozin 600 mg TABLET</i> MO	1	
OXAYDO 5 MG, 7.5 MG TABLET, ORAL ONLY DL	4	PA,QL(360 per 30 days)
<i>oxycodone 10 mg, 15 mg, 5 mg TABLET</i> DL	1	QL(360 per 30 days)
<i>oxycodone 10 mg, 20 mg, 40 mg TABLET, ER 12 HR.</i> DL	3	ST,QL(90 per 30 days)
<i>oxycodone 20 mg, 30 mg TABLET</i> DL	1	QL(360 per 30 days)
<i>oxycodone 20 mg/ml CONCENTRATE</i> DL	1	QL(270 per 30 days)
<i>oxycodone 5 mg CAPSULE</i> DL	1	QL(360 per 30 days)
<i>oxycodone 5 mg/5 ml SOLUTION</i> DL	1	QL(5400 per 30 days)
<i>oxycodone 80 mg TABLET, ER 12 HR.</i> DL	3	ST,QL(120 per 30 days)
<i>oxycodone-acetaminophen 10-300 mg, 5-300 mg, 7.5-300 mg TABLET</i> DL	4	PA,QL(390 per 30 days)
<i>oxycodone-acetaminophen 10-300 mg/5 ml SOLUTION</i> DL	4	PA,QL(900 per 30 days)
<i>oxycodone-acetaminophen 10-325 mg, 5-325 mg, 7.5-325 mg TABLET</i> DL	1	QL(360 per 30 days)
<i>oxycodone-acetaminophen 2.5-300 mg TABLET</i> DL	1	PA,QL(360 per 30 days)
<i>oxycodone-acetaminophen 2.5-325 mg TABLET</i> DL	1	QL(360 per 30 days)
<i>oxycodone-acetaminophen 5-325 mg/5 ml SOLUTION</i> DL	1	QL(1800 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OXYCONTIN 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG TABLET, ER 12 HR. DL	3	ST,QL(90 per 30 days)
OXYCONTIN 80 MG TABLET, ER 12 HR. DL	3	ST,QL(120 per 30 days)
<i>oxymorphone 10 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg TABLET, ER 12 HR. DL</i>	1	ST,QL(60 per 30 days)
<i>oxymorphone 10 mg, 5 mg TABLET DL</i>	1	QL(360 per 30 days)
<i>oxymorphone 40 mg TABLET, ER 12 HR. DL</i>	4	ST,QL(60 per 30 days)
PENNSAID 2 % SOLUTION IN PACKET DL	4	PA
PENNSAID 20 MG/GRAM /ACTUATION(2 %) SOLUTION IN METERED DOSE PUMP DL	4	PA,QL(224 per 28 days)
<i>pentazocine-naloxone 50-0.5 mg TABLET DL</i>	1	QL(360 per 30 days)
PERCOCET 10-325 MG, 5-325 MG, 7.5-325 MG TABLET DL	4	PA,QL(360 per 30 days)
PERCOCET 2.5-325 MG TABLET DL	1	PA,QL(360 per 30 days)
<i>piroxicam 10 mg, 20 mg CAPSULE MO</i>	1	
<i>primlev 10-300 mg, 5-300 mg, 7.5-300 mg TABLET DL</i>	4	PA,QL(390 per 30 days)
<i>prolate 10-300 mg, 5-300 mg, 7.5-300 mg TABLET DL</i>	4	PA,QL(390 per 30 days)
PROLATE 10-300 MG/5 ML SOLUTION DL	4	PA,QL(900 per 30 days)
QDOLO 5 MG/ML SOLUTION DL	4	QL(2400 per 30 days)
RELAFEN 500 MG, 750 MG TABLET DL	4	ST
RELAFEN DS 1,000 MG TABLET DL	4	ST,QL(60 per 30 days)
ROXICODONE 15 MG TABLET DL	3	PA,QL(360 per 30 days)
ROXICODONE 30 MG TABLET DL	4	PA,QL(360 per 30 days)
ROXYBOND 15 MG, 30 MG TABLET, ORAL ONLY DL	4	PA,QL(180 per 30 days)
ROXYBOND 5 MG TABLET, ORAL ONLY DL	4	PA,QL(360 per 30 days)
SEGLENTIS 44-56 MG TABLET DL	3	PA,QL(120 per 30 days)
SPRIX 15.75 MG/SPRAY SPRAY, NON-AEROSOL DL	4	PA,QL(5 per 30 days)
<i>sulindac 150 mg, 200 mg TABLET MO</i>	1	
<i>tolectin 600 600 mg TABLET MO</i>	1	
<i>tolmetin 200 mg, 600 mg TABLET MO</i>	1	
<i>tolmetin 400 mg CAPSULE MO</i>	1	
<i>tramadol 100 mg TABLET DL</i>	1	QL(120 per 30 days)
<i>tramadol 100 mg, 200 mg, 300 mg CAPSULE, ER, BIPHASIC DL</i>	1	ST,QL(30 per 30 days)
<i>tramadol 100 mg, 200 mg, 300 mg TABLET, ER 24 HR. DL</i>	1	ST,QL(30 per 30 days)
<i>tramadol 100 mg, 200 mg, 300 mg TABLET, ER 24 HR., MULTIPHASE DL</i>	1	ST,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
tramadol 25 mg TABLET DL	1	QL(180 per 30 days)
tramadol 5 mg/ml SOLUTION DL	4	QL(2400 per 30 days)
tramadol 50 mg TABLET DL	1	QL(240 per 30 days)
tramadol-acetaminophen 37.5-325 mg TABLET DL	1	QL(240 per 30 days)
TREZIX 320.5-30-16 MG CAPSULE DL	1	QL(300 per 30 days)
ULTRACET 37.5-325 MG TABLET DL	3	QL(240 per 30 days)
ULTRAM 50 MG TABLET DL	3	QL(240 per 30 days)
VIMOVO 375-20 MG, 500-20 MG TABLET, IR, DR, BIPHASIC DL	4	PA,QL(60 per 30 days)
VIVLODEX 10 MG, 5 MG CAPSULE MO	3	QL(30 per 30 days)
XTAMPZA ER 13.5 MG, 18 MG, 27 MG, 36 MG, 9 MG CAPSULE ER SPRINKLE 12 HR. DL	3	ST,QL(60 per 30 days)
ZIPSOR 25 MG CAPSULE DL	4	ST,QL(120 per 30 days)
ZORVOLEX 18 MG, 35 MG CAPSULE MO	3	ST,QL(90 per 30 days)
ANESTHETICS		
bupivacaine (pf) 0.25 % (2.5 mg/ml), 0.5 % (5 mg/ml), 0.75 % (7.5 mg/ml) SOLUTION MO	1	
bupivacaine hcl 0.25 % (2.5 mg/ml), 0.5 % (5 mg/ml) SOLUTION MO	1	
bupivacaine-dextrose-water(pf) 0.75 % (7.5 mg/ml) SOLUTION MO	1	
bupivacaine-epinephrine 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	1	
bupivacaine-epinephrine (pf) 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	1	
CARBOCAINE WITH NEO-COBEFRIN 2 % -1:20,000 CARTRIDGE MO	1	
chloroprocaine (pf) 20 mg/ml (2 %), 30 mg/ml (3 %) SOLUTION MO	1	
CLOROTEKAL (PF) 10 MG/ML (1 %) SOLUTION MO	3	
dermacinrx lidocan 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
EXPAREL (PF) 1.3 % (13.3 MG/ML) SUSPENSION MO	3	
glydo 2 % JELLY IN APPLICATOR MO	1	
lidocaine 5 % ADHESIVE PATCH, MEDICATED MO	1	PA,QL(90 per 30 days)
lidocaine 5 % OINTMENT MO	1	PA
lidocaine (pf) 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %), 40 mg/ml (4 %), 5 mg/ml (0.5 %) SOLUTION MO	1	
lidocaine hcl 10 mg/ml (1 %), 2 %, 20 mg/ml (2 %), 4 %, 4 % (40 mg/ml), 5 mg/ml (0.5 %) SOLUTION MO	1	
lidocaine hcl 2 % JELLY MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
lidocaine hcl 2 % JELLY IN APPLICATOR MO	1	
lidocaine viscous 2 % SOLUTION MO	1	
lidocaine-epinephrine 0.5 %-1:200,000, 1 %-1:100,000, 2 %-1:100,000 SOLUTION MO	1	
lidocaine-epinephrine bit 2 %-1:100,000, 2 %-1:50,000 CARTRIDGE MO	1	
lidocaine-prilocaine 2.5-2.5 % CREAM MO	1	
lidocan iii 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
lidocan iv 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
lidocan v 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
LIDODERM 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
lignospan standard 2 %-1:100,000 CARTRIDGE MO	1	
MARCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) SOLUTION MO	3	
MARCAINE (PF) 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML), 0.75 % (7.5 MG/ML) SOLUTION MO	3	
MARCAINE SPINAL (PF) 0.75 % (7.5 MG/ML) SOLUTION MO	3	
MARCAINE-EPINEPHRINE 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	3	
marcaine-epinephrine 0.5 %-1:200,000 CARTRIDGE MO	1	
MARCAINE-EPINEPHRINE (PF) 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	3	
NAROPIN (PF) 10 MG/ML (1 %), 2 MG/ML (0.2 %), 5 MG/ML (0.5 %), 7.5 MG/ML (0.75 %) SOLUTION MO	3	
NESACAINE 10 MG/ML (1 %), 20 MG/ML (2 %) SOLUTION MO	3	
NESACAINE-MPF 20 MG/ML (2 %), 30 MG/ML (3 %) SOLUTION MO	3	
PLIAGLIS 7-7 % CREAM MO	3	
polocaine 1 % (10 mg/ml), 2 % SOLUTION MO	1	
polocaine-mpf 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %) SOLUTION MO	1	
ropivacaine (pf) 10 mg/ml (1 %), 2 mg/ml (0.2 %), 5 mg/ml (0.5 %), 7.5 mg/ml (0.75 %) SOLUTION MO	1	
SENSORCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) SOLUTION MO	1	
sensorcaine-epinephrine 0.25 %-1:200,000, 0.5 %-1:200,000 SOLUTION MO	1	
SENSORCAINE-MPF 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML), 0.75 % (7.5 MG/ML) SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
sensorcaine-mpf 0.25 % (2.5 mg/ml), 0.5 % (5 mg/ml), 0.75 % (7.5 mg/ml) SOLUTION MO	1	
sensorcaine-mpf spinal 0.75 % (7.5 mg/ml) SOLUTION MO	1	
sensorcaine-mpf/epinephrine 0.25 %-1:200,000 SOLUTION MO	1	
SENSORCAINE-MPF/EPINEPHRINE 0.5 %-1:200,000, 0.75 %-1:200,000 SOLUTION MO	1	
tridacaine ii 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
tridacaine iii 5 % ADHESIVE PATCH, MEDICATED DL	4	PA,QL(90 per 30 days)
vivacaine 0.5 %-1:200,000 CARTRIDGE MO	1	
ZTLIDO 1.8 % ADHESIVE PATCH, MEDICATED MO	3	PA,QL(90 per 30 days)
ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS		
acamprosate 333 mg TABLET, DR/EC MO	1	
buprenorphine hcl 2 mg, 8 mg SUBLINGUAL TABLET MO	1	QL(90 per 30 days)
buprenorphine-naloxone 12-3 mg FILM MO	1	QL(60 per 30 days)
buprenorphine-naloxone 2-0.5 mg, 4-1 mg, 8-2 mg FILM MO	1	QL(90 per 30 days)
buprenorphine-naloxone 2-0.5 mg, 8-2 mg SUBLINGUAL TABLET MO	1	QL(90 per 30 days)
bupropion hcl (smoking deter) 150 mg TABLET, ER 12 HR. MO	1	QL(90 per 30 days)
CHANTIX 1 MG TABLET MO	3	PA,QL(56 per 28 days)
CHANTIX CONTINUING MONTH BOX 1 MG TABLET MO	3	PA,QL(56 per 28 days)
CHANTIX STARTING MONTH BOX 0.5 MG (11)- 1 MG (42) TABLET, DOSE PACK MO	3	PA,QL(53 per 28 days)
disulfiram 250 mg, 500 mg TABLET MO	1	
KLOXXADO 8 MG/ACTUATION SPRAY, NON-AEROSOL MO	3	PA,QL(2 per 30 days)
lofexidine 0.18 mg TABLET DL	4	PA,QL(224 per 365 days)
LUCEMYRA 0.18 MG TABLET DL	4	PA,QL(224 per 365 days)
nalmefene 1 mg/ml SOLUTION MO	1	
naloxone 0.4 mg/ml SOLUTION MO	1	
naloxone 0.4 mg/ml, 1 mg/ml SYRINGE MO	1	
naloxone 4 mg/actuation SPRAY, NON-AEROSOL MO	2	QL(2 per 30 days)
naltrexone 50 mg TABLET MO	1	
NARCAN 4 MG/ACTUATION SPRAY, NON-AEROSOL MO	3	PA,QL(2 per 30 days)
NICOTROL 10 MG CARTRIDGE MO	3	
NICOTROL NS 10 MG/ML SPRAY, NON-AEROSOL MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OPVEE 2.7 MG/ACTUATION SPRAY, NON-AEROSOL MO	2	QL(2 per 30 days)
SUBOXONE 12-3 MG FILM MO	3	PA,QL(60 per 30 days)
SUBOXONE 2-0.5 MG, 4-1 MG, 8-2 MG FILM MO	3	PA,QL(90 per 30 days)
varenicline 0.5 mg (11)- 1 mg (42) TABLET, DOSE PACK MO	1	QL(53 per 28 days)
varenicline 0.5 mg, 1 mg TABLET MO	1	QL(56 per 28 days)
VIVITROL 380 MG SUSPENSION, ER, RECON DL	4	QL(1 per 28 days)
ZIMHI 5 MG/0.5 ML SYRINGE MO	3	PA,QL(1 per 30 days)
ZUBSOLV 0.7-0.18 MG, 1.4-0.36 MG, 2.9-0.71 MG, 5.7-1.4 MG SUBLINGUAL TABLET MO	1	QL(90 per 30 days)
ZUBSOLV 11.4-2.9 MG SUBLINGUAL TABLET MO	1	QL(30 per 30 days)
ZUBSOLV 8.6-2.1 MG SUBLINGUAL TABLET MO	1	QL(60 per 30 days)
ANTIBACTERIALS		
acetic acid 2 % SOLUTION MO	1	
ACTICLATE 150 MG TABLET DL	4	ST,QL(30 per 30 days)
ACTICLATE 75 MG TABLET DL	4	ST,QL(60 per 30 days)
amikacin 1,000 mg/4 ml, 500 mg/2 ml SOLUTION MO	1	
amoxicillin 125 mg, 250 mg CHEWABLE TABLET MO	1	
amoxicillin 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
amoxicillin 250 mg CAPSULE MO	1	
amoxicillin 500 mg CAPSULE MO	1	
amoxicillin 500 mg TABLET MO	1	
amoxicillin 875 mg TABLET MO	1	
amoxicillin-pot clavulanate 1,000-62.5 mg TABLET, ER 12 HR. MO	1	
amoxicillin-pot clavulanate 200-28.5 mg, 400-57 mg CHEWABLE TABLET MO	1	
amoxicillin-pot clavulanate 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
amoxicillin-pot clavulanate 250-125 mg, 500-125 mg TABLET MO	1	
amoxicillin-pot clavulanate 875-125 mg TABLET MO	1	
ampicillin 500 mg CAPSULE MO	1	
ampicillin sodium 1 gram, 10 gram, 125 mg, 2 gram, 250 mg, 500 mg RECON SOLUTION MO	1	
ampicillin-sulbactam 1.5 gram, 15 gram, 3 gram RECON SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ARIKAYCE 590 MG/8.4 ML SUSPENSION FOR NEBULIZATION DL	4	PA,QL(235.2 per 28 days)
AUGMENTIN 125-31.25 MG/5 ML, 250-62.5 MG/5 ML SUSPENSION FOR RECONSTITUTION DL	4	
AUGMENTIN 500-125 MG TABLET MO	3	PA
AUGMENTIN ES-600 600-42.9 MG/5 ML SUSPENSION FOR RECONSTITUTION MO	3	
AUGMENTIN XR 1,000-62.5 MG TABLET, ER 12 HR. MO	3	
AVELOX IN NACL (ISO-OSMOTIC) 400 MG/250 ML PIGGYBACK MO	3	PA
<i>avidoxy 100 mg TABLET</i> MO	1	ST
AVYCAZ 2.5 GRAM RECON SOLUTION DL	4	
AZACTAM 1 GRAM, 2 GRAM RECON SOLUTION MO	3	PA
<i>azithromycin 1 gram PACKET</i> MO	1	
<i>azithromycin 100 mg/5 ml, 200 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>azithromycin 250 mg TABLET</i> MO	1	
<i>azithromycin 500 mg RECON SOLUTION</i> MO	1	
<i>azithromycin 500 mg, 600 mg TABLET</i> MO	1	
<i>aztreonam 1 gram, 2 gram RECON SOLUTION</i> MO	1	
<i>bacitracin 50,000 unit RECON SOLUTION</i> MO	1	
BACTRIM 400-80 MG TABLET MO	3	
BACTRIM DS 800-160 MG TABLET MO	3	
BAXDELA 300 MG RECON SOLUTION DL	4	QL(28 per 14 days)
BAXDELA 450 MG TABLET DL	4	QL(28 per 14 days)
BETHKIS 300 MG/4 ML SOLUTION FOR NEBULIZATION DL	4	PA
BICILLIN C-R 1,200,000 UNIT/ 2 ML(600K/600K) SYRINGE MO	3	
BICILLIN C-R 1,200,000 UNIT/ 2 ML(900K/300K) SYRINGE DL	3	
BICILLIN L-A 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML SYRINGE MO	3	
<i>cefaclor 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>cefaclor 250 mg, 500 mg CAPSULE</i> MO	1	
<i>cefaclor 500 mg TABLET, ER 12 HR.</i> MO	1	
<i>cefadroxil 1 gram TABLET</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
cefadroxil 250 mg/5 ml, 500 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefadroxil 500 mg CAPSULE MO	1	
cefazolin 1 gram, 10 gram, 2 gram, 3 gram, 500 mg RECON SOLUTION MO	1	
CEFAZOLIN 2 GRAM, 3 GRAM RECON SOLUTION MO	1	
cefazolin in dextrose (iso-os) 1 gram/50 ml, 2 gram/100 ml, 2 gram/50 ml PIGGYBACK MO	1	
cefdinir 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefdinir 300 mg CAPSULE MO	1	
cefepime 1 gram, 2 gram RECON SOLUTION MO	1	
cefepime in dextrose 5 % 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	1	
cefepime in dextrose,iso-osm 1 gram/50 ml, 2 gram/100 ml PIGGYBACK MO	3	
cefixime 100 mg/5 ml, 200 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefixime 400 mg CAPSULE MO	1	
cefotetan 1 gram, 10 gram, 2 gram RECON SOLUTION MO	1	
cefoxitin 1 gram, 10 gram, 2 gram RECON SOLUTION MO	1	
cefoxitin in dextrose, iso-osm 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	1	
cefpodoxime 100 mg, 200 mg TABLET MO	1	
cefpodoxime 100 mg/5 ml, 50 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefprozil 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cefprozil 250 mg, 500 mg TABLET MO	1	
ceftazidime 1 gram, 2 gram, 6 gram RECON SOLUTION MO	1	
ceftazidime in d5w 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	1	
ceftriaxone 1 gram, 10 gram, 100 gram, 2 gram, 250 mg, 500 mg RECON SOLUTION MO	1	
ceftriaxone in dextrose,iso-os 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	1	
cefuroxime axetil 250 mg, 500 mg TABLET MO	1	
cefuroxime sodium 1.5 gram, 7.5 gram, 750 mg RECON SOLUTION MO	1	
cephalexin 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
cephalexin 250 mg, 500 mg TABLET MO	1	
cephalexin 250 mg, 750 mg CAPSULE MO	1	
cephalexin 500 mg CAPSULE MO	1	
chloramphenicol sod succinate 1 gram RECON SOLUTION MO	1	
CIPRO 250 MG, 500 MG TABLET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CIPRO 250 MG/5 ML, 500 MG/5 ML SUSPENSION, MICROCAPSULE RECON MO	3	
<i>ciprofloxacin 250 mg/5 ml, 500 mg/5 ml SUSPENSION, MICROCAPSULE RECON</i> MO	1	
<i>ciprofloxacin hcl 100 mg, 250 mg, 750 mg TABLET</i> MO	1	
<i>ciprofloxacin hcl 500 mg TABLET</i> MO	1	
<i>ciprofloxacin in 5 % dextrose 200 mg/100 ml, 400 mg/200 ml PIGGYBACK</i> MO	1	
CLAFORAN 1 GRAM, 10 GRAM, 2 GRAM RECON SOLUTION MO	3	
<i>clarithromycin 125 mg/5 ml, 250 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>clarithromycin 250 mg, 500 mg TABLET</i> MO	1	
<i>clarithromycin 500 mg TABLET, ER 24 HR.</i> MO	1	
CLEOCIN 100 MG SUPPOSITORY MO	3	
CLEOCIN 150 MG/ML SOLUTION MO	1	
CLEOCIN 2 % CREAM MO	3	PA
CLEOCIN HCL 150 MG, 300 MG, 75 MG CAPSULE MO	3	
CLEOCIN PEDIATRIC 75 MG/5 ML RECON SOLUTION MO	1	
<i>clindamycin hcl 150 mg, 300 mg, 75 mg CAPSULE</i> MO	1	
<i>clindamycin in 0.9 % sod chlor 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml PIGGYBACK</i> MO	1	
<i>clindamycin in 5 % dextrose 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml PIGGYBACK</i> MO	1	
<i>clindamycin palmitate hcl 75 mg/5 ml RECON SOLUTION</i> MO	1	
<i>clindamycin pediatric 75 mg/5 ml RECON SOLUTION</i> MO	1	
<i>clindamycin phosphate 150 mg/ml SOLUTION</i> MO	1	
<i>clindamycin phosphate 2 % CREAM</i> MO	1	
CLINDESSE 2 % CREAM, ER MO	3	
<i>colistin (colistimethate na) 150 mg RECON SOLUTION</i> MO	1	
COLY-MYCIN M PARENTERAL 150 MG RECON SOLUTION DL	4	
<i>coremino 135 mg, 45 mg, 90 mg TABLET, ER 24 HR.</i> MO	1	ST,QL(30 per 30 days)
CUBICIN RF 500 MG RECON SOLUTION DL	4	
DALVANCE 500 MG SOLUTION DL	4	QL(4 per 28 days)
<i>daptomycin 350 mg RECON SOLUTION</i> MO	1	
<i>daptomycin 500 mg RECON SOLUTION</i> DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
daptomycin in 0.9 % sod chlor 1,000 mg/100 ml, 350 mg/50 ml, 500 mg/50 ml, 700 mg/100 ml PIGGYBACK MO	3	
demeclocycline 150 mg TABLET MO	1	QL(240 per 30 days)
demeclocycline 300 mg TABLET MO	1	QL(120 per 30 days)
dicloxacillin 250 mg, 500 mg CAPSULE MO	1	
DIFICID 200 MG TABLET DL	4	
DIFICID 40 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	
DORYX 200 MG TABLET, DR/EC MO	3	ST,QL(30 per 30 days)
DORYX 50 MG TABLET, DR/EC MO	3	ST,QL(60 per 30 days)
DORYX 80 MG TABLET, DR/EC DL	4	ST,QL(60 per 30 days)
DORYX MPC 120 MG TABLET, DR/EC MO	3	ST,QL(60 per 30 days)
DORYX MPC 60 MG TABLET, DR/EC DL	4	ST,QL(60 per 30 days)
doxy-100 100 mg RECON SOLUTION MO	1	
doxycycline hyclate 100 mg CAPSULE MO	1	
doxycycline hyclate 100 mg RECON SOLUTION MO	1	
doxycycline hyclate 100 mg TABLET MO	1	
doxycycline hyclate 100 mg TABLET, DR/EC MO	1	ST,QL(90 per 30 days)
doxycycline hyclate 150 mg TABLET MO	1	ST,QL(30 per 30 days)
doxycycline hyclate 150 mg, 50 mg, 75 mg TABLET, DR/EC MO	1	ST,QL(60 per 30 days)
doxycycline hyclate 20 mg TABLET MO	1	
doxycycline hyclate 200 mg TABLET, DR/EC MO	1	ST,QL(30 per 30 days)
doxycycline hyclate 50 mg CAPSULE MO	1	
doxycycline hyclate 50 mg TABLET MO	1	ST,QL(180 per 30 days)
doxycycline hyclate 75 mg TABLET MO	1	ST,QL(60 per 30 days)
doxycycline hyclate 80 mg TABLET, DR/EC DL	4	ST,QL(60 per 30 days)
doxycycline monohydrate 100 mg, 150 mg, 50 mg, 75 mg TABLET MO	1	
doxycycline monohydrate 100 mg, 50 mg CAPSULE MO	1	
doxycycline monohydrate 150 mg CAPSULE MO	1	QL(30 per 30 days)
doxycycline monohydrate 25 mg/5 ml SUSPENSION FOR RECONSTITUTION MO	1	
doxycycline monohydrate 40 mg CAPSULE, IR/DR, BIPHASIC MO	1	ST,QL(30 per 30 days)
doxycycline monohydrate 75 mg CAPSULE MO	1	QL(60 per 30 days)
E.E.S. 400 400 MG TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
E.E.S. GRANULES 200 MG/5 ML SUSPENSION FOR RECONSTITUTION MO	3	
<i>ertapenem 1 gram RECON SOLUTION</i> MO	1	
ERY-TAB 250 MG, 333 MG, 500 MG TABLET, DR/EC MO	1	
ERYPED 200 200 MG/5 ML SUSPENSION FOR RECONSTITUTION MO	3	
ERYPED 400 400 MG/5 ML SUSPENSION FOR RECONSTITUTION DL	4	
ERYTHROCIN 500 MG RECON SOLUTION MO	1	
ERYTHROCIN (AS STEARATE) 250 MG TABLET MO	1	
<i>erythromycin 250 mg CAPSULE, DR/EC</i> MO	1	
<i>erythromycin 250 mg, 333 mg, 500 mg TABLET, DR/EC</i> MO	1	
<i>erythromycin 250 mg, 500 mg TABLET</i> MO	1	
<i>erythromycin ethylsuccinate 200 mg/5 ml, 400 mg/5 ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>erythromycin ethylsuccinate 400 mg TABLET</i> MO	1	
<i>erythromycin lactobionate 500 mg RECON SOLUTION</i> DL	4	
FETROJA 1 GRAM RECON SOLUTION DL	4	QL(84 per 14 days)
FIRVANQ 25 MG/ML, 50 MG/ML RECON SOLUTION MO	3	
FLAGYL 375 MG CAPSULE MO	3	QL(320 per 30 days)
<i>fosfomycin tromethamine 3 gram PACKET</i> MO	1	
FURADANTIN 25 MG/5 ML SUSPENSION MO	3	
<i>gentamicin 0.1 % CREAM</i> MO	1	
<i>gentamicin 0.1 % OINTMENT</i> MO	1	
<i>gentamicin 20 mg/2 ml, 40 mg/ml SOLUTION</i> MO	1	
<i>gentamicin in nacl (iso-osm) 100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml, 90 mg/100 ml PIGGYBACK</i> MO	1	
<i>gentamicin sulfate (ped) (pf) 20 mg/2 ml SOLUTION</i> MO	1	
<i>gentamicin sulfate (pf) 100 mg/10 ml, 60 mg/6 ml SOLUTION</i> MO	1	
HIPREX 1 GRAM TABLET MO	3	PA
HUMATIN 250 MG CAPSULE DL	4	
<i>imipenem-cilastatin 250 mg, 500 mg RECON SOLUTION</i> MO	1	
INVANZ 1 GRAM RECON SOLUTION MO	3	
KIMYRSA 1,200 MG RECON SOLUTION DL	4	QL(1 per 30 days)
KITABIS PAK 300 MG/5 ML SOLUTION FOR NEBULIZATION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KLARON 10 % SUSPENSION MO	3	QL(118 per 30 days)
levofloxacin 25 mg/ml, 250 mg/10 ml SOLUTION MO	1	
levofloxacin 250 mg, 750 mg TABLET MO	1	
levofloxacin 500 mg TABLET MO	1	
levofloxacin in d5w 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK MO	1	
LINCOCIN 300 MG/ML SOLUTION MO	3	
lincomycin 300 mg/ml SOLUTION MO	1	
linezolid 100 mg/5 ml SUSPENSION FOR RECONSTITUTION DL	4	QL(1800 per 30 days)
linezolid 600 mg TABLET MO	1	QL(60 per 30 days)
linezolid in dextrose 5% 600 mg/300 ml PIGGYBACK MO	1	
linezolid-0.9% sodium chloride 600 mg/300 ml PARENTERAL SOLUTION MO	1	
MACROBID 100 MG CAPSULE MO	3	
MACRODANTIN 100 MG, 25 MG, 50 MG CAPSULE MO	3	
meropenem 1 gram, 500 mg RECON SOLUTION MO	1	
meropenem-0.9% sodium chloride 1 gram/50 ml, 500 mg/50 ml PIGGYBACK MO	1	
methenamine hippurate 1 gram TABLET MO	1	
METRO I.V. 500 MG/100 ML PIGGYBACK MO	3	
METROCREAM 0.75 % CREAM MO	3	PA
METROGEL 1 % GEL MO	3	ST
METROLOTION 0.75 % LOTION MO	3	PA
metronidazole 0.75 % CREAM MO	1	
metronidazole 0.75 % LOTION MO	1	
metronidazole 0.75 %, 0.75 % (37.5mg/5 gram), 1 %, 1.3 % (65 mg/5 gram) GEL MO	1	
metronidazole 1 % GEL WITH PUMP MO	1	
metronidazole 250 mg, 500 mg TABLET MO	1	
metronidazole 375 mg CAPSULE MO	1	QL(320 per 30 days)
metronidazole in nacl (iso-os) 500 mg/100 ml PIGGYBACK MO	1	
MINOCIN 100 MG RECON SOLUTION DL	4	PA
minocycline 100 mg, 50 mg, 75 mg CAPSULE MO	1	
minocycline 100 mg, 50 mg, 75 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
minocycline 105 mg, 115 mg, 135 mg, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg TABLET, ER 24 HR. MO	1	ST,QL(30 per 30 days)
mondoxyne nl 100 mg CAPSULE MO	1	
mondoxyne nl 75 mg CAPSULE MO	1	ST,QL(60 per 30 days)
MONODOX 100 MG, 50 MG CAPSULE MO	3	ST
MONODOX 75 MG CAPSULE MO	3	ST,QL(60 per 30 days)
MONUROL 3 GRAM PACKET MO	3	
morgidox 100 mg, 50 mg CAPSULE MO	1	ST
moxifloxacin 400 mg TABLET MO	1	
moxifloxacin-sod.ace,sul-water 400 mg/250 ml PIGGYBACK MO	1	
moxifloxacin-sod.chloride(iso) 400 mg/250 ml PIGGYBACK MO	1	
nafcillin 1 gram, 10 gram, 2 gram RECON SOLUTION MO	1	
nafcillin in dextrose iso-osm 1 gram/50 ml, 2 gram/100 ml PIGGYBACK DL	4	
neomycin 500 mg TABLET MO	1	
nitrofurantoin 25 mg/5 ml, 50 mg/5 ml SUSPENSION DL	4	
nitrofurantoin macrocrystal 100 mg, 25 mg, 50 mg CAPSULE MO	1	
nitrofurantoin monohyd/m-cryst 100 mg CAPSULE MO	1	
NORITATE 1 % CREAM DL	4	ST,QL(60 per 30 days)
NUVESSA 1.3 % (65 MG/5 GRAM) GEL MO	3	
NUZYRA 100 MG RECON SOLUTION DL	4	
NUZYRA 150 MG TABLET DL	4	QL(30 per 14 days)
ofloxacin 300 mg, 400 mg TABLET MO	1	
ORACEA 40 MG CAPSULE, IR/DR, BIPHASIC MO	3	ST,QL(30 per 30 days)
ORBACTIV 400 MG RECON SOLUTION DL	4	QL(3 per 28 days)
oxacillin 1 gram, 10 gram, 2 gram RECON SOLUTION MO	1	
oxacillin in dextrose(iso-osm) 1 gram/50 ml, 2 gram/50 ml PIGGYBACK MO	3	
paramomycin 250 mg CAPSULE MO	1	
penicillin g pot in dextrose 1 million unit/50 ml, 2 million unit/50 ml, 3 million unit/50 ml PIGGYBACK MO	3	
penicillin g potassium 20 million unit, 5 million unit RECON SOLUTION MO	1	
penicillin g procaine 1.2 million unit/2 ml, 600,000 unit/ml SYRINGE MO	1	
penicillin g sodium 5 million unit RECON SOLUTION MO	1	
penicillin v potassium 125 mg/5 ml, 250 mg/5 ml RECON SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
penicillin v potassium 250 mg, 500 mg TABLET MO	1	
pfizerpen-g 20 million unit, 5 million unit RECON SOLUTION MO	1	
piperacillin-tazobactam 13.5 gram, 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram RECON SOLUTION MO	1	
polymyxin b sulfate 500,000 unit RECON SOLUTION MO	1	
PRIMAXIN IV 500 MG RECON SOLUTION MO	3	
PRIMSOL 50 MG/5 ML SOLUTION MO	3	
RECARBRIO 1.25 GRAM RECON SOLUTION DL	4	
rosadan 0.75 % CREAM MO	1	ST
rosadan 0.75 % GEL MO	1	ST
SEYSARA 100 MG, 150 MG, 60 MG TABLET DL	4	ST,QL(30 per 30 days)
SIVEXTRO 200 MG RECON SOLUTION DL	4	QL(6 per 28 days)
SIVEXTRO 200 MG TABLET DL	4	QL(6 per 28 days)
SOLODYN 105 MG, 115 MG, 55 MG, 65 MG, 80 MG TABLET, ER 24 HR. DL	4	ST,QL(30 per 30 days)
SOLOSEC 2 GRAM DR GRANULES IN PACKET MO	3	PA
streptomycin 1 gram RECON SOLUTION DL	4	
sulfacetamide sodium 10 % OINTMENT MO	1	
sulfacetamide sodium (acne) 10 % SUSPENSION MO	1	QL(118 per 30 days)
sulfadiazine 500 mg TABLET MO	1	
sulfamethoxazole-trimethoprim 200-40 mg/5 ml SUSPENSION MO	1	
sulfamethoxazole-trimethoprim 400-80 mg TABLET MO	1	
sulfamethoxazole-trimethoprim 400-80 mg/5 ml SOLUTION MO	1	
sulfamethoxazole-trimethoprim 800-160 mg TABLET MO	1	
TARGADOX 50 MG TABLET MO	1	ST,QL(180 per 30 days)
tazicef 1 gram, 2 gram, 6 gram RECON SOLUTION MO	1	
TEFLARO 400 MG, 600 MG RECON SOLUTION DL	4	
tetracycline 250 mg, 500 mg CAPSULE MO	1	
tetracycline 250 mg, 500 mg TABLET DL	4	
tigecycline 50 mg RECON SOLUTION DL	4	
tinidazole 250 mg, 500 mg TABLET MO	1	
TOBI 300 MG/5 ML SOLUTION FOR NEBULIZATION DL	4	PA
tobramycin 300 mg/4 ml SOLUTION FOR NEBULIZATION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>tobramycin in 0.225 % nacl 300 mg/5 ml SOLUTION FOR NEBULIZATION</i> DL	4	BvsD
<i>tobramycin sulfate 1.2 gram RECON SOLUTION</i> DL	4	
<i>tobramycin sulfate 10 mg/ml, 40 mg/ml SOLUTION</i> MO	1	
<i>trimethoprim 100 mg TABLET</i> MO	1	
TYGACIL 50 MG RECON SOLUTION DL	4	
UNASYN 1.5 GRAM, 15 GRAM, 3 GRAM RECON SOLUTION MO	3	
VABOMERE 2 GRAM RECON SOLUTION DL	4	QL(84 per 14 days)
VANOCIN 125 MG CAPSULE MO	3	PA,QL(120 per 30 days)
VANOCIN 250 MG CAPSULE DL	4	PA,QL(240 per 30 days)
<i>vancomycin 1,000 mg, 1.25 gram, 1.5 gram, 10 gram, 25 mg/ml, 5 gram, 50 mg/ml, 500 mg, 750 mg RECON SOLUTION</i> MO	1	
<i>vancomycin 1.75 gram, 2 gram RECON SOLUTION</i> MO	3	
<i>vancomycin 125 mg CAPSULE</i> MO	1	QL(120 per 30 days)
<i>vancomycin 250 mg CAPSULE</i> MO	1	QL(240 per 30 days)
<i>vancomycin in 0.9 % sodium chl 1 gram/200 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK</i> MO	3	
<i>vancomycin in dextrose 5 % 1 gram/200 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK</i> MO	3	
VANCOMYCIN IN DEXTROSE 5 % 1.25 GRAM/250 ML, 1.5 GRAM/300 ML PIGGYBACK MO	3	
<i>vancomycin-diluent combo no.1 1 gram/200 ml, 1.25 gram/250 ml, 1.5 gram/300 ml, 1.75 gram/350 ml, 2 gram/400 ml, 500 mg/100 ml, 750 mg/150 ml PIGGYBACK</i> MO	3	
VANDAZOLE 0.75 % (37.5MG/5 GRAM) GEL MO	3	
VIBATIV 750 MG RECON SOLUTION DL	4	
VIBRAMYCIN 100 MG CAPSULE MO	3	
VIBRAMYCIN (CALCIUM) 50 MG/5 ML SYRUP MO	3	ST
XACIATO 2 % GEL MO	3	
XERAVA 100 MG, 50 MG RECON SOLUTION MO	3	
ZEMDRI 50 MG/ML SOLUTION DL	4	
ZERBAXA 1.5 GRAM RECON SOLUTION DL	4	
ZITHROMAX 1 GRAM PACKET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZITHROMAX 100 MG/5 ML, 200 MG/5 ML SUSPENSION FOR RECONSTITUTION MO	3	
ZITHROMAX 250 MG, 500 MG TABLET MO	3	
ZITHROMAX 500 MG RECON SOLUTION MO	3	
ZITHROMAX TRI-PAK 500 MG TABLET MO	3	
ZITHROMAX Z-PAK 250 MG TABLET MO	3	
ZOSYN IN DEXTROSE (ISO-OSM) 2.25 GRAM/50 ML, 3.375 GRAM/50 ML, 4.5 GRAM/100 ML PIGGYBACK MO	3	
ZYVOX 100 MG/5 ML SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(1800 per 30 days)
ZYVOX 200 MG/100 ML, 600 MG/300 ML PIGGYBACK MO	3	
ZYVOX 600 MG TABLET DL	4	PA,QL(60 per 30 days)
ANTICONVULSANTS		
APTIOM 200 MG, 400 MG TABLET	4	PA,QL(30 per 30 days)
APTIOM 600 MG, 800 MG TABLET	4	PA,QL(60 per 30 days)
BANZEL 200 MG TABLET DL	4	PA,QL(480 per 30 days)
BANZEL 40 MG/ML SUSPENSION DL	4	PA,QL(2760 per 30 days)
BANZEL 400 MG TABLET DL	4	PA,QL(240 per 30 days)
BRIVIACT 10 MG, 100 MG, 25 MG, 50 MG, 75 MG TABLET	4	PA,QL(60 per 30 days)
BRIVIACT 10 MG/ML SOLUTION	4	PA,QL(600 per 30 days)
BRIVIACT 50 MG/5 ML SOLUTION	4	PA
carbamazepine 100 mg CHEWABLE TABLET MO	1	
carbamazepine 100 mg, 200 mg, 300 mg CAPSULE ER MULTIPHASE 12 HR. MO	1	
carbamazepine 100 mg, 200 mg, 400 mg TABLET, ER 12 HR. MO	1	
carbamazepine 100 mg/5 ml, 100 mg/5 ml (5 ml), 200 mg/10 ml SUSPENSION MO	1	
carbamazepine 200 mg TABLET MO	1	
CARBATROL 100 MG, 200 MG, 300 MG CAPSULE ER MULTIPHASE 12 HR. MO	3	
CELONTIN 300 MG CAPSULE MO	3	
CEREBYX 100 MG PE/2 ML, 500 MG PE/10 ML SOLUTION MO	3	
clobazam 10 mg, 20 mg TABLET DL	1	PA
clobazam 2.5 mg/ml SUSPENSION DL	1	PA
DEPAKOTE 125 MG, 250 MG, 500 MG TABLET, DR/EC MO	3	
DEPAKOTE ER 250 MG, 500 MG TABLET, ER 24 HR. MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DEPAKOTE SPRINKLES 125 MG CAPSULE, DR SPRINKLE MO	3	
DIACOMIT 250 MG, 500 MG CAPSULE DL	4	PA,QL(180 per 30 days)
DIACOMIT 250 MG, 500 MG POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
DIASTAT 2.5 MG KIT DL	3	PA
DIASTAT ACUDIAL 12.5-15-17.5-20 MG, 5-7.5-10 MG KIT DL	3	PA
<i>diazepam 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg KIT DL</i>	1	
DILANTIN 30 MG CAPSULE MO	1	
DILANTIN EXTENDED 100 MG CAPSULE MO	1	
DILANTIN INFATABS 50 MG CHEWABLE TABLET MO	1	
DILANTIN-125 125 MG/5 ML SUSPENSION MO	3	
<i>divalproex 125 mg CAPSULE, DR SPRINKLE MO</i>	1	
<i>divalproex 125 mg, 250 mg, 500 mg TABLET, DR/EC MO</i>	1	
<i>divalproex 250 mg, 500 mg TABLET, ER 24 HR. MO</i>	1	
EPIDIOLEX 100 MG/ML SOLUTION DL	4	PA
<i>epitol 200 mg TABLET MO</i>	1	
EPRONTIA 25 MG/ML SOLUTION MO	3	PA,QL(480 per 30 days)
EQUETRO 100 MG, 200 MG, 300 MG CAPSULE ER MULTIPHASE 12 HR. MO	3	PA
<i>ethosuximide 250 mg CAPSULE MO</i>	1	
<i>ethosuximide 250 mg/5 ml SOLUTION MO</i>	1	
<i>felbamate 400 mg, 600 mg TABLET MO</i>	1	
<i>felbamate 600 mg/5 ml SUSPENSION MO</i>	1	
FELBATOL 400 MG, 600 MG TABLET DL	4	PA
FELBATOL 600 MG/5 ML SUSPENSION DL	4	PA
FINTEPLA 2.2 MG/ML SOLUTION DL,LA	4	PA,QL(360 per 30 days)
<i>fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml SOLUTION MO</i>	1	
FYCOMPA 0.5 MG/ML SUSPENSION	4	PA,QL(680 per 28 days)
FYCOMPA 10 MG, 12 MG, 4 MG, 6 MG, 8 MG TABLET	4	PA,QL(30 per 30 days)
FYCOMPA 2 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>gabapentin 100 mg, 300 mg, 400 mg CAPSULE MO</i>	1	QL(270 per 30 days)
<i>gabapentin 250 mg/5 ml, 250 mg/5 ml (5 ml), 300 mg/6 ml (6 ml) SOLUTION MO</i>	1	QL(2250 per 30 days)
<i>gabapentin 600 mg, 800 mg TABLET MO</i>	1	QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GABITRIL 12 MG, 16 MG, 2 MG, 4 MG TABLET DL	4	PA
KEPPRA 1,000 MG, 500 MG, 750 MG TABLET	4	PA
KEPPRA 100 MG/ML, 500 MG/5 ML SOLUTION	4	PA
KEPPRA 250 MG TABLET MO	3	PA
KEPPRA XR 500 MG TABLET, ER 24 HR.	4	PA,QL(180 per 30 days)
KEPPRA XR 750 MG TABLET, ER 24 HR.	4	PA,QL(120 per 30 days)
<i>lacosamide</i> 10 mg/ml SOLUTION MO	1	QL(1395 per 30 days)
<i>lacosamide</i> 100 mg, 150 mg, 200 mg, 50 mg TABLET MO	1	QL(60 per 30 days)
<i>lacosamide</i> 200 mg/20 ml SOLUTION DL	4	
LAMICTAL 100 MG, 150 MG, 200 MG, 25 MG TABLET	4	
LAMICTAL 25 MG, 5 MG TABLET, CHEWABLE DISPERSIBLE	4	
LAMICTAL ODT 100 MG, 200 MG, 25 MG, 50 MG TABLET, DISINTEGRATING	4	
LAMICTAL ODT STARTER (BLUE) 25 MG (21) -50 MG (7) TABLET, DISINTEGRATING,DOSE PK	4	
LAMICTAL ODT STARTER (GREEN) 50 MG (42) -100 MG (14) TABLET, DISINTEGRATING,DOSE PK	4	
LAMICTAL ODT STARTER (ORANGE) 25 MG(14)-50 MG (14)-100 MG (7) TABLET, DISINTEGRATING,DOSE PK	4	
LAMICTAL STARTER (BLUE) KIT 25 MG (35) TABLET, DOSE PACK MO	3	
LAMICTAL STARTER (GREEN) KIT 25 MG (84) -100 MG (14) TABLET, DOSE PACK MO	3	
LAMICTAL STARTER (ORANGE) KIT 25 MG (42) -100 MG (7) TABLET, DOSE PACK MO	3	
LAMICTAL XR 100 MG, 200 MG, 25 MG, 250 MG, 300 MG, 50 MG TABLET, ER 24 HR.	4	
LAMICTAL XR STARTER (BLUE) 25 MG (21) -50 MG (7) TABLET, ER, DOSE PACK MO	3	
LAMICTAL XR STARTER (GREEN) 50 MG(14)-100MG (14)-200 MG (7) TABLET, ER, DOSE PACK MO	3	
LAMICTAL XR STARTER (ORANGE) 25MG (14)-50 MG (14)-100MG (7) TABLET, ER, DOSE PACK MO	3	
<i>lamotrigine</i> 100 mg, 150 mg, 200 mg, 25 mg TABLET MO	1	
<i>lamotrigine</i> 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg TABLET, ER 24 HR. MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
lamotrigine 100 mg, 200 mg, 25 mg, 50 mg TABLET, DISINTEGRATING MO	1	
lamotrigine 25 mg (21) -50 mg (7), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg (42) -100 mg (14) TABLET, DISINTEGRATING,DOSE PK MO	1	
lamotrigine 25 mg (35), 25 mg (42) -100 mg (7), 25 mg (84) -100 mg (14) TABLET, DOSE PACK MO	1	
lamotrigine 25 mg, 5 mg TABLET, CHEWABLE DISPERSIBLE MO	1	
levetiracetam 1,000 mg, 250 mg, 750 mg TABLET MO	1	
levetiracetam 100 mg/ml, 500 mg/5 ml SOLUTION MO	1	
levetiracetam 500 mg TABLET MO	1	
levetiracetam 500 mg TABLET, ER 24 HR. MO	1	QL(180 per 30 days)
levetiracetam 500 mg/5 ml (5 ml) SOLUTION MO	1	QL(900 per 30 days)
levetiracetam 750 mg TABLET, ER 24 HR. MO	1	QL(120 per 30 days)
levetiracetam in nacl (iso-os) 1,000 mg/100 ml, 1,500 mg/100 ml, 500 mg/100 ml PIGGYBACK MO	1	
LIBERVANT 10 MG, 12.5 MG, 15 MG, 5 MG, 7.5 MG FILM DL	4	QL(10 per 30 days)
methsuximide 300 mg CAPSULE MO	1	
MOTPOLY XR 100 MG, 150 MG, 200 MG CAPSULE, ER 24 HR. DL	4	PA,QL(60 per 30 days)
MYSOLINE 250 MG, 50 MG TABLET DL	4	PA
NAYZILAM 5 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL DL	3	QL(10 per 30 days)
NEMBUTAL SODIUM 50 MG/ML SOLUTION MO	1	
NEURONTIN 100 MG, 300 MG, 400 MG CAPSULE MO	3	PA,QL(270 per 30 days)
NEURONTIN 250 MG/5 ML SOLUTION MO	3	PA,QL(2250 per 30 days)
NEURONTIN 600 MG, 800 MG TABLET	4	PA,QL(180 per 30 days)
ONFI 10 MG, 20 MG TABLET DL	4	PA
ONFI 2.5 MG/ML SUSPENSION DL	4	PA
oxcarbazepine 150 mg, 300 mg, 600 mg TABLET MO	1	
oxcarbazepine 300 mg/5 ml (60 mg/ml) SUSPENSION MO	1	
OXTELLAR XR 150 MG, 300 MG TABLET, ER 24 HR. MO	3	ST
OXTELLAR XR 600 MG TABLET, ER 24 HR.	4	ST
pentobarbital sodium 50 mg/ml SOLUTION MO	1	
phenobarbital 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg TABLET MO	1	QL(90 per 30 days)
phenobarbital 15 mg, 60 mg TABLET MO	1	QL(120 per 30 days)
phenobarbital 20 mg/5 ml (4 mg/ml) ELIXIR MO	1	QL(1500 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
phenobarbital 30 mg TABLET MO	1	QL(300 per 30 days)
phenobarbital sodium 130 mg/ml, 65 mg/ml SOLUTION DL	4	
PHENYTEK 200 MG, 300 MG CAPSULE MO	1	
phenytoin 100 mg/4 ml, 125 mg/5 ml SUSPENSION MO	1	
phenytoin 50 mg CHEWABLE TABLET MO	1	
phenytoin sodium 50 mg/ml SOLUTION MO	1	
phenytoin sodium 50 mg/ml SYRINGE MO	1	
phenytoin sodium extended 100 mg, 200 mg, 300 mg CAPSULE MO	1	
primidone 125 mg, 250 mg, 50 mg TABLET MO	1	
QUDEXY XR 100 MG, 50 MG CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(30 per 30 days)
QUDEXY XR 150 MG, 200 MG CAPSULE ER SPRINKLE 24 HR. DL	4	PA,QL(60 per 30 days)
QUDEXY XR 25 MG CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(90 per 30 days)
roweepra 1,000 mg, 500 mg, 750 mg TABLET MO	1	
roweepra xr 500 mg TABLET, ER 24 HR. MO	1	QL(180 per 30 days)
roweepra xr 750 mg TABLET, ER 24 HR. MO	1	QL(120 per 30 days)
rufinamide 200 mg TABLET MO	1	PA,QL(480 per 30 days)
rufinamide 40 mg/ml SUSPENSION MO	1	PA,QL(2760 per 30 days)
rufinamide 400 mg TABLET MO	1	PA,QL(240 per 30 days)
SABRIL 500 MG POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
SABRIL 500 MG TABLET DL	4	PA,QL(180 per 30 days)
SEZABY 100 MG RECON SOLUTION DL	4	
SPRITAM 1,000 MG TABLET FOR SUSPENSION MO	3	ST,QL(90 per 30 days)
SPRITAM 250 MG TABLET FOR SUSPENSION MO	3	ST,QL(360 per 30 days)
SPRITAM 500 MG TABLET FOR SUSPENSION MO	3	ST,QL(180 per 30 days)
SPRITAM 750 MG TABLET FOR SUSPENSION MO	3	ST,QL(120 per 30 days)
subvenite 100 mg, 150 mg, 200 mg, 25 mg TABLET MO	1	
subvenite starter (blue) kit 25 mg (35) TABLET, DOSE PACK MO	1	
subvenite starter (green) kit 25 mg (84) -100 mg (14) TABLET, DOSE PACK MO	1	
subvenite starter (orange) kit 25 mg (42) -100 mg (7) TABLET, DOSE PACK MO	1	
SYMPAZAN 10 MG, 20 MG, 5 MG FILM DL	4	PA,QL(60 per 30 days)
TEGRETOL 100 MG/5 ML SUSPENSION MO	3	
TEGRETOL 200 MG TABLET MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TEGRETOL XR 100 MG, 200 MG, 400 MG TABLET, ER 12 HR. MO	3	
tiagabine 12 mg, 16 mg, 2 mg, 4 mg TABLET MO	1	
TOPAMAX 100 MG, 200 MG, 50 MG TABLET	4	QL(120 per 30 days)
TOPAMAX 15 MG, 25 MG CAPSULE, SPRINKLE	4	
TOPAMAX 25 MG TABLET MO	3	QL(90 per 30 days)
topiramate 100 mg, 200 mg, 50 mg TABLET MO	1	QL(120 per 30 days)
topiramate 100 mg, 50 mg CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(30 per 30 days)
topiramate 100 mg, 50 mg CAPSULE, ER 24 HR. MO	1	PA,QL(30 per 30 days)
topiramate 15 mg, 25 mg CAPSULE, SPRINKLE MO	1	
topiramate 150 mg, 200 mg CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(60 per 30 days)
topiramate 200 mg CAPSULE, ER 24 HR. MO	1	PA,QL(60 per 30 days)
topiramate 25 mg CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(90 per 30 days)
topiramate 25 mg CAPSULE, ER 24 HR. MO	1	PA,QL(90 per 30 days)
topiramate 25 mg TABLET MO	1	QL(90 per 30 days)
TRILEPTAL 150 MG TABLET MO	3	PA
TRILEPTAL 300 MG, 600 MG TABLET	4	PA
TRILEPTAL 300 MG/5 ML (60 MG/ML) SUSPENSION	4	PA
TROKENDI XR 100 MG CAPSULE, ER 24 HR.	4	PA,QL(30 per 30 days)
TROKENDI XR 200 MG CAPSULE, ER 24 HR.	4	PA,QL(60 per 30 days)
TROKENDI XR 25 MG CAPSULE, ER 24 HR. MO	3	PA,QL(90 per 30 days)
TROKENDI XR 50 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
valproate sodium 500 mg/5 ml (100 mg/ml) SOLUTION MO	1	
valproic acid 250 mg CAPSULE MO	1	
valproic acid (as sodium salt) 250 mg/5 ml, 250 mg/5 ml (5 ml), 500 mg/10 ml (10 ml) SOLUTION MO	1	
VALTOCO 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL DL	4	QL(10 per 30 days)
vigabatrin 500 mg POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
vigabatrin 500 mg TABLET DL	4	PA,QL(180 per 30 days)
vigadrone 500 mg POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
vigadrone 500 mg TABLET DL	4	PA,QL(180 per 30 days)
VIGAFYDE 100 MG/ML SOLUTION DL	4	PA,QL(600 per 25 days)
vigpoder 500 mg POWDER IN PACKET DL	4	PA,QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VIMPAT 10 MG/ML SOLUTION DL	4	PA,QL(1395 per 30 days)
VIMPAT 100 MG, 150 MG, 200 MG TABLET DL	4	PA,QL(60 per 30 days)
VIMPAT 200 MG/20 ML SOLUTION DL	4	PA
VIMPAT 50 MG TABLET MO	3	PA,QL(60 per 30 days)
XCOPRI 100 MG, 25 MG, 50 MG TABLET DL	4	PA,QL(30 per 30 days)
XCOPRI 150 MG, 200 MG TABLET DL	4	PA,QL(60 per 30 days)
XCOPRI MAINTENANCE PACK 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) TABLET DL	4	PA,QL(56 per 28 days)
XCOPRI TITRATION PACK 12.5 MG (14)- 25 MG (14) TABLET, DOSE PACK DL	3	PA,QL(28 per 28 days)
XCOPRI TITRATION PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) TABLET, DOSE PACK DL	4	PA,QL(28 per 28 days)
ZARONTIN 250 MG CAPSULE MO	3	
ZARONTIN 250 MG/5 ML SOLUTION MO	1	
ZONEGRAN 100 MG, 25 MG CAPSULE	4	PA
ZONISADE 100 MG/5 ML SUSPENSION MO	3	PA,QL(900 per 30 days)
<i>zonisamide 100 mg, 25 mg, 50 mg CAPSULE</i> MO	1	
ZTALMY 50 MG/ML SUSPENSION DL	4	PA,QL(1080 per 30 days)
ANTIDEMENTIA AGENTS		
ADLARITY 10 MG/24 HOUR, 5 MG/24 HOUR PATCH, WEEKLY MO	3	ST,QL(4 per 28 days)
ARICEPT 10 MG TABLET MO	3	PA,QL(60 per 30 days)
ARICEPT 23 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>donepezil 10 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>donepezil 10 mg, 5 mg TABLET, DISINTEGRATING</i> MO	1	QL(30 per 30 days)
<i>donepezil 23 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>donepezil 5 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>ergoloid 1 mg TABLET</i> MO	1	
EXELON PATCH 13.3 MG/24 HOUR, 4.6 MG/24 HOUR, 9.5 MG/24 HOUR PATCH, 24 HR. MO	3	PA,QL(30 per 30 days)
<i>galantamine 12 mg, 4 mg, 8 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>galantamine 16 mg, 24 mg, 8 mg CAPSULE ER PELLETS 24 HR.</i> MO	1	QL(30 per 30 days)
<i>galantamine 4 mg/ml SOLUTION</i> MO	1	QL(200 per 30 days)
<i>memantine 10 mg, 5 mg TABLET</i> MO	1	PA,QL(60 per 30 days)
<i>memantine 14 mg, 21 mg, 28 mg, 7 mg CAPSULE ER SPRINKLE 24 HR.</i> MO	1	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
memantine 2 mg/ml SOLUTION MO	1	PA,QL(360 per 30 days)
memantine 5-10 mg TABLET, DOSE PACK MO	1	PA,QL(98 per 30 days)
NAMENDA 10 MG TABLET MO	3	PA,QL(60 per 30 days)
NAMENDA TITRATION PAK 5-10 MG TABLET, DOSE PACK MO	3	PA,QL(98 per 30 days)
NAMENDA XR 14 MG, 21 MG, 28 MG, 7 MG CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(30 per 30 days)
NAMENDA XR 7-14-21-28 MG CAPSULE ER SPRINKLE 24 HR. MO	3	PA,QL(28 per 28 days)
NAMZARIC 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG CAPSULE ER SPRINKLE 24 HR. MO	2	QL(30 per 30 days)
NAMZARIC 7/14/21/28 MG-10 MG CAPSULE ER SPRINKLE 24 HR. MO	2	QL(28 per 28 days)
RAZADYNE ER 16 MG, 24 MG, 8 MG CAPSULE ER PELLETS 24 HR. MO	3	PA,QL(30 per 30 days)
rivastigmine 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour PATCH, 24 HR. MO	1	QL(30 per 30 days)
rivastigmine tartrate 1.5 mg, 3 mg CAPSULE MO	1	QL(90 per 30 days)
rivastigmine tartrate 4.5 mg, 6 mg CAPSULE MO	1	QL(60 per 30 days)
ANTIDEPRESSANTS		
amitriptyline 10 mg, 100 mg, 150 mg, 50 mg, 75 mg TABLET MO	1	
amitriptyline 25 mg TABLET MO	1	
amitriptyline-chlordiazepoxide 12.5-5 mg, 25-10 mg TABLET DL	1	
amoxapine 100 mg, 150 mg, 25 mg, 50 mg TABLET MO	1	
ANAFRANIL 25 MG, 50 MG, 75 MG CAPSULE DL	4	
APLENZIN 174 MG, 348 MG, 522 MG TABLET, ER 24 HR.	4	ST,QL(30 per 30 days)
AUVELITY 45-105 MG TABLET, IR/ER, BIPHASIC MO	3	PA,QL(60 per 30 days)
bupropion hcl 100 mg TABLET, SR 12 HR. MO	1	QL(120 per 30 days)
bupropion hcl 100 mg, 75 mg TABLET MO	1	QL(180 per 30 days)
bupropion hcl 150 mg TABLET, ER 24 HR. MO	1	QL(90 per 30 days)
bupropion hcl 150 mg TABLET, SR 12 HR. MO	1	QL(90 per 30 days)
bupropion hcl 200 mg TABLET, SR 12 HR. MO	1	QL(60 per 30 days)
bupropion hcl 300 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
bupropion hcl 450 mg TABLET, ER 24 HR. MO	1	ST,QL(30 per 30 days)
CELEXA 10 MG, 40 MG TABLET MO	3	PA,QL(30 per 30 days)
CELEXA 20 MG TABLET MO	3	PA,QL(60 per 30 days)
citalopram 10 mg, 40 mg TABLET MO	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>citalopram 10 mg/5 ml SOLUTION</i> MO	1	
<i>citalopram 20 mg TABLET</i> MO	1	QL(60 per 30 days)
CITALOPRAM 30 MG CAPSULE MO	3	QL(30 per 30 days)
<i>clomipramine 25 mg, 50 mg, 75 mg CAPSULE</i> MO	1	
<i>desipramine 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg TABLET</i> MO	1	
<i>desvenlafaxine 100 mg, 50 mg TABLET, ER 24 HR.</i> MO	3	ST,QL(30 per 30 days)
<i>desvenlafaxine succinate 100 mg, 25 mg, 50 mg TABLET, ER 24 HR.</i> MO	1	QL(30 per 30 days)
EFFEXOR XR 150 MG CAPSULE, ER 24 HR. MO	3	PA,QL(60 per 30 days)
EFFEXOR XR 37.5 MG, 75 MG CAPSULE, ER 24 HR. MO	3	PA,QL(90 per 30 days)
EMSAM 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR PATCH, 24 HR.	4	PA,QL(30 per 30 days)
<i>escitalopram oxalate 10 mg TABLET</i> MO	1	QL(45 per 30 days)
<i>escitalopram oxalate 20 mg, 5 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>escitalopram oxalate 5 mg/5 ml SOLUTION</i> MO	1	QL(600 per 30 days)
FETZIMA 120 MG, 20 MG, 40 MG, 80 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
FETZIMA 20 MG (2)- 40 MG (26) CAPSULE, ER 24 HR. MO	3	PA,QL(28 per 28 days)
<i>fluoxetine 10 mg CAPSULE</i> MO	1	QL(60 per 30 days)
<i>fluoxetine 10 mg TABLET</i> MO	1	QL(240 per 30 days)
<i>fluoxetine 20 mg CAPSULE</i> MO	1	QL(120 per 30 days)
<i>fluoxetine 20 mg TABLET</i> MO	1	QL(120 per 30 days)
<i>fluoxetine 20 mg/5 ml (4 mg/ml) SOLUTION</i> MO	1	
<i>fluoxetine 40 mg CAPSULE</i> MO	1	QL(60 per 30 days)
<i>fluoxetine 60 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>fluoxetine 90 mg CAPSULE, DR/EC</i> MO	1	QL(4 per 28 days)
<i>fluvoxamine 100 mg, 150 mg CAPSULE, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>fluvoxamine 100 mg, 25 mg, 50 mg TABLET</i> MO	1	QL(90 per 30 days)
FORFIVO XL 450 MG TABLET, ER 24 HR. MO	3	ST,QL(30 per 30 days)
<i>imipramine hcl 10 mg, 25 mg, 50 mg TABLET</i> MO	1	
<i>imipramine pamoate 100 mg, 125 mg, 150 mg, 75 mg CAPSULE</i> MO	1	
LEXAPRO 10 MG TABLET MO	3	PA,QL(45 per 30 days)
LEXAPRO 20 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
MARPLAN 10 MG TABLET MO	3	
<i>mirtazapine 15 mg, 30 mg, 45 mg TABLET, DISINTEGRATING</i> MO	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
mirtazapine 15 mg, 30 mg, 7.5 mg TABLET MO	1	
mirtazapine 45 mg TABLET MO	1	
NARDIL 15 MG TABLET MO	3	
nefazodone 100 mg, 150 mg, 200 mg, 250 mg, 50 mg TABLET MO	1	
NORPRAMIN 10 MG, 25 MG TABLET MO	3	
nortriptyline 10 mg, 25 mg, 50 mg, 75 mg CAPSULE MO	1	
nortriptyline 10 mg/5 ml SOLUTION MO	1	
olanzapine-fluoxetine 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg CAPSULE MO	1	QL(30 per 30 days)
PAMELOR 10 MG, 25 MG, 50 MG, 75 MG CAPSULE DL	4	
PARNATE 10 MG TABLET DL	4	
paroxetine hcl 10 mg, 20 mg TABLET MO	1	QL(30 per 30 days)
paroxetine hcl 10 mg/5 ml SUSPENSION MO	1	
paroxetine hcl 12.5 mg, 37.5 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
paroxetine hcl 25 mg TABLET, ER 24 HR. MO	1	QL(90 per 30 days)
paroxetine hcl 30 mg, 40 mg TABLET MO	1	QL(60 per 30 days)
paroxetine mesylate(menop.sym) 7.5 mg CAPSULE MO	1	QL(30 per 30 days)
PAXIL 10 MG, 20 MG TABLET MO	3	QL(30 per 30 days)
PAXIL 10 MG/5 ML SUSPENSION MO	3	PA
PAXIL 30 MG, 40 MG TABLET MO	3	QL(60 per 30 days)
PAXIL CR 12.5 MG, 37.5 MG TABLET, ER 24 HR. MO	3	QL(60 per 30 days)
PAXIL CR 25 MG TABLET, ER 24 HR. MO	3	QL(90 per 30 days)
perphenazine-amitriptyline 2-10 mg, 2-25 mg, 4-10 mg, 4-25 mg, 4-50 mg TABLET MO	1	
PEXEVA 10 MG, 20 MG TABLET MO	3	QL(30 per 30 days)
PEXEVA 30 MG TABLET MO	3	QL(60 per 30 days)
phenelzine 15 mg TABLET MO	1	
PRISTIQ 100 MG, 25 MG, 50 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
protriptyline 10 mg, 5 mg TABLET MO	1	
PROZAC 10 MG, 40 MG CAPSULE	4	PA,QL(60 per 30 days)
PROZAC 20 MG CAPSULE	4	PA,QL(120 per 30 days)
REMERON 15 MG, 30 MG TABLET MO	3	
REMERON SOLTAB 15 MG, 30 MG, 45 MG TABLET, DISINTEGRATING MO	3	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>sertraline 100 mg TABLET</i> MO	1	QL(60 per 30 days)
SERTRALINE 150 MG, 200 MG CAPSULE MO	3	QL(30 per 30 days)
<i>sertraline 20 mg/ml CONCENTRATE</i> MO	1	
<i>sertraline 25 mg, 50 mg TABLET</i> MO	1	QL(90 per 30 days)
SYMBYAX 12-50 MG, 3-25 MG, 6-25 MG, 6-50 MG CAPSULE MO	3	PA,QL(30 per 30 days)
<i>tranylcypromine 10 mg TABLET</i> MO	1	
<i>trazodone 100 mg, 150 mg, 50 mg TABLET</i> MO	1	
<i>trazodone 300 mg TABLET</i> MO	1	
<i>trimipramine 100 mg, 25 mg, 50 mg CAPSULE</i> MO	1	
TRINTELLIX 10 MG, 20 MG, 5 MG TABLET MO	3	ST,QL(30 per 30 days)
<i>venlafaxine 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg TABLET</i> MO	1	
<i>venlafaxine 150 mg CAPSULE, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>venlafaxine 150 mg, 225 mg, 37.5 mg TABLET, ER 24 HR.</i> MO	1	QL(30 per 30 days)
<i>venlafaxine 37.5 mg CAPSULE, ER 24 HR.</i> MO	1	QL(90 per 30 days)
<i>venlafaxine 75 mg CAPSULE, ER 24 HR.</i> MO	1	QL(90 per 30 days)
<i>venlafaxine 75 mg TABLET, ER 24 HR.</i> MO	1	QL(60 per 30 days)
VENLAFAXINE BESYLATE 112.5 MG TABLET, ER 24 HR. MO	3	QL(60 per 30 days)
VIIBRYD 10 MG (7)- 20 MG (23) TABLET, DOSE PACK MO	3	PA,QL(30 per 30 days)
VIIBRYD 10 MG, 20 MG, 40 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>vilazodone 10 mg, 20 mg, 40 mg TABLET</i> MO	1	PA,QL(30 per 30 days)
WELLBUTRIN SR 100 MG TABLET, SR 12 HR. MO	3	PA,QL(120 per 30 days)
WELLBUTRIN SR 150 MG TABLET, SR 12 HR. MO	3	PA,QL(90 per 30 days)
WELLBUTRIN SR 200 MG TABLET, SR 12 HR. MO	3	PA,QL(60 per 30 days)
WELLBUTRIN XL 150 MG TABLET, ER 24 HR.	4	PA,QL(90 per 30 days)
WELLBUTRIN XL 300 MG TABLET, ER 24 HR.	4	PA,QL(60 per 30 days)
ZOLOFT 100 MG TABLET MO	3	PA,QL(60 per 30 days)
ZOLOFT 20 MG/ML CONCENTRATE MO	3	PA
ZOLOFT 25 MG, 50 MG TABLET MO	3	PA,QL(90 per 30 days)
ZULRESSO 5 MG/ML SOLUTION DL	4	PA,QL(100 per 365 days)
ZURZUVAE 20 MG, 25 MG CAPSULE DL	4	PA,QL(28 per 365 days)
ZURZUVAE 30 MG CAPSULE DL	4	PA,QL(14 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ANTIEMETICS		
AKYNZEO (FOSNETUPITANT) 235 MG-0.25 MG /20 ML SOLUTION DL	4	PA,QL(80 per 28 days)
AKYNZEO (FOSNETUPITANT) 235-0.25 MG RECON SOLUTION DL	4	PA,QL(4 per 28 days)
AKYNZEO (NETUPITANT) 300-0.5 MG CAPSULE MO	3	PA
ANTIVERT 25 MG CHEWABLE TABLET MO	3	
ANTIVERT 50 MG TABLET MO	3	
ANZEMET 50 MG TABLET MO	3	BvsD,QL(4 per 28 days)
APONVIE 32 MG/4.4 ML (7.2 MG/ML) EMULSION MO	3	
<i>aprepitant 125 mg (1)- 80 mg (2) CAPSULE, DOSE PACK</i> MO	1	BvsD
<i>aprepitant 125 mg, 40 mg CAPSULE</i> MO	1	BvsD,QL(2 per 28 days)
<i>aprepitant 80 mg CAPSULE</i> MO	1	BvsD,QL(4 per 28 days)
BONJESTA 20-20 MG TABLET, IR, DR, BIPHASIC MO	3	QL(60 per 30 days)
CINVANTI 130 MG/18 ML (7.2 MG/ML) EMULSION MO	3	PA,QL(36 per 28 days)
COMPAZINE 10 MG, 5 MG TABLET MO	3	BvsD
COMPAZINE 25 MG SUPPOSITORY MO	1	
<i>compro 25 mg SUPPOSITORY</i> MO	1	
DICLEGIS 10-10 MG TABLET, DR/EC MO	3	QL(120 per 30 days)
<i>dimenhydrinate 50 mg/ml SOLUTION</i> MO	1	
<i>doxylamine-pyridoxine (vit b6) 10-10 mg TABLET, DR/EC</i> MO	1	QL(120 per 30 days)
<i>dronabinol 10 mg, 2.5 mg, 5 mg CAPSULE</i> MO	1	BvsD,QL(120 per 30 days)
EMEND 125 MG (1)- 80 MG (2) CAPSULE, DOSE PACK MO	3	BvsD
EMEND 125 MG (25 MG/ ML FINAL CONC.) SUSPENSION FOR RECONSTITUTION MO	3	BvsD,QL(3 per 28 days)
EMEND 80 MG CAPSULE MO	3	BvsD,QL(4 per 28 days)
EMEND (FOSAPREPITANT) 150 MG RECON SOLUTION MO	3	PA
FOCINVEZ 150 MG/50 ML (3 MG/ML) SOLUTION MO	3	PA
<i>fosaprepitant 150 mg RECON SOLUTION</i> MO	1	PA
GIMOTI 15 MG/SPRAY SPRAY WITH PUMP DL	4	PA,QL(9.8 per 28 days)
<i>granisetron (pf) 1 mg/ml (1 ml), 100 mcg/ml SOLUTION</i> MO	1	
<i>granisetron hcl 1 mg TABLET</i> MO	1	BvsD,QL(28 per 28 days)
<i>granisetron hcl 1 mg/ml, 1 mg/ml (1 ml) SOLUTION</i> MO	1	
MARINOL 10 MG, 2.5 MG, 5 MG CAPSULE DL	4	BvsD,QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
meclizine 12.5 mg TABLET MO	1	
meclizine 25 mg TABLET MO	1	
meclizine 50 mg TABLET MO	3	
metoclopramide hcl 10 mg, 5 mg TABLET MO	1	
metoclopramide hcl 5 mg/5 ml, 5 mg/ml SOLUTION MO	1	
metoclopramide hcl 5 mg/ml SYRINGE MO	1	
ondansetron 16 mg TABLET, DISINTEGRATING DL	4	BvsD
ondansetron 4 mg TABLET, DISINTEGRATING MO	1	BvsD
ondansetron 8 mg TABLET, DISINTEGRATING MO	1	BvsD
ondansetron hcl 2 mg/ml SOLUTION MO	1	
ondansetron hcl 4 mg TABLET MO	1	BvsD
ondansetron hcl 4 mg/5 ml SOLUTION MO	1	BvsD,QL(450 per 30 days)
ondansetron hcl 8 mg TABLET MO	1	BvsD
ondansetron hcl (pf) 4 mg/2 ml SOLUTION MO	1	
ondansetron hcl (pf) 4 mg/2 ml SYRINGE MO	1	
PHENERGAN 25 MG/ML, 50 MG/ML SOLUTION MO	1	
prochlorperazine 25 mg SUPPOSITORY MO	1	
prochlorperazine edisylate 10 mg/2 ml (5 mg/ml), 5 mg/ml SOLUTION MO	1	
prochlorperazine maleate 10 mg, 5 mg TABLET MO	1	BvsD
promethazine 12.5 mg, 25 mg, 50 mg SUPPOSITORY MO	1	
promethazine 12.5 mg, 50 mg TABLET MO	1	
promethazine 25 mg TABLET MO	1	
promethazine 25 mg/ml, 50 mg/ml SOLUTION MO	1	
promethazine 6.25 mg/5 ml SYRUP MO	1	
promethegan 12.5 mg, 25 mg, 50 mg SUPPOSITORY MO	1	
REGLAN 10 MG, 5 MG TABLET MO	3	
SANCUSO 3.1 MG/24 HOUR PATCH, WEEKLY DL	4	PA,QL(4 per 30 days)
scopolamine base 1 mg over 3 days PATCH, 3 DAY MO	1	QL(10 per 30 days)
TIGAN 100 MG/ML SOLUTION MO	3	
TRANSDERM-SCOP 1 MG OVER 3 DAYS PATCH, 3 DAY MO	3	QL(10 per 30 days)
trimethobenzamide 300 mg CAPSULE MO	1	BvsD
VARUBI 90 MG TABLET MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ANTIFUNGALS		
ABELCET 5 MG/ML SUSPENSION MO	3	BvsD
AMBISOME 50 MG SUSPENSION FOR RECONSTITUTION DL	4	BvsD
<i>amphotericin b 50 mg RECON SOLUTION</i> MO	1	BvsD
<i>amphotericin b liposome 50 mg SUSPENSION FOR RECONSTITUTION</i> DL	4	BvsD
ANCOBON 250 MG, 500 MG CAPSULE MO	3	
CANCIDAS 50 MG, 70 MG RECON SOLUTION DL	4	PA
<i>caspofungin 50 mg, 70 mg RECON SOLUTION</i> MO	1	
<i>ciclodan 8 % SOLUTION</i> MO	1	QL(13.2 per 30 days)
<i>ciclopirox 0.77 % CREAM</i> MO	1	QL(90 per 30 days)
<i>ciclopirox 0.77 % GEL</i> MO	1	QL(100 per 30 days)
<i>ciclopirox 0.77 % SUSPENSION</i> MO	1	QL(60 per 30 days)
<i>ciclopirox 1 % SHAMPOO</i> MO	1	QL(120 per 30 days)
<i>ciclopirox 8 % SOLUTION</i> MO	1	QL(13.2 per 30 days)
<i>clotrimazole 1 % CREAM</i> MO	1	
<i>clotrimazole 1 % SOLUTION</i> MO	1	
<i>clotrimazole 10 mg TROCHE</i> MO	1	
<i>clotrimazole-betamethasone 1-0.05 % CREAM</i> MO	1	QL(180 per 30 days)
<i>clotrimazole-betamethasone 1-0.05 % LOTION</i> MO	1	QL(90 per 28 days)
CRESEMBA 186 MG, 74.5 MG CAPSULE DL	4	PA
CRESEMBA 372 MG RECON SOLUTION DL	4	PA
DIFLUCAN 10 MG/ML, 40 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	PA
DIFLUCAN 100 MG, 150 MG, 200 MG, 50 MG TABLET MO	3	PA
<i>econazole 1 % CREAM</i> MO	1	PA,QL(85 per 30 days)
ERAXIS(WATER DILUENT) 100 MG, 50 MG RECON SOLUTION DL	4	
ERTACZO 2 % CREAM DL	4	QL(60 per 30 days)
EXELDERM 1 % CREAM MO	3	
EXELDERM 1 % SOLUTION MO	3	QL(60 per 30 days)
EXTINA 2 % FOAM MO	3	QL(100 per 30 days)
<i>fluconazole 10 mg/ml, 40 mg/ml SUSPENSION FOR RECONSTITUTION</i> MO	1	
<i>fluconazole 100 mg, 200 mg, 50 mg TABLET</i> MO	1	
<i>fluconazole 150 mg TABLET</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
fluconazole in nacl (iso-osm) 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml PIGGYBACK MO	1	
flucytosine 250 mg, 500 mg CAPSULE DL	4	
griseofulvin microsize 125 mg/5 ml SUSPENSION MO	1	
griseofulvin microsize 500 mg TABLET MO	1	
griseofulvin ultramicrosize 125 mg, 250 mg TABLET MO	1	
gynazole-1 2 % CREAM MO	1	
itraconazole 10 mg/ml SOLUTION DL	4	
itraconazole 100 mg CAPSULE MO	1	QL(120 per 30 days)
JUBLIA 10 % SOLUTION W/APPLICATOR DL	4	PA,QL(4 per 28 days)
KERYDIN 5 % SOLUTION W/APPLICATOR MO	3	PA,QL(10 per 30 days)
ketoconazole 2 % CREAM MO	1	QL(60 per 30 days)
ketoconazole 2 % FOAM MO	1	QL(100 per 30 days)
ketoconazole 2 % SHAMPOO MO	1	QL(120 per 30 days)
ketoconazole 200 mg TABLET MO	1	PA
ketodan 2 % FOAM MO	1	QL(100 per 30 days)
klayesta 100,000 unit/gram POWDER MO	1	PA
LOPROX 1 % SHAMPOO MO	3	PA,QL(120 per 30 days)
LOPROX (AS OLAMINE) 0.77 % CREAM MO	3	PA,QL(90 per 30 days)
LOPROX (AS OLAMINE) 0.77 % SUSPENSION MO	3	PA,QL(60 per 30 days)
luliconazole 1 % CREAM MO	1	ST,QL(60 per 28 days)
LUZU 1 % CREAM MO	3	ST,QL(60 per 28 days)
MENTAX 1 % CREAM MO	3	QL(30 per 30 days)
micafungin 100 mg, 50 mg RECON SOLUTION MO	1	
MICAFUNGIN IN 0.9 % SODIUM CHL 100 MG/100 ML, 50 MG/50 ML PIGGYBACK DL	4	
miconazole nitrate-zinc ox-pet 0.25-15-81.35 % OINTMENT MO	1	
miconazole-3 200 mg SUPPOSITORY MO	1	
MYCAMINE 100 MG, 50 MG RECON SOLUTION DL	4	
naftifine 1 % CREAM MO	1	ST,QL(90 per 30 days)
naftifine 2 % CREAM MO	1	ST,QL(120 per 30 days)
naftifine 2 % GEL MO	1	ST,QL(120 per 30 days)
NAFTIN 1 % GEL MO	3	ST,QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NAFTIN 2 % GEL MO	3	ST,QL(120 per 30 days)
NOXAFIL 100 MG TABLET, DR/EC DL	4	PA
NOXAFIL 200 MG/5 ML (40 MG/ML) SUSPENSION DL	4	PA,QL(840 per 28 days)
NOXAFIL 300 MG SUSPENSION, DR FOR RECON DL	4	PA,QL(32 per 30 days)
NOXAFIL 300 MG/16.7 ML SOLUTION DL	4	PA
<i>nyamyc 100,000 unit/gram POWDER</i> MO	1	PA
<i>nystatin 100,000 unit/gram CREAM</i> MO	1	
<i>nystatin 100,000 unit/gram OINTMENT</i> MO	1	
<i>nystatin 100,000 unit/gram POWDER</i> MO	1	PA
<i>nystatin 100,000 unit/ml SUSPENSION</i> MO	1	
<i>nystatin 500,000 unit TABLET</i> MO	1	
<i>nystatin-triamcinolone 100,000-0.1 unit/g-% CREAM</i> MO	1	
<i>nystatin-triamcinolone 100,000-0.1 unit/gram-% OINTMENT</i> MO	1	
<i>nystop 100,000 unit/gram POWDER</i> MO	1	PA
<i>oxiconazole 1 % CREAM</i> MO	1	PA,QL(60 per 30 days)
OXISTAT 1 % CREAM MO	3	QL(60 per 30 days)
OXISTAT 1 % LOTION MO	3	PA
<i>posaconazole 100 mg TABLET, DR/EC</i> DL	4	PA
<i>posaconazole 200 mg/5 ml (40 mg/ml) SUSPENSION</i> DL	4	PA,QL(840 per 28 days)
<i>posaconazole 300 mg/16.7 ml SOLUTION</i> DL	4	PA
REZZAYO 200 MG RECON SOLUTION DL	4	PA
SPORANOX 10 MG/ML SOLUTION DL	4	
SPORANOX 100 MG CAPSULE MO	3	PA,QL(120 per 30 days)
SPORANOX PULSEPAK 100 MG CAPSULE MO	3	PA,QL(120 per 30 days)
<i>tavaborole 5 % SOLUTION W/APPLICATOR</i> MO	1	PA,QL(10 per 30 days)
<i>terbinafine hcl 250 mg TABLET</i> MO	1	
<i>terconazole 0.4 %, 0.8 % CREAM</i> MO	1	
<i>terconazole 80 mg SUPPOSITORY</i> MO	1	
TOLSURA 65 MG CAPSULE, SOLID DISPERSION DL	4	PA,QL(120 per 30 days)
VFEND 200 MG, 50 MG TABLET MO	3	PA,QL(120 per 30 days)
VFEND 200 MG/5 ML (40 MG/ML) SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(400 per 30 days)
VFEND IV 200 MG RECON SOLUTION MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VIVJOA 150 MG CAPSULE MO	3	PA
voriconazole 200 mg RECON SOLUTION MO	1	PA
voriconazole 200 mg, 50 mg TABLET MO	1	PA,QL(120 per 30 days)
voriconazole 200 mg/5 ml (40 mg/ml) SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(400 per 30 days)
VUSION 0.25-15-81.35 % OINTMENT MO	3	
XOLEGEL 2 % GEL MO	3	
ANTIGOUT AGENTS		
allopurinol 100 mg, 300 mg TABLET MO	1	
allopurinol 200 mg TABLET MO	3	
allopurinol sodium 500 mg RECON SOLUTION MO	1	
ALOPRIM 500 MG RECON SOLUTION MO	3	
colchicine 0.6 mg CAPSULE MO	1	PA
colchicine 0.6 mg TABLET MO	1	QL(120 per 30 days)
COLCRYS 0.6 MG TABLET MO	3	PA,QL(120 per 30 days)
DUZALLO 200-200 MG, 200-300 MG TABLET MO	3	PA,QL(30 per 30 days)
febuxostat 40 mg, 80 mg TABLET MO	1	ST,QL(30 per 30 days)
GLOPERBA 0.6 MG/5 ML SOLUTION MO	3	PA,QL(300 per 30 days)
MITIGARE 0.6 MG CAPSULE MO	3	PA
probenecid 500 mg TABLET MO	1	
probenecid-colchicine 500-0.5 mg TABLET MO	1	
ULORIC 40 MG, 80 MG TABLET MO	3	ST,QL(30 per 30 days)
ZYLOPRIM 100 MG TABLET MO	3	
ANTIMIGRAINE AGENTS		
AIMOVIG AUTOINJECTOR 140 MG/ML AUTO-INJECTOR MO	3	PA,QL(1 per 28 days)
AIMOVIG AUTOINJECTOR 70 MG/ML AUTO-INJECTOR MO	3	PA,QL(2 per 28 days)
AJOVY AUTOINJECTOR 225 MG/1.5 ML AUTO-INJECTOR MO	3	PA,QL(1.5 per 28 days)
AJOVY SYRINGE 225 MG/1.5 ML SYRINGE MO	3	PA,QL(1.5 per 28 days)
almotriptan malate 12.5 mg, 6.25 mg TABLET MO	1	ST,QL(9 per 30 days)
dihydroergotamine 0.5 mg/pump act. (4 mg/ml) SPRAY, NON-AEROSOL DL	4	PA,QL(8 per 30 days)
dihydroergotamine 1 mg/ml SOLUTION DL	4	PA
eletriptan 20 mg, 40 mg TABLET MO	1	ST,QL(9 per 30 days)
EMGALITY PEN 120 MG/ML PEN INJECTOR MO	3	PA,QL(2 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EMGALITY SYRINGE 120 MG/ML SYRINGE MO	3	PA,QL(2 per 30 days)
EMGALITY SYRINGE 300 MG/3 ML (100 MG/ML X 3) SYRINGE MO	3	PA,QL(3 per 30 days)
ERGOMAR 2 MG SUBLINGUAL TABLET DL	4	QL(20 per 28 days)
ergotamine-caffeine 1-100 mg TABLET MO	1	QL(40 per 30 days)
FROVA 2.5 MG TABLET DL	4	ST,QL(12 per 30 days)
frovatriptan 2.5 mg TABLET MO	1	ST,QL(12 per 30 days)
IMITREX 100 MG TABLET DL	4	PA,QL(9 per 30 days)
IMITREX 20 MG/ACTUATION, 5 MG/ACTUATION SPRAY, NON-AEROSOL MO	3	PA,QL(12 per 30 days)
IMITREX 25 MG, 50 MG TABLET MO	3	PA,QL(9 per 30 days)
IMITREX 6 MG/0.5 ML SOLUTION DL	4	PA,QL(6 per 30 days)
IMITREX STATDOSE PEN 4 MG/0.5 ML, 6 MG/0.5 ML PEN INJECTOR MO	3	PA,QL(6 per 30 days)
IMITREX STATDOSE REFILL 4 MG/0.5 ML, 6 MG/0.5 ML CARTRIDGE DL	4	PA,QL(6 per 30 days)
MAXALT 10 MG TABLET MO	3	PA,QL(12 per 30 days)
MAXALT-MLT 10 MG TABLET, DISINTEGRATING MO	3	PA,QL(12 per 30 days)
migergot 2-100 mg SUPPOSITORY DL	4	QL(20 per 28 days)
MIGRANAL 0.5 MG/PUMP ACT. (4 MG/ML) SPRAY, NON-AEROSOL DL	4	QL(8 per 30 days)
naratriptan 1 mg, 2.5 mg TABLET MO	1	QL(9 per 30 days)
NURTEC ODT 75 MG TABLET, DISINTEGRATING	4	PA,QL(18 per 30 days)
ONZETRA XSAIL 11 MG AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(16 per 30 days)
QULIPTA 10 MG, 30 MG, 60 MG TABLET MO	3	PA,QL(30 per 30 days)
RELPAX 20 MG, 40 MG TABLET DL	4	ST,QL(9 per 30 days)
REYVOW 100 MG TABLET MO	3	PA,QL(8 per 30 days)
REYVOW 50 MG TABLET MO	3	PA,QL(4 per 30 days)
rizatriptan 10 mg, 5 mg TABLET MO	1	QL(12 per 30 days)
rizatriptan 10 mg, 5 mg TABLET, DISINTEGRATING MO	1	QL(12 per 30 days)
sumatriptan 20 mg/actuation, 5 mg/actuation SPRAY, NON-AEROSOL MO	1	QL(12 per 30 days)
sumatriptan succinate 100 mg, 25 mg, 50 mg TABLET MO	1	QL(9 per 30 days)
sumatriptan succinate 4 mg/0.5 ml, 6 mg/0.5 ml CARTRIDGE MO	3	QL(6 per 30 days)
sumatriptan succinate 4 mg/0.5 ml, 6 mg/0.5 ml PEN INJECTOR MO	1	QL(6 per 30 days)
sumatriptan succinate 6 mg/0.5 ml SOLUTION MO	1	QL(6 per 30 days)
sumatriptan succinate 6 mg/0.5 ml SYRINGE MO	1	QL(6 per 30 days)
sumatriptan-naproxen 85-500 mg TABLET MO	1	ST,QL(18 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TOSYMRA 10 MG/ACTUATION SPRAY, NON-AEROSOL MO	3	ST,QL(12 per 30 days)
TREXIMET 85-500 MG TABLET DL	4	ST,QL(18 per 30 days)
TRUDHESA 0.725 MG/PUMP ACT. (4 MG/ML) SPRAY, NON-AEROSOL DL	4	PA,QL(8 per 30 days)
UBRELVY 100 MG, 50 MG TABLET MO	2	PA,QL(16 per 30 days)
VYEPTI 100 MG/ML SOLUTION MO	3	PA,QL(3 per 90 days)
ZAVZPRET 10 MG/ACTUATION SPRAY, NON-AEROSOL DL	4	PA,QL(8 per 30 days)
ZEMBRACE SYMTOUCH 3 MG/0.5 ML PEN INJECTOR DL	4	ST,QL(6 per 30 days)
zolmitriptan 2.5 mg TABLET MO	1	ST,QL(9 per 30 days)
zolmitriptan 2.5 mg TABLET, DISINTEGRATING MO	1	ST,QL(9 per 30 days)
zolmitriptan 2.5 mg, 5 mg SPRAY, NON-AEROSOL MO	1	ST,QL(12 per 30 days)
zolmitriptan 5 mg TABLET MO	1	ST,QL(6 per 30 days)
zolmitriptan 5 mg TABLET, DISINTEGRATING MO	1	ST,QL(6 per 30 days)
ZOMIG 2.5 MG TABLET MO	3	ST,QL(9 per 30 days)
zomig 2.5 mg TABLET MO	3	ST,QL(9 per 30 days)
ZOMIG 2.5 MG, 5 MG SPRAY, NON-AEROSOL MO	3	ST,QL(12 per 30 days)
zomig 5 mg TABLET MO	3	ST,QL(6 per 30 days)
ZOMIG 5 MG TABLET MO	3	ST,QL(6 per 30 days)
ANTIMYASTHENIC AGENTS		
MESTINON 60 MG TABLET	4	PA
MESTINON 60 MG/5 ML SYRUP	4	
MESTINON TIMESPAN 180 MG TABLET ER	4	PA
pyridostigmine bromide 180 mg TABLET ER MO	1	
pyridostigmine bromide 30 mg, 60 mg TABLET MO	1	
pyridostigmine bromide 60 mg/5 ml SYRUP MO	1	
REGONOL 5 MG/ML SOLUTION MO	3	
VYVGART 20 MG/ML SOLUTION DL	4	PA
VYVGART HYTRULO 1,008 MG-11,200 UNIT/5.6 ML SOLUTION DL	4	PA,QL(22.4 per 28 days)
ANTIMYCOBACTERIALS		
cycloserine 250 mg CAPSULE DL	4	
dapsone 100 mg, 25 mg TABLET MO	1	
ethambutol 100 mg, 400 mg TABLET MO	1	
isoniazid 100 mg, 300 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>isoniazid 100 mg/ml, 50 mg/5 ml SOLUTION</i> MO	1	
MYAMBUTOL 400 MG TABLET MO	3	
MYCOBUTIN 150 MG CAPSULE MO	3	
PRETOMANID 200 MG TABLET MO	3	PA,QL(30 per 30 days)
PRIFTIN 150 MG TABLET MO	3	
<i>pyrazinamide 500 mg TABLET</i> MO	1	
<i>rifabutin 150 mg CAPSULE</i> MO	1	
RIFADIN 600 MG RECON SOLUTION MO	3	
<i>rifampin 150 mg, 300 mg CAPSULE</i> MO	1	
<i>rifampin 600 mg RECON SOLUTION</i> MO	1	
SIRTURO 100 MG, 20 MG TABLET DL	4	PA
TRECTOR 250 MG TABLET MO	3	
ANTINEOPLASTICS		
<i>abiraterone 250 mg TABLET</i> DL	4	PA,QL(120 per 30 days)
<i>abiraterone 500 mg TABLET</i> DL	4	PA,QL(60 per 30 days)
ABRAXANE 100 MG SUSPENSION FOR RECONSTITUTION DL	4	PA
ADCETRIS 50 MG RECON SOLUTION DL	4	PA
ADRIAMYCIN 50 MG RECON SOLUTION MO	1	BvsD
<i>adrucil 2.5 gram/50 ml SOLUTION</i> MO	1	BvsD
AFINITOR 10 MG, 2.5 MG, 5 MG, 7.5 MG TABLET DL	4	PA,QL(30 per 30 days)
AFINITOR DISPERZ 2 MG, 3 MG, 5 MG TABLET FOR SUSPENSION DL	4	PA
AKEEGA 100-500 MG, 50-500 MG TABLET DL	4	PA,QL(60 per 30 days)
ALECENSA 150 MG CAPSULE DL	4	PA,QL(240 per 30 days)
ALIMTA 100 MG, 500 MG RECON SOLUTION DL	4	PA
ALIQOPA 60 MG RECON SOLUTION DL	4	PA,QL(3 per 28 days)
ALUNBRIG 180 MG, 90 MG TABLET DL	4	PA,QL(30 per 30 days)
ALUNBRIG 30 MG TABLET DL	4	PA,QL(180 per 30 days)
ALUNBRIG 90 MG (7)- 180 MG (23) TABLET, DOSE PACK DL	4	PA,QL(30 per 30 days)
ALYMSYS 25 MG/ML SOLUTION DL	4	PA
<i>anastrozole 1 mg TABLET</i> MO	1	QL(30 per 30 days)
ANKTIVA 400 MCG/0.4 ML SOLUTION DL	4	PA
ARIMIDEX 1 MG TABLET DL	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AROMASIN 25 MG TABLET DL	4	PA,QL(60 per 30 days)
ARRANON 250 MG/50 ML SOLUTION DL	4	
<i>arsenic trioxide</i> 1 mg/ml, 2 mg/ml SOLUTION DL	4	PA
ASPARLAS 750 UNIT/ML SOLUTION DL	4	PA
AUGTYRO 40 MG CAPSULE DL	4	PA,QL(240 per 30 days)
AVASTIN 25 MG/ML SOLUTION DL	4	PA
AYVAKIT 100 MG, 200 MG, 25 MG, 300 MG, 50 MG TABLET DL	4	PA,QL(30 per 30 days)
<i>azacitidine</i> 100 mg RECON SOLUTION DL	4	PA
BALVERSA 3 MG TABLET DL	4	PA,QL(90 per 30 days)
BALVERSA 4 MG TABLET DL	4	PA,QL(60 per 30 days)
BALVERSA 5 MG TABLET DL	4	PA,QL(30 per 30 days)
BAVENCIO 20 MG/ML SOLUTION DL	4	PA
BELEODAQ 500 MG RECON SOLUTION DL	4	PA
<i>bendamustine</i> 100 mg, 25 mg RECON SOLUTION DL	4	PA
<i>bendamustine</i> 25 mg/ml SOLUTION DL	4	PA
BENDEKA 25 MG/ML SOLUTION DL	4	PA
BESPONSA 0.9 MG (0.25 MG/ML INITIAL) RECON SOLUTION DL	4	PA
<i>bexarotene</i> 1 % GEL DL	4	PA,QL(240 per 30 days)
<i>bexarotene</i> 75 mg CAPSULE DL	4	PA,QL(300 per 30 days)
<i>bicalutamide</i> 50 mg TABLET MO	1	QL(30 per 30 days)
BICNU 100 MG RECON SOLUTION MO	3	
<i>bleomycin</i> 15 unit, 30 unit RECON SOLUTION MO	1	BvsD
BORTEZOMIB 1 MG, 2.5 MG RECON SOLUTION DL	4	PA
<i>bortezomib</i> 3.5 mg RECON SOLUTION DL	4	PA
BOSULIF 100 MG CAPSULE DL	4	PA,QL(180 per 30 days)
BOSULIF 100 MG TABLET DL	4	PA,QL(120 per 30 days)
BOSULIF 400 MG, 500 MG TABLET DL	4	PA,QL(30 per 30 days)
BOSULIF 50 MG CAPSULE DL	4	PA,QL(360 per 30 days)
BRAFTOVI 75 MG CAPSULE DL	4	PA,QL(180 per 30 days)
BRUKINSA 80 MG CAPSULE DL	4	PA,QL(120 per 30 days)
<i>busulfan</i> 60 mg/10 ml SOLUTION MO	1	
BUSULFEX 60 MG/10 ML SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CABOMETYX 20 MG, 40 MG, 60 MG TABLET DL	4	PA,QL(30 per 30 days)
CALQUENCE 100 MG CAPSULE DL	4	PA,QL(60 per 30 days)
CALQUENCE (ACALABRUTINIB MAL) 100 MG TABLET DL	4	PA,QL(60 per 30 days)
CAMPTOSAR 100 MG/5 ML, 300 MG/15 ML, 40 MG/2 ML SOLUTION DL	4	
CAPRELSA 100 MG TABLET DL,LA	4	PA,QL(60 per 30 days)
CAPRELSA 300 MG TABLET DL,LA	4	PA,QL(30 per 30 days)
carboplatin 10 mg/ml SOLUTION MO	1	
carmustine 100 mg RECON SOLUTION MO	1	
CASODEX 50 MG TABLET DL	4	QL(30 per 30 days)
cisplatin 1 mg/ml SOLUTION MO	1	
cladribine 10 mg/10 ml SOLUTION DL	4	BvsD
clofarabine 1 mg/ml SOLUTION DL	4	
CLOLAR 1 MG/ML SOLUTION DL	4	
COLUMVI 1 MG/ML SOLUTION DL	4	PA
COMETRIQ 100 MG/DAY(80 MG X1-20 MG X1) CAPSULE DL	4	PA,QL(56 per 28 days)
COMETRIQ 140 MG/DAY(80 MG X1-20 MG X3) CAPSULE DL	4	PA,QL(112 per 28 days)
COMETRIQ 60 MG/DAY (20 MG X 3/DAY) CAPSULE DL	4	PA,QL(84 per 28 days)
COPIKTRA 15 MG, 25 MG CAPSULE DL	4	PA,QL(56 per 28 days)
COSMEGEN 0.5 MG RECON SOLUTION DL	4	
COTELLIC 20 MG TABLET DL	4	PA,QL(63 per 28 days)
cyclophosphamide 1 gram, 2 gram, 500 mg RECON SOLUTION MO	1	BvsD
CYCLOPHOSPHAMIDE 100 MG/ML, 200 MG/ML SOLUTION MO	1	BvsD
cyclophosphamide 200 mg/ml SOLUTION MO	1	BvsD
cyclophosphamide 25 mg, 50 mg CAPSULE MO	1	BvsD
cyclophosphamide 25 mg, 50 mg TABLET MO	1	BvsD
CYRAMZA 10 MG/ML SOLUTION DL	4	PA
cytarabine 20 mg/ml SOLUTION MO	1	BvsD
cytarabine (pf) 100 mg/5 ml (20 mg/ml), 2 gram/20 ml (100 mg/ml), 20 mg/ml SOLUTION MO	1	BvsD
dacarbazine 100 mg, 200 mg RECON SOLUTION MO	1	
DACOGEN 50 MG RECON SOLUTION DL	4	PA
dactinomycin 0.5 mg RECON SOLUTION DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DANYELZA 4 MG/ML SOLUTION DL	4	PA,QL(120 per 28 days)
DARZALEX 20 MG/ML SOLUTION DL	4	PA
DARZALEX FASPRO 1,800 MG-30,000 UNIT/15 ML SOLUTION DL	4	PA
<i>daunorubicin 5 mg/ml SOLUTION</i> MO	1	
DAURISMO 100 MG TABLET DL	4	PA,QL(30 per 30 days)
DAURISMO 25 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>decitabine 50 mg RECON SOLUTION</i> DL	4	PA
<i>dexrazoxane hcl 250 mg, 500 mg RECON SOLUTION</i> MO	1	
DOCEFREZ 20 MG RECON SOLUTION MO	3	
DOCEFREZ 80 MG RECON SOLUTION DL	4	
<i>docetaxel 160 mg/16 ml (10 mg/ml), 160 mg/8 ml (20 mg/ml), 20 mg/2 ml (10 mg/ml), 20 mg/ml (1 ml), 80 mg/4 ml (20 mg/ml), 80 mg/8 ml (10 mg/ml) SOLUTION</i> MO	1	
DOXIL 2 MG/ML SUSPENSION DL	4	PA
<i>doxorubicin 10 mg, 50 mg RECON SOLUTION</i> MO	1	BvsD
<i>doxorubicin 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml SOLUTION</i> MO	1	BvsD
<i>doxorubicin, peg-liposomal 2 mg/ml SUSPENSION</i> DL	4	PA
ELITEK 1.5 MG, 7.5 MG RECON SOLUTION DL	4	PA
ELLENC 200 MG/100 ML, 50 MG/25 ML SOLUTION DL	4	
ELREXFIO 40 MG/ML SOLUTION DL	4	PA
ELZONRIS 1,000 MCG/ML SOLUTION DL	4	PA,QL(10 per 21 days)
EMCYT 140 MG CAPSULE DL	4	
EMPLICITI 300 MG, 400 MG RECON SOLUTION DL	4	PA
ENHERTU 100 MG RECON SOLUTION DL	4	PA
<i>epirubicin 200 mg/100 ml, 50 mg/25 ml SOLUTION</i> MO	1	
EPKINLY 4 MG/0.8 ML, 48 MG/0.8 ML SOLUTION DL	4	PA
ERBITUX 100 MG/50 ML, 200 MG/100 ML SOLUTION DL	4	PA
<i>eribulin 1 mg/2 ml (0.5 mg/ml) SOLUTION</i> DL	4	
ERIVEDGE 150 MG CAPSULE DL	4	PA,QL(28 per 28 days)
ERLEADA 240 MG TABLET DL	4	PA,QL(30 per 30 days)
ERLEADA 60 MG TABLET DL	4	PA,QL(120 per 30 days)
<i>erlotinib 100 mg, 150 mg TABLET</i> DL	4	PA,QL(30 per 30 days)
<i>erlotinib 25 mg TABLET</i> DL	4	PA,QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ETOPOPHOS 100 MG RECON SOLUTION MO	3	
<i>etoposide 20 mg/ml SOLUTION</i> MO	1	
EULEXIN 125 MG CAPSULE DL	4	PA
<i>everolimus (antineoplastic) 10 mg, 2.5 mg, 5 mg, 7.5 mg TABLET</i> DL	4	PA,QL(30 per 30 days)
<i>everolimus (antineoplastic) 2 mg, 3 mg, 5 mg TABLET FOR SUSPENSION</i> DL	4	PA
EVOMELA 50 MG RECON SOLUTION DL	4	
<i>exemestane 25 mg TABLET</i> MO	1	QL(60 per 30 days)
EXKIVITY 40 MG CAPSULE DL	4	PA,QL(120 per 30 days)
FARESTON 60 MG TABLET DL	4	QL(30 per 30 days)
FASLODEX 250 MG/5 ML SYRINGE DL	4	PA,QL(30 per 30 days)
FEMARA 2.5 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>floruridine 0.5 gram RECON SOLUTION</i> MO	1	BvsD
<i>fludarabine 50 mg RECON SOLUTION</i> MO	1	
<i>fludarabine 50 mg/2 ml SOLUTION</i> DL	4	
<i>fluorouracil 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml SOLUTION</i> MO	1	BvsD
FOLOTYN 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML) SOLUTION DL	4	PA
FOTIVDA 0.89 MG, 1.34 MG CAPSULE DL	4	PA,QL(21 per 28 days)
FRUZAQLA 1 MG CAPSULE DL	4	PA,QL(84 per 28 days)
FRUZAQLA 5 MG CAPSULE DL	4	PA,QL(21 per 28 days)
<i>fulvestrant 250 mg/5 ml SYRINGE</i> MO	1	PA,QL(30 per 30 days)
FUSILEV 50 MG RECON SOLUTION DL	4	PA
FYARRO 100 MG SUSPENSION FOR RECONSTITUTION DL	4	PA
GAVRETO 100 MG CAPSULE DL,LA	4	PA,QL(120 per 30 days)
GAZYVA 1,000 MG/40 ML SOLUTION DL	4	PA,QL(120 per 28 days)
<i>gefitinib 250 mg TABLET</i> DL	4	PA
<i>gemcitabine 1 gram, 2 gram, 200 mg RECON SOLUTION</i> MO	1	
<i>gemcitabine 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml) SOLUTION</i> MO	1	
GILOTRIF 20 MG, 30 MG, 40 MG TABLET DL,LA	4	PA,QL(30 per 30 days)
GLEEVEC 100 MG TABLET DL	4	PA,QL(90 per 30 days)
GLEEVEC 400 MG TABLET DL	4	PA,QL(60 per 30 days)
GLEOSTINE 10 MG CAPSULE MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GLEOSTINE 100 MG CAPSULE DL	4	PA
GLEOSTINE 40 MG CAPSULE	4	PA
HALAVEN 1 MG/2 ML (0.5 MG/ML) SOLUTION DL	4	
HERCEPTIN 150 MG RECON SOLUTION DL	4	PA
HERCEPTIN HYLECTA 600 MG-10,000 UNIT/5 ML SOLUTION DL	4	PA,QL(5 per 21 days)
HERZUMA 150 MG, 420 MG RECON SOLUTION DL	4	PA
HYCAMTIN 4 MG RECON SOLUTION DL	4	
HYDREA 500 MG CAPSULE MO	3	
<i>hydroxyurea 500 mg CAPSULE MO</i>	1	
IBRANCE 100 MG, 125 MG, 75 MG CAPSULE DL	4	PA,QL(21 per 28 days)
IBRANCE 100 MG, 125 MG, 75 MG TABLET DL	4	PA,QL(21 per 28 days)
ICLUSIG 10 MG, 30 MG, 45 MG TABLET DL	4	PA,QL(30 per 30 days)
ICLUSIG 15 MG TABLET DL	4	PA,QL(60 per 30 days)
IDAMYCIN PFS 1 MG/ML SOLUTION DL	4	
<i>idarubicin 1 mg/ml SOLUTION DL</i>	4	
IDHIFA 100 MG, 50 MG TABLET DL	4	PA,QL(30 per 30 days)
IFEX 1 GRAM, 3 GRAM RECON SOLUTION MO	3	
<i>ifosfamide 1 gram, 3 gram RECON SOLUTION MO</i>	1	
<i>ifosfamide 1 gram/20 ml, 3 gram/60 ml SOLUTION MO</i>	1	
<i>imatinib 100 mg TABLET DL</i>	4	PA,QL(90 per 30 days)
<i>imatinib 400 mg TABLET DL</i>	4	PA,QL(60 per 30 days)
IMBRUVICA 140 MG CAPSULE DL	4	PA,QL(120 per 30 days)
IMBRUVICA 420 MG TABLET DL	4	PA,QL(28 per 28 days)
IMBRUVICA 560 MG TABLET DL	4	PA,QL(28 per 28 days)
IMBRUVICA 70 MG CAPSULE DL	4	PA,QL(28 per 28 days)
IMBRUVICA 70 MG/ML SUSPENSION DL	4	PA
IMDELLTRA 1 MG, 10 MG RECON SOLUTION DL	4	PA
IMFINZI 50 MG/ML SOLUTION DL	4	PA
IMJUDO 20 MG/ML SOLUTION DL	4	PA
IMLYGIC 10EXP6 (1 MILLION) PFU/ML SUSPENSION DL	4	PA,QL(4 per 365 days)
IMLYGIC 10EXP8 (100 MILLION) PFU/ML SUSPENSION DL	4	PA,QL(8 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INFUGEM 1,200 MG/120 ML (10 MG/ML), 1,300 MG/130 ML (10 MG/ML), 1,400 MG/140 ML (10 MG/ML), 1,500 MG/150 ML (10 MG/ML), 1,600 MG/160 ML (10 MG/ML), 1,700 MG/170 ML (10 MG/ML), 1,800 MG/180 ML (10 MG/ML), 1,900 MG/190 ML (10 MG/ML), 2,000 MG/200 ML (10 MG/ML), 2,200 MG/220 ML (10 MG/ML) PIGGYBACK DL	4	
INLYTA 1 MG TABLET DL	4	PA,QL(180 per 30 days)
INLYTA 5 MG TABLET DL	4	PA,QL(60 per 30 days)
INQOVI 35-100 MG TABLET DL	4	PA,QL(5 per 28 days)
INREBIC 100 MG CAPSULE DL	4	PA,QL(120 per 30 days)
IRESSA 250 MG TABLET DL	4	PA
ir inotecan 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml SOLUTION MO	1	
ISTODAX 10 MG/2 ML RECON SOLUTION DL	4	PA
IWILFIN 192 MG TABLET DL	4	PA,QL(240 per 30 days)
IXEMPRA 15 MG, 45 MG RECON SOLUTION DL	4	PA
JAKAFI 10 MG, 15 MG, 20 MG, 25 MG, 5 MG TABLET DL	4	PA,QL(60 per 30 days)
JAYPIRCA 100 MG, 50 MG TABLET DL	4	PA,QL(90 per 30 days)
JEMPERLI 50 MG/ML SOLUTION	4	PA,QL(20 per 42 days)
JEVTANA 10 MG/ML (FIRST DILUTION) SOLUTION DL	4	PA
KADCYLA 100 MG, 160 MG RECON SOLUTION DL	4	PA
KANJINTI 150 MG, 420 MG RECON SOLUTION DL	4	PA
KEYTRUDA 25 MG/ML SOLUTION DL	4	PA
KHAPZORY 175 MG, 300 MG RECON SOLUTION DL	4	PA
KIMMTRAK 100 MCG/0.5 ML SOLUTION DL	4	PA
KISQALI 200 MG/DAY (200 MG X 1) TABLET DL	4	PA,QL(21 per 28 days)
KISQALI 400 MG/DAY (200 MG X 2) TABLET DL	4	PA,QL(42 per 28 days)
KISQALI 600 MG/DAY (200 MG X 3) TABLET DL	4	PA,QL(63 per 28 days)
KISQALI FEMARA CO-PACK 200 MG/DAY(200 MG X 1)-2.5 MG TABLET DL	4	PA,QL(49 per 28 days)
KISQALI FEMARA CO-PACK 400 MG/DAY(200 MG X 2)-2.5 MG TABLET DL	4	PA,QL(70 per 28 days)
KISQALI FEMARA CO-PACK 600 MG/DAY(200 MG X 3)-2.5 MG TABLET DL	4	PA,QL(91 per 28 days)
KOSELUGO 10 MG CAPSULE DL	4	PA,QL(240 per 30 days)
KOSELUGO 25 MG CAPSULE DL	4	PA,QL(120 per 30 days)
KRAZATI 200 MG TABLET DL	4	PA,QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KYPROLIS 10 MG RECON SOLUTION DL	4	PA,QL(6 per 28 days)
KYPROLIS 30 MG RECON SOLUTION DL	4	PA,QL(3 per 28 days)
KYPROLIS 60 MG RECON SOLUTION DL	4	PA,QL(12 per 28 days)
<i>lapatinib</i> 250 mg TABLET DL	4	PA,QL(180 per 30 days)
LAZCLUZE 240 MG TABLET DL	4	PA,QL(30 per 30 days)
LAZCLUZE 80 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>lenalidomide</i> 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg CAPSULE DL	4	PA,QL(28 per 28 days)
LENVIMA 10 MG/DAY (10 MG X 1), 4 MG CAPSULE DL	4	PA,QL(30 per 30 days)
LENVIMA 12 MG/DAY (4 MG X 3), 18 MG/DAY (10 MG X 1-4 MG X2), 24 MG/DAY(10 MG X 2-4 MG X 1) CAPSULE DL	4	PA,QL(90 per 30 days)
LENVIMA 14 MG/DAY(10 MG X 1-4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY (4 MG X 2) CAPSULE DL	4	PA,QL(60 per 30 days)
<i>letrozole</i> 2.5 mg TABLET MO	1	QL(30 per 30 days)
<i>leucovorin calcium</i> 10 mg, 15 mg, 25 mg, 5 mg TABLET MO	1	
<i>leucovorin calcium</i> 10 mg/ml SOLUTION MO	1	
<i>leucovorin calcium</i> 100 mg, 200 mg, 350 mg, 50 mg, 500 mg RECON SOLUTION MO	1	
LEUKERAN 2 MG TABLET DL	4	
<i>levoleucovorin calcium</i> 10 mg/ml SOLUTION MO	1	PA
<i>levoleucovorin calcium</i> 50 mg RECON SOLUTION MO	1	PA
LEVULAN 20 % SOLUTION MO	3	
LIBTAYO 50 MG/ML SOLUTION DL	4	PA,QL(7 per 21 days)
LONSURF 15-6.14 MG TABLET DL	4	PA,QL(100 per 30 days)
LONSURF 20-8.19 MG TABLET DL	4	PA,QL(80 per 30 days)
LOQTORZI 240 MG/6 ML (40 MG/ML) SOLUTION DL	4	PA
LORBRENA 100 MG TABLET DL	4	PA,QL(30 per 30 days)
LORBRENA 25 MG TABLET DL	4	PA,QL(90 per 30 days)
LUMAKRAS 120 MG TABLET DL	4	PA,QL(240 per 30 days)
LUMAKRAS 320 MG TABLET DL	4	PA,QL(90 per 30 days)
LUNSUMIO 1 MG/ML SOLUTION DL	4	PA
LYNPARZA 100 MG, 150 MG TABLET DL	4	PA,QL(120 per 30 days)
LYSODREN 500 MG TABLET DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LYTGOBI 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) TABLET DL	4	PA,QL(140 per 28 days)
MARGENZA 25 MG/ML SOLUTION DL	4	PA
MATULANE 50 MG CAPSULE DL	4	
MEKINIST 0.05 MG/ML RECON SOLUTION DL	4	PA,QL(1170 per 28 days)
MEKINIST 0.5 MG TABLET DL	4	PA,QL(120 per 30 days)
MEKINIST 2 MG TABLET DL	4	PA,QL(30 per 30 days)
MEKTOVI 15 MG TABLET DL	4	PA,QL(180 per 30 days)
<i>melphalan 2 mg TABLET MO</i>	1	BvsD
<i>melphalan hcl 50 mg RECON SOLUTION MO</i>	1	
<i>mercaptopurine 50 mg TABLET MO</i>	1	
<i>mesna 100 mg/ml SOLUTION MO</i>	1	
MESNEX 100 MG/ML SOLUTION DL	4	
MESNEX 400 MG TABLET DL	4	
<i>mitomycin 20 mg, 40 mg, 5 mg RECON SOLUTION DL</i>	4	
<i>mitoxantrone 2 mg/ml CONCENTRATE MO</i>	1	
MUTAMYCIN 20 MG, 40 MG, 5 MG RECON SOLUTION DL	4	
MVASI 25 MG/ML SOLUTION DL	4	PA
MYLOTARG 4.5 MG (1 MG/ML INITIAL CONC) RECON SOLUTION DL	4	PA
<i>nelarabine 250 mg/50 ml SOLUTION DL</i>	4	
NERLYNX 40 MG TABLET DL	4	PA,QL(180 per 30 days)
NEXAVAR 200 MG TABLET DL	4	PA,QL(120 per 30 days)
NILANDRON 150 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>nilutamide 150 mg TABLET DL</i>	4	QL(60 per 30 days)
NINLARO 2.3 MG, 3 MG, 4 MG CAPSULE DL	4	PA,QL(3 per 28 days)
NIPENT 10 MG RECON SOLUTION DL	4	
NUBEQA 300 MG TABLET DL	4	PA,QL(120 per 30 days)
ODOMZO 200 MG CAPSULE DL	4	PA,QL(30 per 30 days)
OGIVRI 150 MG, 420 MG RECON SOLUTION DL	4	PA
OGSIVEO 100 MG, 150 MG TABLET DL	4	PA,QL(60 per 30 days)
OGSIVEO 50 MG TABLET DL	4	PA,QL(180 per 30 days)
OJEMDA 25 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(96 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OJEMDA 400 MG/WEEK (100 MG X 4) TABLET DL	4	PA,QL(16 per 28 days)
OJEMDA 500 MG/WEEK (100 MG X 5) TABLET DL	4	PA,QL(20 per 28 days)
OJEMDA 600 MG/WEEK (100 MG X 6) TABLET DL	4	PA,QL(24 per 28 days)
OJJAARA 100 MG, 150 MG, 200 MG TABLET DL	4	PA,QL(30 per 30 days)
ONCASPAR 750 UNIT/ML SOLUTION DL	4	PA
ONIVYDE 4.3 MG/ML DISPERSION DL	4	PA
ONTRUZANT 150 MG, 420 MG RECON SOLUTION DL	4	PA
ONUREG 200 MG, 300 MG TABLET DL	4	PA,QL(14 per 28 days)
OPDIVO 100 MG/10 ML SOLUTION DL	4	PA,QL(40 per 28 days)
OPDIVO 120 MG/12 ML, 240 MG/24 ML SOLUTION DL	4	PA,QL(48 per 28 days)
OPDIVO 40 MG/4 ML SOLUTION DL	4	PA,QL(16 per 28 days)
OPDUALAG 240-80 MG/20 ML SOLUTION DL	4	PA,QL(40 per 28 days)
ORGOVYX 120 MG TABLET DL	4	PA,QL(32 per 30 days)
ORSERDU 345 MG TABLET DL	4	PA,QL(30 per 30 days)
ORSERDU 86 MG TABLET DL	4	PA,QL(90 per 30 days)
oxaliplatin 100 mg, 50 mg RECON SOLUTION MO	1	
oxaliplatin 100 mg/20 ml, 200 mg/40 ml, 50 mg/10 ml (5 mg/ml) SOLUTION MO	1	
paclitaxel 6 mg/ml CONCENTRATE MO	1	
paclitaxel protein-bound 100 mg SUSPENSION FOR RECONSTITUTION DL	4	PA
PADCEV 20 MG RECON SOLUTION DL	4	PA,QL(21 per 28 days)
PADCEV 30 MG RECON SOLUTION DL	4	PA,QL(15 per 28 days)
PANRETIN 0.1 % GEL DL	4	PA
paraplatin 10 mg/ml SOLUTION MO	1	
pazopanib 200 mg TABLET DL	4	PA,QL(120 per 30 days)
PEDMARK 12.5 GRAM/100ML (125 MG/ML) SOLUTION DL	4	PA
PEMAZYRE 13.5 MG, 4.5 MG, 9 MG TABLET DL	4	PA,QL(28 per 28 days)
pemetrexed 1 gram, 100 mg, 500 mg RECON SOLUTION DL	4	PA
pemetrexed 25 mg/ml SOLUTION DL	4	PA,QL(120 per 21 days)
pemetrexed disodium 1,000 mg, 100 mg, 500 mg, 750 mg RECON SOLUTION DL	4	PA
pemetrexed disodium 25 mg/ml SOLUTION DL	4	PA
PEMRYDI RTU 10 MG/ML SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PERJETA 420 MG/14 ML (30 MG/ML) SOLUTION DL	4	PA
PHESGO 1,200 MG-600MG- 30000 UNIT/15ML SOLUTION DL	4	PA,QL(15 per 21 days)
PHESGO 600 MG-600 MG- 20000 UNIT/10ML SOLUTION DL	4	PA,QL(10 per 21 days)
PIQRAY 200 MG/DAY (200 MG X 1) TABLET DL	4	PA,QL(28 per 28 days)
PIQRAY 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) TABLET DL	4	PA,QL(56 per 28 days)
POLIVY 140 MG RECON SOLUTION DL	4	PA,QL(2 per 21 days)
POLIVY 30 MG RECON SOLUTION DL	4	PA,QL(8 per 21 days)
POMALYST 1 MG, 2 MG, 3 MG, 4 MG CAPSULE DL	4	PA,QL(21 per 28 days)
PORTRAZZA 800 MG/50 ML (16 MG/ML) SOLUTION DL	4	PA,QL(100 per 21 days)
POTELIGEO 4 MG/ML SOLUTION DL	4	PA
<i>pralatrexate 20 mg/ml (1 ml), 40 mg/2 ml (20 mg/ml) SOLUTION DL</i>	4	PA
PURIXAN 20 MG/ML SUSPENSION DL	4	
QINLOCK 50 MG TABLET DL	4	PA,QL(90 per 30 days)
RETEVMO 120 MG, 160 MG, 80 MG TABLET DL	4	PA,QL(60 per 30 days)
RETEVMO 40 MG CAPSULE DL	4	PA,QL(180 per 30 days)
RETEVMO 40 MG TABLET DL	4	PA,QL(90 per 30 days)
RETEVMO 80 MG CAPSULE DL	4	PA,QL(120 per 30 days)
REZLIDHIA 150 MG CAPSULE DL	4	PA,QL(60 per 30 days)
RIABNI 10 MG/ML SOLUTION DL	4	PA
RITUXAN 10 MG/ML CONCENTRATE DL	4	PA
RITUXAN HYCELA 1400 MG/11.7 ML (120 MG/ML) SOLUTION DL	4	PA,QL(46.8 per 28 days)
RITUXAN HYCELA 1600 MG/13.4 ML (120 MG/ML) SOLUTION DL	4	PA,QL(13.4 per 28 days)
<i>romidepsin 10 mg/2 ml RECON SOLUTION DL</i>	4	PA
ROMIDEPSIN 5 MG/ML SOLUTION DL	4	PA
ROZLYTREK 100 MG CAPSULE DL	4	PA,QL(150 per 30 days)
ROZLYTREK 200 MG CAPSULE DL	4	PA,QL(90 per 30 days)
ROZLYTREK 50 MG PELLETS IN PACKET DL	4	PA,QL(360 per 30 days)
RUBRACA 200 MG, 250 MG, 300 MG TABLET DL	4	PA,QL(120 per 30 days)
RUXIENCE 10 MG/ML SOLUTION DL	4	PA
RYBREVANT 50 MG/ML SOLUTION DL	4	PA,QL(784 per 365 days)
RYDAPT 25 MG CAPSULE DL	4	PA,QL(224 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RYLAZE 10 MG/0.5 ML SOLUTION DL	4	PA
RYTELO 188 MG, 47 MG RECON SOLUTION DL	4	PA
SARCLISA 20 MG/ML SOLUTION DL	4	PA
SCEMBLIX 100 MG TABLET DL	4	PA,QL(120 per 30 days)
SCEMBLIX 20 MG TABLET DL	4	PA,QL(60 per 30 days)
SCEMBLIX 40 MG TABLET DL	4	PA,QL(300 per 30 days)
SOLTAMOX 20 MG/10 ML SOLUTION DL	4	
<i>sorafenib 200 mg TABLET</i> DL	4	PA,QL(120 per 30 days)
SPRYCEL 100 MG, 50 MG, 70 MG, 80 MG TABLET DL	4	PA,QL(60 per 30 days)
SPRYCEL 140 MG TABLET DL	4	PA,QL(30 per 30 days)
SPRYCEL 20 MG TABLET DL	4	PA,QL(90 per 30 days)
STIVARGA 40 MG TABLET DL	4	PA,QL(84 per 28 days)
<i>sunitinib malate 12.5 mg, 25 mg, 37.5 mg, 50 mg CAPSULE</i> DL	4	PA,QL(28 per 28 days)
SUTENT 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE DL	4	PA,QL(28 per 28 days)
SYNRIBO 3.5 MG RECON SOLUTION DL	4	PA
TABLOID 40 MG TABLET MO	3	
TABRECTA 150 MG, 200 MG TABLET DL	4	PA,QL(112 per 28 days)
TAFINLAR 10 MG TABLET FOR SUSPENSION DL	4	PA,QL(840 per 28 days)
TAFINLAR 50 MG CAPSULE DL	4	PA,QL(180 per 30 days)
TAFINLAR 75 MG CAPSULE DL	4	PA,QL(120 per 30 days)
TAGRISSO 40 MG, 80 MG TABLET DL	4	PA,QL(30 per 30 days)
TALVEY 2 MG/ML, 40 MG/ML SOLUTION DL	4	PA
TALZENNA 0.1 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG CAPSULE DL	4	PA,QL(30 per 30 days)
TALZENNA 0.25 MG CAPSULE DL	4	PA,QL(90 per 30 days)
<i>tamoxifen 10 mg, 20 mg TABLET</i> MO	1	
TARCEVA 100 MG, 150 MG TABLET DL	4	PA,QL(30 per 30 days)
TARCEVA 25 MG TABLET DL	4	PA,QL(90 per 30 days)
TARGRETIN 1 % GEL DL	4	PA,QL(240 per 30 days)
TARGRETIN 75 MG CAPSULE DL	4	PA,QL(300 per 30 days)
TASIGNA 150 MG, 200 MG, 50 MG CAPSULE DL	4	PA,QL(120 per 30 days)
TAZVERIK 200 MG TABLET DL	4	PA,QL(240 per 30 days)
TECENTRIQ 1,200 MG/20 ML (60 MG/ML) SOLUTION DL	4	PA,QL(20 per 21 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TECENTRIQ 840 MG/14 ML (60 MG/ML) SOLUTION DL	4	PA,QL(28 per 28 days)
TECVAYLI 10 MG/ML, 90 MG/ML SOLUTION DL	4	PA
TEMODAR 100 MG RECON SOLUTION DL	4	PA,QL(27 per 30 days)
<i>temsirolimus 30 mg/3 ml (10 mg/ml) (first) RECON SOLUTION</i> DL	4	PA,QL(8 per 28 days)
TEPADINA 100 MG, 15 MG RECON SOLUTION DL	4	
TEPMETKO 225 MG TABLET DL	4	PA,QL(60 per 30 days)
TEVIMBRA 10 MG/ML SOLUTION DL	4	PA,QL(20 per 21 days)
THALOMID 100 MG, 200 MG, 50 MG CAPSULE DL	4	PA,QL(30 per 30 days)
THALOMID 150 MG CAPSULE DL	4	PA,QL(60 per 30 days)
<i>thiotepa 100 mg RECON SOLUTION</i> DL	4	
<i>thiotepa 15 mg RECON SOLUTION</i> MO	1	
TIBSOVO 250 MG TABLET DL	4	PA,QL(60 per 30 days)
TIVDAK 40 MG RECON SOLUTION DL	4	PA,QL(5 per 21 days)
<i>toposar 20 mg/ml SOLUTION</i> MO	1	
<i>topotecan 4 mg RECON SOLUTION</i> MO	1	
<i>topotecan 4 mg/4 ml (1 mg/ml) SOLUTION</i> MO	1	
<i>toremifene 60 mg TABLET</i>	4	QL(30 per 30 days)
TORISEL 30 MG/3 ML (10 MG/ML) (FIRST) RECON SOLUTION DL	4	PA,QL(8 per 28 days)
<i>torpenz 10 mg, 2.5 mg, 5 mg, 7.5 mg TABLET</i> DL	4	PA,QL(30 per 30 days)
TRAZIMERA 150 MG RECON SOLUTION DL	4	PA
TRAZIMERA 420 MG RECON SOLUTION DL	4	PA
TREANDA 100 MG, 25 MG RECON SOLUTION DL	4	PA
<i>tretinoin (antineoplastic) 10 mg CAPSULE</i> DL	4	
TRISENOX 2 MG/ML SOLUTION DL	4	PA
TRODELVY 180 MG RECON SOLUTION DL	4	PA
TRUQAP 160 MG, 200 MG TABLET DL	4	PA,QL(64 per 28 days)
TRUXIMA 10 MG/ML SOLUTION DL	4	PA
TUKYSA 150 MG TABLET DL	4	PA,QL(120 per 30 days)
TUKYSA 50 MG TABLET DL	4	PA,QL(300 per 30 days)
TURALIO 125 MG, 200 MG CAPSULE DL,LA	4	PA,QL(120 per 30 days)
TYKERB 250 MG TABLET DL	4	PA,QL(180 per 30 days)
UNITUXIN 3.5 MG/ML SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VALCHLOR 0.016 % GEL DL	4	PA,QL(60 per 28 days)
<i>valrubicin</i> 40 mg/ml SOLUTION DL	4	PA,QL(80 per 28 days)
VALSTAR 40 MG/ML SOLUTION DL	4	PA,QL(80 per 28 days)
VANFLYTA 17.7 MG, 26.5 MG TABLET DL	4	PA,QL(56 per 28 days)
VECTIBIX 100 MG/5 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML) SOLUTION DL	4	PA
VEGZELMA 25 MG/ML SOLUTION DL	4	PA
VELCADE 3.5 MG RECON SOLUTION DL	4	PA
VENCLEXTA 10 MG TABLET MO	2	PA,QL(56 per 28 days)
VENCLEXTA 100 MG TABLET DL	4	PA,QL(180 per 30 days)
VENCLEXTA 50 MG TABLET MO	2	PA,QL(28 per 28 days)
VENCLEXTA STARTING PACK 10 MG-50 MG- 100 MG TABLET, DOSE PACK DL	4	PA,QL(42 per 28 days)
VERZENIO 100 MG, 150 MG, 200 MG, 50 MG TABLET DL	4	PA,QL(60 per 30 days)
VIDAZA 100 MG RECON SOLUTION DL	4	PA
<i>vinblastine</i> 1 mg/ml SOLUTION MO	1	BvsD
<i>vincasar pfs</i> 1 mg/ml, 2 mg/2 ml SOLUTION MO	1	BvsD
<i>vincristine</i> 1 mg/ml, 2 mg/2 ml SOLUTION MO	1	BvsD
<i>vinorelbine</i> 10 mg/ml, 50 mg/5 ml SOLUTION MO	1	
VITRAKVI 100 MG CAPSULE DL	4	PA,QL(60 per 30 days)
VITRAKVI 20 MG/ML SOLUTION DL	4	PA,QL(300 per 30 days)
VITRAKVI 25 MG CAPSULE DL	4	PA,QL(180 per 30 days)
VIZIMPRO 15 MG, 30 MG, 45 MG TABLET DL	4	PA,QL(30 per 30 days)
VONJO 100 MG CAPSULE DL	4	PA,QL(120 per 30 days)
VORANIGO 10 MG TABLET DL	4	PA,QL(60 per 30 days)
VORANIGO 40 MG TABLET DL	4	PA,QL(30 per 30 days)
VOTRIENT 200 MG TABLET DL	4	PA,QL(120 per 30 days)
VYXEOS 44-100 MG RECON SOLUTION DL	4	PA
XALKORI 150 MG PELLETT DL	4	PA,QL(180 per 30 days)
XALKORI 20 MG PELLETT DL	4	PA,QL(120 per 30 days)
XALKORI 200 MG, 250 MG CAPSULE DL	4	PA,QL(120 per 30 days)
XALKORI 50 MG PELLETT DL	4	PA,QL(240 per 30 days)
XOSPATA 40 MG TABLET DL	4	PA,QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XPOVIO 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2) TABLET DL	4	PA,QL(8 per 28 days)
XPOVIO 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) TABLET DL	4	PA,QL(4 per 28 days)
XPOVIO 60MG TWICE WEEK (120 MG/WEEK) TABLET DL	4	PA,QL(24 per 28 days)
XPOVIO 80MG TWICE WEEK (160 MG/WEEK) TABLET DL	4	PA,QL(32 per 28 days)
XTANDI 40 MG CAPSULE DL	4	PA,QL(120 per 30 days)
XTANDI 40 MG TABLET DL	4	PA,QL(120 per 30 days)
XTANDI 80 MG TABLET DL	4	PA,QL(60 per 30 days)
YERVOY 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) SOLUTION DL	4	PA
YONDELIS 1 MG RECON SOLUTION DL	4	PA
YONSA 125 MG TABLET DL	4	PA,QL(120 per 30 days)
ZALTRAP 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML) SOLUTION DL	4	PA
ZANOSAR 1 GRAM RECON SOLUTION MO	3	
ZEJULA 100 MG CAPSULE DL	4	PA,QL(90 per 30 days)
ZEJULA 100 MG, 200 MG, 300 MG TABLET DL	4	PA,QL(30 per 30 days)
ZELBORAF 240 MG TABLET DL	4	PA,QL(240 per 30 days)
ZEPZELCA 4 MG RECON SOLUTION DL	4	PA
ZIRABEV 25 MG/ML SOLUTION DL	4	PA
ZOLINZA 100 MG CAPSULE DL	4	PA,QL(120 per 30 days)
ZYDELIG 100 MG, 150 MG TABLET DL	4	PA,QL(60 per 30 days)
ZYKADIA 150 MG TABLET DL	4	PA,QL(150 per 30 days)
ZYNLONTA 10 MG RECON SOLUTION DL	4	PA
ZYNYZ 500 MG/20 ML SOLUTION DL	4	PA,QL(20 per 28 days)
ZYTIGA 250 MG TABLET DL	4	PA,QL(120 per 30 days)
ZYTIGA 500 MG TABLET DL	4	PA,QL(60 per 30 days)
ANTIPARASITICS		
<i>albendazole 200 mg TABLET MO</i>	1	
<i>atovaquone 750 mg/5 ml SUSPENSION MO</i>	1	
<i>atovaquone-proguanil 250-100 mg, 62.5-25 mg TABLET MO</i>	1	
<i>benznidazole 100 mg, 12.5 mg TABLET MO</i>	3	
BILTRICIDE 600 MG TABLET DL	4	PA
<i>chloroquine phosphate 250 mg, 500 mg TABLET MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COARTEM 20-120 MG TABLET MO	3	QL(24 per 30 days)
DARAPRIM 25 MG TABLET DL	4	PA,QL(90 per 30 days)
EGATEN 250 MG TABLET MO	3	
emverm 100 mg CHEWABLE TABLET DL	4	
hydroxychloroquine 100 mg, 300 mg, 400 mg TABLET MO	1	
hydroxychloroquine 200 mg TABLET MO	1	
IMPAVIDO 50 MG CAPSULE DL	4	QL(84 per 28 days)
ivermectin 3 mg TABLET MO	1	
KRINTAFEL 150 MG TABLET MO	3	QL(4 per 180 days)
LAMPIT 120 MG, 30 MG TABLET MO	3	
MALARONE 250-100 MG TABLET MO	3	PA
MALARONE PEDIATRIC 62.5-25 MG TABLET MO	3	PA
mefloquine 250 mg TABLET MO	1	
MEPRON 750 MG/5 ML SUSPENSION DL	4	
NEBUPENT 300 MG RECON SOLUTION MO	3	BvsD
nitazoxanide 500 mg TABLET DL	4	
PENTAM 300 MG RECON SOLUTION MO	3	
pentamidine 300 mg RECON SOLUTION MO	1	BvsD
pentamidine 300 mg RECON SOLUTION MO	1	
PLAQUENIL 200 MG TABLET MO	3	PA
praziquantel 600 mg TABLET MO	1	
primaquine 26.3 mg (15 mg base) TABLET MO	1	
pyrimethamine 25 mg TABLET DL	4	QL(90 per 30 days)
QUALAQUIN 324 MG CAPSULE MO	3	PA,QL(42 per 7 days)
quinine sulfate 324 mg CAPSULE MO	1	PA,QL(42 per 7 days)
SOVUNA 200 MG, 300 MG TABLET MO	3	
STROMEKTOL 3 MG TABLET MO	3	PA
ANTIPARKINSON AGENTS		
amantadine hcl 100 mg CAPSULE MO	1	
amantadine hcl 100 mg TABLET MO	1	
amantadine hcl 50 mg/5 ml SOLUTION MO	1	
APOKYN 10 MG/ML CARTRIDGE DL	4	PA,QL(84 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
apomorphine 10 mg/ml CARTRIDGE DL	4	PA,QL(84 per 28 days)
AZILECT 0.5 MG, 1 MG TABLET DL	4	PA,QL(30 per 30 days)
benztropine 0.5 mg, 1 mg, 2 mg TABLET MO	1	
benztropine 1 mg/ml SOLUTION MO	1	
bromocriptine 2.5 mg TABLET MO	1	
bromocriptine 5 mg CAPSULE MO	1	QL(600 per 30 days)
carbidopa 25 mg TABLET MO	1	
carbidopa-levodopa 10-100 mg, 25-100 mg, 25-250 mg TABLET, DISINTEGRATING MO	1	
carbidopa-levodopa 10-100 mg, 25-250 mg TABLET MO	1	
carbidopa-levodopa 25-100 mg TABLET MO	1	
carbidopa-levodopa 25-100 mg, 50-200 mg TABLET ER MO	1	
carbidopa-levodopa-entacapone 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg TABLET MO	1	
COMTAN 200 MG TABLET MO	3	PA,QL(300 per 30 days)
CREXONT 35-140 MG, 52.5-210 MG, 70-280 MG, 87.5-350 MG CAPSULE, IR/ER, BIPHASIC MO	3	ST,QL(180 per 30 days)
DHIVY 25-100 MG TABLET MO	3	
DUOPA 4.63-20 MG/ML INTESTINAL PUMP SUSPENSION DL	4	PA,QL(2800 per 28 days)
entacapone 200 mg TABLET MO	1	QL(300 per 30 days)
GOCOVRI 137 MG CAPSULE, ER 24 HR.	4	PA,QL(60 per 30 days)
GOCOVRI 68.5 MG CAPSULE, ER 24 HR.	4	PA,QL(30 per 30 days)
INBRIJA 42 MG CAPSULE DL	4	PA,QL(300 per 30 days)
INBRIJA 42 MG CAPSULE, W/INHALATION DEVICE DL	4	PA,QL(300 per 30 days)
LODOSYN 25 MG TABLET DL	4	PA
MIRAPEX ER 0.375 MG, 0.75 MG, 1.5 MG, 2.25 MG, 3 MG, 3.75 MG, 4.5 MG TABLET, ER 24 HR. MO	3	ST,QL(30 per 30 days)
NEUPRO 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR PATCH, 24 HR. MO	3	ST,QL(30 per 30 days)
NOURIANZ 20 MG, 40 MG TABLET DL	4	PA,QL(30 per 30 days)
ONGENTYS 25 MG, 50 MG CAPSULE MO	3	PA,QL(30 per 30 days)
OSMOLEX ER 129 MG, 193 MG, 258 MG TABLET, IR/ER 24 HR., BIPHASIC MO	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OSMOLEX ER 322 MG/DAY(129 MG X1-193MG X1) TABLET, IR/ER 24 HR., BIPHASIC MO	3	PA,QL(60 per 30 days)
PARLODEL 2.5 MG TABLET MO	3	PA
PARLODEL 5 MG CAPSULE MO	3	PA,QL(600 per 30 days)
pramipexole 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg TABLET MO	1	
pramipexole 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg TABLET, ER 24 HR. MO	1	ST,QL(30 per 30 days)
rasagiline 0.5 mg, 1 mg TABLET MO	1	QL(30 per 30 days)
ropinirole 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg TABLET MO	1	
ropinirole 12 mg, 2 mg, 4 mg, 6 mg, 8 mg TABLET, ER 24 HR. MO	1	ST,QL(90 per 30 days)
RYTARY 23.75-95 MG, 48.75-195 MG CAPSULE, ER MO	3	ST,QL(360 per 30 days)
RYTARY 36.25-145 MG CAPSULE, ER MO	3	ST,QL(270 per 30 days)
RYTARY 61.25-245 MG CAPSULE, ER MO	3	ST,QL(300 per 30 days)
selegiline hcl 5 mg CAPSULE MO	1	
selegiline hcl 5 mg TABLET MO	1	
SINEMET 10-100 MG, 25-100 MG TABLET MO	3	PA
STALEVO 100 25-100-200 MG TABLET DL	4	PA
STALEVO 125 31.25-125-200 MG TABLET DL	4	PA
STALEVO 150 37.5-150-200 MG TABLET DL	4	PA
STALEVO 200 50-200-200 MG TABLET DL	4	PA
STALEVO 50 12.5-50-200 MG TABLET DL	4	PA
STALEVO 75 18.75-75-200 MG TABLET DL	4	PA
TASMAR 100 MG TABLET DL	4	PA
tolcapone 100 mg TABLET DL	4	PA
trihexyphenidyl 0.4 mg/ml ELIXIR MO	1	
trihexyphenidyl 2 mg, 5 mg TABLET MO	1	
XADAGO 100 MG, 50 MG TABLET	4	PA,QL(30 per 30 days)
ZELAPAR 1.25 MG TABLET, DISINTEGRATING DL	4	
ANTIPSYCHOTICS		
ABILIFY 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET MO	3	PA
ABILIFY ASIMTUFII 720 MG/2.4 ML SUSPENSION, ER, SYRINGE	4	QL(2.4 per 56 days)
ABILIFY ASIMTUFII 960 MG/3.2 ML SUSPENSION, ER, SYRINGE	4	QL(3.2 per 56 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ABILIFY MAINTENA 300 MG, 400 MG SUSPENSION, ER, RECON DL	4	QL(1 per 28 days)
ABILIFY MAINTENA 300 MG, 400 MG SUSPENSION, ER, SYRINGE DL	4	QL(1 per 28 days)
ABILIFY MYCITE MAINTENANCE KIT 10 MG TABLET WITH SENSOR AND STRIP DL	4	PA,QL(30 per 30 days)
ABILIFY MYCITE MAINTENANCE KIT 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET WITH SENSOR AND STRIP DL	4	PA,QL(30 per 30 days)
ABILIFY MYCITE STARTER KIT 10 MG TABLET W/SENSOR AND STRIP, POD DL	4	PA,QL(30 per 30 days)
ABILIFY MYCITE STARTER KIT 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET W/SENSOR AND STRIP, POD DL	4	PA,QL(30 per 30 days)
<i>aripiprazole 1 mg/ml SOLUTION</i> MO	1	QL(750 per 30 days)
<i>aripiprazole 10 mg, 15 mg TABLET, DISINTEGRATING</i> MO	1	QL(60 per 30 days)
<i>aripiprazole 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg TABLET</i> MO	1	
ARISTADA 1,064 MG/3.9 ML SUSPENSION, ER, SYRINGE	4	QL(3.9 per 56 days)
ARISTADA 441 MG/1.6 ML SUSPENSION, ER, SYRINGE	4	QL(1.6 per 28 days)
ARISTADA 662 MG/2.4 ML SUSPENSION, ER, SYRINGE	4	QL(2.4 per 28 days)
ARISTADA 882 MG/3.2 ML SUSPENSION, ER, SYRINGE	4	QL(3.2 per 28 days)
ARISTADA INITIO 675 MG/2.4 ML SUSPENSION, ER, SYRINGE	4	QL(2.4 per 42 days)
<i>asenapine maleate 10 mg, 2.5 mg, 5 mg SUBLINGUAL TABLET</i> MO	1	PA,QL(60 per 30 days)
CAPLYTA 10.5 MG, 21 MG CAPSULE DL	4	PA,QL(30 per 30 days)
CAPLYTA 42 MG CAPSULE	4	PA,QL(30 per 30 days)
<i>chlorpromazine 10 mg, 25 mg TABLET</i> MO	1	BvsD
<i>chlorpromazine 100 mg, 200 mg, 50 mg TABLET</i> MO	1	
<i>chlorpromazine 100 mg/ml, 30 mg/ml CONCENTRATE</i> MO	1	
<i>chlorpromazine 25 mg/ml SOLUTION</i> MO	1	
<i>clozapine 100 mg TABLET</i> MO	1	QL(270 per 30 days)
<i>clozapine 100 mg TABLET, DISINTEGRATING</i> MO	1	PA,QL(270 per 30 days)
<i>clozapine 12.5 mg TABLET, DISINTEGRATING</i> MO	1	PA
<i>clozapine 150 mg TABLET, DISINTEGRATING</i> MO	1	PA,QL(180 per 30 days)
<i>clozapine 200 mg TABLET</i> MO	1	QL(135 per 30 days)
<i>clozapine 200 mg TABLET, DISINTEGRATING</i> MO	1	PA,QL(135 per 30 days)
<i>clozapine 25 mg TABLET</i> MO	1	QL(1080 per 30 days)
<i>clozapine 25 mg TABLET, DISINTEGRATING</i> MO	1	PA,QL(1080 per 30 days)
<i>clozapine 50 mg TABLET</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CLOZARIL 100 MG TABLET DL	4	QL(270 per 30 days)
CLOZARIL 200 MG TABLET DL	4	QL(135 per 30 days)
CLOZARIL 25 MG TABLET DL	4	QL(1080 per 30 days)
CLOZARIL 50 MG TABLET DL	4	
<i>droperidol 2.5 mg/ml SOLUTION</i> MO	1	
FANAPT 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET DL	4	PA,QL(60 per 30 days)
FANAPT 1MG(2)-2MG(2)- 4MG(2)-6MG(2) TABLET, DOSE PACK MO	3	PA,QL(56 per 28 days)
<i>fluphenazine decanoate 25 mg/ml SOLUTION</i> MO	1	
<i>fluphenazine hcl 1 mg, 10 mg, 2.5 mg, 5 mg TABLET</i> MO	1	
<i>fluphenazine hcl 2.5 mg/5 ml ELIXIR</i> MO	1	
<i>fluphenazine hcl 2.5 mg/ml SOLUTION</i> MO	1	
<i>fluphenazine hcl 5 mg/ml CONCENTRATE</i> MO	1	
GEODON 20 MG, 40 MG, 60 MG, 80 MG CAPSULE DL	4	PA
GEODON 20 MG/ML (FINAL CONC.) RECON SOLUTION MO	3	PA
HALDOL DECANOATE 100 MG/ML, 50 MG/ML SOLUTION MO	3	PA
<i>haloperidol 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg TABLET</i> MO	1	
<i>haloperidol decanoate 100 mg/ml, 50 mg/ml SOLUTION</i> MO	1	
<i>haloperidol lactate 2 mg/ml CONCENTRATE</i> MO	1	
<i>haloperidol lactate 5 mg/ml SOLUTION</i> MO	1	
<i>haloperidol lactate 5 mg/ml SYRINGE</i> MO	1	
INVEGA 1.5 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
INVEGA 3 MG, 9 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
INVEGA 6 MG TABLET, ER 24 HR. DL	4	PA,QL(60 per 30 days)
INVEGA HAFYERA 1,092 MG/3.5 ML SYRINGE	4	QL(3.5 per 180 days)
INVEGA HAFYERA 1,560 MG/5 ML SYRINGE	4	QL(5 per 180 days)
INVEGA SUSTENNA 117 MG/0.75 ML, 234 MG/1.5 ML, 78 MG/0.5 ML SYRINGE DL	4	QL(1.5 per 28 days)
INVEGA SUSTENNA 156 MG/ML SYRINGE DL	4	QL(1 per 28 days)
INVEGA SUSTENNA 39 MG/0.25 ML SYRINGE MO	3	QL(1.5 per 28 days)
INVEGA TRINZA 273 MG/0.88 ML SYRINGE	4	QL(0.88 per 90 days)
INVEGA TRINZA 410 MG/1.32 ML SYRINGE	4	QL(1.32 per 90 days)
INVEGA TRINZA 546 MG/1.75 ML SYRINGE	4	QL(1.75 per 90 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INVEGA TRINZA 819 MG/2.63 ML SYRINGE	4	QL(2.63 per 90 days)
LATUDA 120 MG, 20 MG, 40 MG, 60 MG TABLET	4	PA,QL(30 per 30 days)
LATUDA 80 MG TABLET	4	PA,QL(60 per 30 days)
loxapine succinate 10 mg, 25 mg, 5 mg, 50 mg CAPSULE MO	1	
lurasidone 120 mg, 20 mg, 40 mg, 60 mg TABLET MO	1	QL(30 per 30 days)
lurasidone 80 mg TABLET MO	1	QL(60 per 30 days)
LYBALVI 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG TABLET DL	4	PA,QL(30 per 30 days)
molindone 10 mg TABLET MO	1	PA,QL(240 per 30 days)
molindone 25 mg TABLET MO	1	PA,QL(270 per 30 days)
molindone 5 mg TABLET MO	1	PA,QL(360 per 30 days)
NUPLAZID 10 MG TABLET DL	4	PA,QL(30 per 30 days)
NUPLAZID 34 MG CAPSULE DL	4	PA,QL(30 per 30 days)
olanzapine 10 mg RECON SOLUTION MO	1	
olanzapine 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg TABLET MO	1	
olanzapine 10 mg, 5 mg TABLET, DISINTEGRATING MO	1	QL(30 per 30 days)
olanzapine 15 mg, 20 mg TABLET, DISINTEGRATING MO	1	QL(60 per 30 days)
paliperidone 1.5 mg, 3 mg, 9 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
paliperidone 6 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
perphenazine 16 mg, 2 mg, 4 mg, 8 mg TABLET MO	1	
PERSERIS 120 MG, 90 MG SUSPENSION, ER, SYRINGE DL	4	QL(1 per 28 days)
pimozide 1 mg, 2 mg TABLET MO	1	
quetiapine 100 mg TABLET MO	1	QL(90 per 30 days)
quetiapine 150 mg TABLET MO	1	QL(30 per 30 days)
quetiapine 150 mg TABLET, ER 24 HR. MO	1	QL(90 per 30 days)
quetiapine 200 mg TABLET MO	1	QL(120 per 30 days)
quetiapine 200 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
quetiapine 25 mg, 50 mg TABLET MO	1	QL(120 per 30 days)
quetiapine 300 mg, 400 mg TABLET MO	1	QL(60 per 30 days)
quetiapine 300 mg, 400 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
quetiapine 50 mg TABLET, ER 24 HR. MO	1	QL(120 per 30 days)
REXULTI 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG TABLET DL	4	PA,QL(30 per 30 days)
RISPERDAL 0.5 MG TABLET MO	3	QL(120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RISPERDAL 1 MG, 2 MG TABLET MO	3	QL(60 per 30 days)
RISPERDAL 1 MG/ML SOLUTION DL	4	
RISPERDAL 3 MG, 4 MG TABLET DL	4	QL(60 per 30 days)
RISPERDAL CONSTA 12.5 MG/2 ML, 25 MG/2 ML SUSPENSION, ER, RECON MO	3	QL(2 per 28 days)
RISPERDAL CONSTA 37.5 MG/2 ML, 50 MG/2 ML SUSPENSION, ER, RECON DL	4	QL(2 per 28 days)
<i>risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg TABLET, DISINTEGRATING</i> MO	1	ST,QL(60 per 30 days)
<i>risperidone 0.5 mg TABLET</i> MO	1	QL(120 per 30 days)
<i>risperidone 0.5 mg TABLET, DISINTEGRATING</i> MO	1	ST,QL(120 per 30 days)
<i>risperidone 1 mg/ml SOLUTION</i> MO	1	
SAPHRIS 10 MG, 2.5 MG, 5 MG SUBLINGUAL TABLET DL	4	PA,QL(60 per 30 days)
SECUADO 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR PATCH, 24 HR. DL	4	PA,QL(30 per 30 days)
SEROQUEL 100 MG TABLET MO	3	QL(90 per 30 days)
SEROQUEL 200 MG, 25 MG, 50 MG TABLET MO	3	QL(120 per 30 days)
SEROQUEL 300 MG, 400 MG TABLET MO	3	QL(60 per 30 days)
SEROQUEL XR 150 MG TABLET, ER 24 HR. MO	3	PA,QL(90 per 30 days)
SEROQUEL XR 200 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
SEROQUEL XR 300 MG, 400 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)
SEROQUEL XR 50 MG TABLET, ER 24 HR. MO	3	PA,QL(120 per 30 days)
SEROQUEL XR 50 MG(3)-200 MG (1)-300 MG(11) TABLET, ER 24 HR., DOSE PACK MO	3	PA,QL(15 per 30 days)
<i>thioridazine 10 mg, 100 mg, 25 mg, 50 mg TABLET</i> MO	1	
<i>thiothixene 1 mg, 10 mg, 2 mg, 5 mg CAPSULE</i> MO	1	
<i>trifluoperazine 1 mg, 10 mg, 2 mg, 5 mg TABLET</i> MO	1	
UZEDY 100 MG/0.28 ML SUSPENSION, ER, SYRINGE DL	4	QL(0.28 per 28 days)
UZEDY 125 MG/0.35 ML SUSPENSION, ER, SYRINGE DL	4	QL(0.35 per 28 days)
UZEDY 150 MG/0.42 ML SUSPENSION, ER, SYRINGE	4	QL(0.42 per 56 days)
UZEDY 200 MG/0.56 ML SUSPENSION, ER, SYRINGE	4	QL(0.56 per 56 days)
UZEDY 250 MG/0.7 ML SUSPENSION, ER, SYRINGE	4	QL(0.7 per 56 days)
UZEDY 50 MG/0.14 ML SUSPENSION, ER, SYRINGE DL	4	QL(0.14 per 28 days)
UZEDY 75 MG/0.21 ML SUSPENSION, ER, SYRINGE DL	4	QL(0.21 per 28 days)
VERSACLOZ 50 MG/ML SUSPENSION DL	4	PA,QL(540 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VRAYLAR 1.5 MG (1)- 3 MG (6) CAPSULE, DOSE PACK MO	3	PA
VRAYLAR 1.5 MG, 3 MG, 4.5 MG, 6 MG CAPSULE	4	PA,QL(30 per 30 days)
ziprasidone hcl 20 mg, 40 mg, 60 mg, 80 mg CAPSULE MO	1	
ziprasidone mesylate 20 mg/ml (final conc.) RECON SOLUTION MO	1	
ZYPREXA 10 MG RECON SOLUTION MO	3	
ZYPREXA 10 MG, 15 MG, 2.5 MG, 20 MG, 5 MG, 7.5 MG TABLET	4	
ZYPREXA RELPREVV 210 MG SUSPENSION FOR RECONSTITUTION MO	3	QL(4 per 28 days)
ZYPREXA RELPREVV 300 MG SUSPENSION FOR RECONSTITUTION	4	QL(2 per 28 days)
ZYPREXA RELPREVV 405 MG SUSPENSION FOR RECONSTITUTION	4	QL(1 per 28 days)
ZYPREXA ZYDIS 10 MG TABLET, DISINTEGRATING	4	QL(30 per 30 days)
ZYPREXA ZYDIS 15 MG, 20 MG TABLET, DISINTEGRATING	4	QL(60 per 30 days)
ZYPREXA ZYDIS 5 MG TABLET, DISINTEGRATING MO	3	QL(30 per 30 days)
ANTISPASTICITY AGENTS		
baclofen 10 mg TABLET MO	1	
baclofen 10 mg/5 ml (2 mg/ml), 5 mg/5 ml SOLUTION DL	4	
baclofen 15 mg, 20 mg TABLET MO	1	
baclofen 25 mg/5 ml (5 mg/ml) SUSPENSION DL	4	QL(480 per 30 days)
baclofen 5 mg TABLET MO	1	QL(90 per 30 days)
DANTRIUM 20 MG RECON SOLUTION MO	3	
DANTRIUM 25 MG CAPSULE MO	3	
dantrolene 100 mg, 25 mg, 50 mg CAPSULE MO	1	
dantrolene 20 mg RECON SOLUTION MO	1	
FLEQSUVY 25 MG/5 ML (5 MG/ML) SUSPENSION DL	4	QL(480 per 30 days)
LYVISPAH 10 MG, 20 MG GRANULES IN PACKET MO	3	ST,QL(120 per 30 days)
LYVISPAH 5 MG GRANULES IN PACKET MO	3	ST,QL(270 per 30 days)
OZOBAX 5 MG/5 ML SOLUTION DL	4	
OZOBAX DS 10 MG/5 ML (2 MG/ML) SOLUTION DL	4	
revonto 20 mg RECON SOLUTION MO	1	
tizanidine 2 mg, 4 mg TABLET MO	1	
tizanidine 2 mg, 4 mg, 6 mg CAPSULE MO	1	ST
ZANAFLEX 2 MG, 4 MG, 6 MG CAPSULE MO	3	ST
ZANAFLEX 4 MG TABLET MO	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ANTIVIRALS		
<i>abacavir</i> 20 mg/ml SOLUTION MO	1	QL(960 per 30 days)
<i>abacavir</i> 300 mg TABLET MO	1	QL(60 per 30 days)
<i>abacavir-lamivudine</i> 600-300 mg TABLET MO	1	QL(30 per 30 days)
<i>acyclovir</i> 200 mg CAPSULE MO	1	
<i>acyclovir</i> 200 mg/5 ml SUSPENSION MO	1	
<i>acyclovir</i> 400 mg, 800 mg TABLET MO	1	
<i>acyclovir</i> 5 % CREAM MO	3	PA,QL(5 per 30 days)
<i>acyclovir</i> 5 % OINTMENT MO	1	PA,QL(30 per 30 days)
<i>acyclovir sodium</i> 50 mg/ml SOLUTION MO	1	BvsD
<i>adefovir</i> 10 mg TABLET MO	1	
APRETUDE 600 MG/3 ML (200 MG/ML) SUSPENSION, ER DL	4	QL(21 per 365 days)
APTIVUS 250 MG CAPSULE DL	4	QL(120 per 30 days)
<i>atazanavir</i> 150 mg, 200 mg CAPSULE MO	1	QL(60 per 30 days)
<i>atazanavir</i> 300 mg CAPSULE MO	1	QL(30 per 30 days)
ATRIPLA 600-200-300 MG TABLET DL	4	QL(30 per 30 days)
BARACLUDE 0.05 MG/ML SOLUTION DL	4	QL(630 per 30 days)
BARACLUDE 0.5 MG, 1 MG TABLET DL	4	PA,QL(30 per 30 days)
BIKTARVY 30-120-15 MG, 50-200-25 MG TABLET DL	4	QL(30 per 30 days)
CABENUVA 400 MG/2 ML- 600 MG/2 ML, 600 MG/3 ML- 900 MG/3 ML SUSPENSION, ER DL	4	QL(50 per 365 days)
<i>cidofovir</i> 75 mg/ml SOLUTION DL	4	
CIMDUO 300-300 MG TABLET DL	4	QL(30 per 30 days)
COMBIVIR 150-300 MG TABLET DL	4	QL(60 per 30 days)
COMPLERA 200-25-300 MG TABLET DL	4	QL(30 per 30 days)
<i>darunavir</i> 600 mg TABLET DL	4	QL(60 per 30 days)
<i>darunavir</i> 800 mg TABLET DL	4	QL(30 per 30 days)
DELSTRIGO 100-300-300 MG TABLET DL	4	QL(30 per 30 days)
DENAVIR 1 % CREAM MO	3	PA
DESCOVY 120-15 MG, 200-25 MG TABLET DL	4	QL(30 per 30 days)
<i>didanosine</i> 250 mg, 400 mg CAPSULE, DR/EC MO	1	QL(30 per 30 days)
DOVATO 50-300 MG TABLET DL	4	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EDURANT 25 MG TABLET DL	4	QL(30 per 30 days)
efavirenz 200 mg CAPSULE MO	1	QL(120 per 30 days)
efavirenz 50 mg CAPSULE MO	1	QL(480 per 30 days)
efavirenz 600 mg TABLET MO	1	QL(30 per 30 days)
efavirenz-emtricitabin-tenofovir 600-200-300 mg TABLET MO	1	QL(30 per 30 days)
efavirenz-lamivudine-tenofovir disoproxil fumarate 400-300-300 mg, 600-300-300 mg TABLET DL	4	QL(30 per 30 days)
emtricitabine 200 mg CAPSULE MO	1	QL(30 per 30 days)
emtricitabine-tenofovir (tdf) 100-150 mg, 133-200 mg, 167-250 mg, 200-300 mg TABLET MO	1	QL(30 per 30 days)
EMTRIVA 10 MG/ML SOLUTION MO	3	QL(680 per 28 days)
EMTRIVA 200 MG CAPSULE MO	3	QL(30 per 30 days)
entecavir 0.5 mg, 1 mg TABLET MO	1	QL(30 per 30 days)
EPCLUSA 150-37.5 MG PELLETS IN PACKET DL	4	PA,QL(28 per 28 days)
EPCLUSA 200-50 MG PELLETS IN PACKET DL	4	PA,QL(56 per 28 days)
EPCLUSA 200-50 MG, 400-100 MG TABLET DL	4	PA,QL(28 per 28 days)
EPIVIR 10 MG/ML SOLUTION MO	3	QL(900 per 30 days)
EPIVIR 150 MG TABLET MO	3	QL(60 per 30 days)
EPIVIR 300 MG TABLET MO	3	QL(30 per 30 days)
EPIVIR HBV 100 MG TABLET MO	3	QL(90 per 30 days)
EPIVIR HBV 25 MG/5 ML (5 MG/ML) SOLUTION MO	3	
EPZICOM 600-300 MG TABLET DL	4	QL(30 per 30 days)
etravirine 100 mg TABLET DL	4	QL(120 per 30 days)
etravirine 200 mg TABLET DL	4	QL(60 per 30 days)
EVOTAZ 300-150 MG TABLET DL	4	QL(30 per 30 days)
famciclovir 125 mg, 250 mg, 500 mg TABLET MO	1	QL(90 per 30 days)
FLUMADINE 100 MG TABLET MO	3	
fosamprenavir 700 mg TABLET DL	4	QL(120 per 30 days)
foscarnet 24 mg/ml SOLUTION MO	1	BvsD
FUZEON 90 MG RECON SOLUTION DL	4	QL(60 per 30 days)
ganciclovir sodium 50 mg/ml SOLUTION MO	1	BvsD
ganciclovir sodium 500 mg RECON SOLUTION MO	1	BvsD
GENVOYA 150-150-200-10 MG TABLET DL	4	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HARVONI 33.75-150 MG PELLETS IN PACKET DL	4	PA,QL(28 per 28 days)
HARVONI 45-200 MG PELLETS IN PACKET DL	4	PA,QL(56 per 28 days)
HARVONI 45-200 MG, 90-400 MG TABLET DL	4	PA,QL(28 per 28 days)
HEPSERA 10 MG TABLET DL	4	
INTELENCE 100 MG TABLET DL	4	QL(120 per 30 days)
INTELENCE 200 MG TABLET DL	4	QL(60 per 30 days)
INTELENCE 25 MG TABLET MO	3	QL(120 per 30 days)
ISENTRESS 100 MG CHEWABLE TABLET DL	4	QL(180 per 30 days)
ISENTRESS 100 MG POWDER IN PACKET MO	3	QL(300 per 30 days)
ISENTRESS 25 MG CHEWABLE TABLET MO	2	QL(180 per 30 days)
ISENTRESS 400 MG TABLET DL	4	QL(120 per 30 days)
ISENTRESS HD 600 MG TABLET DL	4	QL(60 per 30 days)
JULUCA 50-25 MG TABLET DL	4	QL(30 per 30 days)
KALETRA 100-25 MG TABLET MO	3	QL(300 per 30 days)
KALETRA 200-50 MG TABLET MO	3	QL(150 per 30 days)
KALETRA 400-100 MG/5 ML SOLUTION DL	4	
LAGEVRIO (EUA) 200 MG CAPSULE MO	2	QL(40 per 5 days)
<i>lamivudine 10 mg/ml SOLUTION</i> MO	1	QL(900 per 30 days)
<i>lamivudine 100 mg TABLET</i> MO	1	QL(90 per 30 days)
<i>lamivudine 150 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>lamivudine 300 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>lamivudine-zidovudine 150-300 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>ledipasvir-sofosbuvir 90-400 mg TABLET</i> DL	4	PA,QL(28 per 28 days)
LEXIVA 50 MG/ML SUSPENSION MO	3	QL(1575 per 28 days)
LEXIVA 700 MG TABLET DL	4	QL(120 per 30 days)
LIVTENCITY 200 MG TABLET DL	4	PA,QL(120 per 30 days)
<i>lopinavir-ritonavir 100-25 mg TABLET</i> MO	1	QL(300 per 30 days)
<i>lopinavir-ritonavir 200-50 mg TABLET</i> MO	1	QL(150 per 30 days)
<i>lopinavir-ritonavir 400-100 mg/5 ml SOLUTION</i> MO	1	
<i>maraviroc 150 mg TABLET</i> DL	4	QL(240 per 30 days)
<i>maraviroc 300 mg TABLET</i> DL	4	QL(120 per 30 days)
MAVYRET 100-40 MG TABLET DL	4	PA,QL(84 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MAVYRET 50-20 MG PELLETS IN PACKET DL	4	PA,QL(150 per 30 days)
nevirapine 100 mg TABLET, ER 24 HR. MO	1	QL(120 per 30 days)
nevirapine 200 mg TABLET MO	1	QL(60 per 30 days)
nevirapine 400 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
nevirapine 50 mg/5 ml SUSPENSION MO	1	QL(1200 per 30 days)
NORVIR 100 MG CAPSULE MO	3	QL(360 per 30 days)
NORVIR 100 MG POWDER IN PACKET MO	3	QL(360 per 30 days)
NORVIR 100 MG TABLET MO	3	QL(360 per 30 days)
NORVIR 80 MG/ML SOLUTION MO	3	QL(480 per 30 days)
ODEFSEY 200-25-25 MG TABLET DL	4	QL(30 per 30 days)
oseltamivir 30 mg CAPSULE MO	1	QL(224 per 365 days)
oseltamivir 45 mg, 75 mg CAPSULE MO	1	QL(112 per 365 days)
oseltamivir 6 mg/ml SUSPENSION FOR RECONSTITUTION MO	1	QL(1440 per 365 days)
PAXLOVID 150-100 MG TABLET, DOSE PACK MO	2	QL(40 per 10 days)
PAXLOVID 300 MG (150 MG X 2)-100 MG TABLET, DOSE PACK MO	2	QL(60 per 10 days)
penciclovir 1 % CREAM MO	1	PA
PIFELTRO 100 MG TABLET DL	4	QL(60 per 30 days)
PREVYMIS 240 MG TABLET DL	4	PA,QL(28 per 28 days)
PREVYMIS 240 MG/12 ML SOLUTION DL	4	PA,QL(336 per 28 days)
PREVYMIS 480 MG TABLET DL	4	PA
PREVYMIS 480 MG/24 ML SOLUTION DL	4	PA,QL(672 per 28 days)
PREZCOBIX 800-150 MG-MG TABLET DL	4	QL(30 per 30 days)
PREZISTA 100 MG/ML SUSPENSION DL	4	QL(360 per 30 days)
PREZISTA 150 MG TABLET DL	4	QL(240 per 30 days)
PREZISTA 600 MG TABLET DL	4	QL(60 per 30 days)
PREZISTA 75 MG TABLET MO	3	QL(480 per 30 days)
PREZISTA 800 MG TABLET DL	4	QL(30 per 30 days)
RELENZA DISKHALER 5 MG/ACTUATION BLISTER WITH DEVICE MO	3	QL(60 per 180 days)
RETROVIR 10 MG/ML SOLUTION MO	3	
RETROVIR 10 MG/ML SYRUP MO	3	QL(1680 per 28 days)
RETROVIR 100 MG CAPSULE MO	3	QL(180 per 30 days)
REYATAZ 200 MG CAPSULE DL	4	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
REYATAZ 300 MG CAPSULE DL	4	QL(30 per 30 days)
REYATAZ 50 MG POWDER IN PACKET MO	3	
<i>ribavirin 200 mg CAPSULE</i> MO	1	
<i>ribavirin 200 mg TABLET</i> MO	1	
<i>rimantadine 100 mg TABLET</i> MO	1	
<i>ritonavir 100 mg TABLET</i> MO	1	QL(360 per 30 days)
RUKOBIA 600 MG TABLET, ER 12 HR. DL	4	QL(60 per 30 days)
SELZENTRY 150 MG TABLET DL	4	QL(240 per 30 days)
SELZENTRY 20 MG/ML SOLUTION DL	4	QL(1800 per 30 days)
SELZENTRY 25 MG TABLET MO	3	QL(240 per 30 days)
SELZENTRY 300 MG, 75 MG TABLET DL	4	QL(120 per 30 days)
SOVALDI 150 MG PELLETS IN PACKET DL	4	PA,QL(28 per 28 days)
SOVALDI 200 MG PELLETS IN PACKET DL	4	PA,QL(56 per 28 days)
SOVALDI 200 MG, 400 MG TABLET DL	4	PA,QL(28 per 28 days)
<i>stavudine 15 mg, 20 mg CAPSULE</i> MO	1	QL(120 per 30 days)
<i>stavudine 30 mg, 40 mg CAPSULE</i> MO	1	QL(60 per 30 days)
STRIBILD 150-150-200-300 MG TABLET DL	4	QL(30 per 30 days)
SUNLENCA 300 MG TABLET DL	4	QL(10 per 365 days)
SUNLENCA 309 MG/ML SOLUTION	4	QL(9 per 365 days)
SUSTIVA 200 MG CAPSULE DL	4	QL(120 per 30 days)
SUSTIVA 50 MG CAPSULE DL	4	QL(480 per 30 days)
SUSTIVA 600 MG TABLET DL	4	QL(30 per 30 days)
SYMFI 600-300-300 MG TABLET DL	4	QL(30 per 30 days)
SYMFI LO 400-300-300 MG TABLET DL	4	QL(30 per 30 days)
SYMTUZA 800-150-200-10 MG TABLET DL	4	QL(30 per 30 days)
TAMIFLU 30 MG CAPSULE MO	3	PA,QL(224 per 365 days)
TAMIFLU 45 MG, 75 MG CAPSULE MO	3	PA,QL(112 per 365 days)
TAMIFLU 6 MG/ML SUSPENSION FOR RECONSTITUTION MO	3	PA,QL(1440 per 365 days)
<i>tenofovir disoproxil fumarate 300 mg TABLET</i> MO	1	QL(30 per 30 days)
TIVICAY 10 MG TABLET MO	3	QL(60 per 30 days)
TIVICAY 25 MG, 50 MG TABLET DL	4	QL(60 per 30 days)
TIVICAY PD 5 MG TABLET FOR SUSPENSION DL	4	QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TRIUMEQ 600-50-300 MG TABLET DL	4	QL(30 per 30 days)
TRIUMEQ PD 60-5-30 MG TABLET FOR SUSPENSION MO	3	QL(180 per 30 days)
TRIZIVIR 300-150-300 MG TABLET DL	4	QL(60 per 30 days)
TROGARZO 200 MG/1.33 ML (150 MG/ML) SOLUTION DL	4	
TRUVADA 100-150 MG, 133-200 MG, 167-250 MG, 200-300 MG TABLET DL	4	QL(30 per 30 days)
TYBOST 150 MG TABLET MO	2	QL(30 per 30 days)
<i>valacyclovir 1 gram, 500 mg TABLET MO</i>	1	
VALCYTE 450 MG TABLET DL	4	PA,QL(120 per 30 days)
VALCYTE 50 MG/ML RECON SOLUTION DL	4	PA,QL(1056 per 30 days)
<i>valganciclovir 450 mg TABLET MO</i>	1	QL(120 per 30 days)
<i>valganciclovir 50 mg/ml RECON SOLUTION DL</i>	4	QL(1056 per 30 days)
VALTREX 1 GRAM, 500 MG TABLET MO	3	PA
VEMLIDY 25 MG TABLET DL	4	QL(30 per 30 days)
VIRACEPT 250 MG TABLET DL	4	QL(300 per 30 days)
VIRACEPT 625 MG TABLET DL	4	QL(120 per 30 days)
VIREAD 150 MG, 200 MG, 250 MG, 300 MG TABLET DL	4	QL(30 per 30 days)
VIREAD 40 MG/SCOOP (40 MG/GRAM) POWDER DL	4	QL(240 per 30 days)
VOCABRIA 30 MG TABLET DL	4	QL(30 per 30 days)
VOSEVI 400-100-100 MG TABLET DL	4	PA,QL(28 per 28 days)
XERESE 5-1 % CREAM DL	4	QL(5 per 30 days)
XOFLUZA 20 MG, 40 MG, 80 MG TABLET MO	3	
ZEPATIER 50-100 MG TABLET DL	4	PA,QL(28 per 28 days)
ZIAGEN 20 MG/ML SOLUTION MO	3	QL(960 per 30 days)
ZIAGEN 300 MG TABLET MO	3	QL(60 per 30 days)
<i>zidovudine 10 mg/ml SYRUP MO</i>	1	QL(1680 per 28 days)
<i>zidovudine 100 mg CAPSULE MO</i>	1	QL(180 per 30 days)
<i>zidovudine 300 mg TABLET MO</i>	1	QL(60 per 30 days)
ZIRGAN 0.15 % GEL MO	3	QL(5 per 30 days)
ZOVIRAX 200 MG/5 ML SUSPENSION MO	3	PA
ZOVIRAX 5 % CREAM MO	3	PA,QL(5 per 30 days)
ZOVIRAX 5 % OINTMENT MO	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ANXIOLYTICS		
alprazolam 0.25 mg, 0.5 mg, 1 mg TABLET DL	1	QL(120 per 30 days)
alprazolam 0.25 mg, 0.5 mg, 1 mg, 2 mg TABLET, DISINTEGRATING DL	1	
alprazolam 0.5 mg, 1 mg, 2 mg, 3 mg TABLET, ER 24 HR. DL	1	QL(60 per 30 days)
alprazolam 2 mg TABLET DL	1	QL(150 per 30 days)
alprazolam intensol 1 mg/ml CONCENTRATE DL	1	
ATIVAN 0.5 MG, 1 MG TABLET DL	4	PA,QL(90 per 30 days)
ATIVAN 2 MG TABLET DL	4	PA,QL(150 per 30 days)
ATIVAN 2 MG/ML, 4 MG/ML SOLUTION DL	3	PA
bupirone 10 mg, 5 mg TABLET MO	1	
bupirone 15 mg, 30 mg, 7.5 mg TABLET MO	1	
chlordiazepoxide hcl 10 mg, 25 mg, 5 mg CAPSULE DL	1	QL(120 per 30 days)
clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg TABLET, DISINTEGRATING DL	1	
clonazepam 0.5 mg, 1 mg TABLET DL	1	
clonazepam 2 mg TABLET DL	1	
clorazepate dipotassium 15 mg, 3.75 mg, 7.5 mg TABLET DL	1	
diazepam 10 mg TABLET DL	1	QL(120 per 30 days)
diazepam 2 mg TABLET DL	1	QL(90 per 30 days)
diazepam 5 mg TABLET DL	1	QL(90 per 30 days)
diazepam 5 mg/5 ml (1 mg/ml), 5 mg/5 ml (1 mg/ml, 5 ml) SOLUTION DL	1	QL(1200 per 30 days)
diazepam 5 mg/ml CONCENTRATE DL	1	QL(240 per 30 days)
diazepam 5 mg/ml SOLUTION DL	1	
diazepam 5 mg/ml SYRINGE DL	1	
diazepam intensol 5 mg/ml CONCENTRATE DL	1	QL(240 per 30 days)
doxepin 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg CAPSULE MO	1	
doxepin 10 mg/ml CONCENTRATE MO	1	
hydroxyzine hcl 10 mg, 50 mg TABLET MO	1	
hydroxyzine hcl 10 mg/5 ml, 25 mg/ml, 50 mg/ml SOLUTION MO	1	
hydroxyzine hcl 25 mg TABLET MO	1	
KLONOPIN 0.5 MG, 1 MG, 2 MG TABLET DL	3	PA
lorazepam 0.5 mg, 1 mg TABLET DL	1	QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
lorazepam 2 mg TABLET DL	1	QL(150 per 30 days)
lorazepam 2 mg/ml CONCENTRATE DL	1	QL(150 per 30 days)
lorazepam 2 mg/ml SYRINGE DL	1	
lorazepam 2 mg/ml, 4 mg/ml SOLUTION DL	1	
lorazepam intensol 2 mg/ml CONCENTRATE DL	1	QL(150 per 30 days)
LOREEV XR 1 MG CAPSULE, ER 24 HR. DL	4	PA,QL(210 per 30 days)
LOREEV XR 1.5 MG, 2 MG CAPSULE, ER 24 HR. DL	4	PA,QL(150 per 30 days)
LOREEV XR 3 MG CAPSULE, ER 24 HR. DL	4	PA,QL(90 per 30 days)
meprobamate 200 mg, 400 mg TABLET MO	1	
oxazepam 10 mg, 15 mg, 30 mg CAPSULE DL	1	
TRANXENE T-TAB 7.5 MG TABLET DL	3	PA
VALIUM 10 MG TABLET DL	3	PA,QL(120 per 30 days)
VALIUM 2 MG, 5 MG TABLET DL	3	PA,QL(90 per 30 days)
XANAX 0.25 MG, 0.5 MG, 1 MG TABLET DL	3	PA,QL(120 per 30 days)
XANAX 2 MG TABLET DL	3	PA,QL(150 per 30 days)
XANAX XR 0.5 MG, 1 MG, 2 MG, 3 MG TABLET, ER 24 HR. DL	3	PA,QL(60 per 30 days)
BIPOLAR AGENTS		
lithium carbonate 150 mg, 300 mg, 600 mg CAPSULE MO	1	
lithium carbonate 300 mg TABLET MO	1	
lithium carbonate 300 mg, 450 mg TABLET ER MO	1	
lithium citrate 8 meq/5 ml SOLUTION MO	1	
LITHOBID 300 MG TABLET ER MO	3	
BLOOD GLUCOSE REGULATORS		
acarbose 100 mg, 25 mg, 50 mg TABLET MO	1	
ACTOPLUS MET 15-850 MG TABLET MO	3	PA,QL(90 per 30 days)
ACTOS 15 MG, 30 MG, 45 MG TABLET MO	3	PA,QL(30 per 30 days)
ADLYXIN 10 MCG/0.2 ML- 20 MCG/0.2 ML, 20 MCG/0.2 ML PEN INJECTOR MO	3	PA,QL(6 per 28 days)
ADMELOG SOLOSTAR U-100 INSULIN 100 UNIT/ML INSULIN PEN CI,MO	3	ST
ADMELOG U-100 INSULIN LISPRO 100 UNIT/ML SOLUTION CI,MO	3	ST
AFREZZA 12 UNIT CARTRIDGE WITH INHALER CI	4	PA,QL(90 per 30 days)
AFREZZA 4 UNIT (90)/ 8 UNIT (90), 4 UNIT/8 UNIT/ 12 UNIT (60), 8 UNIT (90)/ 12 UNIT (90) CARTRIDGE WITH INHALER CI	4	PA,QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AFREZZA 4 UNIT, 8 UNIT CARTRIDGE WITH INHALER CI,MO	3	PA,QL(90 per 30 days)
AMARYL 1 MG, 2 MG, 4 MG TABLET MO	3	PA
APIDRA SOLOSTAR U-100 INSULIN 100 UNIT/ML INSULIN PEN CI,MO	3	ST
APIDRA U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	3	ST
BAQSIMI 3 MG/ACTUATION SPRAY, NON-AEROSOL MO	3	ST
BASAGLAR KWIKPEN U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
BASAGLAR TEMPO PEN(U-100)INSLN 100 UNIT/ML (3 ML) INSULIN PEN, SENSOR CI,MO	3	PA
BYDUREON BCISE 2 MG/0.85 ML AUTO-INJECTOR MO	3	PA,QL(3.4 per 28 days)
BYETTA 10 MCG/DOSE(250 MCG/ML) 2.4 ML, 5 MCG/DOSE (250 MCG/ML) 1.2 ML PEN INJECTOR MO	3	PA,QL(2.4 per 30 days)
CYCLOSET 0.8 MG TABLET MO	3	ST,QL(180 per 30 days)
<i>diazoxide 50 mg/ml SUSPENSION</i> DL	4	
DUETACT 30-2 MG, 30-4 MG TABLET MO	3	QL(30 per 30 days)
FARXIGA 10 MG, 5 MG TABLET MO	3	QL(30 per 30 days)
FIASP FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
FIASP PENFILL U-100 INSULIN 100 UNIT/ML (3 ML) CARTRIDGE CI,MO	2	
FIASP U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
<i>glimepiride 1 mg TABLET</i> MO	1	
<i>glimepiride 2 mg, 4 mg TABLET</i> MO	1	
<i>glipizide 10 mg, 2.5 mg, 5 mg TABLET, ER 24 HR.</i> MO	1	
<i>glipizide 10 mg, 5 mg TABLET</i> MO	1	
<i>glipizide 2.5 mg TABLET</i> MO	1	
<i>glipizide-metformin 2.5-250 mg, 2.5-500 mg, 5-500 mg TABLET</i> MO	1	
GLUCAGEN HYPOKIT 1 MG RECON SOLUTION MO	3	ST
GLUCAGON (HCL) EMERGENCY KIT 1 MG RECON SOLUTION MO	3	ST
GLUCAGON EMERGENCY KIT (HUMAN) 1 MG RECON SOLUTION MO	3	ST
<i>glucagon emergency kit (human) 1 mg RECON SOLUTION</i> MO	3	ST
GLUCOTROL XL 10 MG, 2.5 MG, 5 MG TABLET, ER 24 HR. MO	3	
GLUMETZA 1,000 MG TABLET, GAST. RETENTION 24 HR. DL	4	ST,QL(60 per 30 days)
GLUMETZA 500 MG TABLET, GAST. RETENTION 24 HR. DL	4	ST,QL(120 per 30 days)
<i>glyburide 1.25 mg, 2.5 mg, 5 mg TABLET</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
glyburide micronized 1.5 mg, 3 mg, 6 mg TABLET MO	1	
glyburide-metformin 1.25-250 mg, 2.5-500 mg, 5-500 mg TABLET MO	1	
GLYNASE 1.5 MG, 3 MG, 6 MG TABLET MO	3	
GLYXAMBI 10-5 MG, 25-5 MG TABLET MO	2	QL(30 per 30 days)
GVOKE 1 MG/0.2 ML SOLUTION MO	3	ST
GVOKE HYPOPEN 1-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML AUTO-INJECTOR MO	3	ST
GVOKE HYPOPEN 2-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML AUTO-INJECTOR MO	3	ST
GVOKE PFS 1-PACK SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML SYRINGE MO	3	ST
GVOKE PFS 2-PACK SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML SYRINGE MO	3	ST
HUMALOG JUNIOR KWIKPEN U-100 100 UNIT/ML INSULIN PEN, HALF-UNIT CI,MO	2	
HUMALOG KWIKPEN INSULIN 100 UNIT/ML, 200 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
HUMALOG MIX 50-50 INSULN U-100 100 UNIT/ML (50-50) SUSPENSION CI,MO	2	
HUMALOG MIX 50-50 KWIKPEN 100 UNIT/ML (50-50) INSULIN PEN CI,MO	2	
HUMALOG MIX 75-25 KWIKPEN 100 UNIT/ML (75-25) INSULIN PEN CI,MO	2	
HUMALOG MIX 75-25(U-100)INSULN 100 UNIT/ML (75-25) SUSPENSION CI,MO	2	
HUMALOG TEMPO PEN(U-100)INSULN 100 UNIT/ML INSULIN PEN, SENSOR CI,MO	3	ST
HUMALOG U-100 INSULIN 100 UNIT/ML CARTRIDGE CI,MO	2	
HUMALOG U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
HUMULIN 70/30 U-100 INSULIN 100 UNIT/ML (70-30) SUSPENSION CI,MO	2	
HUMULIN 70/30 U-100 KWIKPEN 100 UNIT/ML (70-30) INSULIN PEN CI,MO	2	
HUMULIN N NPH INSULIN KWIKPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
HUMULIN N NPH U-100 INSULIN 100 UNIT/ML SUSPENSION CI,MO	2	
HUMULIN R REGULAR U-100 INSULN 100 UNIT/ML SOLUTION CI,MO	2	
HUMULIN R U-500 (CONC) INSULIN 500 UNIT/ML SOLUTION CI	4	
HUMULIN R U-500 (CONC) KWIKPEN 500 UNIT/ML (3 ML) INSULIN PEN CI	4	
INSULIN ASP PRT-INSULIN ASPART 100 UNIT/ML (70-30) INSULIN PEN CI,MO	2	
INSULIN ASP PRT-INSULIN ASPART 100 UNIT/ML (70-30) SOLUTION CI,MO	2	
INSULIN ASPART U-100 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INSULIN ASPART U-100 100 UNIT/ML CARTRIDGE CI,MO	2	
INSULIN ASPART U-100 100 UNIT/ML SOLUTION CI,MO	2	
INSULIN DEGLUDEC 100 UNIT/ML (3 ML), 200 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
INSULIN DEGLUDEC 100 UNIT/ML SOLUTION CI,MO	3	PA
INSULIN GLARGINE 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
INSULIN GLARGINE 100 UNIT/ML SOLUTION CI,MO	3	PA
INSULIN GLARGINE U-300 CONC 300 UNIT/ML (1.5 ML), 300 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
INSULIN GLARGINE-YFGN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
INSULIN GLARGINE-YFGN 100 UNIT/ML SOLUTION CI,MO	3	PA
INSULIN LISPRO 100 UNIT/ML INSULIN PEN CI,MO	2	
INSULIN LISPRO 100 UNIT/ML INSULIN PEN, HALF-UNIT CI,MO	2	
INSULIN LISPRO 100 UNIT/ML SOLUTION CI,MO	2	
INSULIN LISPRO PROTAMIN-LISPRO 100 UNIT/ML (75-25) INSULIN PEN CI,MO	2	
INVOKAMET 150-1,000 MG, 150-500 MG, 50-1,000 MG, 50-500 MG TABLET MO	2	QL(60 per 30 days)
INVOKAMET XR 150-1,000 MG, 150-500 MG, 50-1,000 MG, 50-500 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(60 per 30 days)
INVOKANA 100 MG, 300 MG TABLET MO	2	QL(30 per 30 days)
JANUMET 50-1,000 MG, 50-500 MG TABLET MO	2	QL(60 per 30 days)
JANUMET XR 100-1,000 MG TABLET, ER 24 HR., MULTIPHASE MO	2	QL(30 per 30 days)
JANUMET XR 50-1,000 MG, 50-500 MG TABLET, ER 24 HR., MULTIPHASE MO	2	QL(60 per 30 days)
JANUVIA 100 MG, 25 MG, 50 MG TABLET MO	2	QL(30 per 30 days)
JARDIANCE 10 MG, 25 MG TABLET MO	2	QL(30 per 30 days)
JENTADUETO 2.5-1,000 MG, 2.5-500 MG TABLET MO	2	QL(60 per 30 days)
JENTADUETO 2.5-850 MG TABLET MO	2	QL(60 per 30 days)
JENTADUETO XR 2.5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(60 per 30 days)
JENTADUETO XR 5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(30 per 30 days)
KAZANO 12.5-1,000 MG, 12.5-500 MG TABLET MO	3	PA,QL(60 per 30 days)
LANTUS SOLOSTAR U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
LANTUS U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LEVEMIR FLEXPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
LEVEMIR FLEXTOUCH U100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
LEVEMIR U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	3	PA
<i>liraglutide 0.6 mg/0.1 ml (18 mg/3 ml) PEN INJECTOR</i> MO	3	PA,QL(9 per 30 days)
LYUMJEV KWIKPEN U-100 INSULIN 100 UNIT/ML INSULIN PEN CI,MO	2	
LYUMJEV KWIKPEN U-200 INSULIN 200 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
LYUMJEV TEMPO PEN(U-100)INSULN 100 UNIT/ML INSULIN PEN, SENSOR CI,MO	3	ST
LYUMJEV U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
<i>metformin 1,000 mg TABLET, ER 24 HR.</i> MO	3	ST,QL(60 per 30 days)
<i>metformin 1,000 mg TABLET, GAST. RETENTION 24 HR.</i>	4	ST,QL(60 per 30 days)
<i>metformin 1,000 mg, 500 mg TABLET</i> MO	1	
<i>metformin 500 mg TABLET, ER 24 HR.</i> MO	3	ST,QL(150 per 30 days)
<i>metformin 500 mg TABLET, ER 24 HR.</i> MO	1	QL(120 per 30 days)
<i>metformin 500 mg TABLET, GAST. RETENTION 24 HR.</i>	4	ST,QL(120 per 30 days)
<i>metformin 500 mg/5 ml SOLUTION</i> MO	1	QL(750 per 30 days)
<i>metformin 625 mg TABLET</i> DL	4	ST,QL(120 per 30 days)
<i>metformin 750 mg TABLET, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>metformin 850 mg TABLET</i> MO	1	
<i>migliitol 100 mg, 25 mg, 50 mg TABLET</i> MO	1	
MOUNJARO 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML PEN INJECTOR MO	2	PA,QL(2 per 28 days)
<i>nateglinide 120 mg, 60 mg TABLET</i> MO	1	
NESINA 12.5 MG, 25 MG, 6.25 MG TABLET MO	3	PA,QL(30 per 30 days)
NOVOLIN 70-30 FLEXPEN U-100 100 UNIT/ML (70-30) INSULIN PEN CI,MO	2	
NOVOLIN 70/30 U-100 INSULIN 100 UNIT/ML (70-30) SUSPENSION CI,MO	2	
NOVOLIN N FLEXPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
NOVOLIN N NPH U-100 INSULIN 100 UNIT/ML SUSPENSION CI,MO	2	
NOVOLIN R FLEXPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
NOVOLIN R REGULAR U100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
NOVOLOG FLEXPEN U-100 INSULIN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
NOVOLOG MIX 70-30 U-100 INSULN 100 UNIT/ML (70-30) SOLUTION CI,MO	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NOVOLOG MIX 70-30FLEXPEN U-100 100 UNIT/ML (70-30) INSULIN PEN CI,MO	2	
NOVOLOG PENFILL U-100 INSULIN 100 UNIT/ML CARTRIDGE CI,MO	2	
NOVOLOG U-100 INSULIN ASPART 100 UNIT/ML SOLUTION CI,MO	2	
OSENI 12.5-30 MG, 25-15 MG, 25-30 MG, 25-45 MG TABLET MO	3	PA,QL(30 per 30 days)
OZEMPIC 0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) PEN INJECTOR MO	2	PA,QL(3 per 28 days)
OZEMPIC 0.25 MG OR 0.5 MG(2 MG/1.5 ML) PEN INJECTOR MO	2	PA,QL(1.5 per 28 days)
pioglitazone 15 mg, 45 mg TABLET MO	1	QL(30 per 30 days)
pioglitazone 30 mg TABLET MO	1	QL(30 per 30 days)
pioglitazone-glimepiride 30-2 mg, 30-4 mg TABLET MO	1	QL(30 per 30 days)
pioglitazone-metformin 15-500 mg, 15-850 mg TABLET MO	1	QL(90 per 30 days)
PRECOSE 100 MG, 25 MG, 50 MG TABLET MO	3	
PROGLYCEM 50 MG/ML SUSPENSION DL	4	PA
QTERN 10-5 MG, 5-5 MG TABLET MO	3	PA,QL(30 per 30 days)
repaglinide 0.5 mg, 1 mg, 2 mg TABLET MO	1	
REZVOGLAR KWIKPEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
RIOMET 500 MG/5 ML SOLUTION MO	3	QL(750 per 30 days)
RYBELSUS 14 MG, 3 MG, 7 MG TABLET MO	2	PA,QL(30 per 30 days)
saxagliptin 2.5 mg, 5 mg TABLET MO	1	QL(30 per 30 days)
saxagliptin-metformin 2.5-1,000 mg TABLET, ER 24 HR., MULTIPHASE MO	1	QL(60 per 30 days)
saxagliptin-metformin 5-1,000 mg, 5-500 mg TABLET, ER 24 HR., MULTIPHASE MO	1	QL(30 per 30 days)
SEGLUROMET 2.5-1,000 MG, 2.5-500 MG, 7.5-1,000 MG, 7.5-500 MG TABLET MO	3	PA,QL(60 per 30 days)
SEMGLEE(INSULIN GLARG-YFGN)PEN 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	3	PA
SEMGLEE(INSULIN GLARGINE-YFGN) 100 UNIT/ML SOLUTION CI,MO	3	PA
sitagliptin 100 mg, 25 mg, 50 mg TABLET MO	3	PA,QL(30 per 30 days)
sitagliptin-metformin 50-1,000 mg, 50-500 mg TABLET MO	3	PA,QL(60 per 30 days)
SOLIQUA 100/33 100 UNIT-33 MCG/ML INSULIN PEN CI,MO	2	QL(15 per 24 days)
STEGLATRO 15 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
STEGLUJAN 15-100 MG, 5-100 MG TABLET MO	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SYMLINPEN 120 2,700 MCG/2.7 ML PEN INJECTOR	4	QL(10.8 per 30 days)
SYMLINPEN 60 1,500 MCG/1.5 ML PEN INJECTOR	4	QL(10.5 per 28 days)
SYNJARDY 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG TABLET MO	2	QL(60 per 30 days)
SYNJARDY XR 10-1,000 MG, 25-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(30 per 30 days)
SYNJARDY XR 12.5-1,000 MG, 5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(60 per 30 days)
TOUJEO MAX U-300 SOLOSTAR 300 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
TOUJEO SOLOSTAR U-300 INSULIN 300 UNIT/ML (1.5 ML) INSULIN PEN CI,MO	2	
TRADJENTA 5 MG TABLET MO	2	QL(30 per 30 days)
TRESIBA FLEXTOUCH U-100 100 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
TRESIBA FLEXTOUCH U-200 200 UNIT/ML (3 ML) INSULIN PEN CI,MO	2	
TRESIBA U-100 INSULIN 100 UNIT/ML SOLUTION CI,MO	2	
TRIJARDY XR 10-5-1,000 MG, 25-5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(30 per 30 days)
TRIJARDY XR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	2	QL(60 per 30 days)
TRULICITY 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML PEN INJECTOR MO	2	PA,QL(2 per 28 days)
VICTOZA 2-PAK 0.6 MG/0.1 ML (18 MG/3 ML) PEN INJECTOR MO	3	PA,QL(9 per 30 days)
VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) PEN INJECTOR MO	3	PA,QL(9 per 30 days)
XIGDUO XR 10-1,000 MG, 10-500 MG, 5-500 MG TABLET, IR/ER 24 HR., BIPHASIC MO	3	QL(30 per 30 days)
XIGDUO XR 2.5-1,000 MG, 5-1,000 MG TABLET, IR/ER 24 HR., BIPHASIC MO	3	QL(60 per 30 days)
XULTOPHY 100/3.6 100 UNIT-3.6 MG /ML (3 ML) INSULIN PEN CI,MO	3	PA,QL(15 per 30 days)
ZEGALOGUE AUTOINJECTOR 0.6 MG/0.6 ML AUTO-INJECTOR MO	2	
ZEGALOGUE SYRINGE 0.6 MG/0.6 ML SYRINGE MO	2	
ZITUVIO 100 MG, 25 MG, 50 MG TABLET MO	3	PA,QL(30 per 30 days)
BLOOD PRODUCTS AND MODIFIERS		
ADZYNMA 1,500 (+/-) UNIT, 500 (+/-) UNIT KIT DL	4	PA
AGGRASTAT CONCENTRATE 250 MCG/ML CONCENTRATE MO	3	
AGGRASTAT IN SODIUM CHLORIDE 12.5 MG/250 ML (50 MCG/ML), 5 MG/100 ML (50 MCG/ML) SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AGRYLIN 0.5 MG CAPSULE MO	3	PA
ALVAIZ 18 MG, 9 MG TABLET DL	4	PA,QL(30 per 30 days)
ALVAIZ 36 MG, 54 MG TABLET DL	4	PA,QL(60 per 30 days)
aminocaproic acid 1,000 mg TABLET DL	4	
aminocaproic acid 250 mg/ml, 250 mg/ml (25 %) SOLUTION MO	1	
aminocaproic acid 500 mg TABLET MO	1	
anagrelide 0.5 mg, 1 mg CAPSULE MO	1	
ARANESP (IN POLYSORBATE) 10 MCG/0.4 ML, 40 MCG/0.4 ML SYRINGE MO	3	PA,QL(1.6 per 30 days)
ARANESP (IN POLYSORBATE) 100 MCG/0.5 ML SYRINGE DL	4	PA,QL(2 per 30 days)
ARANESP (IN POLYSORBATE) 100 MCG/ML, 200 MCG/ML, 60 MCG/ML SOLUTION DL	4	PA,QL(4 per 30 days)
ARANESP (IN POLYSORBATE) 150 MCG/0.3 ML SYRINGE DL	4	PA,QL(1.2 per 30 days)
ARANESP (IN POLYSORBATE) 200 MCG/0.4 ML SYRINGE DL	4	PA,QL(1.6 per 30 days)
ARANESP (IN POLYSORBATE) 25 MCG/0.42 ML SYRINGE MO	3	PA,QL(1.68 per 30 days)
ARANESP (IN POLYSORBATE) 25 MCG/ML, 40 MCG/ML SOLUTION MO	3	PA,QL(4 per 30 days)
ARANESP (IN POLYSORBATE) 300 MCG/0.6 ML SYRINGE DL	4	PA,QL(2.4 per 30 days)
ARANESP (IN POLYSORBATE) 500 MCG/ML SYRINGE DL	4	PA,QL(4 per 30 days)
ARANESP (IN POLYSORBATE) 60 MCG/0.3 ML SYRINGE MO	3	PA,QL(1.2 per 30 days)
ARIXTRA 10 MG/0.8 ML SYRINGE DL	4	PA,QL(24 per 30 days)
ARIXTRA 2.5 MG/0.5 ML SYRINGE DL	4	PA,QL(15 per 30 days)
ARIXTRA 5 MG/0.4 ML SYRINGE DL	4	PA,QL(12 per 30 days)
ARIXTRA 7.5 MG/0.6 ML SYRINGE DL	4	PA,QL(18 per 30 days)
aspirin-dipyridamole 25-200 mg CAPSULE ER MULTIPHASE 12 HR. MO	1	ST,QL(60 per 30 days)
BRILINTA 60 MG, 90 MG TABLET MO	2	QL(60 per 30 days)
CABLIVI 11 MG KIT DL	4	PA,QL(30 per 30 days)
cilostazol 100 mg, 50 mg TABLET MO	1	
clopidogrel 300 mg TABLET MO	1	
clopidogrel 75 mg TABLET MO	1	QL(30 per 30 days)
CYKLOKAPRON 1,000 MG/10 ML (100 MG/ML) SOLUTION DL	4	PA
dabigatran etexilate 110 mg, 150 mg, 75 mg CAPSULE MO	1	QL(60 per 30 days)
dipyridamole 25 mg, 50 mg, 75 mg TABLET MO	1	
DOPTELET (10 TAB PACK) 20 MG TABLET DL	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DOPTELET (15 TAB PACK) 20 MG TABLET DL	4	PA,QL(60 per 30 days)
DOPTELET (30 TAB PACK) 20 MG TABLET DL	4	PA,QL(60 per 30 days)
EFFIENT 10 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
ELIQUIS 2.5 MG TABLET MO	2	QL(60 per 30 days)
ELIQUIS 5 MG TABLET MO	2	QL(74 per 30 days)
ELIQUIS DVT-PE TREAT 30D START 5 MG (74 TABS) TABLET, DOSE PACK MO	2	QL(74 per 30 days)
enoxaparin 100 mg/ml, 120 mg/0.8 ml, 150 mg/ml, 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml SYRINGE MO	1	
enoxaparin 300 mg/3 ml SOLUTION MO	1	
EPOGEN 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML SOLUTION MO	3	PA,QL(14 per 30 days)
EPOGEN 20,000 UNIT/2 ML SOLUTION MO	3	PA,QL(28 per 30 days)
eptifibatide 0.75 mg/ml, 2 mg/ml SOLUTION MO	1	
fondaparinux 10 mg/0.8 ml SYRINGE DL	4	QL(24 per 30 days)
fondaparinux 2.5 mg/0.5 ml SYRINGE DL	4	QL(15 per 30 days)
fondaparinux 5 mg/0.4 ml SYRINGE DL	4	QL(12 per 30 days)
fondaparinux 7.5 mg/0.6 ml SYRINGE DL	4	QL(18 per 30 days)
FRAGMIN 10,000 ANTI-XA UNIT/ML SYRINGE DL	4	QL(30 per 30 days)
FRAGMIN 12,500 ANTI-XA UNIT/0.5 ML SYRINGE DL	4	QL(15 per 30 days)
FRAGMIN 15,000 ANTI-XA UNIT/0.6 ML SYRINGE DL	4	QL(18 per 30 days)
FRAGMIN 18,000 ANTI-XA UNIT/0.72 ML SYRINGE DL	4	QL(21.6 per 30 days)
FRAGMIN 2,500 ANTI-XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML SYRINGE DL	4	QL(6 per 30 days)
FRAGMIN 2,500 ANTI-XA UNIT/ML SOLUTION DL	4	QL(120 per 30 days)
FRAGMIN 25,000 ANTI-XA UNIT/ML SOLUTION DL	4	QL(22.8 per 30 days)
FRAGMIN 7,500 ANTI-XA UNIT/0.3 ML SYRINGE DL	4	QL(9 per 30 days)
FULPHILA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
FYLNETRA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
GRANIX 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 28 days)
GRANIX 300 MCG/ML SOLUTION DL	4	PA,QL(14 per 28 days)
GRANIX 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 28 days)
GRANIX 480 MCG/1.6 ML SOLUTION DL	4	PA,QL(22.4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
heparin (porcine) 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml SOLUTION MO	1	
heparin (porcine) 5,000 unit/ml (1 ml) CARTRIDGE MO	1	
heparin (porcine) 5,000 unit/ml SYRINGE MO	1	
heparin, porcine (pf) 1,000 unit/ml, 5,000 unit/0.5 ml SOLUTION MO	1	
heparin, porcine (pf) 5,000 unit/0.5 ml, 5,000 unit/ml SYRINGE MO	1	
jantoven 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg TABLET MO	1	
KENGREAL 50 MG RECON SOLUTION DL	4	
LEUKINE 250 MCG RECON SOLUTION DL	4	PA
LOVENOX 100 MG/ML, 120 MG/0.8 ML, 150 MG/ML, 30 MG/0.3 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML SYRINGE DL	4	PA
LOVENOX 300 MG/3 ML SOLUTION DL	4	PA
LYSTEDA 650 MG TABLET MO	3	QL(30 per 5 days)
MOZOBIL 24 MG/1.2 ML (20 MG/ML) SOLUTION DL	4	PA,QL(9.6 per 30 days)
MULPLETA 3 MG TABLET DL	4	PA
NEULASTA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
NEULASTA ONPRO 6 MG/0.6 ML SYRINGE W/WEARABLE INJECTOR DL	4	PA,QL(1.2 per 28 days)
NEUPOGEN 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 30 days)
NEUPOGEN 300 MCG/ML SOLUTION DL	4	PA,QL(14 per 30 days)
NEUPOGEN 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 30 days)
NEUPOGEN 480 MCG/1.6 ML SOLUTION DL	4	PA,QL(22.4 per 30 days)
NIVESTYM 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 30 days)
NIVESTYM 300 MCG/ML SOLUTION DL	4	PA,QL(14 per 30 days)
NIVESTYM 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 30 days)
NIVESTYM 480 MCG/1.6 ML SOLUTION DL	4	PA,QL(22.4 per 30 days)
NYVEPRIA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
PLAVIX 75 MG TABLET MO	3	PA,QL(30 per 30 days)
plerixafor 24 mg/1.2 ml (20 mg/ml) SOLUTION DL	4	PA,QL(9.6 per 30 days)
PRADAXA 110 MG, 150 MG, 75 MG CAPSULE MO	3	QL(60 per 30 days)
PRADAXA 110 MG, 30 MG, 40 MG, 50 MG PELLETS IN PACKET DL	4	PA,QL(120 per 30 days)
PRADAXA 150 MG, 20 MG PELLETS IN PACKET DL	4	PA,QL(60 per 30 days)
prasugrel 10 mg, 5 mg TABLET MO	1	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROCRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML SOLUTION MO	3	PA,QL(14 per 30 days)
PROCRIT 20,000 UNIT/2 ML SOLUTION MO	3	PA,QL(28 per 30 days)
PROCRIT 20,000 UNIT/ML, 40,000 UNIT/ML SOLUTION DL	4	PA,QL(14 per 30 days)
PROMACTA 12.5 MG POWDER IN PACKET DL,LA	4	PA,QL(360 per 30 days)
PROMACTA 12.5 MG, 25 MG TABLET DL,LA	4	PA,QL(30 per 30 days)
PROMACTA 25 MG POWDER IN PACKET DL,LA	4	PA,QL(180 per 30 days)
PROMACTA 50 MG TABLET DL,LA	4	PA,QL(90 per 30 days)
PROMACTA 75 MG TABLET DL,LA	4	PA,QL(60 per 30 days)
REBLOZYL 25 MG, 75 MG RECON SOLUTION DL	4	PA
RELEUKO 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 30 days)
RELEUKO 300 MCG/ML SOLUTION DL	4	PA,QL(14 per 30 days)
RELEUKO 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 30 days)
RELEUKO 480 MCG/1.6 ML SOLUTION DL	4	PA,QL(22.4 per 30 days)
RETACRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML SOLUTION MO	3	PA,QL(14 per 30 days)
RETACRIT 40,000 UNIT/ML SOLUTION DL	4	PA,QL(14 per 30 days)
RIASTAP 1 GRAM (900MG-1,300MG) RECON SOLUTION MO	3	
ROLVEDON 13.2 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
SAVAYSA 15 MG, 30 MG, 60 MG TABLET MO	3	PA,QL(30 per 30 days)
STIMUFEND 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
TAVALISSE 100 MG, 150 MG TABLET DL	4	PA,QL(60 per 30 days)
<i>tirofiban-0.9% sodium chloride 12.5 mg/250 ml (50 mcg/ml), 5 mg/100 ml (50 mcg/ml) SOLUTION MO</i>	1	
<i>tranexamic acid 1,000 mg/10 ml (100 mg/ml) SOLUTION MO</i>	1	PA
<i>tranexamic acid 650 mg TABLET MO</i>	1	QL(30 per 5 days)
UDENYCA 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
UDENYCA AUTOINJECTOR 6 MG/0.6 ML AUTO-INJECTOR DL	4	PA,QL(1.2 per 28 days)
UDENYCA ONBODY 6 MG/0.6 ML SYRINGE W/WEARABLE INJECTOR DL	4	PA,QL(1.2 per 28 days)
<i>warfarin 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 6 mg, 7.5 mg TABLET MO</i>	1	
<i>warfarin 5 mg TABLET MO</i>	1	
XARELTO 1 MG/ML SUSPENSION FOR RECONSTITUTION MO	2	ST,QL(600 per 30 days)
XARELTO 10 MG, 20 MG TABLET MO	2	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XARELTO 15 MG, 2.5 MG TABLET MO	2	QL(60 per 30 days)
XARELTO DVT-PE TREAT 30D START 15 MG (42)- 20 MG (9) TABLET, DOSE PACK MO	2	QL(51 per 30 days)
XOLREMDI 100 MG CAPSULE DL	4	PA,QL(120 per 30 days)
ZARXIO 300 MCG/0.5 ML SYRINGE DL	4	PA,QL(7 per 30 days)
ZARXIO 480 MCG/0.8 ML SYRINGE DL	4	PA,QL(11.2 per 30 days)
ZIEXTENZO 6 MG/0.6 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
ZONTIVITY 2.08 MG TABLET MO	3	QL(30 per 30 days)
CARDIOVASCULAR AGENTS		
ACCUPRIL 10 MG, 20 MG, 40 MG, 5 MG TABLET MO	3	
ACCURETIC 10-12.5 MG, 20-12.5 MG, 20-25 MG TABLET MO	3	
acebutolol 200 mg, 400 mg CAPSULE MO	1	
acetazolamide 125 mg, 250 mg TABLET MO	1	
acetazolamide 500 mg CAPSULE, ER MO	1	
acetazolamide sodium 500 mg RECON SOLUTION MO	1	
adenosine 3 mg/ml SOLUTION MO	1	
adenosine 3 mg/ml SYRINGE MO	1	
ALDACTAZIDE 25-25 MG, 50-50 MG TABLET MO	3	
ALDACTONE 100 MG, 25 MG, 50 MG TABLET MO	3	
aliskiren 150 mg, 300 mg TABLET MO	1	QL(30 per 30 days)
ALTACE 1.25 MG, 10 MG, 2.5 MG, 5 MG CAPSULE MO	3	PA
ALTOPREV 20 MG, 40 MG, 60 MG TABLET, ER 24 HR. DL	4	ST,QL(30 per 30 days)
amiloride 5 mg TABLET MO	1	
amiloride-hydrochlorothiazide 5-50 mg TABLET MO	1	
amiodarone 100 mg, 400 mg TABLET MO	1	
amiodarone 150 mg/3 ml SYRINGE MO	1	
amiodarone 200 mg TABLET MO	1	
amiodarone 50 mg/ml SOLUTION MO	1	
amlodipine 10 mg, 2.5 mg, 5 mg TABLET MO	1	
amlodipine-atorvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg TABLET MO	1	QL(30 per 30 days)
amlodipine-benazepril 10-20 mg, 2.5-10 mg, 5-10 mg, 5-20 mg CAPSULE MO	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
amlodipine-benazepril 10-40 mg, 5-40 mg CAPSULE MO	1	QL(30 per 30 days)
amlodipine-olmesartan 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg TABLET MO	1	QL(30 per 30 days)
amlodipine-valsartan 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg TABLET MO	1	QL(30 per 30 days)
amlodipine-valsartan-hcthiazid 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg TABLET MO	1	QL(30 per 30 days)
ASPRUZYO SPRINKLE 1,000 MG, 500 MG ER GRANULES, PACKET MO	3	QL(60 per 30 days)
ATACAND 16 MG, 4 MG, 8 MG TABLET MO	3	PA,QL(60 per 30 days)
ATACAND 32 MG TABLET MO	3	PA,QL(30 per 30 days)
ATACAND HCT 16-12.5 MG, 32-12.5 MG, 32-25 MG TABLET MO	3	PA,QL(30 per 30 days)
atenolol 100 mg TABLET MO	1	
atenolol 25 mg, 50 mg TABLET MO	1	
atenolol-chlorthalidone 100-25 mg, 50-25 mg TABLET MO	1	
ATORVALIQ 20 MG/5 ML (4 MG/ML) SUSPENSION MO	3	ST,QL(600 per 30 days)
atorvastatin 10 mg, 20 mg, 40 mg, 80 mg TABLET MO	1	
AVALIDE 150-12.5 MG TABLET MO	3	PA,QL(60 per 30 days)
AVALIDE 300-12.5 MG TABLET MO	3	PA,QL(30 per 30 days)
AVAPRO 150 MG, 300 MG, 75 MG TABLET MO	3	PA,QL(30 per 30 days)
AZOR 10-20 MG, 10-40 MG, 5-20 MG, 5-40 MG TABLET MO	3	PA,QL(30 per 30 days)
benazepril 10 mg, 20 mg, 40 mg, 5 mg TABLET MO	1	
benazepril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg TABLET MO	1	
BENICAR 20 MG, 40 MG TABLET MO	3	PA,QL(30 per 30 days)
BENICAR 5 MG TABLET MO	3	PA,QL(60 per 30 days)
BENICAR HCT 20-12.5 MG, 40-12.5 MG, 40-25 MG TABLET MO	3	PA,QL(30 per 30 days)
BETAPACE 120 MG, 160 MG, 240 MG, 80 MG TABLET DL	4	PA
BETAPACE AF 120 MG, 160 MG, 80 MG TABLET DL	4	PA
betaxolol 10 mg, 20 mg TABLET MO	1	
BIDIL 20-37.5 MG TABLET MO	3	PA,QL(180 per 30 days)
BIORPHEN 0.1 MG/ML SOLUTION MO	3	
bisoprolol fumarate 10 mg, 5 mg TABLET MO	1	
bisoprolol-hydrochlorothiazide 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg TABLET MO	1	
bretylum tosylate 50 mg/ml SOLUTION MO	1	
BREVIBLOC 100 MG/10 ML (10 MG/ML) SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BREVIBLOC IN NACL (ISO-OSM) 2,000 MG/100 ML, 2,500 MG/250 ML (10 MG/ML) PARENTERAL SOLUTION MO	3	
<i>bumetanide 0.25 mg/ml SOLUTION MO</i>	1	
<i>bumetanide 0.5 mg, 2 mg TABLET MO</i>	1	
<i>bumetanide 1 mg TABLET MO</i>	1	
BYSTOLIC 10 MG TABLET MO	3	PA,QL(120 per 30 days)
BYSTOLIC 2.5 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
BYSTOLIC 20 MG TABLET MO	3	PA,QL(60 per 30 days)
CADUET 10-10 MG, 10-20 MG, 10-40 MG, 10-80 MG, 5-10 MG, 5-20 MG, 5-40 MG, 5-80 MG TABLET MO	3	PA,QL(30 per 30 days)
CALAN SR 120 MG, 240 MG TABLET ER MO	3	
CAMZYOS 10 MG, 15 MG, 2.5 MG, 5 MG CAPSULE DL	4	PA,QL(30 per 30 days)
<i>candesartan 16 mg, 4 mg, 8 mg TABLET MO</i>	1	QL(60 per 30 days)
<i>candesartan 32 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>candesartan-hydrochlorothiazid 16-12.5 mg, 32-12.5 mg, 32-25 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>captopril 100 mg, 12.5 mg, 25 mg, 50 mg TABLET MO</i>	1	
<i>captopril-hydrochlorothiazide 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg TABLET MO</i>	1	
CARDIZEM 120 MG, 30 MG, 60 MG TABLET MO	3	
CARDIZEM CD 120 MG, 180 MG, 240 MG CAPSULE, ER 24 HR. DL	4	PA,QL(60 per 30 days)
CARDIZEM CD 300 MG, 360 MG CAPSULE, ER 24 HR. DL	4	PA,QL(30 per 30 days)
CARDIZEM LA 120 MG, 300 MG, 360 MG, 420 MG TABLET, ER 24 HR. MO	3	QL(30 per 30 days)
CARDIZEM LA 180 MG, 240 MG TABLET, ER 24 HR. MO	3	QL(60 per 30 days)
CARDURA 1 MG, 2 MG, 4 MG, 8 MG TABLET MO	3	
CARDURA XL 4 MG, 8 MG TABLET, ER 24 HR. MO	3	QL(30 per 30 days)
CAROSPIR 25 MG/5 ML SUSPENSION MO	3	PA,QL(450 per 30 days)
<i>cartia xt 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. MO</i>	1	QL(60 per 30 days)
<i>cartia xt 300 mg CAPSULE, ER 24 HR. MO</i>	1	QL(30 per 30 days)
<i>carvedilol 12.5 mg, 25 mg, 3.125 mg, 6.25 mg TABLET MO</i>	1	
<i>carvedilol phosphate 10 mg, 20 mg, 40 mg, 80 mg CAPSULE ER MULTIPHASE 24 HR. MO</i>	1	QL(30 per 30 days)
<i>chlorothiazide sodium 500 mg RECON SOLUTION MO</i>	1	
<i>chlorthalidone 25 mg TABLET MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
chlorthalidone 50 mg TABLET MO	1	
cholestyramine (with sugar) 4 gram POWDER MO	1	
cholestyramine (with sugar) 4 gram POWDER IN PACKET MO	1	
cholestyramine light 4 gram POWDER MO	1	
cholestyramine light 4 gram POWDER IN PACKET MO	1	
cholestyramine-aspartame 4 gram POWDER IN PACKET MO	1	
CLEVIPREX 25 MG/50 ML, 50 MG/100 ML EMULSION MO	3	
clonidine 0.1 mg/24 hr, 0.2 mg/24 hr, 0.3 mg/24 hr PATCH, WEEKLY MO	1	QL(4 per 28 days)
clonidine hcl 0.1 mg TABLET MO	1	
clonidine hcl 0.17 mg TABLET, ER 24 HR. DL	4	PA,QL(90 per 30 days)
clonidine hcl 0.2 mg, 0.3 mg TABLET MO	1	
colesevelam 3.75 gram POWDER IN PACKET MO	1	QL(30 per 30 days)
colesevelam 625 mg TABLET MO	1	QL(180 per 30 days)
COLESTID 1 GRAM TABLET MO	3	
COLESTID 5 GRAM GRANULES MO	3	QL(1000 per 30 days)
COLESTID 5 GRAM PACKET MO	3	
COLESTID FLAVORED 5 GRAM GRANULES MO	3	QL(1000 per 30 days)
COLESTID FLAVORED 7.5 GRAM PACKET MO	3	
colestipol 1 gram TABLET MO	1	
colestipol 5 gram GRANULES MO	1	QL(1000 per 30 days)
colestipol 5 gram PACKET MO	1	
COREG 12.5 MG, 25 MG, 3.125 MG, 6.25 MG TABLET MO	3	PA
COREG CR 10 MG, 20 MG, 40 MG, 80 MG CAPSULE ER MULTIPHASE 24 HR. MO	3	PA,QL(30 per 30 days)
CORGARD 20 MG, 40 MG, 80 MG TABLET MO	3	PA
CORLANOR 5 MG, 7.5 MG TABLET MO	3	PA,QL(60 per 30 days)
CORLANOR 5 MG/5 ML SOLUTION MO	3	PA,QL(560 per 28 days)
CORLOPAM 10 MG/ML SOLUTION MO	3	
CORVERT 0.1 MG/ML SOLUTION MO	3	
COZAAR 100 MG, 25 MG, 50 MG TABLET MO	3	PA,QL(60 per 30 days)
CRESTOR 10 MG, 20 MG, 40 MG, 5 MG TABLET MO	3	PA
DEMSER 250 MG CAPSULE DL	4	
DIBENZYLINE 10 MG CAPSULE DL	4	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
digitek 125 mcg (0.125 mg), 250 mcg (0.25 mg) TABLET MO	1	QL(30 per 30 days)
digox 125 mcg (0.125 mg), 250 mcg (0.25 mg) TABLET MO	1	QL(30 per 30 days)
digoxin 125 mcg (0.125 mg), 250 mcg (0.25 mg), 62.5 mcg (0.0625 mg) TABLET MO	1	QL(30 per 30 days)
digoxin 250 mcg/ml (0.25 mg/ml), 50 mcg/ml (0.05 mg/ml) SOLUTION MO	1	
dilt-xr 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. MO	1	QL(60 per 30 days)
diltiazem hcl 100 mg RECON SOLUTION MO	1	
diltiazem hcl 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR. MO	1	QL(60 per 30 days)
diltiazem hcl 120 mg, 30 mg, 60 mg, 90 mg TABLET MO	1	
diltiazem hcl 120 mg, 300 mg, 360 mg, 420 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
diltiazem hcl 120 mg, 60 mg, 90 mg CAPSULE, ER 12 HR. MO	1	
diltiazem hcl 180 mg, 240 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
diltiazem hcl 300 mg, 360 mg, 420 mg CAPSULE, ER 24 HR. MO	1	QL(30 per 30 days)
diltiazem hcl 5 mg/ml SOLUTION MO	1	
DIOVAN 160 MG, 320 MG, 40 MG, 80 MG TABLET MO	3	PA,QL(60 per 30 days)
DIOVAN HCT 160-12.5 MG, 160-25 MG, 320-12.5 MG, 320-25 MG, 80-12.5 MG TABLET MO	3	PA,QL(30 per 30 days)
disopyramide phosphate 100 mg, 150 mg CAPSULE MO	1	
DIURIL 250 MG/5 ML SUSPENSION MO	3	
dobutamine 250 mg/20 ml (12.5 mg/ml) SOLUTION MO	1	BvsD
dobutamine in d5w 1,000 mg/250 ml (4,000 mcg/ml), 250 mg/250 ml (1 mg/ml), 500 mg/250 ml (2,000 mcg/ml) PARENTERAL SOLUTION MO	1	BvsD
dofetilide 125 mcg, 250 mcg, 500 mcg CAPSULE MO	1	
dopamine 200 mg/5 ml (40 mg/ml), 400 mg/10 ml (40 mg/ml), 400 mg/5 ml (80 mg/ml), 800 mg/10 ml (80 mg/ml), 800 mg/5 ml (160 mg/ml) SOLUTION MO	1	BvsD
dopamine in 5 % dextrose 200 mg/250 ml (800 mcg/ml), 400 mg/250 ml (1,600 mcg/ml), 400 mg/500 ml (800 mcg/ml), 800 mg/250 ml (3,200 mcg/ml), 800 mg/500 ml (1,600 mcg/ml) SOLUTION MO	1	BvsD
doxazosin 1 mg, 2 mg, 4 mg, 8 mg TABLET MO	1	
droxidopa 100 mg, 200 mg CAPSULE MO	1	PA,QL(90 per 30 days)
droxidopa 300 mg CAPSULE MO	1	PA,QL(180 per 30 days)
DYRENIUM 100 MG, 50 MG CAPSULE MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EDARBI 40 MG, 80 MG TABLET MO	3	ST,QL(30 per 30 days)
EDARBYCLOR 40-12.5 MG, 40-25 MG TABLET MO	3	ST,QL(30 per 30 days)
EDECIN 25 MG TABLET DL	4	QL(480 per 30 days)
enalapril maleate 1 mg/ml SOLUTION MO	1	
enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg TABLET MO	1	
enalapril-hydrochlorothiazide 10-25 mg, 5-12.5 mg TABLET MO	1	
enalaprilat 1.25 mg/ml SOLUTION MO	1	
ENTRESTO 24-26 MG, 49-51 MG, 97-103 MG TABLET MO	2	QL(60 per 30 days)
ENTRESTO SPRINKLE 15-16 MG, 6-6 MG PELLETT MO	2	QL(240 per 30 days)
EPANED 1 MG/ML SOLUTION DL	4	
eplerenone 25 mg, 50 mg TABLET MO	1	PA
eprosartan 600 mg TABLET MO	1	QL(60 per 30 days)
esmolol 100 mg/10 ml (10 mg/ml) SOLUTION MO	1	
esmolol in nacl (iso-osm) 2,000 mg/100 ml, 2,500 mg/250 ml (10 mg/ml) PARENTERAL SOLUTION MO	1	
ethacrynate sodium 50 mg RECON SOLUTION MO	1	
ethacrynic acid 25 mg TABLET MO	1	QL(480 per 30 days)
EVKEEZA 150 MG/ML SOLUTION DL	4	PA
EXFORGE 10-160 MG, 10-320 MG, 5-160 MG, 5-320 MG TABLET MO	3	PA,QL(30 per 30 days)
EXFORGE HCT 10-160-12.5 MG, 10-160-25 MG, 10-320-25 MG, 5-160-12.5 MG, 5-160-25 MG TABLET MO	3	PA,QL(30 per 30 days)
EZALLOR SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG CAPSULE, SPRINKLE MO	3	ST,QL(30 per 30 days)
ezetimibe 10 mg TABLET MO	1	QL(30 per 30 days)
ezetimibe-atorvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg TABLET MO	1	ST,QL(30 per 30 days)
ezetimibe-rosuvastatin 10-5 mg TABLET MO	3	ST,QL(30 per 30 days)
ezetimibe-simvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg TABLET MO	1	QL(30 per 30 days)
felodipine 10 mg, 2.5 mg, 5 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
fenofibrate 120 mg TABLET MO	1	QL(30 per 30 days)
fenofibrate 150 mg CAPSULE MO	1	QL(30 per 30 days)
fenofibrate 160 mg TABLET MO	1	QL(30 per 30 days)
fenofibrate 40 mg, 54 mg TABLET MO	1	QL(60 per 30 days)
fenofibrate 50 mg CAPSULE MO	1	QL(60 per 30 days)
fenofibrate micronized 130 mg, 43 mg CAPSULE MO	1	ST,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>fenofibrate micronized 134 mg, 200 mg CAPSULE</i> ^{MO}	1	QL(30 per 30 days)
<i>fenofibrate micronized 30 mg, 90 mg CAPSULE</i> ^{MO}	3	QL(30 per 30 days)
<i>fenofibrate micronized 67 mg CAPSULE</i> ^{MO}	1	QL(60 per 30 days)
<i>fenofibrate nanocrystallized 145 mg TABLET</i> ^{MO}	1	QL(30 per 30 days)
<i>fenofibrate nanocrystallized 48 mg TABLET</i> ^{MO}	1	QL(60 per 30 days)
<i>fenofibric acid 105 mg, 35 mg TABLET</i> ^{MO}	2	QL(30 per 30 days)
<i>fenofibric acid (choline) 135 mg, 45 mg CAPSULE, DR/EC</i> ^{MO}	1	QL(30 per 30 days)
FENOGLIDE 120 MG TABLET ^{MO}	3	QL(30 per 30 days)
FENOGLIDE 40 MG TABLET ^{MO}	3	QL(60 per 30 days)
FIBRICOR 105 MG, 35 MG TABLET ^{MO}	3	QL(30 per 30 days)
<i>flecainide 100 mg, 150 mg, 50 mg TABLET</i> ^{MO}	1	
FLOLIPID 20 MG/5 ML (4 MG/ML), 40 MG/5 ML (8 MG/ML) SUSPENSION ^{MO}	3	ST,QL(150 per 30 days)
<i>fluvastatin 20 mg, 40 mg CAPSULE</i> ^{MO}	1	ST,QL(60 per 30 days)
<i>fluvastatin 80 mg TABLET, ER 24 HR.</i> ^{MO}	1	ST,QL(30 per 30 days)
<i>fosinopril 10 mg, 20 mg, 40 mg TABLET</i> ^{MO}	1	
<i>fosinopril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg TABLET</i> ^{MO}	1	
FUROSCIX 80 MG/10 ML KIT ^{MO}	3	PA
<i>furosemide 10 mg/ml SYRINGE</i> ^{MO}	1	
<i>furosemide 10 mg/ml, 40 mg/5 ml (8 mg/ml) SOLUTION</i> ^{MO}	1	
<i>furosemide 20 mg, 40 mg TABLET</i> ^{MO}	1	
<i>furosemide 80 mg TABLET</i> ^{MO}	1	
<i>gemfibrozil 600 mg TABLET</i> ^{MO}	1	QL(60 per 30 days)
GONITRO 400 MCG POWDER IN PACKET ^{MO}	3	
<i>guanfacine 1 mg, 2 mg TABLET</i> ^{MO}	1	
HEMANGEOL 4.28 MG/ML SOLUTION ^{MO}	3	
<i>hydralazine 10 mg, 100 mg TABLET</i> ^{MO}	1	
<i>hydralazine 20 mg/ml SOLUTION</i> ^{MO}	1	
<i>hydralazine 25 mg, 50 mg TABLET</i> ^{MO}	1	
<i>hydrochlorothiazide 12.5 mg CAPSULE</i> ^{MO}	1	
<i>hydrochlorothiazide 12.5 mg, 25 mg TABLET</i> ^{MO}	1	
<i>hydrochlorothiazide 50 mg TABLET</i> ^{MO}	1	
HYZAAR 100-12.5 MG, 100-25 MG, 50-12.5 MG TABLET ^{MO}	3	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ibutilide fumarate</i> 0.1 mg/ml SOLUTION MO	1	
IMMPHENTIV 0.1 MG/ML SOLUTION MO	3	
<i>indapamide</i> 1.25 mg, 2.5 mg TABLET MO	1	
INDERAL LA 120 MG, 160 MG, 60 MG, 80 MG CAPSULE, ER 24 HR. DL	4	PA
INNOPRAN XL 120 MG, 80 MG CAPSULE, ER 24 HR.	4	
INPEFA 200 MG, 400 MG TABLET MO	3	PA,QL(30 per 30 days)
INSPRA 25 MG, 50 MG TABLET MO	3	PA
<i>irbesartan</i> 150 mg, 300 mg, 75 mg TABLET MO	1	QL(30 per 30 days)
<i>irbesartan-hydrochlorothiazide</i> 150-12.5 mg TABLET MO	1	QL(60 per 30 days)
<i>irbesartan-hydrochlorothiazide</i> 300-12.5 mg TABLET MO	1	QL(30 per 30 days)
ISORDIL 40 MG TABLET DL	4	
ISORDIL TITRADOSE 5 MG TABLET DL	4	PA
<i>isosorbide dinitrate</i> 10 mg, 20 mg, 30 mg, 40 mg, 5 mg TABLET MO	1	
<i>isosorbide mononitrate</i> 10 mg, 20 mg TABLET MO	1	
<i>isosorbide mononitrate</i> 120 mg TABLET, ER 24 HR. MO	1	
<i>isosorbide mononitrate</i> 30 mg, 60 mg TABLET, ER 24 HR. MO	1	
<i>isosorbide-hydralazine</i> 20-37.5 mg TABLET MO	1	QL(180 per 30 days)
<i>isradipine</i> 2.5 mg, 5 mg CAPSULE MO	1	
ISUPREL 0.2 MG/ML SOLUTION MO	3	
<i>ivabradine</i> 5 mg, 7.5 mg TABLET MO	1	PA,QL(60 per 30 days)
JUXTAPID 10 MG, 30 MG, 5 MG CAPSULE DL	4	PA,QL(28 per 28 days)
JUXTAPID 20 MG CAPSULE DL	4	PA,QL(84 per 28 days)
KAPSPARGO SPRINKLE 100 MG, 25 MG, 50 MG CAPSULE ER SPRINKLE 24 HR. MO	3	ST,QL(30 per 30 days)
KAPSPARGO SPRINKLE 200 MG CAPSULE ER SPRINKLE 24 HR. MO	3	ST,QL(60 per 30 days)
KATERZIA 1 MG/ML SUSPENSION MO	3	ST,QL(300 per 30 days)
KERENDIA 10 MG, 20 MG TABLET MO	2	PA,QL(30 per 30 days)
<i>labetalol</i> 100 mg, 200 mg, 300 mg TABLET MO	1	
<i>labetalol</i> 5 mg/ml SOLUTION MO	1	
LABELALOL IN DEXTROSE,ISO-OSM 1 MG/ML SOLUTION MO	1	
LABELALOL IN NACL (ISO-OSMOT) 1 MG/ ML SOLUTION MO	1	
LANOXIN 125 MCG (0.125 MG), 250 MCG (0.25 MG), 62.5 MCG (0.0625 MG) TABLET MO	3	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LANOXIN 250 MCG/ML (0.25 MG/ML), 500 MCG/2 ML (0.5 MG/2 ML) SOLUTION MO	3	
LANOXIN PEDIATRIC 100 MCG/ML (0.1 MG/ML) SOLUTION MO	3	
LASIX 20 MG, 40 MG, 80 MG TABLET MO	3	
LEQVIO 284 MG/1.5 ML SYRINGE	4	PA,QL(4.5 per 365 days)
LESCOL XL 80 MG TABLET, ER 24 HR. MO	3	ST,QL(30 per 30 days)
levamlodipine 2.5 mg, 5 mg TABLET MO	3	QL(30 per 30 days)
LEVOPHED (BITARTRATE) 1 MG/ML SOLUTION MO	3	
lidocaine (pf) 20 mg/ml (2 %) SOLUTION MO	1	
lidocaine in 5 % dextrose (pf) 4 mg/ml (0.4 %), 8 mg/ml (0.8 %) PARENTERAL SOLUTION MO	1	
LIPITOR 10 MG, 20 MG, 40 MG, 80 MG TABLET MO	3	PA
LIPOFEN 150 MG CAPSULE MO	3	QL(30 per 30 days)
LIPOFEN 50 MG CAPSULE MO	3	QL(60 per 30 days)
lisinopril 10 mg, 2.5 mg, 20 mg, 40 mg, 5 mg TABLET MO	1	
lisinopril 30 mg TABLET MO	1	
lisinopril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg, 20-25 mg TABLET MO	1	
LIVALO 1 MG, 2 MG, 4 MG TABLET MO	3	ST,QL(30 per 30 days)
LODOCO 0.5 MG TABLET MO	3	PA,QL(30 per 30 days)
LOPID 600 MG TABLET MO	3	PA,QL(60 per 30 days)
LOPRESSOR 100 MG, 50 MG TABLET MO	3	
losartan 100 mg, 25 mg, 50 mg TABLET MO	1	QL(60 per 30 days)
losartan-hydrochlorothiazide 100-12.5 mg, 100-25 mg, 50-12.5 mg TABLET MO	1	QL(60 per 30 days)
LOTENSIN 10 MG, 20 MG, 40 MG TABLET MO	3	
LOTENSIN HCT 10-12.5 MG, 20-12.5 MG, 20-25 MG TABLET MO	3	
LOTREL 10-20 MG, 5-10 MG, 5-20 MG CAPSULE MO	3	PA,QL(60 per 30 days)
LOTREL 10-40 MG CAPSULE MO	3	PA,QL(30 per 30 days)
lovastatin 10 mg, 20 mg, 40 mg TABLET MO	1	
LOVAZA 1 GRAM CAPSULE MO	3	PA,QL(120 per 30 days)
mannitol 10 % 10 % PARENTERAL SOLUTION MO	1	
mannitol 20 % 20 % PARENTERAL SOLUTION MO	1	
mannitol 25 % 25 % SOLUTION MO	1	
mannitol 5 % 5 % PARENTERAL SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
matzim la 180 mg, 240 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
matzim la 300 mg, 360 mg, 420 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
MAXZIDE 75-50 MG TABLET MO	3	PA
MAXZIDE-25MG 37.5-25 MG TABLET MO	3	PA
methyldopa 250 mg, 500 mg TABLET MO	1	
methyldopa-hydrochlorothiazide 250-15 mg, 250-25 mg TABLET MO	1	
methyldopate 250 mg/5 ml SOLUTION MO	1	
metolazone 10 mg, 2.5 mg, 5 mg TABLET MO	1	
metoprolol succinate 100 mg, 25 mg, 50 mg TABLET, ER 24 HR. MO	1	
metoprolol succinate 200 mg TABLET, ER 24 HR. MO	1	
metoprolol ta-hydrochlorothiaz 100-25 mg, 100-50 mg, 50-25 mg TABLET MO	1	
metoprolol tartrate 100 mg, 25 mg, 50 mg TABLET MO	1	
metoprolol tartrate 37.5 mg, 75 mg TABLET MO	1	
metoprolol tartrate 5 mg/5 ml SOLUTION MO	1	
metyrosine 250 mg CAPSULE DL	4	
mexiletine 150 mg, 200 mg, 250 mg CAPSULE MO	1	
MICARDIS 20 MG, 40 MG TABLET MO	3	PA,QL(30 per 30 days)
MICARDIS 80 MG TABLET MO	3	PA,QL(60 per 30 days)
MICARDIS HCT 40-12.5 MG, 80-25 MG TABLET MO	3	PA,QL(30 per 30 days)
MICARDIS HCT 80-12.5 MG TABLET MO	3	PA,QL(60 per 30 days)
midodrine 10 mg, 2.5 mg, 5 mg TABLET MO	1	
milrinone 1 mg/ml SOLUTION MO	1	BvsD
milrinone in 5 % dextrose 20 mg/100 ml (200 mcg/ml), 40 mg/200 ml (200 mcg/ml) PIGGYBACK MO	1	BvsD
MINIPRESS 1 MG, 2 MG, 5 MG CAPSULE MO	3	
minoxidil 10 mg, 2.5 mg TABLET MO	1	
moexipril 15 mg, 7.5 mg TABLET MO	1	
MULTAQ 400 MG TABLET MO	2	QL(60 per 30 days)
nadolol 20 mg, 40 mg, 80 mg TABLET MO	1	
nebivolol 10 mg TABLET MO	1	QL(120 per 30 days)
nebivolol 2.5 mg, 5 mg TABLET MO	1	QL(30 per 30 days)
nebivolol 20 mg TABLET MO	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NEXICLON XR 0.17 MG TABLET, ER 24 HR. DL	4	PA,QL(90 per 30 days)
NEXLETOL 180 MG TABLET MO	3	PA,QL(30 per 30 days)
NEXLIZET 180-10 MG TABLET MO	3	PA,QL(30 per 30 days)
NEXTERONE 150 MG/100 ML (1.5 MG/ML), 360 MG/200 ML (1.8 MG/ML) SOLUTION MO	3	
niacin 1,000 mg, 500 mg, 750 mg TABLET, ER 24 HR. MO	1	
niacin 500 mg TABLET MO	1	
niacor 500 mg TABLET MO	1	
nicardipine 20 mg, 30 mg CAPSULE MO	1	
nicardipine 25 mg/10 ml SOLUTION MO	1	
nifedipine 10 mg, 20 mg CAPSULE MO	1	
nifedipine 30 mg, 60 mg, 90 mg TABLET ER MO	1	QL(60 per 30 days)
nifedipine 30 mg, 60 mg, 90 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
nimodipine 30 mg CAPSULE MO	1	
nisoldipine 17 mg, 20 mg, 34 mg, 40 mg, 8.5 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
nisoldipine 25.5 mg, 30 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
NITRO-BID 2 % OINTMENT MO	1	
NITRO-DUR 0.1 MG/HR, 0.4 MG/HR PATCH, 24 HR. MO	3	
NITRO-DUR 0.2 MG/HR, 0.3 MG/HR, 0.6 MG/HR, 0.8 MG/HR PATCH, 24 HR.	4	
nitroglycerin 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr PATCH, 24 HR. MO	1	
nitroglycerin 0.3 mg, 0.6 mg SUBLINGUAL TABLET MO	1	
nitroglycerin 0.4 mg SUBLINGUAL TABLET MO	1	
nitroglycerin 400 mcg/spray SPRAY, NON-AEROSOL MO	1	
nitroglycerin 50 mg/10 ml (5 mg/ml) SOLUTION MO	1	
nitroglycerin in 5 % dextrose 100 mg/250 ml (400 mcg/ml), 25 mg/250 ml (100 mcg/ml), 50 mg/250 ml (200 mcg/ml) SOLUTION MO	1	
NITROLINGUAL 400 MCG/SPRAY SPRAY, NON-AEROSOL MO	3	
NITROSTAT 0.3 MG, 0.4 MG, 0.6 MG SUBLINGUAL TABLET MO	2	
norepinephrine bitartrate 1 mg/ml SOLUTION MO	1	
NORLIQVA 1 MG/ML SOLUTION DL	4	ST,QL(300 per 30 days)
NORPACE 100 MG, 150 MG CAPSULE MO	3	
NORPACE CR 100 MG, 150 MG CAPSULE, ER MO	3	
NORTHERA 100 MG, 200 MG CAPSULE DL	4	PA,QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NORTHERA 300 MG CAPSULE DL	4	PA,QL(180 per 30 days)
NORVASC 10 MG, 2.5 MG, 5 MG TABLET MO	3	PA
NYMALIZE 30 MG/5 ML SYRINGE DL	4	QL(630 per 28 days)
NYMALIZE 60 MG/10 ML SOLUTION DL	4	QL(1260 per 28 days)
NYMALIZE 60 MG/10 ML SYRINGE DL	4	QL(1260 per 28 days)
olmesartan 20 mg TABLET MO	1	QL(30 per 30 days)
olmesartan 40 mg TABLET MO	1	QL(30 per 30 days)
olmesartan 5 mg TABLET MO	1	QL(60 per 30 days)
olmesartan-amlodipin-hcthiazyd 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg TABLET MO	1	QL(30 per 30 days)
olmesartan-hydrochlorothiazide 20-12.5 mg, 40-12.5 mg, 40-25 mg TABLET MO	1	QL(30 per 30 days)
omega-3 acid ethyl esters 1 gram CAPSULE MO	1	QL(120 per 30 days)
OSMITROL 10 % 10 % PARENTERAL SOLUTION MO	3	
OSMITROL 15 % 15 % PARENTERAL SOLUTION MO	3	
OSMITROL 20 % 20 % PARENTERAL SOLUTION MO	3	
OSMITROL 5 % 5 % PARENTERAL SOLUTION MO	3	
PACERONE 100 MG, 400 MG TABLET MO	1	
pacerone 200 mg TABLET MO	1	
pentoxifylline 400 mg TABLET ER MO	1	
perindopril erbumine 2 mg, 4 mg, 8 mg TABLET MO	1	
phenoxybenzamine 10 mg CAPSULE DL	4	
phenylephrine hcl 10 mg/ml SOLUTION MO	1	
pindolol 10 mg, 5 mg TABLET MO	1	
pitavastatin calcium 1 mg, 2 mg, 4 mg TABLET MO	1	ST,QL(30 per 30 days)
PRALUENT PEN 150 MG/ML, 75 MG/ML PEN INJECTOR MO	3	PA,QL(2 per 28 days)
pravastatin 10 mg, 80 mg TABLET MO	1	
pravastatin 20 mg, 40 mg TABLET MO	1	
prazosin 1 mg, 2 mg, 5 mg CAPSULE MO	1	
prevalite 4 gram POWDER MO	1	
prevalite 4 gram POWDER IN PACKET MO	1	
procainamide 100 mg/ml, 500 mg/ml SOLUTION MO	1	
PROCARDIA XL 30 MG, 60 MG, 90 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
propafenone 150 mg, 225 mg, 300 mg TABLET MO	1	
propafenone 225 mg, 325 mg, 425 mg CAPSULE, ER 12 HR. MO	1	
propranolol 1 mg/ml, 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml) SOLUTION MO	1	
propranolol 10 mg, 20 mg, 40 mg, 60 mg, 80 mg TABLET MO	1	
propranolol 120 mg, 160 mg, 60 mg, 80 mg CAPSULE, ER 24 HR. MO	1	
propranolol-hydrochlorothiazid 40-25 mg, 80-25 mg TABLET MO	1	
QBRELIS 1 MG/ML SOLUTION DL	4	QL(1200 per 30 days)
QUESTRAN 4 GRAM POWDER MO	1	
QUESTRAN 4 GRAM POWDER IN PACKET MO	1	
QUESTRAN LIGHT 4 GRAM POWDER MO	1	
quinapril 10 mg, 20 mg, 40 mg, 5 mg TABLET MO	1	
quinapril-hydrochlorothiazide 10-12.5 mg, 20-12.5 mg, 20-25 mg TABLET MO	1	
quinidine gluconate 324 mg TABLET ER MO	1	
quinidine sulfate 200 mg, 300 mg TABLET MO	1	
ramipril 1.25 mg, 10 mg, 2.5 mg, 5 mg CAPSULE MO	1	
RANEXA 1,000 MG, 500 MG TABLET, ER 12 HR. MO	3	PA,QL(120 per 30 days)
ranolazine 1,000 mg, 500 mg TABLET, ER 12 HR. MO	1	QL(120 per 30 days)
REPATHA PUSHTRONEX 420 MG/3.5 ML WEARABLE INJECTOR MO	2	PA,QL(3.5 per 28 days)
REPATHA SURECLICK 140 MG/ML PEN INJECTOR MO	2	PA,QL(3 per 28 days)
REPATHA SYRINGE 140 MG/ML SYRINGE MO	2	PA,QL(3 per 28 days)
rosuvastatin 10 mg, 20 mg, 40 mg, 5 mg TABLET MO	1	
RYTHMOL SR 225 MG, 325 MG, 425 MG CAPSULE, ER 12 HR. MO	3	PA
simvastatin 10 mg, 20 mg, 40 mg TABLET MO	1	
simvastatin 5 mg, 80 mg TABLET MO	1	
SOAANZ 20 MG, 40 MG, 60 MG TABLET MO	3	ST
SODIUM EDECRIN 50 MG RECON SOLUTION MO	3	
sorine 120 mg, 160 mg, 240 mg, 80 mg TABLET MO	1	
sotalol 120 mg, 160 mg, 240 mg, 80 mg TABLET MO	1	
sotalol af 120 mg, 160 mg, 80 mg TABLET MO	1	
SOTYLIZE 5 MG/ML SOLUTION MO	3	
spironolacton-hydrochlorothiaz 25-25 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>spironolactone 100 mg TABLET</i> MO	1	
<i>spironolactone 25 mg, 50 mg TABLET</i> MO	1	
<i>spironolactone 25 mg/5 ml SUSPENSION</i> MO	3	PA,QL(450 per 30 days)
SULAR 17 MG, 34 MG, 8.5 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
<i>taztia xt 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>taztia xt 300 mg, 360 mg CAPSULE, ER 24 HR.</i> MO	1	QL(30 per 30 days)
TEKTURNA 150 MG, 300 MG TABLET MO	3	PA,QL(30 per 30 days)
TEKTURNA HCT 150-12.5 MG, 150-25 MG, 300-12.5 MG, 300-25 MG TABLET MO	3	ST,QL(30 per 30 days)
<i>telmisartan 20 mg, 40 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>telmisartan 80 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>telmisartan-amlodipine 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>telmisartan-hydrochlorothiazid 40-12.5 mg, 80-25 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>telmisartan-hydrochlorothiazid 80-12.5 mg TABLET</i> MO	1	QL(60 per 30 days)
TENORETIC 100 100-25 MG TABLET MO	3	
TENORETIC 50 50-25 MG TABLET MO	3	PA
TENORMIN 100 MG, 25 MG, 50 MG TABLET MO	3	PA
<i>terazosin 1 mg, 10 mg, 2 mg, 5 mg CAPSULE</i> MO	1	
THALITONE 15 MG TABLET MO	3	
<i>tiadylt er 120 mg, 180 mg, 240 mg CAPSULE, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>tiadylt er 300 mg, 360 mg, 420 mg CAPSULE, ER 24 HR.</i> MO	1	QL(30 per 30 days)
TIAZAC 120 MG, 180 MG, 240 MG CAPSULE, ER 24 HR. MO	3	QL(60 per 30 days)
TIAZAC 300 MG, 360 MG, 420 MG CAPSULE, ER 24 HR. MO	3	QL(30 per 30 days)
TIKOSYN 125 MCG, 250 MCG, 500 MCG CAPSULE MO	3	PA
<i>timolol maleate 10 mg, 20 mg, 5 mg TABLET</i> MO	1	
TOPROL XL 100 MG, 200 MG, 25 MG, 50 MG TABLET, ER 24 HR. MO	3	
<i>torse mide 10 mg, 100 mg, 5 mg TABLET</i> MO	1	
<i>torse mide 20 mg TABLET</i> MO	1	
<i>trandolapril 1 mg, 2 mg, 4 mg TABLET</i> MO	1	
<i>trandolapril-verapamil 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg TABLET, IR/ER 24 HR., BIPHASIC</i> MO	1	
<i>triamterene 100 mg, 50 mg CAPSULE</i> MO	1	
<i>triamterene-hydrochlorothiazid 37.5-25 mg CAPSULE</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
triamterene-hydrochlorothiazid 37.5-25 mg TABLET MO	1	
triamterene-hydrochlorothiazid 75-50 mg TABLET MO	1	
TRIBENZOR 20-5-12.5 MG, 40-10-12.5 MG, 40-10-25 MG, 40-5-12.5 MG, 40-5-25 MG TABLET MO	3	PA,QL(30 per 30 days)
TRICOR 145 MG TABLET MO	3	PA,QL(30 per 30 days)
TRICOR 48 MG TABLET MO	3	PA,QL(60 per 30 days)
TRILIPIX 135 MG, 45 MG CAPSULE, DR/EC MO	3	PA,QL(30 per 30 days)
TRYVIO 12.5 MG TABLET MO	3	PA,QL(30 per 30 days)
valsartan 160 mg TABLET MO	1	QL(60 per 30 days)
valsartan 320 mg, 40 mg, 80 mg TABLET MO	1	QL(60 per 30 days)
valsartan 4 mg/ml SOLUTION DL	4	ST,QL(2400 per 30 days)
VALSARTAN 4 MG/ML SOLUTION DL	4	ST,QL(2400 per 30 days)
valsartan-hydrochlorothiazide 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg TABLET MO	1	QL(30 per 30 days)
VASCEPA 0.5 GRAM CAPSULE MO	2	QL(240 per 30 days)
VASCEPA 1 GRAM CAPSULE MO	2	QL(120 per 30 days)
VASERETIC 10-25 MG TABLET MO	3	
VASOTEC 10 MG, 2.5 MG, 20 MG, 5 MG TABLET DL	4	PA
vecamyl 2.5 mg TABLET DL	4	QL(300 per 30 days)
verapamil 100 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg, 360 mg CAPSULE ER PELLETS 24 HR. MO	1	
verapamil 120 mg, 180 mg, 240 mg TABLET ER MO	1	
verapamil 120 mg, 40 mg, 80 mg TABLET MO	1	
verapamil 2.5 mg/ml SOLUTION MO	1	
verapamil 2.5 mg/ml SYRINGE MO	1	
VERELAN PM 100 MG, 200 MG, 300 MG CAPSULE ER PELLETS 24 HR. MO	3	PA
VERQUVO 10 MG, 2.5 MG, 5 MG TABLET MO	2	PA,QL(30 per 30 days)
VYTORIN 10-10 10-10 MG TABLET MO	3	PA,QL(30 per 30 days)
VYTORIN 10-20 10-20 MG TABLET MO	3	PA,QL(30 per 30 days)
VYTORIN 10-40 10-40 MG TABLET MO	3	PA,QL(30 per 30 days)
VYTORIN 10-80 10-80 MG TABLET MO	3	PA,QL(30 per 30 days)
WELCHOL 3.75 GRAM POWDER IN PACKET MO	3	QL(30 per 30 days)
WELCHOL 625 MG TABLET MO	3	QL(180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZESTORETIC 10-12.5 MG, 20-12.5 MG, 20-25 MG TABLET MO	3	
ZESTRIL 10 MG, 2.5 MG, 20 MG, 30 MG, 40 MG, 5 MG TABLET MO	3	PA
ZETIA 10 MG TABLET MO	3	PA,QL(30 per 30 days)
ZIAC 10-6.25 MG, 2.5-6.25 MG, 5-6.25 MG TABLET MO	3	PA
ZOCOR 10 MG, 20 MG, 40 MG, 80 MG TABLET MO	3	PA
ZYPITAMAG 2 MG, 4 MG TABLET MO	2	ST,QL(30 per 30 days)
CENTRAL NERVOUS SYSTEM AGENTS		
ADDERALL 10 MG, 12.5 MG, 15 MG, 20 MG, 5 MG, 7.5 MG TABLET MO	1	PA,QL(90 per 30 days)
ADDERALL 30 MG TABLET MO	1	PA,QL(60 per 30 days)
ADDERALL XR 10 MG, 15 MG, 5 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
ADDERALL XR 20 MG, 25 MG, 30 MG CAPSULE, ER 24 HR. MO	3	PA,QL(60 per 30 days)
ADZENYS XR-ODT 12.5 MG, 15.7 MG, 18.8 MG, 3.1 MG, 6.3 MG, 9.4 MG TABLET, DISINTEGRATING ER BIPH MO	3	QL(30 per 30 days)
<i>amphetamine 1.25 mg/ml SUSPENSION, IR/ER BIPHASIC</i> MO	3	QL(450 per 30 days)
<i>amphetamine sulfate 10 mg, 5 mg TABLET</i> MO	1	QL(90 per 30 days)
AMPYRA 10 MG TABLET, ER 12 HR. DL	4	PA,QL(60 per 30 days)
APTENSIO XR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CAPSULE, ER SPRINKLE, BIPHASIC MO	3	QL(30 per 30 days)
<i>atomoxetine 10 mg, 18 mg, 25 mg, 40 mg CAPSULE</i> MO	1	QL(60 per 30 days)
<i>atomoxetine 100 mg, 60 mg, 80 mg CAPSULE</i> MO	1	QL(30 per 30 days)
AUBAGIO 14 MG, 7 MG TABLET DL	4	PA,QL(30 per 30 days)
AUSTEDO 12 MG, 9 MG TABLET DL	4	PA,QL(120 per 30 days)
AUSTEDO 6 MG TABLET DL	4	PA,QL(60 per 30 days)
AUSTEDO XR 12 MG, 6 MG TABLET, ER 24 HR. DL	4	PA,QL(90 per 30 days)
AUSTEDO XR 18 MG, 30 MG, 36 MG, 42 MG, 48 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
AUSTEDO XR 24 MG TABLET, ER 24 HR. DL	4	PA,QL(60 per 30 days)
AUSTEDO XR TITRATION KT(WK1-4) 12-18-24-30 MG TABLET, ER 24 HR., DOSE PACK DL	4	PA,QL(28 per 28 days)
AUSTEDO XR TITRATION KT(WK1-4) 6 MG (14)-12 MG (14)-24 MG (14) TABLET, ER 24 HR., DOSE PACK DL	4	PA,QL(42 per 28 days)
AVONEX 30 MCG/0.5 ML PEN INJECTOR KIT DL	4	PA,QL(1 per 28 days)
AVONEX 30 MCG/0.5 ML SYRINGE KIT DL	4	PA,QL(1 per 28 days)
AZSTARYS 26.1 MG- 5.2 MG, 39.2 MG- 7.8 MG, 52.3 MG- 10.4 MG CAPSULE MO	3	QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BAFIERTAM 95 MG CAPSULE, DR/EC DL	4	PA,QL(120 per 30 days)
BETASERON 0.3 MG KIT DL	4	PA,QL(15 per 30 days)
BRIUMVI 25 MG/ML SOLUTION	4	PA
<i>clonidine hcl 0.1 mg TABLET, ER 12 HR.</i> MO	1	QL(120 per 30 days)
CONCERTA 18 MG, 27 MG, 54 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
CONCERTA 36 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)
COPAXONE 20 MG/ML SYRINGE DL	4	PA,QL(30 per 30 days)
COPAXONE 40 MG/ML SYRINGE DL	4	PA,QL(12 per 28 days)
COTEMPLA XR-ODT 17.3 MG, 8.6 MG TABLET, DISINTEGRATING ER BIPH MO	3	QL(30 per 30 days)
COTEMPLA XR-ODT 25.9 MG TABLET, DISINTEGRATING ER BIPH MO	3	QL(60 per 30 days)
CYMBALTA 20 MG CAPSULE, DR/EC MO	3	PA,QL(120 per 30 days)
CYMBALTA 30 MG CAPSULE, DR/EC MO	3	PA,QL(90 per 30 days)
CYMBALTA 60 MG CAPSULE, DR/EC MO	3	PA,QL(60 per 30 days)
<i>dalfampridine 10 mg TABLET, ER 12 HR.</i> MO	1	PA,QL(60 per 30 days)
DAYTRANA 10 MG/9 HR, 15 MG/9 HR, 20 MG/9 HR, 30 MG/9 HR PATCH, 24 HR. MO	3	QL(30 per 30 days)
DESOXYN 5 MG TABLET DL	4	PA,QL(150 per 30 days)
DEXEDRINE SPANSULE 10 MG CAPSULE, ER DL	4	PA,QL(180 per 30 days)
DEXEDRINE SPANSULE 15 MG CAPSULE, ER DL	4	PA,QL(120 per 30 days)
<i>dexmethylphenidate 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg CAPSULE, ER, BIPHASIC</i> MO	1	QL(30 per 30 days)
<i>dexmethylphenidate 10 mg, 2.5 mg, 5 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>dextroamphetamine sulfate 10 mg CAPSULE, ER</i> MO	1	QL(180 per 30 days)
<i>dextroamphetamine sulfate 10 mg TABLET</i> MO	1	QL(180 per 30 days)
<i>dextroamphetamine sulfate 15 mg CAPSULE, ER</i> MO	1	QL(120 per 30 days)
<i>dextroamphetamine sulfate 15 mg TABLET</i> MO	1	QL(120 per 30 days)
<i>dextroamphetamine sulfate 2.5 mg, 20 mg, 7.5 mg TABLET</i> MO	1	QL(90 per 30 days)
<i>dextroamphetamine sulfate 30 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>dextroamphetamine sulfate 5 mg CAPSULE, ER</i> MO	1	QL(60 per 30 days)
<i>dextroamphetamine sulfate 5 mg TABLET</i> MO	1	QL(150 per 30 days)
<i>dextroamphetamine sulfate 5 mg/5 ml SOLUTION</i> MO	1	QL(1800 per 30 days)
<i>dextroamphetamine-amphetamine 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg TABLET</i> MO	1	QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>dextroamphetamine-amphetamine 10 mg, 15 mg, 5 mg CAPSULE, ER 24 HR.</i> MO	1	QL(30 per 30 days)
<i>dextroamphetamine-amphetamine 12.5 mg, 25 mg, 37.5 mg, 50 mg CAPSULE ER TRIPHASIC 24 HR.</i> MO	1	QL(30 per 30 days)
<i>dextroamphetamine-amphetamine 20 mg, 25 mg, 30 mg CAPSULE, ER 24 HR.</i> MO	1	QL(60 per 30 days)
<i>dextroamphetamine-amphetamine 30 mg TABLET</i> MO	1	QL(60 per 30 days)
<i>dimethyl fumarate 120 mg (14)- 240 mg (46), 240 mg CAPSULE, DR/EC</i> MO	1	PA,QL(60 per 30 days)
<i>dimethyl fumarate 120 mg CAPSULE, DR/EC</i> MO	1	PA,QL(14 per 30 days)
<i>DRIZALMA SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG CAPSULE, DR SPRINKLE</i> MO	3	PA,QL(60 per 30 days)
<i>duloxetine 20 mg CAPSULE, DR/EC</i> MO	1	QL(120 per 30 days)
<i>duloxetine 30 mg CAPSULE, DR/EC</i> MO	1	QL(90 per 30 days)
<i>duloxetine 40 mg CAPSULE, DR/EC</i> MO	1	QL(60 per 30 days)
<i>duloxetine 60 mg CAPSULE, DR/EC</i> MO	1	QL(60 per 30 days)
<i>DYANAVEL XR 10 MG, 15 MG, 20 MG, 5 MG TABLET, IR/ER 24 HR., BIPHASIC</i> MO	3	QL(30 per 30 days)
<i>DYANAVEL XR 2.5 MG/ML SUSPENSION, IR/ER BIPHASIC</i> MO	3	QL(240 per 30 days)
<i>edaravone 30 mg/100 ml, 60 mg/100 ml SOLUTION</i> DL	4	PA
<i>EVEKEO 10 MG, 5 MG TABLET</i> MO	1	QL(90 per 30 days)
<i>EVEKEO ODT 10 MG, 5 MG TABLET, DISINTEGRATING</i> MO	3	QL(90 per 30 days)
<i>EVEKEO ODT 15 MG, 20 MG TABLET, DISINTEGRATING</i> MO	3	QL(60 per 30 days)
<i>EXSERVAN 50 MG FILM</i> DL	4	PA,QL(60 per 30 days)
<i>EXTAVIA 0.3 MG KIT</i> DL	4	PA,QL(15 per 30 days)
<i>EXTAVIA 0.3 MG RECON SOLUTION</i> DL	4	PA,QL(15 per 30 days)
<i>fingolimod 0.5 mg CAPSULE</i> MO	1	PA,QL(30 per 30 days)
<i>FIRDAPSE 10 MG TABLET</i> DL	4	PA,QL(240 per 30 days)
<i>FOCALIN 10 MG, 2.5 MG, 5 MG TABLET</i> MO	3	PA,QL(60 per 30 days)
<i>FOCALIN XR 10 MG, 15 MG, 20 MG, 25 MG, 30 MG, 35 MG, 40 MG, 5 MG CAPSULE, ER, BIPHASIC</i> MO	3	QL(30 per 30 days)
<i>gabapentin 300 mg TABLET, ER 24 HR.</i> MO	1	ST,QL(30 per 30 days)
<i>gabapentin 600 mg TABLET, ER 24 HR.</i> MO	1	ST,QL(90 per 30 days)
<i>GILENYA 0.25 MG, 0.5 MG CAPSULE</i> DL	4	PA,QL(30 per 30 days)
<i>glatiramer 20 mg/ml SYRINGE</i> DL	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
glatiramer 40 mg/ml SYRINGE DL	4	PA,QL(12 per 28 days)
glatopa 20 mg/ml SYRINGE DL	4	PA,QL(30 per 30 days)
glatopa 40 mg/ml SYRINGE DL	4	PA,QL(12 per 28 days)
GRALISE 300 MG TABLET, ER 24 HR. MO	3	ST,QL(30 per 30 days)
GRALISE 450 MG, 600 MG TABLET, ER 24 HR. MO	3	ST,QL(90 per 30 days)
GRALISE 750 MG, 900 MG TABLET, ER 24 HR. MO	3	ST,QL(60 per 30 days)
guanfacine 1 mg, 2 mg, 3 mg, 4 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
HORIZANT 300 MG, 600 MG TABLET ER MO	3	PA,QL(60 per 30 days)
INGREZZA 40 MG, 60 MG, 80 MG CAPSULE DL	4	PA,QL(30 per 30 days)
INGREZZA INITIATION PK(TARDIV) 40 MG (7)- 80 MG (21) CAPSULE, DOSE PACK DL	4	PA,QL(28 per 28 days)
INGREZZA SPRINKLE 40 MG, 60 MG, 80 MG CAPSULE, SPRINKLE DL	4	PA,QL(30 per 30 days)
INTUNIV ER 1 MG, 2 MG, 3 MG, 4 MG TABLET, ER 24 HR. MO	3	QL(30 per 30 days)
JORNAY PM 100 MG, 20 MG, 40 MG, 60 MG, 80 MG CAPSULE, DR, ER SPRINKLE MO	3	QL(30 per 30 days)
KAPVAY 0.1 MG TABLET, ER 12 HR. MO	3	QL(120 per 30 days)
KESIMPTA PEN 20 MG/0.4 ML PEN INJECTOR DL	4	PA,QL(1.2 per 28 days)
LEMTRADA 12 MG/1.2 ML SOLUTION DL	4	PA,QL(6 per 365 days)
lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg CHEWABLE TABLET MO	1	PA,QL(30 per 30 days)
lisdexamfetamine 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg CAPSULE MO	1	PA,QL(30 per 30 days)
LYRICA 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG CAPSULE MO	3	PA,QL(90 per 30 days)
LYRICA 20 MG/ML SOLUTION MO	3	PA,QL(900 per 30 days)
LYRICA 225 MG, 300 MG CAPSULE MO	3	PA,QL(60 per 30 days)
LYRICA CR 165 MG, 82.5 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
LYRICA CR 330 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)
MAVENCLAD (10 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (4 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (5 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (6 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (7 TABLET PACK) 10 MG TABLET DL	4	PA
MAVENCLAD (8 TABLET PACK) 10 MG TABLET DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MAVENCLAD (9 TABLET PACK) 10 MG TABLET DL	4	PA
MAYZENT 0.25 MG TABLET DL	4	PA,QL(120 per 30 days)
MAYZENT 1 MG, 2 MG TABLET DL	4	PA,QL(30 per 30 days)
MAYZENT STARTER(FOR 1MG MAINT) 0.25 MG (7 TABS) TABLET, DOSE PACK DL	4	PA,QL(7 per 30 days)
MAYZENT STARTER(FOR 2MG MAINT) 0.25 MG (12 TABS) TABLET, DOSE PACK DL	4	PA,QL(12 per 30 days)
METADATE CD 10 MG, 40 MG, 50 MG, 60 MG CAPSULE, ER, BIPHASIC MO	3	QL(30 per 30 days)
METADATE CD 20 MG, 30 MG CAPSULE, ER, BIPHASIC MO	3	QL(60 per 30 days)
metadate er 20 mg TABLET ER MO	1	QL(90 per 30 days)
methamphetamine 5 mg TABLET DL	4	QL(150 per 30 days)
METHYLIN 10 MG/5 ML SOLUTION MO	3	PA,QL(900 per 30 days)
METHYLIN 5 MG/5 ML SOLUTION MO	3	PA,QL(1800 per 30 days)
methylphenidate 10 mg/9 hr, 15 mg/9 hr, 20 mg/9 hr, 30 mg/9 hr PATCH, 24 HR. MO	1	QL(30 per 30 days)
methylphenidate hcl 10 mg CHEWABLE TABLET MO	1	QL(180 per 30 days)
methylphenidate hcl 10 mg TABLET ER MO	1	QL(180 per 30 days)
methylphenidate hcl 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg CAPSULE, ER SPRINKLE, BIPHASIC MO	3	QL(30 per 30 days)
methylphenidate hcl 10 mg, 20 mg, 40 mg, 50 mg, 60 mg CAPSULE, ER, BIPHASIC MO	1	QL(30 per 30 days)
methylphenidate hcl 10 mg, 20 mg, 5 mg TABLET MO	1	QL(90 per 30 days)
methylphenidate hcl 10 mg/5 ml SOLUTION MO	1	QL(900 per 30 days)
methylphenidate hcl 18 mg, 27 mg, 54 mg, 72 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
methylphenidate hcl 2.5 mg, 5 mg CHEWABLE TABLET MO	1	QL(150 per 30 days)
methylphenidate hcl 20 mg TABLET ER MO	1	QL(90 per 30 days)
methylphenidate hcl 20 mg, 30 mg CAPSULE, ER, BIPHASIC MO	1	QL(60 per 30 days)
methylphenidate hcl 36 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
methylphenidate hcl 45 mg, 63 mg TABLET, ER 24 HR. MO	3	QL(30 per 30 days)
methylphenidate hcl 5 mg/5 ml SOLUTION MO	1	QL(1800 per 30 days)
MYDAYIS 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE ER TRIPHASIC 24 HR. MO	3	QL(30 per 30 days)
NUJEXTA 20-10 MG CAPSULE	4	PA,QL(60 per 30 days)
OCREVUS 30 MG/ML SOLUTION	4	PA,QL(40 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML PEN INJECTOR DL	4	PA,QL(1 per 28 days)
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML SYRINGE DL	4	PA,QL(1 per 28 days)
PONVORY 20 MG TABLET DL	4	PA,QL(30 per 30 days)
PONVORY 14-DAY STARTER PACK 2 MG (2) - 10 MG (3) TABLET, DOSE PACK DL	4	PA,QL(14 per 30 days)
pregabalin 100 mg, 150 mg, 50 mg, 75 mg CAPSULE MO	1	QL(90 per 30 days)
pregabalin 165 mg, 82.5 mg TABLET, ER 24 HR. MO	1	PA,QL(30 per 30 days)
pregabalin 20 mg/ml SOLUTION MO	1	QL(900 per 30 days)
pregabalin 200 mg, 25 mg CAPSULE MO	1	QL(90 per 30 days)
pregabalin 225 mg, 300 mg CAPSULE MO	1	QL(60 per 30 days)
pregabalin 330 mg TABLET, ER 24 HR. MO	1	PA,QL(60 per 30 days)
procentra 5 mg/5 ml SOLUTION DL	4	QL(1800 per 30 days)
QALSODY 100 MG/15 ML (6.7 MG/ML) SOLUTION DL	4	PA
QELBREE 100 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
QELBREE 150 MG, 200 MG CAPSULE, ER 24 HR. MO	3	PA,QL(60 per 30 days)
QUILLICHEW ER 20 MG, 40 MG CHEWABLE TABLET, IR/ER BIPHASE MO	3	QL(30 per 30 days)
QUILLICHEW ER 30 MG CHEWABLE TABLET, IR/ER BIPHASE MO	3	QL(60 per 30 days)
QUILLIVANT XR 5 MG/ML (25 MG/5 ML) SUSPENSION, ER, RECON MO	3	QL(360 per 30 days)
RADICAVA 30 MG/100 ML SOLUTION DL	4	PA
RADICAVA ORS 105 MG/5 ML SUSPENSION DL	4	PA,QL(70 per 28 days)
RADICAVA ORS STARTER KIT SUSP 105 MG/5 ML SUSPENSION DL	4	PA,QL(70 per 28 days)
REBIF (WITH ALBUMIN) 22 MCG/0.5 ML, 44 MCG/0.5 ML SYRINGE DL	4	PA,QL(6 per 28 days)
REBIF REBIDOSE 22 MCG/0.5 ML, 44 MCG/0.5 ML PEN INJECTOR DL	4	PA,QL(6 per 28 days)
REBIF REBIDOSE 8.8MCG/0.2ML-22 MCG/0.5ML (6) PEN INJECTOR DL	4	PA,QL(4.2 per 28 days)
REBIF TITRATION PACK 8.8MCG/0.2ML-22 MCG/0.5ML (6) SYRINGE DL	4	PA,QL(4.2 per 28 days)
RELEXXII 18 MG, 27 MG, 45 MG, 54 MG, 63 MG, 72 MG TABLET, ER 24 HR. MO	3	QL(30 per 30 days)
RELEXXII 36 MG TABLET, ER 24 HR. MO	3	QL(60 per 30 days)
RILUTEK 50 MG TABLET DL	4	
riluzole 50 mg TABLET MO	1	
RITALIN 10 MG, 20 MG, 5 MG TABLET MO	3	PA,QL(90 per 30 days)
RITALIN LA 10 MG, 20 MG, 40 MG CAPSULE, ER, BIPHASIC MO	3	PA,QL(30 per 30 days)
RITALIN LA 30 MG CAPSULE, ER, BIPHASIC MO	3	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SAVELLA 100 MG, 12.5 MG, 25 MG, 50 MG TABLET MO	3	PA,QL(60 per 30 days)
SAVELLA 12.5 MG (5)-25 MG(8)-50 MG(42) TABLET, DOSE PACK MO	3	PA,QL(55 per 28 days)
SKYCLARYS 50 MG CAPSULE DL	4	PA,QL(90 per 30 days)
STRATTERA 10 MG, 18 MG, 25 MG, 40 MG CAPSULE MO	3	PA,QL(60 per 30 days)
STRATTERA 100 MG, 60 MG, 80 MG CAPSULE MO	3	PA,QL(30 per 30 days)
TASCENSO ODT 0.25 MG, 0.5 MG TABLET, DISINTEGRATING DL	4	PA,QL(30 per 30 days)
TECFIDERA 120 MG (14)- 240 MG (46), 240 MG CAPSULE, DR/EC DL	4	PA,QL(60 per 30 days)
TECFIDERA 120 MG CAPSULE, DR/EC DL	4	PA,QL(14 per 30 days)
TEGLUTIK 50 MG/10 ML SUSPENSION DL	4	PA,QL(600 per 30 days)
teriflunomide 14 mg, 7 mg TABLET MO	1	PA,QL(30 per 30 days)
tetrabenazine 12.5 mg TABLET MO	1	PA,QL(240 per 30 days)
tetrabenazine 25 mg TABLET MO	1	PA,QL(120 per 30 days)
TIGLUTIK 50 MG/10 ML SUSPENSION DL	4	PA,QL(600 per 30 days)
TYSABRI 300 MG/15 ML SOLUTION DL	4	PA,QL(15 per 28 days)
VEOZAH 45 MG TABLET MO	3	PA,QL(30 per 30 days)
VUMERITY 231 MG CAPSULE, DR/EC DL	4	PA,QL(120 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CHEWABLE TABLET MO	3	PA,QL(30 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, 70 MG CAPSULE MO	3	PA,QL(30 per 30 days)
XELSTRYM 13.5 MG/9 HOUR, 18 MG/9 HOUR, 4.5 MG/9 HOUR, 9 MG/9 HOUR PATCH, 24 HR. MO	3	QL(30 per 30 days)
XENAZINE 12.5 MG TABLET DL	4	PA,QL(240 per 30 days)
XENAZINE 25 MG TABLET DL	4	PA,QL(120 per 30 days)
zenzedi 10 mg TABLET MO	1	QL(180 per 30 days)
ZENZEDI 15 MG TABLET MO	1	QL(120 per 30 days)
ZENZEDI 2.5 MG, 20 MG, 7.5 MG TABLET MO	1	QL(90 per 30 days)
ZENZEDI 30 MG TABLET MO	1	QL(60 per 30 days)
zenzedi 5 mg TABLET MO	1	QL(150 per 30 days)
ZEPOSIA 0.92 MG CAPSULE DL	4	PA,QL(30 per 30 days)
ZEPOSIA STARTER KIT (28-DAY) 0.23 MG-0.46 MG -0.92 MG (21) CAPSULE, DOSE PACK DL	4	PA,QL(28 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZEPOSIA STARTER KIT (37-DAY) 0.23 MG-0.46 MG -0.92 MG (30) CAPSULE, DOSE PACK	4	PA,QL(37 per 37 days)
ZEPOSIA STARTER PACK (7-DAY) 0.23 MG (4)- 0.46 MG (3) CAPSULE, DOSE PACK DL	4	PA,QL(7 per 7 days)
DENTAL & ORAL AGENTS		
<i>cevimeline 30 mg CAPSULE</i> MO	1	
<i>chlorhexidine gluconate 0.12 % MOUTHWASH</i> MO	1	
EVOXAC 30 MG CAPSULE MO	3	PA
KEPIVANCE 5.16 MG, 6.25 MG RECON SOLUTION DL	4	
<i>kourzeq 0.1 % PASTE</i> MO	1	
<i>oralone 0.1 % PASTE</i> MO	1	
<i>periogard 0.12 % MOUTHWASH</i> MO	1	
<i>pilocarpine hcl 5 mg, 7.5 mg TABLET</i> MO	1	
SALAGEN (PILOCARPINE) 5 MG, 7.5 MG TABLET MO	3	
<i>triamcinolone acetonide 0.1 % PASTE</i> MO	1	
DERMATOLOGICAL AGENTS		
ABSORICA 10 MG, 20 MG, 25 MG, 30 MG, 35 MG, 40 MG CAPSULE DL	4	ST
ABSORICA LD 16 MG, 24 MG, 32 MG, 8 MG CAPSULE DL	4	ST
ACANYA 1.2-2.5 % GEL WITH PUMP MO	3	QL(50 per 30 days)
<i>accutane 10 mg, 20 mg, 30 mg, 40 mg CAPSULE</i> MO	1	
<i>acitretin 10 mg, 17.5 mg, 25 mg CAPSULE</i> MO	1	PA
ACZONE 5 % GEL MO	3	QL(90 per 30 days)
ACZONE 7.5 % GEL WITH PUMP MO	3	QL(90 per 30 days)
<i>adapalene 0.1 % CREAM</i> MO	1	QL(45 per 30 days)
<i>adapalene 0.1 % SOLUTION</i> DL	4	QL(60 per 30 days)
<i>adapalene 0.1 % SWAB</i> MO	1	QL(30 per 30 days)
<i>adapalene 0.3 % GEL</i> MO	1	QL(45 per 30 days)
<i>adapalene 0.3 % GEL WITH PUMP</i> MO	1	QL(45 per 30 days)
<i>adapalene-benzoyl peroxide 0.1-2.5 % GEL WITH PUMP</i> MO	1	QL(45 per 30 days)
<i>adapalene-benzoyl peroxide 0.3-2.5 % GEL WITH PUMP</i> MO	1	QL(60 per 30 days)
ADBRY 150 MG/ML SYRINGE DL	4	PA,QL(6 per 28 days)
ADBRY 300 MG/2 ML AUTO-INJECTOR DL	4	PA,QL(6 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AKLIEF 0.005 % CREAM MO	3	PA,QL(90 per 30 days)
ALA-CORT 1 % CREAM MO	1	QL(240 per 30 days)
ALA-SCALP 2 % LOTION MO	1	QL(236.8 per 30 days)
<i>alclometasone 0.05 % CREAM MO</i>	1	QL(240 per 30 days)
<i>alclometasone 0.05 % OINTMENT MO</i>	1	QL(240 per 30 days)
ALTABAX 1 % OINTMENT MO	3	
ALTRENO 0.05 % LOTION MO	3	PA,QL(90 per 30 days)
<i>amcinonide 0.1 % CREAM MO</i>	1	QL(120 per 30 days)
<i>amcinonide 0.1 % OINTMENT DL</i>	4	ST,QL(120 per 30 days)
<i>ammonium lactate 12 % CREAM MO</i>	1	
<i>ammonium lactate 12 % LOTION MO</i>	1	
<i>amnestem 10 mg, 20 mg, 40 mg CAPSULE MO</i>	1	
AMZEEQ 4 % FOAM MO	3	PA,QL(30 per 30 days)
<i>anusol-hc 2.5 % CREAM W/PERINEAL APPLICATOR MO</i>	1	QL(60 per 30 days)
<i>apexicon e 0.05 % CREAM MO</i>	1	QL(60 per 30 days)
ARAZLO 0.045 % LOTION MO	3	PA
ATRALIN 0.05 % GEL MO	3	PA,QL(45 per 30 days)
AVITA 0.025 % CREAM MO	3	PA,QL(45 per 30 days)
AVITA 0.025 % GEL MO	3	PA,QL(45 per 30 days)
<i>azelaic acid 15 % GEL MO</i>	1	ST,QL(50 per 30 days)
AZELEX 20 % CREAM MO	3	QL(50 per 30 days)
BENZAMYCIN 3-5 % GEL MO	3	QL(46.6 per 30 days)
<i>beseer 0.05 % LOTION MO</i>	1	QL(240 per 30 days)
<i>betamethasone dipropionate 0.05 % CREAM MO</i>	1	QL(90 per 30 days)
<i>betamethasone dipropionate 0.05 % LOTION MO</i>	1	QL(120 per 30 days)
<i>betamethasone dipropionate 0.05 % OINTMENT MO</i>	1	QL(90 per 30 days)
<i>betamethasone valerate 0.1 % CREAM MO</i>	1	QL(180 per 30 days)
<i>betamethasone valerate 0.1 % LOTION MO</i>	1	QL(120 per 30 days)
<i>betamethasone valerate 0.1 % OINTMENT MO</i>	1	QL(180 per 30 days)
<i>betamethasone valerate 0.12 % FOAM MO</i>	1	QL(200 per 30 days)
<i>betamethasone, augmented 0.05 % CREAM MO</i>	1	QL(100 per 30 days)
<i>betamethasone, augmented 0.05 % GEL MO</i>	1	QL(100 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>betamethasone, augmented 0.05 % LOTION</i> MO	1	QL(120 per 30 days)
<i>betamethasone, augmented 0.05 % OINTMENT</i> MO	1	QL(100 per 30 days)
<i>brimonidine 0.33 % GEL WITH PUMP</i> MO	1	ST,QL(30 per 30 days)
BRYHALI 0.01 % LOTION MO	3	ST,QL(200 per 30 days)
CABTREO 0.15-3.1-1.2 % GEL MO	3	QL(50 per 30 days)
<i>calcipotriene 0.005 % CREAM</i> MO	1	PA,QL(120 per 30 days)
<i>calcipotriene 0.005 % FOAM</i> MO	1	ST,QL(120 per 28 days)
<i>calcipotriene 0.005 % OINTMENT</i> MO	1	QL(240 per 30 days)
<i>calcipotriene 0.005 % SOLUTION</i> MO	1	QL(60 per 30 days)
<i>calcipotriene-betamethasone 0.005-0.064 % OINTMENT</i> MO	1	PA,QL(60 per 30 days)
<i>calcipotriene-betamethasone 0.005-0.064 % SUSPENSION</i> MO	1	PA,QL(420 per 30 days)
<i>calcitriol 3 mcg/gram OINTMENT</i> MO	1	ST,QL(800 per 28 days)
CAPEX 0.01 % SHAMPOO MO	3	QL(840 per 30 days)
CARAC 0.5 % CREAM DL	4	PA,QL(60 per 30 days)
CENTANY 2 % OINTMENT MO	3	
<i>claravis 10 mg, 20 mg, 30 mg, 40 mg CAPSULE</i> MO	1	
CLEOCIN T 1 % LOTION MO	3	QL(60 per 30 days)
<i>clindacin 1 % FOAM</i> MO	1	QL(100 per 30 days)
<i>clindacin etz 1 % SWAB</i> MO	1	
<i>clindacin p 1 % SWAB</i> MO	1	
CLINDAGEL 1 % GEL, ONCE DAILY DL	4	PA,QL(75 per 30 days)
<i>clindamycin phosphate 1 % FOAM</i> MO	1	QL(100 per 30 days)
<i>clindamycin phosphate 1 % GEL</i> MO	1	QL(60 per 30 days)
<i>clindamycin phosphate 1 % GEL, ONCE DAILY</i> MO	1	PA,QL(75 per 30 days)
<i>clindamycin phosphate 1 % LOTION</i> MO	1	QL(60 per 30 days)
<i>clindamycin phosphate 1 % SOLUTION</i> MO	1	QL(60 per 30 days)
<i>clindamycin phosphate 1 % SWAB</i> MO	1	
<i>clindamycin-benzoyl peroxide 1-5 % GEL</i> MO	1	QL(50 per 30 days)
<i>clindamycin-benzoyl peroxide 1-5 %, 1.2 %(1 % base) -3.75 %, 1.2-2.5 % GEL WITH PUMP</i> MO	1	QL(50 per 30 days)
<i>clindamycin-benzoyl peroxide 1.2 %(1 % base) -5 % GEL</i> MO	1	QL(45 per 30 days)
<i>clindamycin-tretinoin 1.2-0.025 % GEL</i> MO	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>clobetasol 0.05 % CREAM</i> MO	1	QL(120 per 30 days)
<i>clobetasol 0.05 % FOAM</i> MO	1	QL(100 per 28 days)
<i>clobetasol 0.05 % GEL</i> MO	1	QL(120 per 28 days)
<i>clobetasol 0.05 % LOTION</i> MO	1	QL(240 per 28 days)
<i>clobetasol 0.05 % OINTMENT</i> MO	1	QL(120 per 28 days)
<i>clobetasol 0.05 % SHAMPOO</i> MO	1	QL(240 per 30 days)
<i>clobetasol 0.05 % SOLUTION</i> MO	1	QL(100 per 30 days)
<i>clobetasol 0.05 % SPRAY, NON-AEROSOL</i> MO	1	QL(240 per 30 days)
<i>clobetasol-emollient 0.05 % CREAM</i> MO	1	QL(120 per 30 days)
<i>clobetasol-emollient 0.05 % FOAM</i> MO	1	QL(100 per 30 days)
CLOBEX 0.05 % LOTION MO	3	ST,QL(240 per 28 days)
CLOBEX 0.05 % SHAMPOO MO	3	ST,QL(240 per 30 days)
CLOBEX 0.05 % SPRAY, NON-AEROSOL MO	3	ST,QL(240 per 30 days)
<i>clocortolone pivalate 0.1 % CREAM</i> MO	1	QL(180 per 30 days)
<i>clodan 0.05 % SHAMPOO</i> MO	1	QL(240 per 30 days)
CONDYLOX 0.5 % GEL MO	3	
CORDRAN 0.025 % CREAM MO	3	ST,QL(240 per 30 days)
CORDRAN 0.05 % CREAM DL	4	ST,QL(240 per 30 days)
CORDRAN 0.05 % LOTION DL	4	ST,QL(240 per 30 days)
CORDRAN 0.05 % OINTMENT MO	3	ST,QL(240 per 30 days)
CORDRAN TAPE LARGE ROLL 4 MCG/CM2 TAPE MO	3	QL(2 per 30 days)
CORTEF 10 MG, 20 MG, 5 MG TABLET MO	3	
<i>crotan 10 % LOTION</i> DL	4	PA,QL(454 per 30 days)
<i>dapsone 5 % GEL</i> MO	1	QL(90 per 30 days)
<i>dapsone 7.5 % GEL WITH PUMP</i> MO	1	QL(90 per 30 days)
DERMA-SMOOTHIE/FS BODY OIL 0.01 % OIL MO	3	QL(118.28 per 30 days)
DERMA-SMOOTHIE/FS SCALP OIL 0.01 % OIL MO	3	QL(118.28 per 30 days)
<i>desonide 0.05 % CREAM</i> MO	1	QL(240 per 30 days)
<i>desonide 0.05 % GEL</i> MO	1	QL(240 per 30 days)
<i>desonide 0.05 % LOTION</i> MO	1	QL(240 per 30 days)
<i>desonide 0.05 % OINTMENT</i> MO	1	QL(240 per 30 days)
DESOWEN 0.05 % CREAM MO	3	QL(240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>desoximetasone 0.05 % CREAM</i> MO	1	QL(240 per 30 days)
<i>desoximetasone 0.05 % GEL</i> MO	1	QL(240 per 30 days)
<i>desoximetasone 0.05 % OINTMENT</i> MO	1	QL(240 per 30 days)
<i>desoximetasone 0.25 % CREAM</i> MO	1	QL(120 per 30 days)
<i>desoximetasone 0.25 % OINTMENT</i> MO	1	QL(120 per 30 days)
<i>desoximetasone 0.25 % SPRAY, NON-AEROSOL</i> MO	1	QL(100 per 30 days)
<i>desrx 0.05 % GEL</i> MO	1	QL(240 per 30 days)
<i>diclofenac sodium 3 % GEL</i> MO	1	PA
DIFFERIN 0.1 % CREAM MO	3	PA,QL(45 per 30 days)
DIFFERIN 0.1 % LOTION MO	3	QL(59 per 30 days)
DIFFERIN 0.3 % GEL WITH PUMP MO	3	QL(45 per 30 days)
<i>diflorasone 0.05 % CREAM</i> DL	4	QL(120 per 30 days)
<i>diflorasone 0.05 % OINTMENT</i> MO	3	QL(120 per 30 days)
DIPROLENE (AUGMENTED) 0.05 % OINTMENT MO	3	QL(100 per 30 days)
DOVONEX 0.005 % CREAM MO	3	PA,QL(120 per 30 days)
<i>doxepin 5 % CREAM</i> DL	4	PA,QL(45 per 30 days)
DUOBRII 0.01-0.045 % LOTION MO	3	PA,QL(200 per 28 days)
EFUDEX 5 % CREAM MO	3	PA
ELIDEL 1 % CREAM MO	3	PA,QL(100 per 30 days)
ELIMITE 5 % CREAM MO	3	
ENSTILAR 0.005-0.064 % FOAM MO	3	QL(120 per 30 days)
EPIDUO 0.1-2.5 % GEL WITH PUMP MO	3	QL(45 per 30 days)
EPIDUO FORTE 0.3-2.5 % GEL WITH PUMP MO	3	QL(60 per 30 days)
EPIFOAM 1-1 % FOAM MO	1	
EPSOLAY 5 % CREAM MO	3	ST,QL(30 per 30 days)
<i>ery pads 2 % SWAB</i> MO	1	QL(60 per 30 days)
ERYGEL 2 % GEL MO	1	QL(60 per 30 days)
<i>erythromycin with ethanol 2 % GEL</i> MO	1	QL(60 per 30 days)
<i>erythromycin with ethanol 2 % SOLUTION</i> MO	1	QL(120 per 30 days)
<i>erythromycin-benzoyl peroxide 3-5 % GEL</i> MO	1	QL(46.6 per 30 days)
EUCRISA 2 % OINTMENT MO	3	PA,QL(100 per 30 days)
EURAX 10 % CREAM MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EURAX 10 % LOTION MO	3	PA,QL(454 per 30 days)
EVOCLIN 1 % FOAM MO	3	PA,QL(100 per 30 days)
FABIOR 0.1 % FOAM MO	3	PA,QL(100 per 30 days)
FINACEA 15 % FOAM MO	3	ST,QL(50 per 30 days)
FINACEA 15 % GEL MO	3	ST,QL(50 per 30 days)
fluocinolone 0.01 % OIL MO	1	QL(118.28 per 30 days)
fluocinolone 0.01 % SOLUTION MO	1	QL(180 per 30 days)
fluocinolone 0.01 %, 0.025 % CREAM MO	1	QL(120 per 30 days)
fluocinolone 0.025 % OINTMENT MO	1	QL(120 per 30 days)
fluocinolone and shower cap 0.01 % OIL MO	1	QL(118.28 per 30 days)
fluocinonide 0.05 % CREAM MO	1	QL(120 per 30 days)
fluocinonide 0.05 % GEL MO	1	QL(120 per 30 days)
fluocinonide 0.05 % OINTMENT MO	1	QL(120 per 30 days)
fluocinonide 0.05 % SOLUTION MO	1	QL(120 per 30 days)
fluocinonide 0.1 % CREAM MO	1	QL(120 per 28 days)
fluocinonide-e 0.05 % CREAM MO	1	QL(120 per 30 days)
fluocinonide-emollient 0.05 % CREAM MO	1	QL(120 per 30 days)
FLUROPLEX 1 % CREAM DL	4	
fluorouracil 0.5 % CREAM DL	4	QL(60 per 30 days)
fluorouracil 2 % SOLUTION MO	1	QL(30 per 30 days)
fluorouracil 5 % CREAM MO	1	
fluorouracil 5 % SOLUTION MO	1	QL(60 per 30 days)
flurandrenolide 0.05 % CREAM MO	1	QL(240 per 30 days)
flurandrenolide 0.05 % LOTION MO	3	QL(240 per 30 days)
flurandrenolide 0.05 % OINTMENT MO	1	QL(240 per 30 days)
fluticasone propionate 0.005 % OINTMENT MO	1	QL(240 per 30 days)
fluticasone propionate 0.05 % CREAM MO	1	QL(240 per 30 days)
fluticasone propionate 0.05 % LOTION MO	1	QL(240 per 30 days)
halcinonide 0.1 % CREAM DL	4	QL(120 per 30 days)
halcinonide 0.1 % SOLUTION MO	1	QL(120 per 30 days)
halobetasol propionate 0.05 % CREAM MO	1	QL(100 per 30 days)
halobetasol propionate 0.05 % FOAM MO	3	PA,QL(100 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>halobetasol propionate</i> 0.05 % OINTMENT MO	1	QL(100 per 30 days)
HALOG 0.1 % CREAM DL	4	QL(120 per 30 days)
HALOG 0.1 % OINTMENT MO	3	QL(120 per 30 days)
HALOG 0.1 % SOLUTION MO	3	QL(120 per 30 days)
<i>hydrocortisone</i> 1 % CREAM W/PERINEAL APPLICATOR MO	1	QL(28.4 per 30 days)
<i>hydrocortisone</i> 1 %, 2.5 % CREAM MO	1	QL(240 per 30 days)
<i>hydrocortisone</i> 1 %, 2.5 % OINTMENT MO	1	QL(240 per 30 days)
<i>hydrocortisone</i> 10 mg, 20 mg, 5 mg TABLET MO	1	
<i>hydrocortisone</i> 2 % LOTION DL	4	QL(236.8 per 30 days)
<i>hydrocortisone</i> 2.5 % CREAM W/PERINEAL APPLICATOR MO	1	QL(60 per 30 days)
<i>hydrocortisone</i> 2.5 % LOTION MO	1	QL(236 per 30 days)
<i>hydrocortisone butyr-emoilient</i> 0.1 % CREAM MO	1	QL(240 per 30 days)
<i>hydrocortisone butyrate</i> 0.1 % CREAM MO	1	QL(240 per 30 days)
<i>hydrocortisone butyrate</i> 0.1 % LOTION MO	1	QL(236 per 30 days)
<i>hydrocortisone butyrate</i> 0.1 % OINTMENT MO	1	QL(180 per 30 days)
<i>hydrocortisone butyrate</i> 0.1 % SOLUTION MO	1	QL(240 per 30 days)
<i>hydrocortisone valerate</i> 0.2 % CREAM MO	1	QL(240 per 30 days)
<i>hydrocortisone valerate</i> 0.2 % OINTMENT MO	1	QL(240 per 30 days)
HYFTOR 0.2 % GEL DL	4	PA
<i>imiquimod</i> 3.75 % CREAM IN PACKET MO	3	ST,QL(28 per 28 days)
<i>imiquimod</i> 3.75 % CREAM, METERED DOSE PUMP DL	4	ST,QL(15 per 30 days)
<i>imiquimod</i> 5 % CREAM IN PACKET MO	1	QL(12 per 30 days)
IMPEKLO 0.05 % LOTION IN METERED DOSE PUMP DL	4	ST,QL(136 per 28 days)
<i>isotretinoin</i> 10 mg, 20 mg, 30 mg, 40 mg CAPSULE MO	1	
<i>isotretinoin</i> 25 mg, 35 mg CAPSULE DL	4	
<i>ivermectin</i> 1 % CREAM MO	1	ST,QL(45 per 30 days)
KLISYRI 1 % OINTMENT IN PACKET DL	4	PA,QL(5 per 30 days)
LEXETTE 0.05 % FOAM MO	3	PA,QL(100 per 30 days)
<i>lindane</i> 1 % SHAMPOO MO	1	QL(60 per 30 days)
LOCOID 0.1 % LOTION MO	3	QL(236 per 30 days)
LOCOID LIPOCREAM 0.1 % CREAM MO	3	QL(240 per 30 days)
LUXIQ 0.12 % FOAM MO	3	ST,QL(200 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>mafenide acetate 50 gram PACKET</i> MO	1	
<i>malathion 0.5 % LOTION</i> MO	1	
<i>methoxsalen 10 mg CAPSULE, LIQ FILLED, RAPID REL</i> MO	1	
MIRVASO 0.33 % GEL WITH PUMP MO	3	ST,QL(30 per 30 days)
<i>mometasone 0.1 % CREAM</i> MO	1	QL(180 per 30 days)
<i>mometasone 0.1 % OINTMENT</i> MO	1	QL(180 per 30 days)
<i>mometasone 0.1 % SOLUTION</i> MO	1	QL(180 per 30 days)
<i>mupirocin 2 % OINTMENT</i> MO	1	
<i>mupirocin calcium 2 % CREAM</i> MO	1	ST
<i>myorisan 10 mg, 20 mg, 30 mg, 40 mg CAPSULE</i> MO	1	
NATROBA 0.9 % SUSPENSION MO	3	QL(240 per 30 days)
NEO-SYNALAR 0.5 % (0.35 % BASE)-0.025 % CREAM MO	3	
<i>neuac 1.2 %(1 % base) -5 % GEL</i> MO	1	QL(45 per 30 days)
OLUX 0.05 % FOAM MO	3	PA,QL(100 per 28 days)
OLUX-E 0.05 % FOAM MO	3	PA,QL(100 per 30 days)
ONEXTON 1.2 %(1 % BASE) -3.75 % GEL MO	3	
ONEXTON 1.2 %(1 % BASE) -3.75 % GEL WITH PUMP MO	3	QL(50 per 30 days)
OPZELURA 1.5 % CREAM DL	4	PA,QL(240 per 28 days)
OTEZLA 20 MG, 30 MG TABLET DL	4	PA,QL(60 per 30 days)
OTEZLA STARTER 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47) TABLET, DOSE PACK DL	4	PA,QL(55 per 28 days)
OTEZLA STARTER 10 MG (4)-20 MG (4)-30 MG(19) TABLET, DOSE PACK DL	4	PA,QL(27 per 30 days)
OVIDE 0.5 % LOTION MO	3	PA
PANDEL 0.1 % CREAM DL	4	QL(160 per 30 days)
<i>permethrin 5 % CREAM</i> MO	1	
<i>pimecrolimus 1 % CREAM</i> MO	1	PA,QL(100 per 30 days)
<i>podofilox 0.5 % GEL</i> MO	1	
<i>podofilox 0.5 % SOLUTION</i> MO	1	QL(7 per 30 days)
<i>prednicarbate 0.1 % CREAM</i> MO	1	QL(240 per 30 days)
<i>prednicarbate 0.1 % OINTMENT</i> MO	1	QL(240 per 30 days)
<i>procto-med hc 2.5 % CREAM W/PERINEAL APPLICATOR</i> MO	1	QL(60 per 30 days)
<i>proctosol hc 2.5 % CREAM W/PERINEAL APPLICATOR</i> MO	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>proctozone-hc</i> 2.5 % CREAM W/PERINEAL APPLICATOR MO	1	QL(60 per 30 days)
PROTOPIC 0.03 %, 0.1 % OINTMENT MO	3	QL(200 per 30 days)
PRUDOXIN 5 % CREAM DL	4	PA,QL(45 per 30 days)
QBREXZA 2.4 % TOWELETTE MO	3	PA,QL(30 per 30 days)
REGRANEX 0.01 % GEL	4	PA
RETIN-A 0.01 %, 0.025 % GEL MO	3	PA,QL(45 per 30 days)
RETIN-A 0.025 %, 0.05 %, 0.1 % CREAM MO	3	PA,QL(45 per 30 days)
RETIN-A MICRO 0.04 % GEL DL	4	PA,QL(45 per 30 days)
RETIN-A MICRO 0.1 % GEL MO	3	PA,QL(45 per 30 days)
RETIN-A MICRO PUMP 0.04 %, 0.1 % GEL WITH PUMP DL	4	PA,QL(50 per 30 days)
RETIN-A MICRO PUMP 0.06 %, 0.08 % GEL WITH PUMP MO	3	PA,QL(50 per 30 days)
SANTYL 250 UNIT/GRAM OINTMENT MO	3	PA,QL(180 per 30 days)
<i>selenium sulfide</i> 2.5 % LOTION MO	1	QL(120 per 30 days)
SILVADENE 1 % CREAM MO	2	
<i>silver sulfadiazine</i> 1 % CREAM MO	1	
SOOLANTRA 1 % CREAM MO	3	ST,QL(45 per 30 days)
SORILUX 0.005 % FOAM DL	4	ST,QL(120 per 28 days)
<i>spinosad</i> 0.9 % SUSPENSION MO	3	QL(240 per 30 days)
SSD 1 % CREAM MO	1	
SULFAMYLON 50 GRAM PACKET MO	3	
SULFAMYLON 85 MG/G CREAM MO	3	
SYNALAR 0.01 % SOLUTION MO	3	QL(180 per 30 days)
TACLONEX 0.005-0.064 % OINTMENT DL	4	PA,QL(60 per 30 days)
TACLONEX 0.005-0.064 % SUSPENSION DL	4	PA,QL(420 per 30 days)
<i>tacrolimus</i> 0.03 %, 0.1 % OINTMENT MO	1	QL(200 per 30 days)
<i>tazarotene</i> 0.05 %, 0.1 % GEL MO	1	PA,QL(200 per 30 days)
<i>tazarotene</i> 0.1 % CREAM MO	1	QL(120 per 30 days)
<i>tazarotene</i> 0.1 % FOAM DL	4	PA,QL(100 per 30 days)
TAZORAC 0.05 %, 0.1 % CREAM MO	3	PA,QL(120 per 30 days)
TAZORAC 0.05 %, 0.1 % GEL MO	3	PA,QL(200 per 30 days)
TEMOVATE 0.05 % OINTMENT MO	3	PA,QL(120 per 28 days)
TEXACORT 2.5 % SOLUTION MO	1	QL(240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TOPICORT 0.05 % CREAM MO	1	QL(240 per 30 days)
TOPICORT 0.05 % GEL MO	1	QL(240 per 30 days)
TOPICORT 0.05 % OINTMENT MO	3	QL(240 per 30 days)
TOPICORT 0.25 % CREAM MO	1	QL(120 per 30 days)
TOPICORT 0.25 % OINTMENT MO	1	QL(120 per 30 days)
TOPICORT 0.25 % SPRAY, NON-AEROSOL MO	3	QL(100 per 30 days)
tovet emollient 0.05 % FOAM MO	1	QL(100 per 30 days)
tretinoin 0.01 %, 0.025 %, 0.05 % GEL MO	1	PA,QL(45 per 30 days)
tretinoin 0.025 %, 0.05 %, 0.1 % CREAM MO	1	PA,QL(45 per 30 days)
tretinoin microspheres 0.04 %, 0.08 %, 0.1 % GEL WITH PUMP MO	1	PA,QL(50 per 30 days)
tretinoin microspheres 0.04 %, 0.1 % GEL MO	1	PA,QL(45 per 30 days)
TWYNEO 0.1-3 % CREAM MO	3	QL(30 per 30 days)
ULTRAVATE 0.05 % LOTION MO	3	QL(120 per 30 days)
VANOS 0.1 % CREAM MO	3	QL(120 per 28 days)
VECTICAL 3 MCG/GRAM OINTMENT DL	4	ST,QL(800 per 28 days)
VELTIN 1.2-0.025 % GEL MO	3	PA,QL(60 per 30 days)
VERDESO 0.05 % FOAM DL	4	QL(200 per 30 days)
VEREGEN 15 % OINTMENT DL	4	QL(30 per 30 days)
VTAMA 1 % CREAM DL	4	PA,QL(60 per 30 days)
WINLEVI 1 % CREAM MO	3	PA
zenatane 10 mg, 20 mg, 30 mg, 40 mg CAPSULE MO	1	
ZIANA 1.2-0.025 % GEL MO	3	PA,QL(60 per 30 days)
ZILXI 1.5 % FOAM MO	3	PA,QL(30 per 30 days)
ZONALON 5 % CREAM MO	3	PA,QL(45 per 30 days)
ZORYVE 0.15 %, 0.3 % CREAM DL	4	PA,QL(120 per 30 days)
ZORYVE 0.3 % FOAM DL	4	PA,QL(120 per 30 days)
ZYCLARA 2.5 %, 3.75 % CREAM, METERED DOSE PUMP DL	4	ST,QL(15 per 30 days)
ZYCLARA 3.75 % CREAM IN PACKET MO	3	ST,QL(28 per 28 days)
ELECTROLYTES/MINERALS/METALS/VITAMINS		
AMINOSYN 10 % 10 % PARENTERAL SOLUTION MO	3	BvsD
AMINOSYN 7 % WITH ELECTROLYTES 7 % PARENTERAL SOLUTION MO	3	BvsD
AMINOSYN 8.5 % 8.5 % PARENTERAL SOLUTION MO	3	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AMINOSYN 8.5 %-ELECTROLYTES 8.5 % PARENTERAL SOLUTION MO	3	BvsD
AMINOSYN II 10 % 10 % PARENTERAL SOLUTION MO	3	BvsD
AMINOSYN II 7 % 7 % PARENTERAL SOLUTION MO	3	BvsD
AMINOSYN II 8.5 % 8.5 % PARENTERAL SOLUTION MO	3	BvsD
AMINOSYN II 8.5 %-ELECTROLYTES 8.5 % PARENTERAL SOLUTION MO	3	BvsD
AMINOSYN M 3.5 % 3.5 % PARENTERAL SOLUTION MO	3	BvsD
AMINOSYN-RF 5.2 % 5.2 % PARENTERAL SOLUTION MO	3	BvsD
<i>bal-care dha 27-1-430 mg COMBO PACK, DR TAB/DR CAP</i> MO	1	
<i>c-nate dha 28 mg iron-1 mg -200 mg CAPSULE</i> MO	1	
<i>calcium chloride 100 mg/ml (10 %) SOLUTION</i> MO	1	
<i>calcium chloride 100 mg/ml (10 %) SYRINGE</i> MO	1	
<i>calcium gluconate 100 mg/ml (10%) SOLUTION</i> MO	1	
CARBAGLU 200 MG TABLET, DISPERSIBLE DL	4	PA
<i>carglumic acid 200 mg TABLET, DISPERSIBLE</i> DL	4	PA
CARNITOR 100 MG/ML, 200 MG/ML SOLUTION MO	3	
CARNITOR 330 MG TABLET MO	3	
CARNITOR (SUGAR-FREE) 100 MG/ML SOLUTION MO	3	
CHEMET 100 MG CAPSULE DL	4	
CITRANATAL B-CALM (FE GLUC) 20 MG IRON-1 MG -25 MG/25 MG TABLET, SEQUENTIAL MO	3	
CLINIMIX 5%/D15W SULFITE FREE 5 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 4.25%/D10W SULF FREE 4.25 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 4.25%/D5W SULFIT FREE 4.25 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 5%-D20W(SULFITE-FREE) 5 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 6%-D5W (SULFITE-FREE) 6-5 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 8%-D10W(SULFITE-FREE) 8-10 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX 8%-D14W(SULFITE-FREE) 8-14 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 2.75%/D5W SULF FREE 2.75 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 4.25%/D10W SUL FREE 4.25 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 4.25%/D5W SULF FREE 4.25 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 5%/D15W SULFIT FREE 5 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 5%/D20W SULFIT FREE 5 % PARENTERAL SOLUTION MO	3	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CLINIMIX E 8%-D10W SULFITEFREE 8-10 % PARENTERAL SOLUTION MO	3	BvsD
CLINIMIX E 8%-D14W SULFITEFREE 8-14 % PARENTERAL SOLUTION MO	3	BvsD
CLINISOL SF 15 % 15 % PARENTERAL SOLUTION MO	1	BvsD
CLINOLIPID 20 % EMULSION MO	3	BvsD
complete natal dha 29 mg iron- 1 mg-200 mg COMBO PACK MO	1	
CUPRIMINE 250 MG CAPSULE DL	4	PA,QL(600 per 30 days)
CUVRIOR 300 MG TABLET DL	4	PA,QL(300 per 30 days)
d10 %-0.45 % sodium chloride PARENTERAL SOLUTION MO	1	
d2.5 %-0.45 % sodium chloride PARENTERAL SOLUTION MO	1	
d5 % and 0.9 % sodium chloride PARENTERAL SOLUTION MO	1	
d5 %-0.45 % sodium chloride PARENTERAL SOLUTION MO	1	
deferasirox 125 mg, 250 mg, 500 mg TABLET, DISPERSIBLE DL	4	PA
deferasirox 180 mg, 360 mg, 90 mg GRANULES IN PACKET DL	4	PA
deferasirox 180 mg, 360 mg, 90 mg TABLET MO	1	PA
deferiprone 1,000 mg TABLET DL	4	PA,QL(300 per 30 days)
deferiprone 500 mg TABLET DL	4	PA,QL(720 per 30 days)
deferoxamine 2 gram, 500 mg RECON SOLUTION MO	1	BvsD
DEPEN TITRATABS 250 MG TABLET DL	4	PA
DESFERAL 500 MG RECON SOLUTION MO	3	BvsD
dextrose 10 % and 0.2 % nacl PARENTERAL SOLUTION MO	1	
dextrose 10 % in water (d10w) 10 % PARENTERAL SOLUTION MO	1	
dextrose 25 % in water (d25w) SYRINGE MO	1	
dextrose 5 % in water (d5w) PARENTERAL SOLUTION MO	1	
dextrose 5 % in water (d5w) 5 % PIGGYBACK MO	1	
dextrose 5 %-lactated ringers PARENTERAL SOLUTION MO	1	
dextrose 5%-0.2 % sod chloride PARENTERAL SOLUTION MO	1	
dextrose 5%-0.3 % sod.chloride PARENTERAL SOLUTION MO	1	
dextrose 50 % in water (d50w) PARENTERAL SOLUTION MO	1	
dextrose 50 % in water (d50w) SYRINGE MO	1	
dextrose 70 % in water (d70w) PARENTERAL SOLUTION MO	1	
DUET DHA WITH OMEGA-3 25 MG IRON-1 MG -400 MG COMBO PACK MO	3	
electrolyte-148 PARENTERAL SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>electrolyte-48 in d5w PARENTERAL SOLUTION</i> MO	1	
<i>electrolyte-a PARENTERAL SOLUTION</i> MO	1	
EXJADE 125 MG, 250 MG, 500 MG TABLET, DISPERSIBLE DL	4	PA
FERRIPROX 1,000 MG TABLET DL	4	PA,QL(300 per 30 days)
FERRIPROX 100 MG/ML SOLUTION DL	4	PA,QL(3600 per 30 days)
FERRIPROX 500 MG TABLET DL	4	PA,QL(720 per 30 days)
FERRIPROX (2 TIMES A DAY) 1,000 MG TABLET, MODIFIED RELEASE DL	4	PA,QL(300 per 30 days)
GLYCOPHOS 1 MMOL/ML SOLUTION MO	1	
INTRALIPID 20 %, 30 % EMULSION MO	3	BvsD
IONOSOL-B IN D5W 5 % PARENTERAL SOLUTION MO	3	
IONOSOL-MB IN D5W 5 % PARENTERAL SOLUTION MO	3	
ISOLYTE S PH 7.4 PARENTERAL SOLUTION MO	3	
ISOLYTE-P IN 5 % DEXTROSE 5 % PARENTERAL SOLUTION MO	3	
ISOLYTE-S PARENTERAL SOLUTION MO	3	
JADENU 180 MG, 360 MG, 90 MG TABLET DL	4	PA
JADENU SPRINKLE 180 MG, 360 MG, 90 MG GRANULES IN PACKET DL	4	PA
JYNARQUE 15 MG (AM)/ 15 MG (PM), 30 MG (AM)/ 15 MG (PM), 45 MG (AM)/ 15 MG (PM), 60 MG (AM)/ 30 MG (PM), 90 MG (AM)/ 30 MG (PM) TABLET, SEQUENTIAL DL	4	PA,QL(56 per 28 days)
JYNARQUE 15 MG, 30 MG TABLET DL	4	PA,QL(60 per 30 days)
KABIVEN 3.31-10.8-3.9 % EMULSION MO	3	BvsD
<i>kionex (with sorbitol) 15-20 gram/60 ml SUSPENSION</i> MO	1	
<i>klor-con 20 meq PACKET</i> MO	1	QL(240 per 30 days)
KLOR-CON 10 10 MEQ TABLET ER MO	1	
KLOR-CON 8 8 MEQ TABLET ER MO	1	
<i>klor-con m10 10 meq TABLET, ER PARTICLES/CRYSTALS</i> MO	1	
KLOR-CON M15 15 MEQ TABLET, ER PARTICLES/CRYSTALS MO	1	
<i>klor-con m20 20 meq TABLET, ER PARTICLES/CRYSTALS</i> MO	1	
KOSHER PRENATAL PLUS IRON 30 MG IRON- 1 MG TABLET MO	3	
<i>lactated ringers PARENTERAL SOLUTION</i> MO	1	
<i>levocarnitine 100 mg/ml, 200 mg/ml SOLUTION</i> MO	1	
<i>levocarnitine 330 mg TABLET</i> MO	1	
<i>levocarnitine (with sugar) 100 mg/ml SOLUTION</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LOKELMA 10 GRAM, 5 GRAM POWDER IN PACKET MO	2	QL(30 per 30 days)
<i>m-natal plus 27 mg iron- 1 mg TABLET MO</i>	1	
<i>magnesium sulfate 500 mg/ml (50 %) SOLUTION MO</i>	1	
<i>magnesium sulfate 500 mg/ml (50 %) SYRINGE MO</i>	1	
<i>magnesium sulfate in d5w 1 gram/100 ml PIGGYBACK MO</i>	1	
<i>magnesium sulfate in water 2 gram/50 ml (4 %), 4 gram/100 ml (4 %), 4 gram/50 ml (8 %) PIGGYBACK MO</i>	1	
<i>magnesium sulfate in water 20 gram/500 ml (4 %), 40 gram/1,000 ml (4 %) PARENTERAL SOLUTION MO</i>	1	
NATACHEW (FE BIS-GLYCINATE) 28 MG IRON -1 MG CHEWABLE TABLET MO	3	
NEONATAL COMPLETE 29-1 MG TABLET MO	1	
NEONATAL PLUS VITAMIN 27 MG IRON- 1 MG TABLET MO	1	
NEONATAL-DHA 29-1-200-500 MG COMBO PACK MO	1	
NORMOSOL-M IN 5 % DEXTROSE PARENTERAL SOLUTION MO	3	
NUTRILIPID 20 % EMULSION MO	3	BvsD
OB COMPLETE ONE 40-10-1-300 MG CAPSULE MO	3	
OB COMPLETE PETITE 35 MG IRON-5 MG IRON-1 MG CAPSULE MO	3	
OB COMPLETE PREMIER 30-20-1 MG TABLET MO	3	
OMEGAVEN 10 % EMULSION DL	4	BvsD
<i>penicillamine 250 mg CAPSULE DL</i>	4	PA,QL(600 per 30 days)
<i>penicillamine 250 mg TABLET DL</i>	4	
PERIKABIVEN 2.36-7.5-3.5 % EMULSION MO	3	BvsD
PLASMA-LYTE 148 PARENTERAL SOLUTION MO	3	
PLASMA-LYTE A PARENTERAL SOLUTION MO	3	
PLENAMINE 15 % PARENTERAL SOLUTION MO	1	BvsD
<i>pnv-dha 27 mg iron-1 mg -300 mg CAPSULE MO</i>	1	
<i>pnv-omega 28-1-300 mg CAPSULE MO</i>	1	
<i>potassium acetate 2 meq/ml SOLUTION MO</i>	1	
<i>potassium chlorid-d5-0.45%nacl 10 meq/l, 20 meq/l, 30 meq/l, 40 meq/l PARENTERAL SOLUTION MO</i>	1	
<i>potassium chloride 10 meq CAPSULE, ER MO</i>	1	
<i>potassium chloride 10 meq, 20 meq TABLET ER MO</i>	1	
<i>potassium chloride 10 meq, 20 meq TABLET, ER PARTICLES/CRYSTALS MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
potassium chloride 15 meq TABLET, ER PARTICLES/CRYSTALS MO	1	
potassium chloride 2 meq/ml SOLUTION MO	1	
potassium chloride 20 meq PACKET MO	1	QL(240 per 30 days)
potassium chloride 20 meq/15 ml, 40 meq/15 ml LIQUID MO	1	
potassium chloride 8 meq CAPSULE, ER MO	1	
potassium chloride 8 meq TABLET ER MO	1	
potassium chloride in 0.9%nacl 20 meq/l, 40 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride in 5 % dex 10 meq/l, 20 meq/l, 30 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride in lr-d5 20 meq/l, 40 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride in water 10 meq/100 ml, 10 meq/50 ml, 20 meq/100 ml, 20 meq/50 ml, 30 meq/100 ml, 40 meq/100 ml PIGGYBACK MO	1	
potassium chloride-0.45 % nacl 20 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride-d5-0.2%nacl 20 meq/l, 40 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride-d5-0.3%nacl 20 meq/l PARENTERAL SOLUTION MO	1	
potassium chloride-d5-0.9%nacl 20 meq/l, 40 meq/l PARENTERAL SOLUTION MO	1	
potassium citrate 10 meq (1,080 mg), 15 meq, 5 meq (540 mg) TABLET ER MO	1	
pr natal 400 29-1-400 mg COMBO PACK MO	1	
pr natal 400 ec 29-1-400 mg COMBO PACK, DR TAB/DR CAP MO	1	
pr natal 430 29 mg iron-1 mg -430 mg COMBO PACK MO	1	
pr natal 430 ec 29-1-430 mg COMBO PACK, DR TAB/DR CAP MO	1	
PREMASOL 10 % 10 % PARENTERAL SOLUTION MO	1	BvsD
PRENATA 29 MG IRON- 1 MG CHEWABLE TABLET MO	1	
PRENATABS FA 29-1 MG TABLET MO	1	
prenatal plus (calcium carb) 27 mg iron- 1 mg TABLET MO	1	
prenatal plus dha 27 mg iron-1 mg -312 mg-250 mg COMBO PACK MO	3	
prenatal plus vitamin-mineral 27 mg iron- 1 mg TABLET MO	1	
prenatal vitamin plus low iron 27 mg iron- 1 mg TABLET MO	1	
prenatal-u 106.5-1 mg CAPSULE MO	1	
PRENATE ELITE 26 MG IRON- 1 MG TABLET MO	1	
PROSOL 20 % PARENTERAL SOLUTION MO	3	BvsD
ringer's PARENTERAL SOLUTION MO	1	
SAMSCA 15 MG, 30 MG TABLET DL	4	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
se-natal 19 chewable 29 mg iron- 1 mg CHEWABLE TABLET MO	1	
SELECT-OB 29 MG IRON- 1 MG CHEWABLE TABLET MO	3	
SELECT-OB (FOLIC ACID) 29 MG IRON- 1 MG CHEWABLE TABLET MO	3	
SELECT-OB + DHA 29 MG IRON-1 MG -250 MG COMBO PACK MO	3	
SMOFLIPID 20 % EMULSION MO	3	BvsD
sodium bicarbonate 8.4 % (1 meq/ml) SYRINGE MO	1	
sodium chloride 2.5 meq/ml SOLUTION MO	1	
sodium chloride 0.45 % 0.45 % PARENTERAL SOLUTION MO	1	
sodium chloride 0.9 % PARENTERAL SOLUTION MO	1	
sodium chloride 0.9 % PIGGYBACK MO	1	
sodium chloride 0.9 % SOLUTION MO	1	
sodium chloride 3 % hypertonic 3 % PARENTERAL SOLUTION MO	1	
sodium chloride 5 % hypertonic 5 % PARENTERAL SOLUTION MO	1	
sodium phosphate 3 mmol/ml SOLUTION MO	1	
sodium polystyrene sulfonate POWDER MO	1	
SPS (WITH SORBITOL) 15-20 GRAM/60 ML SUSPENSION MO	1	
SPS (WITH SORBITOL) 30-40 GRAM/120 ML ENEMA MO	1	
SYPRINE 250 MG CAPSULE DL	4	PA,QL(240 per 30 days)
THAM 36 MG/ML (0.3 M) SOLUTION MO	3	
tolvaptan 15 mg, 30 mg TABLET DL	4	PA,QL(60 per 30 days)
TPN ELECTROLYTES 35-20-5 MEQ/20 ML SOLUTION MO	3	
TRAVASOL 10 % 10 % PARENTERAL SOLUTION MO	3	BvsD
TRICARE 27 MG IRON- 1 MG TABLET MO	1	
trientine 250 mg CAPSULE DL	4	QL(240 per 30 days)
trientine 500 mg CAPSULE DL	4	QL(120 per 30 days)
trinatal rx 1 60 mg iron-1 mg TABLET MO	1	
TRISTART DHA 31 MG IRON- 1 MG-200 MG CAPSULE MO	3	
TROPHAMINE 10 % 10 % PARENTERAL SOLUTION MO	3	BvsD
UROCIT-K 10 10 MEQ (1,080 MG) TABLET ER MO	3	
UROCIT-K 15 15 MEQ TABLET ER MO	3	
UROCIT-K 5 5 MEQ (540 MG) TABLET ER MO	3	
VAPRISOL IN 5 % DEXTROSE 20 MG/100 ML SOLUTION MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VELTASSA 16.8 GRAM, 25.2 GRAM, 8.4 GRAM POWDER IN PACKET MO	3	PA,QL(30 per 30 days)
<i>virt-nate dha 28 mg iron-1 mg -200 mg CAPSULE MO</i>	1	
<i>virt-pn dha 27 mg iron-1 mg -300 mg CAPSULE MO</i>	1	
VITAFOL FE PLUS 90 MG IRON- 1 MG-200 MG CAPSULE MO	3	
VITAFOL GUMMIES 3.33 MG IRON- 0.33 MG CHEWABLE TABLET MO	3	
VITAFOL ULTRA 29 MG IRON- 1 MG-200 MG CAPSULE MO	3	
VITAFOL-OB 65-1 MG TABLET MO	3	
VITAFOL-OB+DHA 65-1-250 MG COMBO PACK MO	3	
VITAFOL-ONE 29 MG IRON- 1 MG-200 MG CAPSULE MO	3	
VITAMEDMD ONE RX 30 MG IRON-1MG -200 MG CAPSULE MO	3	
<i>wescap-pn dha 27 mg iron-1 mg -300 mg CAPSULE MO</i>	1	
<i>wesnatal dha complete 29 mg iron- 1 mg-200 mg COMBO PACK MO</i>	1	
<i>wesnate dha 28 mg iron-1 mg -200 mg CAPSULE MO</i>	1	
<i>westab plus 27 mg iron- 1 mg TABLET MO</i>	1	
<i>westgel dha 31 mg iron- 1 mg-200 mg CAPSULE MO</i>	1	
<i>zatean-pn dha 27 mg iron-1 mg -300 mg CAPSULE MO</i>	1	
<i>zatean-pn plus 28-1-300 mg CAPSULE MO</i>	1	
GASTROINTESTINAL AGENTS		
ACIPHEX 20 MG TABLET, DR/EC MO	3	PA,QL(60 per 30 days)
AEMCOLO 194 MG TABLET, DR/EC MO	3	PA,QL(12 per 30 days)
<i>alose tron 0.5 mg, 1 mg TABLET MO</i>	1	PA,QL(60 per 30 days)
AMITIZA 24 MCG, 8 MCG CAPSULE MO	3	PA,QL(60 per 30 days)
<i>amoxicil-clarithromy-lansopraz 500-500-30 mg COMBO PACK MO</i>	1	ST
<i>atropine 0.1 mg/ml, 0.25 mg/5 ml (0.05 mg/ml) SYRINGE MO</i>	1	
BENTYL 10 MG/ML SOLUTION MO	3	
<i>bismuth subcit k-metronidz-tcn 140-125-125 mg CAPSULE MO</i>	1	ST,QL(120 per 30 days)
CARAFATE 1 GRAM TABLET MO	3	
CARAFATE 100 MG/ML SUSPENSION MO	3	
CHENODAL 250 MG TABLET DL	4	PA
<i>cimetidine 200 mg, 300 mg, 400 mg, 800 mg TABLET MO</i>	1	
<i>cimetidine hcl 300 mg/5 ml SOLUTION MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CLENPIQ 10 MG-3.5 GRAM- 12 GRAM/160 ML, 10 MG-3.5 GRAM- 12 GRAM/175 ML SOLUTION MO	3	ST
constulose 10 gram/15 ml SOLUTION MO	1	
CUVPOSA 1 MG/5 ML (0.2 MG/ML) SOLUTION MO	3	
CYTOTEC 100 MCG, 200 MCG TABLET DL	4	
DARTISLA 1.7 MG TABLET, DISINTEGRATING MO	3	ST,QL(120 per 30 days)
DEXILANT 30 MG, 60 MG CAPSULE, DR, BIPHASIC MO	3	PA,QL(30 per 30 days)
dexlansoprazole 30 mg, 60 mg CAPSULE, DR, BIPHASIC MO	3	QL(30 per 30 days)
dicyclomine 10 mg CAPSULE MO	1	
dicyclomine 10 mg/5 ml, 10 mg/ml SOLUTION MO	1	
dicyclomine 20 mg TABLET MO	1	
diphenoxylate-atropine 2.5-0.025 mg TABLET MO	1	
diphenoxylate-atropine 2.5-0.025 mg/5 ml LIQUID MO	1	
ENDARI 5 GRAM POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
enulose 10 gram/15 ml SOLUTION MO	1	
esomeprazole magnesium 10 mg, 20 mg, 40 mg DR GRANULES IN PACKET MO	1	QL(30 per 30 days)
esomeprazole magnesium 20 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
esomeprazole magnesium 40 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
esomeprazole sodium 20 mg, 40 mg RECON SOLUTION MO	1	
famotidine 10 mg/ml SOLUTION MO	1	
famotidine 20 mg, 40 mg TABLET MO	1	
famotidine 40 mg/5 ml (8 mg/ml) SUSPENSION FOR RECONSTITUTION MO	1	
famotidine (pf) 20 mg/2 ml SOLUTION MO	1	
famotidine (pf)-nacl (iso-os) 20 mg/50 ml PIGGYBACK MO	1	
GATTEX 30-VIAL 5 MG KIT DL	4	PA
GATTEX ONE-VIAL 5 MG KIT DL	4	PA
gavilyte-c 240-22.72-6.72 -5.84 gram RECON SOLUTION MO	1	
gavilyte-g 236-22.74-6.74 -5.86 gram RECON SOLUTION MO	1	
gavilyte-n 420 gram RECON SOLUTION MO	1	
generlac 10 gram/15 ml SOLUTION MO	1	
glutamine (sickle cell) 5 gram POWDER IN PACKET DL	4	PA,QL(180 per 30 days)
GLYCATE 1.5 MG TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
glycopyrrolate 0.2 mg/ml, 1 mg/5 ml (0.2 mg/ml) SOLUTION MO	1	
glycopyrrolate 1 mg, 1.5 mg, 2 mg TABLET MO	1	
glycopyrrolate (pf) 0.6 mg/3 ml (0.2 mg/ml) SYRINGE MO	3	
glycopyrrolate (pf) in water 0.2 mg/ml SYRINGE MO	1	
GOLYTELY 236-22.74-6.74 -5.86 GRAM RECON SOLUTION MO	3	ST
IBSRELA 50 MG TABLET DL	4	PA,QL(60 per 30 days)
IQIRVO 80 MG TABLET DL	4	PA,QL(30 per 30 days)
KONVOMEPE 2-84 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	ST,QL(600 per 30 days)
KRISTALOSE 10 GRAM, 20 GRAM PACKET MO	1	
lactulose 10 gram PACKET DL	4	
lactulose 10 gram/15 ml, 10 gram/15 ml (15 ml), 20 gram/30 ml SOLUTION MO	1	
lansoprazole 15 mg, 30 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
lansoprazole 15 mg, 30 mg TABLET, DISINTEGRATING DR MO	1	QL(30 per 30 days)
LINZESS 145 MCG, 290 MCG, 72 MCG CAPSULE MO	2	QL(30 per 30 days)
LIVDELZI 10 MG CAPSULE DL	4	PA,QL(30 per 30 days)
LIVMARLI 19 MG/ML SOLUTION DL	4	PA,QL(60 per 30 days)
LIVMARLI 9.5 MG/ML SOLUTION DL	4	PA,QL(90 per 30 days)
LOMOTIL 2.5-0.025 MG TABLET MO	3	
loperamide 2 mg CAPSULE MO	1	
LOTRONEX 0.5 MG, 1 MG TABLET	4	PA,QL(60 per 30 days)
lubiprostone 24 mcg, 8 mcg CAPSULE MO	1	QL(60 per 30 days)
methscopolamine 2.5 mg, 5 mg TABLET MO	1	
misoprostol 100 mcg, 200 mcg TABLET MO	1	
MOTEGRITY 1 MG, 2 MG TABLET MO	3	PA,QL(30 per 30 days)
MOTOFEN 1-0.025 MG TABLET MO	3	
MOVANTIK 12.5 MG, 25 MG TABLET MO	2	QL(30 per 30 days)
MOVIPREP 100-7.5-2.691 GRAM POWDER IN PACKET MO	3	ST
MYALEPT 5 MG/ML (FINAL CONC.) RECON SOLUTION DL	4	PA,QL(30 per 30 days)
MYTESI 125 MG TABLET, DR/EC DL	4	PA,QL(60 per 30 days)
NEXIUM 20 MG, 40 MG CAPSULE, DR/EC MO	3	PA,QL(60 per 30 days)
NEXIUM IV 40 MG RECON SOLUTION MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NEXIUM PACKET 10 MG, 2.5 MG, 20 MG, 40 MG, 5 MG DR GRANULES IN PACKET MO	3	QL(30 per 30 days)
nizatidine 150 mg, 300 mg CAPSULE MO	1	
OICALIVA 10 MG, 5 MG TABLET DL	4	PA,QL(30 per 30 days)
OMECLAMOX-PAK 20 MG-500 MG- 500 MG (40) COMBO PACK MO	3	ST
omeprazole 10 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
omeprazole 20 mg, 40 mg CAPSULE, DR/EC MO	1	QL(60 per 30 days)
omeprazole-sodium bicarbonate 20-1,680 mg, 40-1,680 mg PACKET DL	4	ST,QL(30 per 30 days)
omeprazole-sodium bicarbonate 20-1.1 mg-gram, 40-1.1 mg-gram CAPSULE MO	1	QL(30 per 30 days)
opium tincture 10 mg/ml (morphine) TINCTURE MO	3	QL(180 per 30 days)
OSMOPREP 1.5 GRAM TABLET MO	3	ST
pantoprazole 20 mg, 40 mg TABLET, DR/EC MO	1	QL(60 per 30 days)
pantoprazole 40 mg DR GRANULES IN PACKET MO	1	QL(30 per 30 days)
pantoprazole 40 mg RECON SOLUTION MO	1	
pantoprazole in 0.9% sod chlor 40 mg/100 ml (0.4 mg/ml), 80 mg/100 ml (0.8 mg/ml) PIGGYBACK MO	3	
peg 3350-electrolytes 236-22.74-6.74 -5.86 gram RECON SOLUTION MO	1	
peg-electrolyte soln 420 gram RECON SOLUTION MO	1	
peg-prep 5-210 mg-gram KIT MO	1	
peg3350-sod sul-nacl-kcl-asb-c 100-7.5-2.691 gram POWDER IN PACKET MO	1	ST
pepcid 20 mg, 40 mg TABLET MO	3	PA
PLENVU 140-9-5.2 GRAM POWDER IN PACKET, SEQUENTIAL MO	3	ST
PREVACID 30 MG CAPSULE, DR/EC MO	3	PA,QL(60 per 30 days)
PREVACID SOLUTAB 15 MG, 30 MG TABLET, DISINTEGRATING DR MO	3	QL(30 per 30 days)
PRILOSEC 10 MG, 2.5 MG SUSPENSION, DR FOR RECON MO	3	
PROTONIX 20 MG, 40 MG TABLET, DR/EC MO	3	PA,QL(60 per 30 days)
PROTONIX 40 MG DR GRANULES IN PACKET MO	3	QL(30 per 30 days)
PROTONIX 40 MG RECON SOLUTION MO	3	PA
PYLERA 140-125-125 MG CAPSULE MO	3	ST,QL(120 per 30 days)
rabeprazole 20 mg TABLET, DR/EC MO	1	QL(60 per 30 days)
REBYOTA 150 ML ENEMA DL	4	PA
RELISTOR 12 MG/0.6 ML SOLUTION DL	4	PA,QL(36 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RELISTOR 12 MG/0.6 ML SYRINGE DL	4	PA,QL(36 per 28 days)
RELISTOR 150 MG TABLET DL	4	PA,QL(90 per 30 days)
RELISTOR 8 MG/0.4 ML SYRINGE DL	4	PA,QL(12 per 30 days)
RELTONE 200 MG CAPSULE DL	4	PA,QL(150 per 30 days)
RELTONE 400 MG CAPSULE DL	4	PA,QL(60 per 30 days)
ROBINUL 1 MG TABLET MO	3	PA
ROBINUL FORTE 2 MG TABLET MO	3	PA
sodium,potassium,mag sulfates 17.5-3.13-1.6 gram RECON SOLUTION MO	1	
sucralfate 1 gram TABLET MO	1	
sucralfate 100 mg/ml SUSPENSION MO	1	
SUFLAVE 178.7-7.3-0.5 GRAM RECON SOLUTION MO	3	
SUPREP BOWEL PREP KIT 17.5-3.13-1.6 GRAM RECON SOLUTION MO	3	ST
SUTAB 1.479-0.188- 0.225 GRAM TABLET MO	2	
SYMPROIC 0.2 MG TABLET MO	3	PA,QL(30 per 30 days)
TALICIA 10-250-12.5 MG CAPSULE, IR/DR, BIPHASIC MO	3	
TRULANCE 3 MG TABLET MO	3	PA,QL(30 per 30 days)
URSO 250 250 MG TABLET MO	3	PA
URSO FORTE 500 MG TABLET MO	3	PA
ursodiol 200 mg CAPSULE DL	4	PA,QL(150 per 30 days)
ursodiol 250 mg, 500 mg TABLET MO	1	
ursodiol 300 mg CAPSULE MO	1	
ursodiol 400 mg CAPSULE DL	4	PA,QL(60 per 30 days)
VIBERZI 100 MG, 75 MG TABLET	4	PA,QL(60 per 30 days)
VOQUEZNA 10 MG TABLET MO	3	PA,QL(30 per 30 days)
VOQUEZNA 20 MG TABLET MO	3	PA,QL(60 per 30 days)
VOQUEZNA DUAL PAK 20 MG (28)- 500 MG (84) COMBO PACK MO	3	ST,QL(112 per 30 days)
VOQUEZNA TRIPLE PAK 20-500-500 MG COMBO PACK MO	3	ST,QL(112 per 30 days)
VOWST CAPSULE DL	4	PA
XERMELO 250 MG TABLET DL	4	PA,QL(84 per 28 days)
XIFAXAN 200 MG TABLET MO	3	PA,QL(9 per 30 days)
XIFAXAN 550 MG TABLET	4	PA,QL(84 per 28 days)
ZEGERID 20-1,680 MG, 40-1,680 MG PACKET DL	4	ST,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZEGERID 20-1.1 MG-GRAM, 40-1.1 MG-GRAM CAPSULE DL	4	PA,QL(30 per 30 days)
ZINPLAVA 25 MG/ML SOLUTION DL	4	PA
GENETIC/ENZYME/PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT		
ALDURAZYME 2.9 MG/5 ML SOLUTION DL	4	PA
AMVUTTRA 25 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 90 days)
ARALAST NP 1,000 MG, 500 MG RECON SOLUTION DL	4	PA
<i>betaine 1 gram/scoop POWDER</i> DL	4	
BUPHENYL 0.94 GRAM/GRAM POWDER DL	4	PA
BUPHENYL 500 MG TABLET DL	4	PA
CERDELGA 84 MG CAPSULE DL	4	PA
CEREZYME 400 UNIT RECON SOLUTION DL	4	PA
CHOLBAM 250 MG, 50 MG CAPSULE DL	4	PA,QL(120 per 30 days)
CREON 12,000-38,000 -60,000 UNIT, 24,000-76,000 -120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT CAPSULE, DR/EC MO	2	
CRYSVITA 10 MG/ML, 20 MG/ML SOLUTION DL	4	PA,QL(2 per 28 days)
CRYSVITA 30 MG/ML SOLUTION DL	4	PA,QL(6 per 28 days)
CYSTADANE 1 GRAM/SCOOP POWDER DL	4	PA
CYSTAGON 150 MG, 50 MG CAPSULE MO	3	
DAYBUE 200 MG/ML SOLUTION DL	4	PA,QL(3600 per 30 days)
<i>dichlorphenamide 50 mg TABLET</i> DL	4	PA,QL(120 per 30 days)
DOJOLVI 8.3 KCAL/ML LIQUID DL	4	PA
DUVYZAT 8.86 MG/ML SUSPENSION DL	4	PA,QL(360 per 30 days)
ELAPRASE 6 MG/3 ML SOLUTION DL	4	PA
ELELYSO 200 UNIT RECON SOLUTION DL	4	PA
ELEVIDYS 1.33 X 10EXP13 VG/ML SUSPENSION DL	4	PA
ELFABRIO 2 MG/ML SOLUTION DL	4	PA
EVRYSDI 0.75 MG/ML RECON SOLUTION DL	4	PA,QL(240 per 30 days)
FABRAZYME 35 MG, 5 MG RECON SOLUTION DL	4	PA
GALAFOLD 123 MG CAPSULE DL	4	PA,QL(14 per 28 days)
GLASSIA 1 GRAM/50 ML (2 %) SOLUTION DL	4	PA
<i>javygtor 100 mg TABLET, SOLUBLE</i> DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>javygtor</i> 100 mg, 500 mg POWDER IN PACKET DL	4	PA
JOENJA 70 MG TABLET DL	4	PA,QL(60 per 30 days)
KANUMA 2 MG/ML SOLUTION DL	4	PA
KEVEYIS 50 MG TABLET DL	4	PA,QL(120 per 30 days)
KUVAN 100 MG TABLET, SOLUBLE DL	4	PA
KUVAN 100 MG, 500 MG POWDER IN PACKET DL	4	PA
LAMZEDE 10 MG RECON SOLUTION DL	4	PA
LUMIZYME 50 MG RECON SOLUTION DL	4	PA
MEPSEVII 2 MG/ML SOLUTION DL	4	PA
<i>miglustat</i> 100 mg CAPSULE DL	4	PA,QL(90 per 30 days)
NAGLAZYME 5 MG/5 ML SOLUTION DL	4	PA
NEXVIAZYME 100 MG RECON SOLUTION DL	4	PA
<i>nitisinone</i> 10 mg, 2 mg, 20 mg, 5 mg CAPSULE DL	4	
NITYR 10 MG, 2 MG, 5 MG TABLET DL	4	
NULIBRY 9.5 MG RECON SOLUTION DL	4	PA
OLPRUVA 2 GRAM, 3 GRAM, 4 GRAM, 5 GRAM, 6 GRAM, 6.67 GRAM PELLETS IN PACKET DL	4	PA
ONPATTRO 2 MG/ML SOLUTION DL	4	PA
OPFOLDA 65 MG CAPSULE MO	3	PA
ORFADIN 10 MG, 2 MG, 20 MG, 5 MG CAPSULE DL	4	
ORFADIN 4 MG/ML SUSPENSION DL	4	
<i>ormalvi</i> 50 mg TABLET DL	4	PA,QL(120 per 30 days)
OXBRYTA 300 MG TABLET DL	4	PA,QL(240 per 30 days)
OXBRYTA 300 MG TABLET FOR SUSPENSION DL	4	PA,QL(150 per 30 days)
OXBRYTA 500 MG TABLET DL	4	PA,QL(90 per 30 days)
PALYNZIQ 10 MG/0.5 ML SYRINGE DL	4	PA,QL(15 per 30 days)
PALYNZIQ 2.5 MG/0.5 ML SYRINGE DL	4	PA,QL(4 per 28 days)
PALYNZIQ 20 MG/ML SYRINGE DL	4	PA,QL(90 per 30 days)
PANCREAZE 10,500-35,500- 61,500 UNIT, 4,200-14,200- 24,600 UNIT CAPSULE, DR/EC MO	3	ST
PANCREAZE 16,800-56,800- 98,400 UNIT, 2,600-8,800- 15,200 UNIT, 21,000-54,700- 83,900 UNIT CAPSULE, DR/EC	4	ST
PANCREAZE 37,000-97,300- 149,900 UNIT CAPSULE, DR/EC DL	4	ST

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PERTZYE 16,000-57,500- 60,500 UNIT, 24,000-86,250- 90,750 UNIT, 4,000-14,375- 15,125 UNIT, 8,000-28,750- 30,250 UNIT CAPSULE, DR/EC DL	4	ST
PHEBURANE 483 MG/GRAM GRANULES DL	4	PA
POMBILITI 105 MG RECON SOLUTION DL	4	PA
PROCYSBI 25 MG CAPSULE, DR SPRINKLE DL	4	PA,QL(120 per 30 days)
PROCYSBI 300 MG DR GRANULES IN PACKET DL	4	PA,QL(210 per 30 days)
PROCYSBI 75 MG CAPSULE, DR SPRINKLE DL	4	PA,QL(780 per 30 days)
PROCYSBI 75 MG DR GRANULES IN PACKET DL	4	PA,QL(780 per 30 days)
PROLASTIN-C 1,000 MG (+/-)/20 ML SOLUTION DL	4	PA
PYRUKYND 20 MG (7)- 5 MG (7), 50 MG (7)- 20 MG (7) TABLET, DOSE PACK DL	4	PA,QL(14 per 14 days)
PYRUKYND 20 MG, 5 MG, 50 MG TABLET DL	4	PA,QL(60 per 30 days)
RAVICTI 1.1 GRAM/ML LIQUID DL	4	PA,QL(525 per 30 days)
REVCovi 2.4 MG/1.5 ML (1.6 MG/ML) SOLUTION DL	4	
<i>sapropterin 100 mg TABLET, SOLUBLE</i> DL	4	PA
<i>sapropterin 100 mg, 500 mg POWDER IN PACKET</i> DL	4	PA
<i>sodium phenylbutyrate 0.94 gram/gram POWDER</i> DL	4	
<i>sodium phenylbutyrate 500 mg TABLET</i> DL	4	
STRENSIQ 18 MG/0.45 ML, 28 MG/0.7 ML, 80 MG/0.8 ML SOLUTION DL	4	PA
STRENSIQ 40 MG/ML SOLUTION DL	4	PA
SUCRAID 8,500 UNIT/ML SOLUTION DL	4	PA
TEGSEDI 284 MG/1.5 ML SYRINGE DL	4	PA,QL(6 per 28 days)
VIJOICE 125 MG, 50 MG TABLET DL	4	PA,QL(28 per 28 days)
VIJOICE 250 MG/DAY (200 MG X1-50 MG X1) TABLET DL	4	PA,QL(56 per 28 days)
VIJOICE 50 MG GRANULES IN PACKET DL	4	PA,QL(28 per 28 days)
VIOKACE 10,440-39,150- 39,150 UNIT, 20,880-78,300- 78,300 UNIT TABLET DL	4	ST
VOXZOGO 0.4 MG, 0.56 MG, 1.2 MG RECON SOLUTION DL	4	PA,QL(30 per 30 days)
VPRIV 400 UNIT RECON SOLUTION DL	4	PA
VYNDAMAX 61 MG CAPSULE DL	4	PA,QL(30 per 30 days)
VYNDAQEL 20 MG CAPSULE DL	4	PA,QL(120 per 30 days)
WAINUA 45 MG/0.8 ML AUTO-INJECTOR DL	4	PA,QL(0.8 per 28 days)
WELIREG 40 MG TABLET DL	4	PA,QL(90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XENPOZYME 20 MG, 4 MG RECON SOLUTION DL	4	PA
XURIDEN 2 GRAM GRANULES IN PACKET DL	4	PA,QL(120 per 30 days)
<i>yargesa</i> 100 mg CAPSULE DL	4	PA,QL(90 per 30 days)
ZAVESCA 100 MG CAPSULE DL	4	PA,QL(90 per 30 days)
ZEMAIRA 1,000 MG RECON SOLUTION DL	4	PA
ZEMAIRA 4,000 MG, 5,000 MG RECON SOLUTION DL	4	PA
ZENPEP 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT CAPSULE, DR/EC MO	3	
ZOKINVY 50 MG, 75 MG CAPSULE DL	4	PA,QL(120 per 30 days)
GENITOURINARY AGENTS		
<i>alfuzosin</i> 10 mg TABLET, ER 24 HR. MO	1	
AVODART 0.5 MG CAPSULE MO	3	PA,QL(30 per 30 days)
<i>bethanechol chloride</i> 10 mg, 25 mg, 5 mg, 50 mg TABLET MO	1	
CIALIS 2.5 MG, 5 MG TABLET MO	3	PA
<i>darifenacin</i> 15 mg, 7.5 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
DETROL 1 MG, 2 MG TABLET MO	3	PA,QL(60 per 30 days)
DETROL LA 2 MG, 4 MG CAPSULE, ER 24 HR. MO	3	PA,QL(30 per 30 days)
DITROPAN XL 10 MG, 5 MG TABLET, ER 24 HR. MO	3	PA,QL(60 per 30 days)
<i>dutasteride</i> 0.5 mg CAPSULE MO	1	QL(30 per 30 days)
<i>dutasteride-tamsulosin</i> 0.5-0.4 mg CAPSULE ER MULTIPHASE 24 HR. MO	1	QL(30 per 30 days)
ELMIRON 100 MG CAPSULE MO	3	QL(90 per 30 days)
ENTADFI 5-5 MG CAPSULE MO	3	PA,QL(182 per 365 days)
<i>fesoterodine</i> 4 mg, 8 mg TABLET, ER 24 HR. MO	1	QL(30 per 30 days)
<i>finasteride</i> 5 mg TABLET MO	1	QL(30 per 30 days)
<i>flavoxate</i> 100 mg TABLET MO	1	
FLOMAX 0.4 MG CAPSULE MO	3	
GELNIQUE 10 % (100 MG/GRAM) GEL IN PACKET MO	3	ST,QL(30 per 30 days)
GEMTESA 75 MG TABLET MO	3	QL(30 per 30 days)
JALYN 0.5-0.4 MG CAPSULE ER MULTIPHASE 24 HR. MO	3	PA,QL(30 per 30 days)
MYRBETRIQ 25 MG, 50 MG TABLET, ER 24 HR. MO	2	QL(30 per 30 days)
MYRBETRIQ 8 MG/ML SUSPENSION, ER, RECON MO	2	QL(300 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
oxybutynin chloride 10 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
oxybutynin chloride 15 mg, 5 mg TABLET, ER 24 HR. MO	1	QL(60 per 30 days)
oxybutynin chloride 2.5 mg TABLET MO	1	QL(90 per 30 days)
oxybutynin chloride 5 mg TABLET MO	1	
oxybutynin chloride 5 mg/5 ml SYRUP MO	1	
OXYTROL 3.9 MG/24 HR PATCH, SEMIWEEKLY MO	3	ST,QL(8 per 28 days)
PROSCAR 5 MG TABLET MO	3	PA,QL(30 per 30 days)
RAPAFLO 4 MG, 8 MG CAPSULE MO	3	PA,QL(30 per 30 days)
silodosin 4 mg, 8 mg CAPSULE MO	1	QL(30 per 30 days)
solifenacin 10 mg, 5 mg TABLET MO	1	QL(30 per 30 days)
tadalafil 2.5 mg, 5 mg TABLET MO	1	PA
tamsulosin 0.4 mg CAPSULE MO	1	
THIOLA 100 MG TABLET DL	4	
THIOLA EC 100 MG, 300 MG TABLET, DR/EC DL	4	
tiopronin 100 mg TABLET DL	4	
tiopronin 100 mg, 300 mg TABLET, DR/EC DL	4	
tolterodine 1 mg, 2 mg TABLET MO	1	QL(60 per 30 days)
tolterodine 2 mg, 4 mg CAPSULE, ER 24 HR. MO	1	QL(30 per 30 days)
TOVIAZ 4 MG, 8 MG TABLET, ER 24 HR. MO	3	PA,QL(30 per 30 days)
tropium 20 mg TABLET MO	1	
tropium 60 mg CAPSULE, ER 24 HR. MO	1	QL(30 per 30 days)
UROXATRAL 10 MG TABLET, ER 24 HR. MO	3	
VESICARE 10 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
VESICARE LS 1 MG/ML SUSPENSION MO	3	PA,QL(300 per 30 days)
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (ADRENAL)		
ACTHAR 80 UNIT/ML GEL DL	4	PA,QL(30 per 30 days)
ACTHAR SELFJECT 40 UNIT/0.5 ML, 80 UNIT/ML PEN INJECTOR DL	4	PA,QL(45 per 30 days)
AGAMREE 40 MG/ML SUSPENSION DL	4	PA,QL(225 per 30 days)
ALKINDI SPRINKLE 0.5 MG, 1 MG, 2 MG, 5 MG CAPSULE, SPRINKLE DL	4	PA
betamethasone acet,sod phos 6 mg/ml SUSPENSION MO	1	
CELESTONE SOLUSPAN 6 MG/ML SUSPENSION MO	3	
CORTROPHIN GEL 80 UNIT/ML GEL DL	4	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
deflazacort 18 mg, 30 mg, 36 mg, 6 mg TABLET DL	4	PA
deflazacort 22.75 mg/ml SUSPENSION DL	4	PA
DEPO-MEDROL 20 MG/ML, 40 MG/ML, 80 MG/ML SUSPENSION MO	3	
dexabliss 1.5 mg (39 tabs) TABLET, DOSE PACK MO	1	
dexamethasone 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg TABLET MO	1	
dexamethasone 0.5 mg/5 ml ELIXIR MO	1	
dexamethasone 0.5 mg/5 ml SOLUTION MO	1	
dexamethasone 1.5 mg (21 tabs), 1.5 mg (35 tabs), 1.5 mg (51 tabs) TABLET, DOSE PACK MO	1	
dexamethasone intensol 1 mg/ml DROPS MO	1	
dexamethasone sodium phos (pf) 10 mg/ml SOLUTION MO	1	
dexamethasone sodium phos (pf) 10 mg/ml SYRINGE MO	1	
dexamethasone sodium phosphate 10 mg/ml, 4 mg/ml SOLUTION MO	1	
dexamethasone sodium phosphate 4 mg/ml SYRINGE MO	1	
EMFLAZA 18 MG, 30 MG, 36 MG, 6 MG TABLET DL	4	PA
EMFLAZA 22.75 MG/ML SUSPENSION DL	4	PA
fludrocortisone 0.1 mg TABLET MO	1	
HEMADY 20 MG TABLET MO	3	PA,QL(24 per 28 days)
KENALOG 0.147 MG/GRAM AEROSOL MO	3	QL(200 per 30 days)
KENALOG 10 MG/ML, 40 MG/ML SUSPENSION MO	3	
KENALOG-80 80 MG/ML SUSPENSION MO	3	
MEDROL 16 MG, 2 MG, 32 MG, 4 MG, 8 MG TABLET MO	3	BvsD
MEDROL (PAK) 4 MG TABLET, DOSE PACK MO	3	
methylprednisolone 16 mg, 32 mg, 4 mg, 8 mg TABLET MO	1	BvsD
methylprednisolone 4 mg TABLET, DOSE PACK MO	1	
methylprednisolone acetate 40 mg/ml, 80 mg/ml SUSPENSION MO	1	
methylprednisolone sodium succ 1,000 mg, 125 mg, 40 mg, 500 mg RECON SOLUTION MO	1	
millipred 5 mg TABLET MO	1	BvsD
millipred dp 5 mg (21 tabs), 5 mg (48 tabs) TABLET, DOSE PACK MO	1	
ORAPRED ODT 10 MG, 15 MG, 30 MG TABLET, DISINTEGRATING MO	3	
PEDIAPRED 5 MG BASE/5 ML (6.7 MG/5 ML) SOLUTION MO	3	
prednisolone 15 mg/5 ml SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
prednisolone 5 mg TABLET MO	1	BvsD
prednisolone sodium phosphate 10 mg, 15 mg, 30 mg TABLET, DISINTEGRATING MO	1	
prednisolone sodium phosphate 10 mg/5 ml, 15 mg/5 ml (3 mg/ml), 20 mg/5 ml (4 mg/ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml) SOLUTION MO	1	
prednisone 1 mg, 2.5 mg, 5 mg TABLET MO	1	BvsD
prednisone 10 mg, 20 mg, 5 mg TABLET MO	1	BvsD
prednisone 10 mg, 5 mg TABLET, DOSE PACK MO	1	
prednisone 5 mg/5 ml SOLUTION MO	1	BvsD
prednisone intensol 5 mg/ml CONCENTRATE MO	1	BvsD
RAYOS 1 MG, 2 MG, 5 MG TABLET, DR/EC DL	4	PA
SOLU-CORTEF 100 MG RECON SOLUTION MO	3	
SOLU-CORTEF ACT-O-VIAL (PF) 1,000 MG/8 ML, 100 MG/2 ML, 250 MG/2 ML, 500 MG/4 ML RECON SOLUTION MO	3	
SOLU-MEDROL 1,000 MG, 2 GRAM, 500 MG RECON SOLUTION MO	3	
SOLU-MEDROL (PF) 1,000 MG/8 ML, 125 MG/2 ML, 40 MG/ML, 500 MG/4 ML RECON SOLUTION MO	3	
taperdex 1.5 mg (21 tabs), 1.5 mg (27 tabs), 1.5 mg (49 tabs) TABLET, DOSE PACK MO	1	
triamcinolone acetonide 0.025 %, 0.05 %, 0.1 %, 0.5 % OINTMENT MO	1	
triamcinolone acetonide 0.025 %, 0.1 % LOTION MO	1	
triamcinolone acetonide 0.025 %, 0.5 % CREAM MO	1	
triamcinolone acetonide 0.1 % CREAM MO	1	
triamcinolone acetonide 0.147 mg/gram AEROSOL MO	1	QL(200 per 30 days)
triamcinolone acetonide 40 mg/ml SUSPENSION MO	1	
trianex 0.05 % OINTMENT MO	1	
triderm 0.1 %, 0.5 % CREAM MO	1	
tritocin 0.05 % OINTMENT MO	1	
VERIPRED 20 20 MG/5 ML (4 MG/ML) SOLUTION MO	1	
ZCORT 1.5 MG (25 TABS) TABLET, DOSE PACK MO	1	
ZILRETTA 32 MG SUSPENSION, ER, RECON MO	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PITUITARY)		
CHORIONIC GONADOTROPIN, HUMAN 10,000 UNIT RECON SOLUTION MO	3	PA
DDAVP 0.1 MG TABLET MO	3	PA
DDAVP 0.2 MG TABLET DL	4	PA
DDAVP 4 MCG/ML SOLUTION MO	3	PA
<i>desmopressin 0.1 mg, 0.2 mg</i> TABLET MO	1	
<i>desmopressin 10 mcg/spray (0.1 ml) SPRAY WITH PUMP</i> MO	1	PA,QL(25 per 30 days)
<i>desmopressin 10 mcg/spray (0.1 ml) SPRAY, NON-AEROSOL</i> MO	1	PA,QL(25 per 30 days)
<i>desmopressin 4 mcg/ml</i> SOLUTION DL	4	
EGRIFTA SV 2 MG RECON SOLUTION DL	4	PA,QL(30 per 30 days)
GENOTROPIN 12 MG/ML (36 UNIT/ML), 5 MG/ML (15 UNIT/ML) CARTRIDGE DL	4	PA
GENOTROPIN MINIQUICK 0.2 MG/0.25 ML, 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML SYRINGE DL	4	PA
HUMATROPE 12 MG (36 UNIT), 24 MG (72 UNIT), 6 MG (18 UNIT) CARTRIDGE DL	4	PA
HUMATROPE 5 (15 UNIT) MG RECON SOLUTION DL	4	PA
INCRELEX 10 MG/ML SOLUTION DL	4	PA
ISTURISA 1 MG TABLET DL	4	PA,QL(240 per 30 days)
ISTURISA 10 MG TABLET DL	4	PA,QL(180 per 30 days)
ISTURISA 5 MG TABLET DL	4	PA,QL(360 per 30 days)
NGENLA 24 MG/1.2 ML (20 MG/ML), 60 MG/1.2 ML (50 MG/ML) PEN INJECTOR DL	4	PA
NOCDURNA (MEN) 55.3 MCG TABLET, DISINTEGRATING MO	3	PA,QL(30 per 30 days)
NOCDURNA (WOMEN) 27.7 MCG TABLET, DISINTEGRATING MO	3	PA,QL(30 per 30 days)
NORDITROPIN FLEXPRO 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) PEN INJECTOR DL	4	PA
NOVAREL 5,000 UNIT RECON SOLUTION MO	3	PA
NUTROPIN AQ NUSPIN 10 MG/2 ML (5 MG/ML), 20 MG/2 ML (10 MG/ML), 5 MG/2 ML (2.5 MG/ML) PEN INJECTOR DL	4	PA
OMNITROPE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) CARTRIDGE DL	4	PA
OMNITROPE 5.8 MG RECON SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PREGNYL 10,000 UNIT RECON SOLUTION MO	3	PA
SAIZEN 5 MG RECON SOLUTION DL	4	PA,QL(28 per 28 days)
SAIZEN 8.8 MG RECON SOLUTION DL	4	PA
SAIZEN SAIZENPREP 8.8 MG/1.51 ML (FINAL CONC.) CARTRIDGE DL	4	PA
SEROSTIM 4 MG, 5 MG, 6 MG RECON SOLUTION DL	4	PA,QL(28 per 28 days)
SKYTROFA 11 MG, 7.6 MG, 9.1 MG CARTRIDGE DL	4	PA,QL(8 per 28 days)
SKYTROFA 13.3 MG, 3 MG, 3.6 MG, 4.3 MG, 5.2 MG, 6.3 MG CARTRIDGE DL	4	PA,QL(4 per 28 days)
SOGROYA 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) PEN INJECTOR DL	4	PA,QL(6 per 28 days)
ZOMACTON 10 MG RECON SOLUTION DL	4	PA
ZOMACTON 5 MG RECON SOLUTION DL	4	PA,QL(28 per 28 days)
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PROSTAGLANDINS)		
carboprost tromethamine 250 mcg/ml SOLUTION MO	1	
carboprost tromethamine 250 mcg/ml SYRINGE MO	1	
HEMABATE 250 MCG/ML SOLUTION MO	3	
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS)		
ACTIVELLA 1-0.5 MG TABLET MO	3	
afirmelle 0.1-20 mg-mcg TABLET MO	1	
altavera (28) 0.15-0.03 mg TABLET MO	1	
alyacen 1/35 (28) 1-35 mg-mcg TABLET MO	1	
alyacen 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO	1	
amabelz 0.5-0.1 mg, 1-0.5 mg TABLET MO	1	
amethia 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	3	QL(91 per 90 days)
amethyst (28) 90-20 mcg (28) TABLET MO	1	
ANDRODERM 2 MG/24 HOUR PATCH, 24 HR. MO	3	PA,QL(90 per 30 days)
ANDRODERM 4 MG/24 HR PATCH, 24 HR. MO	3	PA,QL(30 per 30 days)
ANDROGEL 1 % (25 MG/2.5GRAM), 1 % (50 MG/5 GRAM) GEL IN PACKET MO	3	PA,QL(300 per 30 days)
ANDROGEL 1.62 % (20.25 MG/1.25 GRAM) GEL IN PACKET DL	4	PA,QL(37.5 per 30 days)
ANDROGEL 1.62 % (40.5 MG/2.5 GRAM) GEL IN PACKET DL	4	PA,QL(150 per 30 days)
ANDROGEL 20.25 MG/1.25 GRAM (1.62 %) GEL IN METERED DOSE PUMP DL	4	PA,QL(150 per 30 days)
ANGELIQ 0.25-0.5 MG, 0.5-1 MG TABLET MO	3	
ANNOVERA 0.15-0.013 MG/24 HOUR RING MO	3	QL(1 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
apri 0.15-0.03 mg TABLET MO	1	
aranelle (28) 0.5/1/0.5-35 mg-mcg TABLET MO	1	
ashlyna 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
aubra 0.1-20 mg-mcg TABLET MO	1	
aubra eq 0.1-20 mg-mcg TABLET MO	1	
aurovela 1.5/30 (21) 1.5-30 mg-mcg TABLET MO	1	
aurovela 1/20 (21) 1-20 mg-mcg TABLET MO	1	
aurovela 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	
aurovela fe 1-20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
aurovela fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
AVEED 750 MG/3 ML (250 MG/ML) SOLUTION	4	PA
aviane 0.1-20 mg-mcg TABLET MO	1	
AYGESTIN 5 MG TABLET MO	1	
ayuna 0.15-0.03 mg TABLET MO	1	
azurette (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
BALCOLTRA 0.1 MG-0.02 MG (21)/IRON (7) TABLET MO	3	
balziva (28) 0.4-35 mg-mcg TABLET MO	1	
BEYAZ 3-0.02-0.451 MG (24) (4) TABLET MO	3	
BIJUVA 0.5-100 MG, 1-100 MG CAPSULE MO	3	QL(30 per 30 days)
blisovi 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	
blisovi fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
blisovi fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
briellyn 0.4-35 mg-mcg TABLET MO	1	
camila 0.35 mg TABLET MO	1	
camrese 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	3	QL(91 per 90 days)
camrese lo 0.1 mg-20 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
charlotte 24 fe 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET MO	1	
chateal eq (28) 0.15-0.03 mg TABLET MO	1	
CLIMARA 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.06 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR PATCH, WEEKLY MO	3	QL(4 per 28 days)
CLIMARA PRO 0.045-0.015 MG/24 HR PATCH, WEEKLY MO	3	QL(4 per 28 days)
COMBIPATCH 0.05-0.14 MG/24 HR, 0.05-0.25 MG/24 HR PATCH, SEMIWEEKLY MO	3	QL(8 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CRINONE 4 %, 8 % GEL MO	3	
cryselle (28) 0.3-30 mg-mcg TABLET MO	1	
cyred 0.15-0.03 mg TABLET MO	1	
cyred eq 0.15-0.03 mg TABLET MO	1	
danazol 100 mg, 200 mg, 50 mg CAPSULE MO	1	
dasetta 1/35 (28) 1-35 mg-mcg TABLET MO	1	
dasetta 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO	1	
daysee 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
deblitane 0.35 mg TABLET MO	1	
DELESTROGEN 10 MG/ML, 20 MG/ML, 40 MG/ML OIL MO	3	
DEPO-ESTRADIOL 5 MG/ML OIL MO	1	QL(5 per 30 days)
DEPO-PROVERA 150 MG/ML SUSPENSION MO	3	QL(1 per 90 days)
DEPO-PROVERA 150 MG/ML SYRINGE MO	3	QL(1 per 90 days)
DEPO-SUBQ PROVERA 104 104 MG/0.65 ML SYRINGE MO	2	QL(0.65 per 90 days)
DEPO-TESTOSTERONE 100 MG/ML, 200 MG/ML OIL MO	1	PA
desog-e.estradiol/e.estradiol 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
desogestrel-ethinyl estradiol 0.15-0.03 mg TABLET MO	1	
DIVIGEL 0.25 MG/0.25 GRAM (0.1 %), 0.5 MG/0.5 GRAM (0.1 %), 0.75 MG/0.75 GRAM (0.1%), 1 MG/GRAM (0.1 %), 1.25 MG/1.25 GRAM (0.1 %) GEL IN PACKET MO	3	
dolishale 90-20 mcg (28) TABLET MO	1	
dotti 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, SEMIWEEKLY MO	1	QL(8 per 28 days)
drospirenone-e.estradiol-lm.f.a 3-0.02-0.451 mg (24) (4), 3-0.03-0.451 mg (21) (7) TABLET MO	1	
drospirenone-ethinyl estradiol 3-0.02 mg, 3-0.03 mg TABLET MO	1	
DUAVEE 0.45-20 MG TABLET MO	3	PA,QL(30 per 30 days)
ELESTRIN 0.87 GRAM/ACTUATION GEL IN METERED DOSE PUMP MO	3	QL(52 per 30 days)
elinest 0.3-30 mg-mcg TABLET MO	1	
eluryng 0.12-0.015 mg/24 hr RING MO	1	QL(1 per 28 days)
emzahh 0.35 mg TABLET MO	1	
ENDOMETRIN 100 MG INSERT MO	3	
enilloring 0.12-0.015 mg/24 hr RING MO	1	QL(1 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>enpresse</i> 50-30 (6)/75-40 (5)/125-30(10) TABLET MO	1	
<i>enskyce</i> 0.15-0.03 mg TABLET MO	1	
<i>errin</i> 0.35 mg TABLET MO	1	
<i>estarylla</i> 0.25-35 mg-mcg TABLET MO	1	
ESTRACE 0.01 % (0.1 MG/GRAM) CREAM MO	3	PA
ESTRACE 0.5 MG, 1 MG, 2 MG TABLET MO	1	
<i>estradiol</i> 0.01 % (0.1 mg/gram) CREAM MO	1	
<i>estradiol</i> 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, WEEKLY MO	1	QL(4 per 28 days)
<i>estradiol</i> 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, SEMIWEEKLY MO	1	QL(8 per 28 days)
<i>estradiol</i> 0.25 mg/0.25 gram (0.1 %), 0.5 mg/0.5 gram (0.1 %), 0.75 mg/0.75 gram (0.1%), 1 mg/gram (0.1 %), 1.25 mg/1.25 gram (0.1 %) GEL IN PACKET MO	1	
<i>estradiol</i> 0.5 mg, 1 mg, 10 mcg, 2 mg TABLET MO	1	
<i>estradiol</i> 1.25 gram/actuation GEL IN METERED DOSE PUMP MO	1	
<i>estradiol valerate</i> 10 mg/ml, 20 mg/ml, 40 mg/ml OIL MO	1	
<i>estradiol-norethindrone acet</i> 0.5-0.1 mg, 1-0.5 mg TABLET MO	1	
ESTRING 2 MG (7.5 MCG/24 HOUR) RING MO	3	QL(1 per 90 days)
ESTROGEL 1.25 GRAM/ACTUATION GEL IN METERED DOSE PUMP MO	3	
<i>ethynodiol diac-eth estradiol</i> 1-35 mg-mcg, 1-50 mg-mcg TABLET MO	1	
<i>etonogestrel-ethinyl estradiol</i> 0.12-0.015 mg/24 hr RING MO	1	QL(1 per 28 days)
EVAMIST 1.53 MG/SPRAY (1.7%) SPRAY, NON-AEROSOL MO	3	
EVISTA 60 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>falmina</i> (28) 0.1-20 mg-mcg TABLET MO	1	
FEMRING 0.05 MG/24 HR, 0.1 MG/24 HR RING MO	3	QL(1 per 90 days)
<i>femynor</i> 0.25-35 mg-mcg TABLET MO	1	
<i>finzala</i> 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET MO	1	
FORTESTA 10 MG/0.5 GRAM /ACTUATION GEL IN METERED DOSE PUMP MO	3	PA,QL(120 per 30 days)
<i>fyavolv</i> 0.5-2.5 mg-mcg, 1-5 mg-mcg TABLET MO	1	
<i>gemmily</i> 1 mg-20 mcg (24)/75 mg (4) CAPSULE MO	1	
GENERESS FE 0.8MG-25MCG(24) AND 75 MG (4) CHEWABLE TABLET MO	3	
<i>hailey</i> 1.5-30 mg-mcg TABLET MO	1	
<i>hailey</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
hailey fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
hailey fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
haloette 0.12-0.015 mg/24 hr RING MO	1	QL(1 per 28 days)
heather 0.35 mg TABLET MO	1	
iclevia 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
IMVEXXY MAINTENANCE PACK 10 MCG, 4 MCG INSERT MO	3	PA,QL(8 per 28 days)
IMVEXXY STARTER PACK 10 MCG, 4 MCG INSERT, DOSE PACK MO	3	PA,QL(18 per 28 days)
incassia 0.35 mg TABLET MO	1	
INTRAROSA 6.5 MG INSERT MO	3	PA
isibloom 0.15-0.03 mg TABLET MO	1	
jaimiess 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
jasmiel (28) 3-0.02 mg TABLET MO	1	
JATENZO 158 MG, 198 MG CAPSULE MO	3	PA,QL(120 per 30 days)
JATENZO 237 MG CAPSULE MO	3	PA,QL(60 per 30 days)
jencycla 0.35 mg TABLET MO	1	
jinteli 1-5 mg-mcg TABLET MO	1	
jolessa 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
joyeaux 0.1 mg-0.02 mg (21)/iron (7) TABLET MO	1	
juleber 0.15-0.03 mg TABLET MO	1	
junel 1.5/30 (21) 1.5-30 mg-mcg TABLET MO	1	
junel 1/20 (21) 1-20 mg-mcg TABLET MO	1	
junel fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
junel fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
junel fe 24 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	
kaitlib fe 0.8mg-25mcg(24) and 75 mg (4) CHEWABLE TABLET MO	1	
kalliga 0.15-0.03 mg TABLET MO	1	
kariva (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
kelnor 1/35 (28) 1-35 mg-mcg TABLET MO	1	
kelnor 1/50 (28) 1-50 mg-mcg TABLET MO	1	
kurvelo (28) 0.15-0.03 mg TABLET MO	1	
l norgest/e.estradiol-e.estradiol 0.1 mg-20 mcg (84)/10 mcg (7), 0.15 mg-20 mcg/ 0.15 mg-25 mcg, 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
larin 1.5/30 (21) 1.5-30 mg-mcg TABLET MO	1	
larin 1/20 (21) 1-20 mg-mcg TABLET MO	1	
larin 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	
larin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
larin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
LAYOLIS FE 0.8MG-25MCG(24) AND 75 MG (4) CHEWABLE TABLET MO	3	
leena 28 0.5/1/0.5-35 mg-mcg TABLET MO	1	
lessina 0.1-20 mg-mcg TABLET MO	1	
levonest (28) 50-30 (6)/75-40 (5)/125-30(10) TABLET MO	1	
levonorg-eth estrad triphasic 50-30 (6)/75-40 (5)/125-30(10) TABLET MO	1	
levonorgest-eth.estradiol-iron 0.1 mg-0.02 mg (21)/iron (7) TABLET MO	3	
levonorgestrel-ethinyl estrad 0.1-20 mg-mcg, 0.15-0.03 mg, 90-20 mcg (28) TABLET MO	1	
levonorgestrel-ethinyl estrad 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
levora-28 0.15-0.03 mg TABLET MO	1	
LO LOESTRIN FE 1 MG-10 MCG (24)/10 MCG (2) TABLET MO	3	
lo-zumandimine (28) 3-0.02 mg TABLET MO	1	
LOESTRIN 1.5/30 (21) 1.5-30 MG-MCG TABLET MO	1	
LOESTRIN 1/20 (21) 1-20 MG-MCG TABLET MO	1	
LOESTRIN FE 1.5/30 (28-DAY) 1.5 MG-30 MCG (21)/75 MG (7) TABLET MO	1	
LOESTRIN FE 1/20 (28-DAY) 1 MG-20 MCG (21)/75 MG (7) TABLET MO	1	
lojaimiess 0.1 mg-20 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO	1	QL(91 per 90 days)
loryna (28) 3-0.02 mg TABLET MO	1	
low-ogestrel (28) 0.3-30 mg-mcg TABLET MO	1	
lutura (28) 0.1-20 mg-mcg TABLET MO	1	
lyleq 0.35 mg TABLET MO	1	
lyllana 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr PATCH, SEMIWEEKLY MO	1	QL(8 per 28 days)
lyza 0.35 mg TABLET MO	1	
marlissa (28) 0.15-0.03 mg TABLET MO	1	
medroxyprogesterone 10 mg, 2.5 mg, 5 mg TABLET MO	1	
medroxyprogesterone 150 mg/ml SUSPENSION MO	1	QL(1 per 90 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
medroxyprogesterone 150 mg/ml SYRINGE MO	1	QL(1 per 90 days)
megestrol 20 mg, 40 mg TABLET MO	1	
megestrol 400 mg/10 ml (10 ml), 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml) SUSPENSION MO	1	
MENEST 0.3 MG, 0.625 MG, 1.25 MG, 2.5 MG TABLET MO	1	
MENOSTAR 14 MCG/24 HR PATCH, WEEKLY MO	3	QL(8 per 28 days)
merzee 1 mg-20 mcg (24)/75 mg (4) CAPSULE MO	1	
METHITEST 10 MG TABLET DL	4	
methyltestosterone 10 mg CAPSULE DL	4	
mibelas 24 fe 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET MO	1	
microgestin 1.5/30 (21) 1.5-30 mg-mcg TABLET MO	1	
microgestin 1/20 (21) 1-20 mg-mcg TABLET MO	1	
microgestin 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO	1	
microgestin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
microgestin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO	1	
mili 0.25-35 mg-mcg TABLET MO	1	
mimvey 1-0.5 mg TABLET MO	1	
MINASTRIN 24 FE 1 MG-20 MCG(24) /75 MG (4) CHEWABLE TABLET MO	3	
MINIVELLE 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR PATCH, SEMIWEEKLY MO	3	QL(8 per 28 days)
mono-lynyah 0.25-35 mg-mcg TABLET MO	1	
NATAZIA 3 MG/2 MG-2 MG/ 2 MG-3 MG/1 MG TABLET MO	3	
NATESTO 5.5 MG/0.122 GRAM/ACTUATION GEL IN METERED DOSE PUMP MO	3	PA,QL(21.96 per 30 days)
necon 0.5/35 (28) 0.5-35 mg-mcg TABLET MO	1	
NEXPLANON 68 MG IMPLANT DL	2	
NEXTSTELLIS 3 MG- 14.2 MG (28) TABLET MO	3	
nikki (28) 3-0.02 mg TABLET MO	1	
NORA-BE 0.35 MG TABLET MO	1	
nora-be 0.35 mg TABLET MO	1	
norelgestromin-ethin.estradiol 150-35 mcg/24 hr PATCH, WEEKLY MO	1	QL(3 per 28 days)
noreth-ethinyl estradiol-iron 0.4mg-35mcg(21) and 75 mg (7), 0.8mg-25mcg(24) and 75 mg (4) CHEWABLE TABLET MO	1	
norethindrone (contraceptive) 0.35 mg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
norethindrone ac-eth estradiol 0.5-2.5 mg-mcg, 1-20 mg-mcg, 1-5 mg-mcg, 1.5-30 mg-mcg TABLET MO	1	
norethindrone acetate 5 mg TABLET MO	1	
norethindrone-e.estradiol-iron 1 mg-20 mcg (21)/75 mg (7), 1-20(5)/1-30(7) /1mg-35mcg (9), 1.5 mg-30 mcg (21)/75 mg (7) TABLET MO	1	
norethindrone-e.estradiol-iron 1 mg-20 mcg (24)/75 mg (4) CAPSULE MO	1	
norethindrone-e.estradiol-iron 1 mg-20 mcg(24) /75 mg (4) CHEWABLE TABLET MO	1	
norgestimate-ethinyl estradiol 0.18/0.215/0.25 mg-25 mcg, 0.18/0.215/0.25 mg-35 mcg (28), 0.25-35 mg-mcg TABLET MO	1	
nortrel 0.5/35 (28) 0.5-35 mg-mcg TABLET MO	1	
nortrel 1/35 (21) 1-35 mg-mcg (21) TABLET MO	1	
nortrel 1/35 (28) 1-35 mg-mcg TABLET MO	1	
nortrel 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO	1	
NUVARING 0.12-0.015 MG/24 HR RING MO	3	QL(1 per 28 days)
nylia 1/35 (28) 1-35 mg-mcg TABLET MO	1	
nylia 7/7/7 (28) 0.5/0.75/1 mg- 35 mcg TABLET MO	1	
nymyo 0.25-35 mg-mcg TABLET MO	1	
ocella 3-0.03 mg TABLET MO	1	
OSPHENA 60 MG TABLET MO	2	PA
oxandrolone 10 mg TABLET MO	1	PA,QL(60 per 30 days)
oxandrolone 2.5 mg TABLET MO	1	PA,QL(120 per 30 days)
philith 0.4-35 mg-mcg TABLET MO	1	
pimtrex (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
portia 28 0.15-0.03 mg TABLET MO	1	
PREFEST 1 MG (15)/1 MG- 0.09 MG (15) TABLET MO	1	
PREMARIN 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG TABLET MO	3	
PREMARIN 0.625 MG/GRAM CREAM MO	2	
PREMARIN 25 MG RECON SOLUTION MO	3	
PREMPHASE 0.625 MG (14)/ 0.625MG-5MG(14) TABLET MO	3	
PREMPRO 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG TABLET MO	3	
progesterone 50 mg/ml OIL MO	1	
progesterone micronized 100 mg, 200 mg CAPSULE MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROMETRIUM 100 MG, 200 MG CAPSULE MO	3	
PROVERA 10 MG, 2.5 MG, 5 MG TABLET MO	3	
QUARTETTE 0.15 MG-20 MCG/ 0.15 MG-25 MCG TABLET, DOSE PACK, 3 MONTH MO	3	QL(91 per 90 days)
<i>raloxifene 60 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>reclipsen (28) 0.15-0.03 mg TABLET MO</i>	1	
<i>rivelsa 0.15 mg-20 mcg/ 0.15 mg-25 mcg TABLET, DOSE PACK, 3 MONTH MO</i>	1	QL(91 per 90 days)
SAFYRAL 3-0.03-0.451 MG (21) (7) TABLET MO	3	
SEASONIQUE 0.15 MG-30 MCG (84)/10 MCG (7) TABLET, DOSE PACK, 3 MONTH MO	3	QL(91 per 90 days)
<i>setlakin 0.15 mg-30 mcg (91) TABLET, DOSE PACK, 3 MONTH MO</i>	1	QL(91 per 90 days)
<i>sharobel 0.35 mg TABLET MO</i>	1	
<i>simliya (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO</i>	1	
<i>simpesse 0.15 mg-30 mcg (84)/10 mcg (7) TABLET, DOSE PACK, 3 MONTH MO</i>	1	QL(91 per 90 days)
SLYND 4 MG (28) TABLET MO	3	
<i>sprintec (28) 0.25-35 mg-mcg TABLET MO</i>	1	
<i>sronyx 0.1-20 mg-mcg TABLET MO</i>	1	
<i>syeda 3-0.03 mg TABLET MO</i>	1	
<i>tarina 24 fe 1 mg-20 mcg (24)/75 mg (4) TABLET MO</i>	1	
<i>tarina fe 1-20 eq (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO</i>	1	
<i>tarina fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) TABLET MO</i>	1	
<i>taysofy 1 mg-20 mcg (24)/75 mg (4) CAPSULE MO</i>	1	
TAYTULLA 1 MG-20 MCG (24)/75 MG (4) CAPSULE MO	3	
TESTIM 50 MG/5 GRAM (1 %) GEL MO	3	PA,QL(300 per 30 days)
<i>testosterone 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram) GEL IN PACKET MO</i>	1	PA,QL(300 per 30 days)
<i>testosterone 1.62 % (20.25 mg/1.25 gram) GEL IN PACKET MO</i>	1	PA,QL(37.5 per 30 days)
<i>testosterone 1.62 % (40.5 mg/2.5 gram) GEL IN PACKET MO</i>	1	PA,QL(150 per 30 days)
<i>testosterone 10 mg/0.5 gram /actuation GEL IN METERED DOSE PUMP MO</i>	1	PA,QL(120 per 30 days)
<i>testosterone 12.5 mg/ 1.25 gram (1 %) GEL IN METERED DOSE PUMP MO</i>	1	PA,QL(300 per 30 days)
<i>testosterone 20.25 mg/1.25 gram (1.62 %) GEL IN METERED DOSE PUMP MO</i>	1	PA,QL(150 per 30 days)
<i>testosterone 30 mg/actuation (1.5 ml) SOLUTION IN METERED DOSE PUMP MO</i>	3	PA,QL(180 per 30 days)
<i>testosterone 50 mg/5 gram (1 %) GEL MO</i>	3	PA,QL(300 per 30 days)
<i>testosterone cypionate 100 mg/ml, 200 mg/ml OIL MO</i>	1	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
testosterone enanthate 200 mg/ml OIL MO	1	PA,QL(25 per 90 days)
tilia fe 1-20(5)/1-30(7) /1mg-35mcg (9) TABLET MO	1	
TLANDO 112.5 MG CAPSULE MO	3	PA,QL(120 per 30 days)
tri-estarylla 0.18/0.215/0.25 mg-35 mcg (28) TABLET MO	1	
tri-legest fe 1-20(5)/1-30(7) /1mg-35mcg (9) TABLET MO	1	
tri-linyah 0.18/0.215/0.25 mg-35 mcg (28) TABLET MO	1	
tri-lo-estarylla 0.18/0.215/0.25 mg-25 mcg TABLET MO	1	
tri-lo-marzia 0.18/0.215/0.25 mg-25 mcg TABLET MO	1	
tri-lo-mili 0.18/0.215/0.25 mg-25 mcg TABLET MO	1	
tri-lo-sprintec 0.18/0.215/0.25 mg-25 mcg TABLET MO	1	
tri-mili 0.18/0.215/0.25 mg-35 mcg (28) TABLET MO	1	
tri-nymyo 0.18/0.215/0.25 mg-35 mcg (28) TABLET MO	1	
tri-sprintec (28) 0.18/0.215/0.25 mg-35 mcg (28) TABLET MO	1	
tri-vylibra 0.18/0.215/0.25 mg-35 mcg (28) TABLET MO	1	
tri-vylibra lo 0.18/0.215/0.25 mg-25 mcg TABLET MO	1	
trivora (28) 50-30 (6)/75-40 (5)/125-30(10) TABLET MO	1	
tulana 0.35 mg TABLET MO	1	
turqoz (28) 0.3-30 mg-mcg TABLET MO	1	
TYBLUME 0.1 MG- 20 MCG CHEWABLE TABLET MO	3	
tydemy 3-0.03-0.451 mg (21) (7) TABLET MO	1	
VAGIFEM 10 MCG TABLET MO	3	PA
velivet triphasic regimen (28) 0.1/.125/.15-25 mg-mcg TABLET MO	1	
vestura (28) 3-0.02 mg TABLET MO	1	
vienna 0.1-20 mg-mcg TABLET MO	1	
violele (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
VIVELLE-DOT 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR PATCH, SEMIWEEKLY MO	3	QL(8 per 28 days)
VOGELXO 1 % (50 MG/5 GRAM) GEL IN PACKET MO	3	PA,QL(300 per 30 days)
VOGELXO 12.5 MG/ 1.25 GRAM (1 %) GEL IN METERED DOSE PUMP MO	3	PA,QL(300 per 30 days)
VOGELXO 50 MG/5 GRAM (1 %) GEL MO	3	PA,QL(300 per 30 days)
volnea (28) 0.15-0.02 mgx21 /0.01 mg x 5 TABLET MO	1	
vyfemla (28) 0.4-35 mg-mcg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>vylibra</i> 0.25-35 mg-mcg TABLET MO	1	
<i>wera</i> (28) 0.5-35 mg-mcg TABLET MO	1	
<i>wymzya</i> fe 0.4mg-35mcg(21) and 75 mg (7) CHEWABLE TABLET MO	1	
<i>xulane</i> 150-35 mcg/24 hr PATCH, WEEKLY MO	1	QL(3 per 28 days)
XYOSTED 100 MG/0.5 ML, 50 MG/0.5 ML, 75 MG/0.5 ML AUTO-INJECTOR MO	3	PA,QL(2 per 28 days)
YASMIN (28) 3-0.03 MG TABLET MO	3	
YAZ (28) 3-0.02 MG TABLET MO	3	
<i>yuvafem</i> 10 mcg TABLET MO	1	
<i>zafemy</i> 150-35 mcg/24 hr PATCH, WEEKLY MO	1	QL(3 per 28 days)
<i>zarah</i> 3-0.03 mg TABLET MO	1	
<i>zovia</i> 1-35 (28) 1-35 mg-mcg TABLET MO	1	
<i>zumandimine</i> (28) 3-0.03 mg TABLET MO	1	
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID)		
ARMOUR THYROID 120 MG, 15 MG, 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG TABLET MO	2	
CYTOMEL 25 MCG, 5 MCG, 50 MCG TABLET MO	3	
ERMEZA 30 MCG/ML SOLUTION MO	3	
EUTHYROX 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	1	
LEVO-T 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	2	
<i>levothyroxine</i> 100 mcg RECON SOLUTION MO	1	
<i>levothyroxine</i> 100 mcg, 112 mcg, 125 mcg, 13 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg CAPSULE MO	1	
<i>levothyroxine</i> 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg TABLET MO	1	
<i>levothyroxine</i> 100 mcg/ml, 20 mcg/ml, 40 mcg/ml SOLUTION MO	1	
<i>levothyroxine</i> 175 mcg, 200 mcg, 300 mcg TABLET MO	1	
<i>levothyroxine</i> 200 mcg, 500 mcg RECON SOLUTION DL	4	
LEVOXYL 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	1	
<i>liothyronine</i> 10 mcg/ml SOLUTION MO	1	
<i>liothyronine</i> 25 mcg, 5 mcg, 50 mcg TABLET MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>np thyroid 120 mg, 15 mg, 30 mg, 60 mg, 90 mg TABLET</i> MO	2	
SYNTHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	2	
THYQUIDITY 20 MCG/ML SOLUTION MO	3	
TIROSINT 100 MCG, 112 MCG, 125 MCG, 13 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 37.5 MCG, 44 MCG, 50 MCG, 62.5 MCG, 75 MCG, 88 MCG CAPSULE MO	3	
TIROSINT-SOL 100 MCG/ML, 112 MCG/ML, 125 MCG/ML, 13 MCG/ML, 137 MCG/ML, 150 MCG/ML, 175 MCG/ML, 200 MCG/ML, 25 MCG/ML, 37.5 MCG/ML, 44 MCG/ML, 50 MCG/ML, 62.5 MCG/ML, 75 MCG/ML, 88 MCG/ML SOLUTION MO	3	
TRIOSTAT 10 MCG/ML SOLUTION MO	3	
UNITHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET MO	2	
HORMONAL AGENTS, SUPPRESSANT (ADRENAL OR PITUITARY)		
<i>cabergoline 0.5 mg TABLET</i> MO	1	
ELIGARD 7.5 MG (1 MONTH) SYRINGE MO	3	PA
ELIGARD (3 MONTH) 22.5 MG SYRINGE MO	3	PA
ELIGARD (4 MONTH) 30 MG SYRINGE MO	3	PA
ELIGARD (6 MONTH) 45 MG SYRINGE MO	3	PA
FENSOLVI 45 MG SYRINGE	4	PA,QL(1 per 180 days)
FIRMAGON 120 MG RECON SOLUTION DL	4	PA
FIRMAGON KIT W DILUENT SYRINGE 120 MG RECON SOLUTION DL	4	PA
FIRMAGON KIT W DILUENT SYRINGE 80 MG RECON SOLUTION MO	3	PA
<i>lanreotide 120 mg/0.5 ml SYRINGE</i> DL	4	PA,QL(0.5 per 28 days)
<i>lanreotide 60 mg/0.2 ml SYRINGE</i> DL	4	PA,QL(0.2 per 28 days)
<i>lanreotide 90 mg/0.3 ml SYRINGE</i> DL	4	PA,QL(0.3 per 28 days)
<i>leuprolide 1 mg/0.2 ml KIT</i> MO	1	
<i>leuprolide (3 month) 22.5 mg SUSPENSION FOR RECONSTITUTION</i> MO	3	PA,QL(1 per 90 days)
LUPRON DEPOT 3.75 MG SYRINGE KIT MO	3	PA,QL(1 per 30 days)
LUPRON DEPOT 7.5 MG SYRINGE KIT DL	4	PA,QL(1 per 30 days)
LUPRON DEPOT (3 MONTH) 11.25 MG, 22.5 MG SYRINGE KIT MO	3	PA,QL(1 per 90 days)
LUPRON DEPOT (4 MONTH) 30 MG SYRINGE KIT MO	3	PA,QL(1 per 112 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LUPRON DEPOT (6 MONTH) 45 MG SYRINGE KIT	4	PA,QL(1 per 168 days)
LUPRON DEPOT-PED 11.25 MG, 15 MG, 7.5 MG (PED) KIT DL	4	PA,QL(1 per 28 days)
LUPRON DEPOT-PED 45 MG SYRINGE KIT	4	PA,QL(1 per 168 days)
LUPRON DEPOT-PED (3 MONTH) 11.25 MG, 30 MG SYRINGE KIT	4	PA,QL(1 per 90 days)
MYCAPSSA 20 MG CAPSULE, DR/EC DL	4	PA,QL(112 per 28 days)
MYFEMBREE 40-1-0.5 MG TABLET DL	4	PA,QL(28 per 28 days)
octreotide acetate 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml SOLUTION MO	1	PA
octreotide acetate 100 mcg/ml (1 ml), 50 mcg/ml (1 ml), 500 mcg/ml (1 ml) SYRINGE MO	1	PA
ORIAHNN 300-1-0.5MG(AM) /300 MG(PM) CAPSULE, SEQUENTIAL DL	4	PA,QL(56 per 28 days)
ORLISSA 150 MG TABLET DL	4	PA,QL(28 per 28 days)
ORLISSA 200 MG TABLET DL	4	PA,QL(56 per 28 days)
RECORLEV 150 MG TABLET DL	4	PA,QL(240 per 30 days)
SANDOSTATIN 100 MCG/ML, 50 MCG/ML, 500 MCG/ML SOLUTION DL	4	PA
SANDOSTATIN LAR DEPOT 10 MG, 20 MG, 30 MG SUSPENSION, ER, RECON DL	4	PA
SIGNIFOR 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) SOLUTION DL	4	PA,QL(60 per 30 days)
SIGNIFOR LAR 10 MG, 20 MG, 30 MG, 40 MG, 60 MG SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(1 per 28 days)
SOMATULINE DEPOT 120 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 28 days)
SOMATULINE DEPOT 60 MG/0.2 ML SYRINGE DL	4	PA,QL(0.2 per 28 days)
SOMATULINE DEPOT 90 MG/0.3 ML SYRINGE DL	4	PA,QL(0.3 per 28 days)
SOMAVERT 10 MG, 15 MG, 20 MG RECON SOLUTION DL	4	PA,QL(60 per 30 days)
SOMAVERT 25 MG, 30 MG RECON SOLUTION DL	4	PA,QL(30 per 30 days)
SYNAREL 2 MG/ML SPRAY, NON-AEROSOL DL	4	
TRELSTAR 11.25 MG, 22.5 MG, 3.75 MG SUSPENSION FOR RECONSTITUTION MO	3	PA
TRIPTODUR 22.5 MG SUSPENSION FOR RECONSTITUTION	4	PA,QL(1 per 168 days)
ZOLADEX 10.8 MG IMPLANT MO	3	PA,QL(1 per 84 days)
ZOLADEX 3.6 MG IMPLANT MO	3	PA,QL(1 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HORMONAL AGENTS, SUPPRESSANT (THYROID)		
methimazole 10 mg, 5 mg TABLET MO	1	
propylthiouracil 50 mg TABLET MO	1	
IMMUNOLOGICAL AGENTS		
ABRILADA(CF) 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
ABRILADA(CF) 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ABRILADA(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ABRYSVO (PF) 120 MCG/0.5 ML RECON SOLUTION \$0,DL	1	
ACTEMRA 162 MG/0.9 ML SYRINGE DL	4	PA,QL(3.6 per 28 days)
ACTEMRA ACTPEN 162 MG/0.9 ML PEN INJECTOR DL	4	PA,QL(3.6 per 28 days)
ACTHIB (PF) 10 MCG/0.5 ML RECON SOLUTION DL	1	
ACTIMMUNE 100 MCG/0.5 ML SOLUTION DL	4	PA
ADACEL(TDAP ADOLESN/ADULT)(PF) 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML SUSPENSION \$0,DL	1	
ADACEL(TDAP ADOLESN/ADULT)(PF) 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML SYRINGE \$0,DL	1	
ADALIMUMAB-AACF 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-AACF 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-AATY 20 MG/0.2 ML, 40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-AATY 40 MG/0.4 ML, 80 MG/0.8 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADAZ 40 MG/0.4 ML PEN INJECTOR DL	4	PA,QL(2.4 per 28 days)
ADALIMUMAB-ADAZ 40 MG/0.4 ML SYRINGE DL	4	PA,QL(2.4 per 28 days)
ADALIMUMAB-ADBM 10 MG/0.2 ML, 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
ADALIMUMAB-ADBM 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADBM 40 MG/0.4 ML, 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADBM(CF) PEN CROHNS 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-ADBM(CF) PEN PS-UV 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-FKJP 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
ADALIMUMAB-FKJP 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-FKJP 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ADALIMUMAB-RYVK 40 MG/0.4 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ADALIMUMAB-RYVK 40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
ALYGLO 10 % SOLUTION DL	4	PA
AMJEVITA(CF) 10 MG/0.2 ML, 20 MG/0.2 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
AMJEVITA(CF) 20 MG/0.4 ML, 40 MG/0.4 ML SYRINGE DL	4	PA,QL(2.4 per 28 days)
AMJEVITA(CF) 40 MG/0.8 ML SYRINGE DL	4	PA,QL(4.8 per 28 days)
AMJEVITA(CF) AUTOINJECTOR 40 MG/0.4 ML AUTO-INJECTOR DL	4	PA,QL(2.4 per 28 days)
AMJEVITA(CF) AUTOINJECTOR 40 MG/0.8 ML, 80 MG/0.8 ML AUTO-INJECTOR DL	4	PA,QL(4.8 per 28 days)
ARAVA 10 MG, 20 MG TABLET DL	4	PA,QL(30 per 30 days)
ARCALYST 220 MG RECON SOLUTION DL	4	PA
AREXVY (PF) 120 MCG/0.5 ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
ASCENIV 10 % SOLUTION DL	4	PA
ASTAGRAF XL 0.5 MG, 1 MG, 5 MG CAPSULE, ER 24 HR. MO	3	BvsD
ATGAM 50 MG/ML SOLUTION DL	4	PA
AVSOLA 100 MG RECON SOLUTION DL	4	PA
AZASAN 100 MG, 75 MG TABLET MO	1	BvsD
<i>azathioprine 100 mg, 50 mg, 75 mg TABLET MO</i>	1	BvsD
<i>azathioprine sodium 100 mg RECON SOLUTION MO</i>	1	BvsD
BCG VACCINE, LIVE (PF) 50 MG SUSPENSION FOR RECONSTITUTION \$0,DL	1	
BENLYSTA 120 MG RECON SOLUTION DL	4	PA,QL(20 per 28 days)
BENLYSTA 200 MG/ML AUTO-INJECTOR DL	4	PA,QL(8 per 28 days)
BENLYSTA 200 MG/ML SYRINGE DL	4	PA,QL(8 per 28 days)
BENLYSTA 400 MG RECON SOLUTION DL	4	PA,QL(6 per 28 days)
BERINERT 500 UNIT (10 ML) KIT DL	4	PA,QL(15 per 30 days)
BERINERT 500 UNIT (10 ML) RECON SOLUTION DL	4	PA,QL(15 per 30 days)
BESREMI 500 MCG/ML SYRINGE DL	4	PA,QL(2 per 28 days)
BEXSERO 50-50-50-25 MCG/0.5 ML SYRINGE \$0,DL	1	
BIMZELX 160 MG/ML SYRINGE DL	4	PA,QL(2 per 28 days)
BIMZELX AUTOINJECTOR 160 MG/ML AUTO-INJECTOR DL	4	PA,QL(2 per 28 days)
BIVIGAM 10 % SOLUTION DL	4	PA
BOOSTRIX TDAP 2.5-8-5 LF-MCG-LF/0.5ML SUSPENSION \$0,DL	1	
BOOSTRIX TDAP 2.5-8-5 LF-MCG-LF/0.5ML SYRINGE \$0,DL	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CELLCEPT 200 MG/ML SUSPENSION FOR RECONSTITUTION	4	BvsD
CELLCEPT 250 MG CAPSULE	4	BvsD
CELLCEPT 500 MG TABLET	4	BvsD
CELLCEPT INTRAVENOUS 500 MG RECON SOLUTION MO	3	BvsD
CIBINQO 100 MG, 200 MG, 50 MG TABLET DL	4	PA,QL(30 per 30 days)
CIMZIA 400 MG/2 ML (200 MG/ML X 2) SYRINGE KIT DL	4	PA,QL(3 per 30 days)
CIMZIA POWDER FOR RECONST 400 MG (200 MG X 2 VIALS) KIT DL	4	PA,QL(3 per 30 days)
CIMZIA STARTER KIT 400 MG/2 ML (200 MG/ML X 2) SYRINGE KIT DL	4	PA,QL(3 per 30 days)
CINRYZE 500 UNIT (5 ML) RECON SOLUTION DL	4	PA,QL(20 per 30 days)
COSENTYX 150 MG/ML SYRINGE DL	4	PA,QL(8 per 28 days)
COSENTYX 25 MG/ML SOLUTION DL	4	PA
COSENTYX 75 MG/0.5 ML SYRINGE DL	4	PA,QL(2 per 28 days)
COSENTYX (2 SYRINGES) 150 MG/ML SYRINGE DL	4	PA,QL(8 per 28 days)
COSENTYX PEN 150 MG/ML PEN INJECTOR DL	4	PA,QL(8 per 28 days)
COSENTYX PEN (2 PENS) 150 MG/ML PEN INJECTOR DL	4	PA,QL(8 per 28 days)
COSENTYX UNOREADY PEN 300 MG/2 ML (150 MG/ML) PEN INJECTOR DL	4	PA,QL(8 per 28 days)
CUTAQUIG 16.5 % SOLUTION DL	4	PA
<i>cyclosporine 100 mg, 25 mg CAPSULE MO</i>	1	BvsD
<i>cyclosporine modified 100 mg, 25 mg, 50 mg CAPSULE MO</i>	1	BvsD
<i>cyclosporine modified 100 mg/ml SOLUTION MO</i>	1	BvsD
CYLTEZO(CF) 10 MG/0.2 ML, 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
CYLTEZO(CF) 40 MG/0.4 ML, 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
CYLTEZO(CF) PEN 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
CYLTEZO(CF) PEN CROHN'S-UC-HS 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
CYLTEZO(CF) PEN PSORIASIS-UV 40 MG/0.4 ML, 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
CYTOGAM 50 MG/ML SOLUTION DL	4	PA
DAPTACEL (DTAP PEDIATRIC) (PF) 15-10-5 LF-MCG-LF/0.5ML SUSPENSION DL	1	
DENGVAXIA (PF) 10EXP4.5-6 CCID50/0.5 ML SUSPENSION FOR RECONSTITUTION DL	1	
DUPIXENT PEN 200 MG/1.14 ML PEN INJECTOR DL	4	PA,QL(3.42 per 28 days)
DUPIXENT PEN 300 MG/2 ML PEN INJECTOR DL	4	PA,QL(8 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DUPIXENT SYRINGE 100 MG/0.67 ML SYRINGE DL	4	PA,QL(1.34 per 28 days)
DUPIXENT SYRINGE 200 MG/1.14 ML SYRINGE DL	4	PA,QL(3.42 per 28 days)
DUPIXENT SYRINGE 300 MG/2 ML SYRINGE DL	4	PA,QL(8 per 28 days)
ENBREL 25 MG (1 ML) RECON SOLUTION DL	4	PA,QL(8 per 28 days)
ENBREL 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) SYRINGE DL	4	PA,QL(8 per 28 days)
ENBREL 25 MG/0.5 ML SOLUTION DL	4	PA,QL(8 per 28 days)
ENBREL MINI 50 MG/ML (1 ML) CARTRIDGE DL	4	PA,QL(8 per 28 days)
ENBREL SURECLICK 50 MG/ML (1 ML) PEN INJECTOR DL	4	PA,QL(8 per 28 days)
ENGERIX-B (PF) 20 MCG/ML SUSPENSION \$0,DL	1	BvsD
ENGERIX-B (PF) 20 MCG/ML SYRINGE \$0,DL	1	BvsD
ENGERIX-B PEDIATRIC (PF) 10 MCG/0.5 ML SYRINGE \$0,DL	1	BvsD
ENJAYMO 50 MG/ML SOLUTION DL	4	PA
ENTYVIO 300 MG RECON SOLUTION	4	PA,QL(8 per 365 days)
ENTYVIO PEN 108 MG/0.68 ML PEN INJECTOR DL	4	PA,QL(1.36 per 28 days)
ENVARUSUS XR 0.75 MG, 1 MG TABLET, ER 24 HR. MO	3	PA
ENVARUSUS XR 4 MG TABLET, ER 24 HR. DL	3	PA
<i>everolimus (immunosuppressive) 0.25 mg TABLET MO</i>	1	BvsD,QL(60 per 30 days)
<i>everolimus (immunosuppressive) 0.5 mg TABLET</i>	4	BvsD,QL(120 per 30 days)
<i>everolimus (immunosuppressive) 0.75 mg TABLET</i>	4	BvsD,QL(60 per 30 days)
<i>everolimus (immunosuppressive) 1 mg TABLET DL</i>	4	BvsD,QL(60 per 30 days)
FABHALTA 200 MG CAPSULE DL	4	PA,QL(60 per 30 days)
FIRAZYR 30 MG/3 ML SYRINGE DL	4	PA,QL(18 per 30 days)
FLEBOGAMMA DIF 10 %, 5 % SOLUTION DL	4	PA
GAMASTAN 15-18 % RANGE SOLUTION MO	3	PA
GAMIFANT 5 MG/ML SOLUTION DL	4	PA
GAMMAGARD LIQUID 10 % SOLUTION DL	4	PA
GAMMAGARD S-D (IGA < 1 MCG/ML) 10 GRAM, 5 GRAM RECON SOLUTION DL	4	PA
GAMMAKED 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 20 GRAM/200 ML (10 %), 5 GRAM/50 ML (10 %) SOLUTION DL	4	PA
GAMMAPLEX 10 % SOLUTION DL	4	PA
GAMMAPLEX (WITH SORBITOL) 5 % SOLUTION DL	4	PA
GAMUNEX-C 1 GRAM/10 ML (10 %) SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GAMUNEX-C 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) SOLUTION DL	4	PA
GARDASIL 9 (PF) 0.5 ML SUSPENSION \$0,DL	1	
GARDASIL 9 (PF) 0.5 ML SYRINGE \$0,DL	1	
<i>gengraf</i> 100 mg, 25 mg CAPSULE MO	1	BvsD
<i>gengraf</i> 100 mg/ml SOLUTION MO	1	BvsD
HADLIMA 40 MG/0.8 ML SYRINGE DL	4	PA,QL(4.8 per 28 days)
HADLIMA PUSHTOUCH 40 MG/0.8 ML AUTO-INJECTOR DL	4	PA,QL(4.8 per 28 days)
HADLIMA(CF) 40 MG/0.4 ML SYRINGE DL	4	PA,QL(2.4 per 28 days)
HADLIMA(CF) PUSHTOUCH 40 MG/0.4 ML AUTO-INJECTOR DL	4	PA,QL(2.4 per 28 days)
HAEGARDA 2,000 UNIT, 3,000 UNIT RECON SOLUTION DL	4	PA,QL(24 per 28 days)
HAVRIX (PF) 1,440 ELISA UNIT/ML SYRINGE \$0,DL	1	
HAVRIX (PF) 720 ELISA UNIT/0.5 ML SYRINGE DL	1	
HEPLISAV-B (PF) 20 MCG/0.5 ML SYRINGE \$0,DL	1	BvsD
HIBERIX (PF) 10 MCG/0.5 ML RECON SOLUTION DL	1	
HIZENTRA 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SOLUTION DL	4	PA
HIZENTRA 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SYRINGE DL	4	PA
HULIO(CF) 20 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
HULIO(CF) 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
HULIO(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
HUMIRA PEN 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA PEN CROHNS-UC-HS START 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA PEN PSOR-UVEITS-ADOL HS 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) 10 MG/0.1 ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)
HUMIRA(CF) 20 MG/0.2 ML, 40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEDI CROHNS STARTER 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN 40 MG/0.4 ML, 80 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN CROHNS-UC-HS 80 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HUMIRA(CF) PEN PEDIATRIC UC 80 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HUMIRA(CF) PEN PSOR-UV-ADOL HS 80 MG/0.8 ML-40 MG/0.4 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
HYPERRAB (PF) 300 UNIT/ML SOLUTION DL	4	BvsD
HYPERTET (PF) 250 UNIT/ML SYRINGE DL	3	BvsD
HYRIMOZ 40 MG/0.8 ML SYRINGE DL	4	PA,QL(4.8 per 28 days)
HYRIMOZ PEN 40 MG/0.8 ML PEN INJECTOR DL	4	PA,QL(4.8 per 28 days)
HYRIMOZ PEN CROHN'S-UC STARTER 80 MG/0.8 ML PEN INJECTOR DL	4	PA,QL(4.8 per 28 days)
HYRIMOZ PEN PSORIASIS STARTER 80MG/0.8ML(X1)- 40 MG/0.4ML(X2) PEN INJECTOR DL	4	PA,QL(3.2 per 28 days)
HYRIMOZ(CF) 10 MG/0.1 ML SYRINGE DL	4	PA,QL(0.2 per 28 days)
HYRIMOZ(CF) 20 MG/0.2 ML SYRINGE DL	4	PA,QL(1.2 per 28 days)
HYRIMOZ(CF) 40 MG/0.4 ML SYRINGE DL	4	PA,QL(2.4 per 28 days)
HYRIMOZ(CF) PEDI CROHN STARTER 80 MG/0.8 ML SYRINGE DL	4	PA,QL(4.8 per 28 days)
HYRIMOZ(CF) PEDI CROHN STARTER 80 MG/0.8 ML - 40 MG/0.4 ML SYRINGE DL	4	PA,QL(3.6 per 28 days)
HYRIMOZ(CF) PEN 40 MG/0.4 ML PEN INJECTOR DL	4	PA,QL(2.4 per 28 days)
HYRIMOZ(CF) PEN 80 MG/0.8 ML PEN INJECTOR DL	4	PA,QL(4.8 per 28 days)
<i>icatibant 30 mg/3 ml SYRINGE</i> DL	4	PA,QL(18 per 30 days)
IDACIO(CF) 40 MG/0.8 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
IDACIO(CF) PEN 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
IDACIO(CF) PEN CROHN-UC STARTR 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
IDACIO(CF) PEN PSORIASIS START 40 MG/0.8 ML PEN INJECTOR KIT DL	4	PA,QL(6 per 28 days)
ILUMYA 100 MG/ML SYRINGE	4	PA,QL(6 per 365 days)
IMOGAM RABIES-HT (PF) 150 UNIT/ML SOLUTION DL	3	BvsD
IMOVAX RABIES VACCINE (PF) 2.5 UNIT RECON SOLUTION \$0,DL	1	BvsD
IMURAN 50 MG TABLET MO	3	PA
INFANRIX (DTAP) (PF) 25-58-10 LF-MCG-LF/0.5ML SYRINGE DL	1	
INFLECTRA 100 MG RECON SOLUTION DL	4	PA
INFLIXIMAB 100 MG RECON SOLUTION DL	4	PA
INTRON A 10 MILLION UNIT (1 ML) RECON SOLUTION MO	3	PA
INTRON A 50 MILLION UNIT (1 ML) RECON SOLUTION MO	2	PA
IPOL 40-8-32 UNIT/0.5 ML SUSPENSION \$0,DL	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
IXCHIQ (PF) 1,000 TCID50/0.5 ML RECON SOLUTION \$0,DL	1	
IXIARO (PF) 6 MCG/0.5 ML SYRINGE \$0,DL	1	
JYLAMVO 2 MG/ML SOLUTION DL	3	PA
JYNNEOS (PF) 0.5X TO 3.95X 10EXP8 UNIT/0.5 SUSPENSION \$0,DL	1	
KEDRAB (PF) 150 UNIT/ML SOLUTION DL	4	BvsD
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML PEN INJECTOR DL	4	PA,QL(2.28 per 28 days)
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML SYRINGE DL	4	PA,QL(2.28 per 28 days)
KINERET 100 MG/0.67 ML SYRINGE DL	4	PA,QL(20.1 per 30 days)
KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML SYRINGE DL	1	
leflunomide 10 mg, 20 mg TABLET MO	1	QL(30 per 30 days)
LITFULO 50 MG CAPSULE DL	4	PA,QL(28 per 28 days)
LUPKYNIS 7.9 MG CAPSULE DL	4	PA,QL(180 per 30 days)
M-M-R II (PF) 1,000-12,500 TCID50/0.5 ML RECON SOLUTION \$0,DL	1	
MENACTRA (PF) 4 MCG/0.5 ML SOLUTION \$0,DL	1	
MENQUADFI (PF) 10 MCG/0.5 ML SOLUTION \$0,DL	1	
MENVEO A-C-Y-W-135-DIP (PF) 10-5 MCG/0.5 ML KIT \$0,DL	1	
MENVEO A-C-Y-W-135-DIP (PF) 10-5 MCG/0.5 ML SOLUTION \$0,DL	1	
methotrexate sodium 2.5 mg TABLET MO	1	BvsD
methotrexate sodium 25 mg/ml SOLUTION MO	1	
methotrexate sodium (pf) 1 gram RECON SOLUTION MO	1	
methotrexate sodium (pf) 25 mg/ml SOLUTION MO	1	
MONJUVI 200 MG RECON SOLUTION DL	4	PA
MRESVIA (PF) 50 MCG/0.5 ML SYRINGE \$0,DL	1	
mycophenolate mofetil 200 mg/ml SUSPENSION FOR RECONSTITUTION MO	1	BvsD
mycophenolate mofetil 250 mg CAPSULE MO	1	BvsD
mycophenolate mofetil 500 mg TABLET MO	1	BvsD
mycophenolate mofetil (hcl) 500 mg RECON SOLUTION MO	1	BvsD
mycophenolate sodium 180 mg, 360 mg TABLET, DR/EC MO	1	BvsD
MYFORTIC 180 MG TABLET, DR/EC MO	3	BvsD
MYFORTIC 360 MG TABLET, DR/EC	4	BvsD
MYHIBBIN 200 MG/ML SUSPENSION DL	4	BvsD
NEMLUVIO 30 MG PEN INJECTOR DL	4	PA,QL(2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NEORAL 100 MG, 25 MG CAPSULE MO	3	BvsD
NEORAL 100 MG/ML SOLUTION MO	3	BvsD
OCTAGAM 10 %, 5 % SOLUTION DL	4	PA
OLUMIANT 1 MG, 2 MG, 4 MG TABLET DL	4	PA,QL(30 per 30 days)
OMVOH 100 MG/ML SYRINGE DL	4	PA,QL(2 per 28 days)
OMVOH 300 MG/15 ML (20 MG/ML) SOLUTION DL	4	PA
OMVOH PEN 100 MG/ML PEN INJECTOR DL	4	PA,QL(2 per 28 days)
ORENCIA 125 MG/ML SYRINGE DL	4	PA,QL(4 per 28 days)
ORENCIA 50 MG/0.4 ML SYRINGE DL	4	PA,QL(1.6 per 28 days)
ORENCIA 87.5 MG/0.7 ML SYRINGE DL	4	PA,QL(2.8 per 28 days)
ORENCIA CLICKJECT 125 MG/ML AUTO-INJECTOR DL	4	PA,QL(4 per 28 days)
ORLADEYO 110 MG, 150 MG CAPSULE DL	4	PA,QL(28 per 28 days)
OTREXUP (PF) 10 MG/0.4 ML, 12.5 MG/0.4 ML, 15 MG/0.4 ML, 17.5 MG/0.4 ML, 20 MG/0.4 ML, 22.5 MG/0.4 ML, 25 MG/0.4 ML AUTO-INJECTOR MO	3	PA,QL(1.6 per 28 days)
PANZYGA 10 % SOLUTION DL	4	PA
PEDIARIX (PF) 10 MCG-25LF-25 MCG-10LF/0.5 ML SYRINGE DL	1	
PEDVAX HIB (PF) 7.5 MCG/0.5 ML SOLUTION DL	1	
PEGASYS 180 MCG/0.5 ML SYRINGE DL	4	PA,QL(2 per 28 days)
PEGASYS 180 MCG/ML SOLUTION DL	4	PA,QL(4 per 28 days)
PENBRAYA (PF) 5-120 MCG/0.5 ML KIT \$0,DL	1	
PENTACEL (PF) 15 LF UNIT-20 MCG-5 LF/0.5 ML, 15LF-48MCG-62DU -10 MCG/0.5ML KIT DL	1	
PIASKY 340 MG/2 ML SOLUTION DL	4	PA
PREHEVBRIO (PF) 10 MCG/ML SUSPENSION \$0,DL	1	BvsD
PRIORIX (PF) 10EXP3.4-4.2- 3.3CCID50/0.5ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
PRIVIGEN 10 % SOLUTION DL	4	PA
PROGRAF 0.2 MG, 1 MG GRANULES IN PACKET MO	3	BvsD
PROGRAF 0.5 MG, 1 MG, 5 MG CAPSULE MO	3	BvsD
PROQUAD (PF) 10EXP3-4.3-3- 3.99 TCID50/0.5 SUSPENSION FOR RECONSTITUTION DL	1	
QUADRACEL (PF) 15 LF-48 MCG- 5 LF UNIT/0.5ML SUSPENSION DL	1	
QUADRACEL (PF) 15 LF-48 MCG- 5 LF UNIT/0.5ML SYRINGE DL	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RABAVERT (PF) 2.5 UNIT SUSPENSION FOR RECONSTITUTION \$0,DL	1	BvsD
RAPAMUNE 0.5 MG, 1 MG, 2 MG TABLET	4	BvsD
RAPAMUNE 1 MG/ML SOLUTION	4	BvsD
RASUVO (PF) 10 MG/0.2 ML AUTO-INJECTOR MO	3	PA,QL(0.8 per 28 days)
RASUVO (PF) 12.5 MG/0.25 ML AUTO-INJECTOR MO	3	PA,QL(1 per 28 days)
RASUVO (PF) 15 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(1.2 per 28 days)
RASUVO (PF) 17.5 MG/0.35 ML AUTO-INJECTOR MO	3	PA,QL(1.4 per 28 days)
RASUVO (PF) 20 MG/0.4 ML AUTO-INJECTOR MO	3	PA,QL(1.6 per 28 days)
RASUVO (PF) 22.5 MG/0.45 ML AUTO-INJECTOR MO	3	PA,QL(1.8 per 28 days)
RASUVO (PF) 25 MG/0.5 ML AUTO-INJECTOR MO	3	PA,QL(2 per 28 days)
RASUVO (PF) 30 MG/0.6 ML AUTO-INJECTOR MO	3	PA,QL(2.4 per 28 days)
RASUVO (PF) 7.5 MG/0.15 ML AUTO-INJECTOR MO	3	PA,QL(0.6 per 28 days)
RECOMBIVAX HB (PF) 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML SUSPENSION \$0,DL	1	BvsD
RECOMBIVAX HB (PF) 10 MCG/ML, 5 MCG/0.5 ML SYRINGE \$0,DL	1	BvsD
REDITREX (PF) 10 MG/0.4 ML SYRINGE MO	3	PA,QL(1.6 per 28 days)
REDITREX (PF) 12.5 MG/0.5 ML SYRINGE MO	3	PA,QL(2 per 28 days)
REDITREX (PF) 15 MG/0.6 ML SYRINGE MO	3	PA,QL(2.4 per 28 days)
REDITREX (PF) 17.5 MG/0.7 ML SYRINGE MO	3	PA,QL(2.8 per 28 days)
REDITREX (PF) 20 MG/0.8 ML SYRINGE MO	3	PA,QL(3.2 per 28 days)
REDITREX (PF) 22.5 MG/0.9 ML SYRINGE MO	3	PA,QL(3.6 per 28 days)
REDITREX (PF) 25 MG/ML SYRINGE MO	3	PA,QL(4 per 28 days)
REDITREX (PF) 7.5 MG/0.3 ML SYRINGE MO	3	PA,QL(1.2 per 28 days)
REMICADE 100 MG RECON SOLUTION DL	4	PA
RENFLXIS 100 MG RECON SOLUTION DL	4	PA
REZUROCK 200 MG TABLET DL	4	PA,QL(30 per 30 days)
RHOPHYLAC 1,500 UNIT (300 MCG)/2 ML SYRINGE MO	3	
RIDAURA 3 MG CAPSULE DL	4	PA
RINVOQ 15 MG, 30 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
RINVOQ 45 MG TABLET, ER 24 HR. DL	4	PA,QL(168 per 365 days)
RINVOQ LQ 1 MG/ML SOLUTION DL	4	PA,QL(360 per 30 days)
ROTARIX 10EXP6 CCID50 /1.5 ML SUSPENSION DL	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ROTARIX 10EXP6 CCID50/ML SUSPENSION FOR RECONSTITUTION DL	1	
ROTATEQ VACCINE 2 ML SOLUTION DL	1	
RUCONEST 2,100 UNIT RECON SOLUTION DL	4	PA,QL(8 per 28 days)
RYSTIGGO 140 MG/ML SOLUTION DL	4	PA
<i>sajazir 30 mg/3 ml SYRINGE</i> DL	4	PA,QL(18 per 30 days)
SANDIMMUNE 100 MG, 25 MG CAPSULE MO	3	BvsD
SANDIMMUNE 100 MG/ML SOLUTION MO	3	BvsD
SAPHNELO 300 MG/2 ML (150 MG/ML) SOLUTION DL	4	PA,QL(2 per 28 days)
SHINGRIX (PF) 50 MCG/0.5 ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
SILIQ 210 MG/1.5 ML SYRINGE DL	4	PA,QL(6 per 28 days)
SIMLANDI(CF) AUTOINJECTOR 40 MG/0.4 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
SIMPONI 100 MG/ML PEN INJECTOR DL	4	PA,QL(3 per 28 days)
SIMPONI 100 MG/ML SYRINGE DL	4	PA,QL(3 per 28 days)
SIMPONI 50 MG/0.5 ML PEN INJECTOR DL	4	PA,QL(0.5 per 30 days)
SIMPONI 50 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 30 days)
SIMPONI ARIA 12.5 MG/ML SOLUTION DL	4	PA,QL(20 per 28 days)
SIMULECT 10 MG, 20 MG RECON SOLUTION DL	4	BvsD
<i>sirolimus 0.5 mg, 1 mg, 2 mg TABLET</i> MO	1	BvsD
<i>sirolimus 1 mg/ml SOLUTION</i> MO	1	BvsD
SKYRIZI 150 MG/ML PEN INJECTOR	4	PA,QL(2 per 84 days)
SKYRIZI 150 MG/ML SYRINGE	4	PA,QL(2 per 84 days)
SKYRIZI 180 MG/1.2 ML (150 MG/ML) WEARABLE INJECTOR DL	4	PA,QL(8.4 per 365 days)
SKYRIZI 360 MG/2.4 ML (150 MG/ML) WEARABLE INJECTOR DL	4	PA,QL(16.8 per 365 days)
SKYRIZI 60 MG/ML SOLUTION DL	4	PA,QL(30 per 365 days)
SOLIRIS 300 MG/30 ML SOLUTION DL	4	PA
SOTYKTU 6 MG TABLET DL	4	PA,QL(30 per 30 days)
SPEVIGO 150 MG/ML SYRINGE DL	4	PA,QL(4 per 28 days)
SPEVIGO 60 MG/ML SOLUTION DL	4	PA,QL(30 per 84 days)
STELARA 130 MG/26 ML SOLUTION DL	4	PA,QL(104 per 30 days)
STELARA 45 MG/0.5 ML SOLUTION DL	4	PA,QL(1.5 per 84 days)
STELARA 45 MG/0.5 ML SYRINGE DL	4	PA,QL(1.5 per 84 days)
STELARA 90 MG/ML SYRINGE DL	4	PA,QL(3 per 84 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SYLVANT 100 MG, 400 MG RECON SOLUTION DL	4	PA
<i>tacrolimus</i> 0.5 mg, 1 mg, 5 mg CAPSULE MO	1	BvsD
<i>tacrolimus</i> 0.5 mg, 1 mg, 5 mg CAPSULE, ER 24 HR. MO	1	BvsD
TAKHZYRO 150 MG/ML SYRINGE DL	4	PA,QL(2 per 28 days)
TAKHZYRO 300 MG/2 ML (150 MG/ML) SOLUTION DL	4	PA,QL(4 per 28 days)
TAKHZYRO 300 MG/2 ML (150 MG/ML) SYRINGE DL	4	PA,QL(4 per 28 days)
TALTZ AUTOINJECTOR 80 MG/ML AUTO-INJECTOR DL	4	PA,QL(4 per 28 days)
TALTZ AUTOINJECTOR (2 PACK) 80 MG/ML AUTO-INJECTOR DL	4	PA,QL(4 per 28 days)
TALTZ AUTOINJECTOR (3 PACK) 80 MG/ML AUTO-INJECTOR DL	4	PA,QL(4 per 28 days)
TALTZ SYRINGE 20 MG/0.25 ML SYRINGE DL	4	PA,QL(0.25 per 28 days)
TALTZ SYRINGE 40 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 28 days)
TALTZ SYRINGE 80 MG/ML SYRINGE DL	4	PA,QL(4 per 28 days)
TAVNEOS 10 MG CAPSULE DL	4	PA,QL(180 per 30 days)
TDVAX 2-2 LF UNIT/0.5 ML SUSPENSION \$0,DL	1	
TENIVAC (PF) 5 LF UNIT- 2 LF UNIT/0.5ML SUSPENSION \$0,DL	1	
TENIVAC (PF) 5-2 LF UNIT/0.5 ML SYRINGE \$0,DL	1	
TETANUS,DIPHThERIA TOX PED(PF) 5-25 LF UNIT/0.5 ML SUSPENSION DL	1	
TEZSPIRE 210 MG/1.91 ML (110 MG/ML) PEN INJECTOR DL	4	PA,QL(1.91 per 28 days)
TEZSPIRE 210 MG/1.91 ML (110 MG/ML) SYRINGE DL	4	PA,QL(1.91 per 28 days)
THYMOGLOBULIN 25 MG RECON SOLUTION MO	3	PA
TICOVAC 1.2 MCG/0.25 ML, 2.4 MCG/0.5 ML SYRINGE \$0,DL	1	
TREMFYA 100 MG/ML AUTO-INJECTOR	4	PA,QL(3 per 84 days)
TREMFYA 100 MG/ML SYRINGE	4	PA,QL(3 per 84 days)
TREXALL 10 MG, 15 MG, 5 MG, 7.5 MG TABLET MO	1	BvsD
TRUMENBA 120 MCG/0.5 ML SYRINGE \$0,DL	1	
TWINRIX (PF) 720 ELISA UNIT- 20 MCG/ML SYRINGE \$0,DL	1	
TYENNE 162 MG/0.9 ML SYRINGE DL	4	PA,QL(3.6 per 28 days)
TYENNE AUTOINJECTOR 162 MG/0.9 ML PEN INJECTOR DL	4	PA,QL(3.6 per 28 days)
TYPHIM VI 25 MCG/0.5 ML SOLUTION \$0,DL	1	
TYPHIM VI 25 MCG/0.5 ML SYRINGE \$0,DL	1	
ULTOMIRIS 100 MG/ML SOLUTION	4	PA
UPLIZNA 10 MG/ML SOLUTION DL	4	PA,QL(120 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VAQTA (PF) 25 UNIT/0.5 ML SUSPENSION DL	1	
VAQTA (PF) 25 UNIT/0.5 ML SYRINGE DL	1	
VAQTA (PF) 50 UNIT/ML SUSPENSION \$0,DL	1	
VAQTA (PF) 50 UNIT/ML SYRINGE \$0,DL	1	
VARIVAX (PF) 1,350 UNIT/0.5 ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
VARIZIG 125 UNIT/1.2 ML SOLUTION DL	4	PA,QL(12 per 30 days)
VELSIPIITY 2 MG TABLET DL	4	PA,QL(30 per 30 days)
VEOPOZ 200 MG/ML SOLUTION DL	4	PA
VOYDEYA 100 MG, 150 MG (50 MG X 1-100 MG X 1) TABLET DL	4	PA,QL(180 per 30 days)
XATMEP 2.5 MG/ML SOLUTION MO	3	PA
XELJANZ 1 MG/ML SOLUTION DL	4	PA,QL(300 per 30 days)
XELJANZ 10 MG, 5 MG TABLET DL	4	PA,QL(60 per 30 days)
XELJANZ XR 11 MG, 22 MG TABLET, ER 24 HR. DL	4	PA,QL(30 per 30 days)
XEMBIFY 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SOLUTION DL	4	PA
XOLAIR 150 MG RECON SOLUTION DL	4	PA,QL(8 per 28 days)
XOLAIR 150 MG/ML, 300 MG/2 ML AUTO-INJECTOR DL,LA	4	PA,QL(8 per 28 days)
XOLAIR 150 MG/ML, 300 MG/2 ML SYRINGE DL,LA	4	PA,QL(8 per 28 days)
XOLAIR 75 MG/0.5 ML AUTO-INJECTOR DL,LA	4	PA,QL(4 per 28 days)
XOLAIR 75 MG/0.5 ML SYRINGE DL,LA	4	PA,QL(4 per 28 days)
YF-VAX (PF) 10 EXP4.74 UNIT/0.5 ML SUSPENSION FOR RECONSTITUTION \$0,DL	1	
YUFLYMA(CF) 20 MG/0.2 ML, 40 MG/0.4 ML SYRINGE KIT DL	4	PA,QL(6 per 28 days)
YUFLYMA(CF) AI CROHN'S-UC-HS 80 MG/0.8 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
YUFLYMA(CF) AUTOINJECTOR 40 MG/0.4 ML, 80 MG/0.8 ML AUTO-INJECTOR, KIT DL	4	PA,QL(6 per 28 days)
YUSIMRY(CF) PEN 40 MG/0.8 ML PEN INJECTOR DL	4	PA,QL(4.8 per 28 days)
ZILBRYSQ 16.6 MG/0.416 ML, 23 MG/0.574 ML, 32.4 MG/0.81 ML SYRINGE DL	4	PA
ZORTRESS 0.25 MG, 0.75 MG, 1 MG TABLET	4	BvsD,QL(60 per 30 days)
ZORTRESS 0.5 MG TABLET	4	BvsD,QL(120 per 30 days)
ZYMFENTRA 120 MG/ML PEN INJECTOR KIT DL	4	PA,QL(2 per 28 days)
ZYMFENTRA 120 MG/ML SYRINGE KIT DL	4	PA,QL(2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INFLAMMATORY BOWEL DISEASE AGENTS		
APRISO 0.375 GRAM CAPSULE, ER 24 HR. MO	3	ST,QL(120 per 30 days)
ASACOL HD 800 MG TABLET, DR/EC MO	3	ST,QL(180 per 30 days)
AZULFIDINE 500 MG TABLET MO	3	
AZULFIDINE EN-TABS 500 MG TABLET, DR/EC MO	3	
<i>balsalazide 750 mg CAPSULE MO</i>	1	
<i>budesonide 2 mg/actuation FOAM MO</i>	1	PA
<i>budesonide 3 mg CAPSULE, DR/EC MO</i>	1	
<i>budesonide 9 mg TABLET, DR/ER</i>	4	PA,QL(30 per 30 days)
CANASA 1,000 MG SUPPOSITORY	4	ST,QL(30 per 30 days)
COLAZAL 750 MG CAPSULE	4	PA
CORTENEMA 100 MG/60 ML ENEMA MO	3	
CORTIFOAM 10 % (80 MG) FOAM MO	3	
DELZICOL 400 MG CAPSULE (WITH DR TABLETS) MO	3	ST,QL(180 per 30 days)
DIPENTUM 250 MG CAPSULE	4	ST,QL(120 per 30 days)
<i>hydrocortisone 100 mg/60 ml ENEMA MO</i>	1	
LIALDA 1.2 GRAM TABLET, DR/EC MO	3	ST,QL(120 per 30 days)
<i>mesalamine 0.375 gram CAPSULE, ER 24 HR. MO</i>	1	QL(120 per 30 days)
<i>mesalamine 1,000 mg SUPPOSITORY MO</i>	1	ST,QL(30 per 30 days)
<i>mesalamine 1.2 gram TABLET, DR/EC MO</i>	1	ST,QL(120 per 30 days)
<i>mesalamine 4 gram/60 ml ENEMA MO</i>	1	QL(1800 per 30 days)
<i>mesalamine 400 mg CAPSULE (WITH DR TABLETS) MO</i>	1	ST,QL(180 per 30 days)
<i>mesalamine 500 mg CAPSULE, ER MO</i>	1	ST,QL(300 per 30 days)
<i>mesalamine 800 mg TABLET, DR/EC MO</i>	1	ST,QL(180 per 30 days)
ORTIKOS 6 MG, 9 MG CAPSULE, ER DL	4	PA,QL(30 per 30 days)
PENTASA 250 MG CAPSULE, ER MO	3	ST,QL(150 per 30 days)
PENTASA 500 MG CAPSULE, ER	4	ST,QL(300 per 30 days)
PROCTOFOAM HC 1-1 % FOAM MO	1	
ROWASA 4 GRAM/60 ML ENEMA MO	3	QL(1800 per 30 days)
SFROWASA 4 GRAM/60 ML ENEMA MO	3	QL(1800 per 30 days)
<i>sulfasalazine 500 mg TABLET MO</i>	1	
<i>sulfasalazine 500 mg TABLET, DR/EC MO</i>	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TARPEYO 4 MG CAPSULE, DR/EC DL	4	PA,QL(120 per 30 days)
UCERIS 2 MG/ACTUATION FOAM MO	3	PA
UCERIS 9 MG TABLET, DR/ER MO	3	PA,QL(30 per 30 days)
METABOLIC BONE DISEASE AGENTS		
ACTONEL 150 MG TABLET MO	3	PA,QL(1 per 30 days)
ACTONEL 35 MG TABLET MO	3	PA,QL(4 per 28 days)
<i>alendronate 10 mg, 5 mg TABLET MO</i>	1	QL(30 per 30 days)
<i>alendronate 35 mg TABLET MO</i>	1	QL(4 per 28 days)
<i>alendronate 70 mg TABLET MO</i>	1	QL(4 per 28 days)
<i>alendronate 70 mg/75 ml SOLUTION MO</i>	1	QL(300 per 28 days)
AELVIA 35 MG TABLET, DR/EC MO	3	PA,QL(4 per 28 days)
BINOSTO 70 MG TABLET, EFFERVESCENT MO	3	ST,QL(4 per 28 days)
BONIVA 150 MG TABLET MO	3	PA,QL(1 per 28 days)
<i>calcitonin (salmon) 200 unit/actuation SPRAY, NON-AEROSOL MO</i>	1	QL(3.7 per 28 days)
<i>calcitonin (salmon) 200 unit/ml SOLUTION DL</i>	4	
<i>calcitriol 0.25 mcg, 0.5 mcg CAPSULE MO</i>	1	
<i>calcitriol 1 mcg/ml SOLUTION MO</i>	1	
<i>cinacalcet 30 mg, 60 mg TABLET MO</i>	1	QL(60 per 30 days)
<i>cinacalcet 90 mg TABLET MO</i>	1	QL(120 per 30 days)
<i>doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg CAPSULE MO</i>	1	
<i>doxercalciferol 4 mcg/2 ml SOLUTION MO</i>	1	
EVENITY 105 MG/1.17 ML, 210MG/2.34ML (105MG/1.17MLX2) SYRINGE DL	4	PA,QL(2.34 per 30 days)
FORTEO 20 MCG/DOSE (600MCG/2.4ML) PEN INJECTOR DL	4	PA,QL(2.4 per 28 days)
FOSAMAX 70 MG TABLET MO	3	PA,QL(4 per 28 days)
FOSAMAX PLUS D 70 MG- 2,800 UNIT, 70 MG- 5,600 UNIT TABLET MO	3	ST,QL(4 per 28 days)
HECTOROL 4 MCG/2 ML SOLUTION MO	3	
<i>ibandronate 150 mg TABLET MO</i>	1	QL(1 per 28 days)
<i>ibandronate 3 mg/3 ml SOLUTION MO</i>	1	PA,QL(3 per 90 days)
<i>ibandronate 3 mg/3 ml SYRINGE MO</i>	1	PA,QL(3 per 90 days)
MIACALCIN 200 UNIT/ML SOLUTION DL	4	
NATPARA 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE CARTRIDGE DL,LA	4	PA,QL(2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>pamidronate 30 mg/10 ml (3 mg/ml) SOLUTION</i> MO	1	QL(30 per 21 days)
<i>pamidronate 60 mg/10 ml (6 mg/ml), 90 mg/10 ml (9 mg/ml) SOLUTION</i> MO	1	QL(10 per 21 days)
<i>paricalcitol 1 mcg, 2 mcg, 4 mcg CAPSULE</i> MO	1	
<i>paricalcitol 2 mcg/ml SOLUTION</i> MO	1	QL(24 per 30 days)
<i>paricalcitol 5 mcg/ml SOLUTION</i> MO	1	QL(48 per 28 days)
PROLIA 60 MG/ML SYRINGE MO	3	QL(1 per 180 days)
RAYALDEE 30 MCG CAPSULE, ER 24 HR. DL	4	QL(60 per 30 days)
RECLAST 5 MG/100 ML PIGGYBACK MO	3	PA,QL(100 per 365 days)
<i>risedronate 150 mg TABLET</i> MO	1	QL(1 per 30 days)
<i>risedronate 30 mg, 5 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>risedronate 35 mg TABLET</i> MO	1	QL(4 per 28 days)
<i>risedronate 35 mg TABLET, DR/EC</i> MO	1	QL(4 per 28 days)
ROCALTROL 0.25 MCG, 0.5 MCG CAPSULE MO	3	
ROCALTROL 1 MCG/ML SOLUTION MO	3	
SENSIPAR 30 MG TABLET MO	3	QL(60 per 30 days)
SENSIPAR 60 MG TABLET	4	QL(60 per 30 days)
SENSIPAR 90 MG TABLET	4	QL(120 per 30 days)
TYMLOS 80 MCG (3,120 MCG/1.56 ML) PEN INJECTOR DL	4	PA,QL(1.56 per 30 days)
XGEVA 120 MG/1.7 ML (70 MG/ML) SOLUTION DL	4	PA,QL(1.7 per 28 days)
ZEMPLAR 1 MCG, 2 MCG CAPSULE MO	3	
ZEMPLAR 2 MCG/ML SOLUTION DL	4	QL(24 per 30 days)
ZEMPLAR 5 MCG/ML SOLUTION DL	4	QL(48 per 28 days)
<i>zoledronic ac-mannitol-0.9nacl 4 mg/100 ml PIGGYBACK</i> MO	1	QL(300 per 21 days)
<i>zoledronic acid 4 mg RECON SOLUTION</i> MO	1	
<i>zoledronic acid 4 mg/5 ml SOLUTION</i> MO	1	QL(15 per 21 days)
<i>zoledronic acid-mannitol-water 4 mg/100 ml PIGGYBACK</i> MO	1	QL(300 per 21 days)
<i>zoledronic acid-mannitol-water 5 mg/100 ml PIGGYBACK</i> MO	1	PA,QL(100 per 365 days)
MISCELLANEOUS THERAPEUTIC AGENTS		
ACETADOTE 200 MG/ML (20 %) SOLUTION MO	3	
acetaminophen 1,000 mg/100 ml (10 mg/ml), 500 mg/50 ml (10 mg/ml) SOLUTION MO	1	
acetic acid 0.25 % SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
acetylcysteine 200 mg/ml (20 %) SOLUTION MO	1	
ADAKVEO 10 MG/ML SOLUTION DL	4	PA
ADSTILADRIN 3X10EXP11 VP/ML SUSPENSION	4	PA
ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
ALCOHOL SWABS PADS, MEDICATED \$0,MO	1	
ALCOHOL WIPES PADS, MEDICATED \$0,MO	1	
ALLZITAL 25-325 MG TABLET MO	1	QL(360 per 30 days)
AMMONUL 10-10 % SOLUTION DL	4	
AUTOJECT 2 INJECTION DEVICE INSULIN PEN \$0,MO	1	
AUTOPEN 1 TO 21 UNITS INSULIN PEN \$0,MO	1	
AUTOPEN 2 TO 42 UNITS INSULIN PEN \$0,MO	1	
BAND-AID GAUZE PADS 2 X 2 " BANDAGE \$0,MO	1	
BD ALCOHOL SWABS PADS, MEDICATED \$0,MO	1	
BD AUTOSHIELD DUO PEN NEEDLE 30 GAUGE X 3/16" NEEDLE \$0,PDS,MO	1	
BD ECLIPSE LUER-LOK 1 ML 30 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE (HALF UNIT) 0.3 ML 31 GAUGE X 5/16" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE MICRO-FINE 1 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE U-500 1/2 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16 SYRINGE \$0,PDS,MO	1	
BD LO-DOSE MICRO-FINE IV 1/2 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
BD NANO 2ND GEN PEN NEEDLE 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
BD SAFETYGLIDE INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 1 ML 29 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BD SAFETYGLIDE SYRINGE 1 ML 27 GAUGE X 5/8" SYRINGE \$0,PDS,MO	1	
BD ULTRA-FINE MICRO PEN NEEDLE 32 GAUGE X 1/4" NEEDLE \$0,PDS,MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BD ULTRA-FINE MINI PEN NEEDLE 31 GAUGE X 3/16" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE NANO PEN NEEDLE 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE ORIG PEN NEEDLE 29 GAUGE X 1/2" NEEDLE \$0,PDS,MO	1	
BD ULTRA-FINE SHORT PEN NEEDLE 31 GAUGE X 5/16" NEEDLE \$0,PDS,MO	1	
BD VEO INSULIN SYR (HALF UNIT) 0.3 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BD VEO INSULIN SYRINGE UF 0.3 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 15/64", 1/2 ML 31 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
BEYFORTUS 100 MG/ML, 50 MG/0.5 ML SYRINGE DL	4	
BORDERED GAUZE 2 X 2 " BANDAGE \$0,MO	1	
bupap 50-300 mg TABLET MO	1	QL(180 per 30 days)
butalbital-acetaminop-caf-cod 50-300-40-30 mg CAPSULE DL	1	QL(180 per 30 days)
butalbital-acetaminop-caf-cod 50-325-40-30 mg CAPSULE DL	1	QL(360 per 30 days)
butalbital-acetaminophen 50-300 mg CAPSULE MO	1	QL(180 per 30 days)
butalbital-acetaminophen 50-300 mg, 50-325 mg TABLET MO	1	QL(180 per 30 days)
butalbital-acetaminophen-caff 50-300-40 mg, 50-325-40 mg CAPSULE MO	1	QL(180 per 30 days)
butalbital-acetaminophen-caff 50-325-40 mg TABLET MO	1	QL(180 per 30 days)
butalbital-aspirin-caffeine 50-325-40 mg CAPSULE MO	1	QL(180 per 30 days)
butalbital-aspirin-caffeine 50-325-40 mg TABLET MO	1	QL(180 per 30 days)
BYLVAY 1,200 MCG CAPSULE DL	4	PA,QL(150 per 30 days)
BYLVAY 200 MCG PELLETT DL	4	PA,QL(360 per 30 days)
BYLVAY 400 MCG CAPSULE DL	4	PA,QL(420 per 30 days)
BYLVAY 600 MCG PELLETT DL	4	PA,QL(120 per 30 days)
CAFCIT 60 MG/3 ML (20 MG/ML) SOLUTION MO	3	
caffeine citrate 60 mg/3 ml (20 mg/ml) SOLUTION MO	1	
calcium disodium versenate 200 mg/ml SOLUTION MO	1	
CARETOUCH ALCOHOL PREP PAD PADS, MEDICATED \$0,MO	1	
CEQUR SIMPLICITY 2 UNIT DEVICE \$0,MO	2	
CEQUR SIMPLICITY INSERTER MISCELLANEOUS MO	2	
CERVIDIL 10 MG INSERT, ER MO	3	
CLARINEX-D 12 HOUR 2.5-120 MG TABLET, ER 12 HR., MULTIPHASE MO	3	ST,QL(60 per 30 days)
COMBOGESIC IV 300-1,000 MG/100 ML SOLUTION MO	3	
CURITY ALCOHOL SWABS PADS, MEDICATED \$0,MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CURITY GAUZE 2 X 2 " BANDAGE \$0,MO	1	
DEFITELIO 80 MG/ML SOLUTION DL	4	PA
DERMACEA 2 X 2 " BANDAGE \$0,MO	1	
DROPLET INSULIN SYR(HALF UNIT) 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 0.5 ML 31 GAUGE X 5/16", 0.5ML 30 GAUGE X 15/64" SYRINGE \$0,PDS,MO	1	
DROPLET INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 15/64", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 15/64", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16 SYRINGE \$0,PDS,MO	1	
DROPLET MICRON PEN NEEDLE 34 GAUGE X 9/64" NEEDLE \$0,PDS,MO	1	
DROPLET PEN NEEDLE 29 GAUGE X 1/2", 29 GAUGE X 3/8", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
DROPSAFE ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
DROPSAFE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16" NEEDLE \$0,PDS,MO	1	
DROXIA 200 MG, 300 MG, 400 MG CAPSULE MO	3	
EASY COMFORT ALCOHOL PAD PADS, MEDICATED \$0,MO	1	
EASY TOUCH ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
edetate calcium disodium 200 mg/ml SOLUTION DL	4	
ELYXYB 120 MG/4.8 ML (25 MG/ML) SOLUTION DL	4	ST,QL(43.2 per 30 days)
EMPAVELI 1,080 MG/20 ML SOLUTION DL	4	PA,QL(160 per 28 days)
EOHILIA 2 MG/10 ML SUSPENSION IN PACKET DL	4	PA
ESGIC 50-325-40 MG CAPSULE MO	1	QL(180 per 30 days)
ESGIC 50-325-40 MG TABLET MO	1	QL(180 per 30 days)
FILSPARI 200 MG, 400 MG TABLET DL	4	PA,QL(30 per 30 days)
FILSUVEZ 10 % GEL DL	4	PA
fioricet 50-300-40 mg CAPSULE MO	1	QL(180 per 30 days)
FIORICET WITH CODEINE 50-300-40-30 MG CAPSULE DL	3	QL(180 per 30 days)
flumazenil 0.1 mg/ml SOLUTION MO	1	
fomepizole 1 gram/ml SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GAUZE BANDAGE 2 X 2 " BANDAGE \$0,MO	1	
GAUZE PAD 2 X 2 " BANDAGE \$0,MO	1	
GIVLAARI 189 MG/ML SOLUTION DL	4	PA
IGALMI 120 MCG, 180 MCG FILM MO	3	PA
INCONTROL ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
INSULIN SYRINGE 0.5 ML 29 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
INSULIN SYRINGE MICROFINE 1 ML 27 GAUGE X 5/8", 1/2 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
INSULIN SYRINGE-NEEDLE U-100 1 ML 28 GAUGE X 1/2" SYRINGE \$0,PDS,MO	1	
IV PREP WIPES PADS, MEDICATED \$0,MO	1	
KORLYM 300 MG TABLET DL	4	PA,QL(120 per 30 days)
<i>lactated ringers</i> SOLUTION MO	1	
LITHOSTAT 250 MG TABLET MO	3	
<i>methylergonovine 0.2 mg</i> TABLET DL	4	
<i>methylergonovine 0.2 mg/ml (1 ml)</i> SOLUTION MO	1	
<i>mifepristone 300 mg</i> TABLET DL	4	PA,QL(120 per 30 days)
MIRENA 21 MCG/24 HR (8 YRS) 52 MG IUD MO	2	
<i>neomycin-polymyxin b gu</i> 40 mg-200,000 unit/ml SOLUTION MO	1	
<i>nitroglycerin 0.4 % (w/w)</i> OINTMENT MO	1	QL(30 per 30 days)
NOVOPEN ECHO INSULIN PEN \$0,MO	1	
OMNIPOD 5 G6 INTRO KIT (GEN 5) CARTRIDGE \$0,MO	2	
OMNIPOD 5 G6 PODS (GEN 5) CARTRIDGE \$0,MO	2	
OMNIPOD 5 G6-G7 INTRO KT(GEN5) CARTRIDGE \$0,MO	2	
OMNIPOD 5 G6-G7 PODS (GEN 5) CARTRIDGE \$0,MO	2	
OMNIPOD CLASSIC PODS (GEN 3) CARTRIDGE \$0,MO	2	
OMNIPOD DASH INTRO KIT (GEN 4) CARTRIDGE \$0,MO	2	
OMNIPOD DASH PODS (GEN 4) CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 10 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 15 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 20 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 25 UNITS/DAY CARTRIDGE \$0,MO	2	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OMNIPOD GO PODS 30 UNITS/DAY CARTRIDGE \$0,MO	2	
OMNIPOD GO PODS 40 UNITS/DAY CARTRIDGE \$0,MO	2	
orlistat 120 mg CAPSULE MO	3	PA
OXLUMO 94.5 MG/0.5 ML SOLUTION	4	PA
oxytocin 10 unit/ml SOLUTION MO	1	
PALFORZIA (LEVEL 1) 3 MG (1 MG X 3) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 2) 6 MG (1 MG X 6) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 3) 12 MG (1 MG X 2, 10 MG X 1) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 4) 20 MG CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 5) 40 MG (20 MG X 2) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 6) 80 MG (20 MG X 4) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 7) 120 MG (20 MG X 1, 100 MG X 1) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 8) 160 MG (20 MG X 3, 100 MG X1) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 9) 200 MG (100 MG X 2) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 10) 240 MG (20 MG X 2, 100 MG X 2) CAPSULE, SPRINKLE MO	3	PA
PALFORZIA (LEVEL 11 UP-DOSE) 300 MG POWDER IN PACKET MO	3	PA
PALFORZIA INITIAL DOSE 0.5/1/1.5/3/6 MG CAPSULE, SPRINKLE MO	3	PA
PALFORZIA LEVEL 11 MAINTENANCE 300 MG POWDER IN PACKET MO	3	PA
PEN NEEDLE, DIABETIC 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE \$0,PDS,MO	1	
phenazopyridine 100 mg, 200 mg TABLET MO	1	
PHEXXI 1.8-1-0.4 % GEL MO	3	QL(60 per 30 days)
PHYSIOLYTE 140-5-3-98 MEQ/L SOLUTION MO	1	
PHYSIOSOL IRRIGATION 140-5-3-98 MEQ/L SOLUTION MO	1	
PITOCIN 10 UNIT/ML SOLUTION MO	3	
PREVDUO 0.6 MG-3 MG/3ML (0.2 MG-1MG/ML) SYRINGE MO	3	
PRIALT 100 MCG/ML, 25 MCG/ML SOLUTION DL	4	PA
PRO COMFORT ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
promethazine vc 6.25-5 mg/5 ml SYRUP MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>promethazine-phenylephrine 6.25-5 mg/5 ml SYRUP</i> MO	1	
<i>protamine 10 mg/ml SOLUTION</i> MO	1	
PURE COMFORT ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
PYRIDIUM 100 MG, 200 MG TABLET MO	3	
QUTENZA 8 % KIT DL	4	PA
RECTIV 0.4 % (W/W) OINTMENT MO	3	QL(30 per 30 days)
RENACIDIN 1980.6 MG-59.4 MG-980.4MG/30ML SOLUTION MO	3	
REZDIFFRA 100 MG, 60 MG, 80 MG TABLET DL	4	PA,QL(30 per 30 days)
<i>ribavirin 6 gram RECON SOLUTION</i> DL	4	BvsD
RIMSO-50 50 % SOLUTION DL	4	
<i>ringer's SOLUTION</i> MO	1	
RIVFLOZA 128 MG/0.8 ML, 160 MG/ML SYRINGE DL	4	PA
RIVFLOZA 80 MG/0.5 ML (160 MG/ML) SOLUTION DL	4	PA
SIKLOS 1,000 MG, 100 MG TABLET MO	3	PA
<i>sodium benzoate-sod phenylacet 10-10 % SOLUTION</i> DL	4	
<i>sodium chloride 0.9 % SOLUTION</i> MO	1	
SOHONOS 1 MG, 1.5 MG, 10 MG, 2.5 MG, 5 MG CAPSULE DL	4	PA
SURE COMFORT ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
SURE-PREP ALCOHOL PREP PADS PADS, MEDICATED \$0,MO	1	
SYNAGIS 100 MG/ML, 50 MG/0.5 ML SOLUTION DL	4	PA
<i>tencon 50-325 mg TABLET</i> MO	1	QL(180 per 30 days)
TEPEZZA 500 MG RECON SOLUTION DL	4	PA
TRUE COMFORT ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
TRUE COMFORT PRO ALCOHOL PADS PADS, MEDICATED \$0,MO	1	
ULTILET ALCOHOL SWAB PADS, MEDICATED \$0,MO	1	
V-GO 20 DEVICE \$0,MO	3	PA
V-GO 30 DEVICE \$0,MO	3	PA
V-GO 40 DEVICE \$0,MO	3	PA
VIRAZOLE 6 GRAM RECON SOLUTION DL	4	BvsD
<i>vtol lq 50-325-40 mg/15 ml SOLUTION</i> DL	4	QL(450 per 30 days)
VYJUVEK 5 X 10EXP9 PFU/2.5 ML GEL DL	4	PA,QL(10 per 28 days)
<i>water for irrigation, sterile SOLUTION</i> MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
WEBCOL PADS, MEDICATED \$0,MO	1	
WEGOVY 0.25 MG/0.5 ML, 0.5 MG/0.5 ML, 1 MG/0.5 ML, 1.7 MG/0.75 ML, 2.4 MG/0.75 ML PEN INJECTOR DL	4	PA
XDEMVI 0.25 % DROPS MO	3	PA,QL(10 per 42 days)
XENICAL 120 MG CAPSULE MO	3	PA
YCANTH 0.7 % SOLUTION W/APPLICATOR DL	4	PA
ZEBUTAL 50-325-40 MG CAPSULE MO	1	QL(180 per 30 days)
ZEVALIN (Y-90) 3.2 MG/2 ML KIT DL	4	PA
zingiber 1.2 mg-40 mg- 124.1 mg-100 mg TABLET MO	1	
ZYNRELF 200 MG-6 MG /7 ML, 400 MG-12 MG /14 ML ER SOLUTION MO	3	
OPHTHALMIC AGENTS		
ACULAR 0.5 % DROPS MO	3	ST,QL(10 per 30 days)
ACULAR LS 0.4 % DROPS MO	3	ST,QL(10 per 30 days)
ACUVAIL (PF) 0.45 % DROPPERETTE MO	3	ST
ak-poly-bac 500-10,000 unit/gram OINTMENT MO	1	
ALCAINE 0.5 % DROPS MO	1	
ALOCRI 2 % DROPS MO	3	
ALOMIDE 0.1 % DROPS MO	3	
ALPHAGAN P 0.1 %, 0.15 % DROPS MO	3	ST
ALREX 0.2 % DROPS, SUSPENSION MO	3	ST
apraclonidine 0.5 % DROPS MO	1	
atropine 1 % DROPS MO	1	
ATROPINE SULFATE (PF) 1 % DROPPERETTE MO	1	
AZASITE 1 % DROPS MO	3	ST,QL(2.5 per 25 days)
azelastine 0.05 % DROPS MO	1	
AZOPT 1 % DROPS, SUSPENSION MO	3	ST,QL(10 per 28 days)
bacitracin 500 unit/gram OINTMENT MO	1	
bacitracin-polymyxin b 500-10,000 unit/gram OINTMENT MO	1	
balanced salt SOLUTION MO	1	
bepotastine besilate 1.5 % DROPS MO	1	ST,QL(5 per 25 days)
BEPREVE 1.5 % DROPS MO	3	ST,QL(5 per 25 days)
BESIVANCE 0.6 % DROPS, SUSPENSION MO	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BETADINE OPHTHALMIC PREP 5 % SOLUTION MO	3	
<i>betaxolol 0.5 % DROPS</i> MO	1	
BETIMOL 0.25 %, 0.5 % DROPS MO	3	ST
BETOPTIC S 0.25 % DROPS, SUSPENSION MO	3	ST
<i>bimatoprost 0.03 % DROPS</i> MO	1	QL(2.5 per 25 days)
<i>brimonidine 0.1 %, 0.15 % DROPS</i> MO	1	ST
<i>brimonidine 0.2 % DROPS</i> MO	1	
<i>brinzolamide 1 % DROPS, SUSPENSION</i> MO	1	ST,QL(10 per 28 days)
<i>bromfenac 0.07 % DROPS</i> MO	1	ST,QL(3 per 30 days)
<i>bromfenac 0.075 % DROPS</i> MO	1	ST,QL(5 per 30 days)
<i>bromfenac 0.09 % DROPS</i> MO	1	QL(1.7 per 30 days)
BROMSITE 0.075 % DROPS MO	3	ST,QL(5 per 30 days)
BSS SOLUTION MO	3	
BSS PLUS SOLUTION MO	3	
<i>carteolol 1 % DROPS</i> MO	1	
CEQUA 0.09 % DROPPERETTE MO	3	PA,QL(60 per 30 days)
CILOXAN 0.3 % OINTMENT MO	3	
<i>ciprofloxacin hcl 0.3 % DROPS</i> MO	1	
COMBIGAN 0.2-0.5 % DROPS MO	2	QL(5 per 25 days)
COSOPT 22.3-6.8 MG/ML DROPS MO	3	ST
COSOPT (PF) 2-0.5 % DROPPERETTE MO	3	ST,QL(60 per 30 days)
<i>cromolyn 4 % DROPS</i> MO	1	
<i>cyclosporine 0.05 % DROPPERETTE</i> MO	1	QL(60 per 30 days)
CYSTADROPS 0.37 % DROPS DL	4	PA,QL(20 per 28 days)
CYSTARAN 0.44 % DROPS DL	4	PA,QL(60 per 28 days)
<i>dexamethasone sodium phosphate 0.1 % DROPS</i> MO	1	
DEXTENZA 0.4 MG INSERT MO	3	QL(1 per 30 days)
<i>diclofenac sodium 0.1 % DROPS</i> MO	1	
<i>difluprednate 0.05 % DROPS</i> MO	1	ST
<i>dorzolamide 2 % DROPS</i> MO	1	
<i>dorzolamide-timolol 22.3-6.8 mg/ml DROPS</i> MO	1	
<i>dorzolamide-timolol (pf) 2-0.5 % DROPPERETTE</i> MO	1	QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DUREZOL 0.05 % DROPS MO	3	ST
DURYSTA 10 MCG IMPLANT DL	4	PA
ENSPRYNG 120 MG/ML SYRINGE DL	4	PA,QL(2 per 28 days)
<i>epinastine 0.05 % DROPS</i> MO	1	ST,QL(5 per 25 days)
<i>erythromycin 5 mg/gram (0.5 %) OINTMENT</i> MO	1	QL(3.5 per 28 days)
EYSUVIS 0.25 % DROPS, SUSPENSION MO	2	QL(16.6 per 30 days)
FLAREX 0.1 % DROPS, SUSPENSION MO	3	ST
<i>fluorometholone 0.1 % DROPS, SUSPENSION</i> MO	1	
<i>flurbiprofen sodium 0.03 % DROPS</i> MO	1	
FML FORTE 0.25 % DROPS, SUSPENSION MO	3	ST
FML LIQUIFILM 0.1 % DROPS, SUSPENSION MO	3	ST
<i>gatifloxacin 0.5 % DROPS</i> MO	1	QL(2.5 per 25 days)
<i>gentak 0.3 % (3 mg/gram) OINTMENT</i> MO	1	
<i>gentamicin 0.3 % DROPS</i> MO	1	
ILEVRO 0.3 % DROPS, SUSPENSION MO	2	QL(3 per 30 days)
INVELTYS 1 % DROPS, SUSPENSION MO	3	ST
IOPIDINE 1 % DROPPERETTE MO	3	
ISTALOL 0.5 % DROPS, ONCE DAILY MO	3	
IYUZEH (PF) 0.005 % DROPPERETTE MO	3	ST,QL(30 per 30 days)
<i>ketorolac 0.4 %, 0.5 % DROPS</i> MO	1	QL(10 per 30 days)
LACRISERT 5 MG INSERT MO	3	
<i>latanoprost 0.005 % DROPS</i> MO	1	QL(5 per 25 days)
<i>levobunolol 0.5 % DROPS</i> MO	1	
<i>levofloxacin 0.5 %, 1.5 % DROPS</i> MO	1	
LOTEMAX 0.5 % DROPS, GEL MO	3	ST
LOTEMAX 0.5 % DROPS, SUSPENSION MO	3	ST
LOTEMAX 0.5 % OINTMENT MO	3	ST
LOTEMAX SM 0.38 % DROPS, GEL MO	3	
<i>loteprednol etabonate 0.2 %, 0.5 % DROPS, SUSPENSION</i> MO	1	ST
<i>loteprednol etabonate 0.5 % DROPS, GEL</i> MO	1	ST
LUMIGAN 0.01 % DROPS MO	2	QL(2.5 per 25 days)
MAXIDEX 0.1 % DROPS, SUSPENSION MO	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MAXITROL 3.5 MG/G-10,000 UNIT/G-0.1 % OINTMENT MO	3	
MAXITROL 3.5MG/ML-10,000 UNIT/ML-0.1 % DROPS, SUSPENSION MO	1	
methazolamide 25 mg, 50 mg TABLET MO	1	
MIEBO (PF) 100 % DROPS MO	3	PA,QL(3 per 30 days)
MIOSTAT 0.01 % SOLUTION MO	3	
moxifloxacin 0.5 % DROPS MO	1	
moxifloxacin 0.5 % DROPS, VISCOUS MO	1	ST
NATACYN 5 % DROPS, SUSPENSION MO	3	
neo-polycin 3.5-400-10,000 mg-unit-unit/g OINTMENT MO	1	
neo-polycin hc 3.5-400-10,000 mg-unit/g-1% OINTMENT MO	1	
neomycin-bacitracin-poly-hc 3.5-400-10,000 mg-unit/g-1% OINTMENT MO	1	
neomycin-bacitracin-polymyxin 3.5-400-10,000 mg-unit-unit/g OINTMENT MO	1	
neomycin-polymyxin b-dexameth 3.5 mg/g-10,000 unit/g-0.1 % OINTMENT MO	1	
neomycin-polymyxin b-dexameth 3.5mg/ml-10,000 unit/ml-0.1 % DROPS, SUSPENSION MO	1	
neomycin-polymyxin-gramicidin 1.75 mg-10,000 unit-0.025mg/ml DROPS MO	1	
neomycin-polymyxin-hc 3.5-10,000-10 mg-unit-mg/ml DROPS, SUSPENSION MO	1	
NEVANAC 0.1 % DROPS, SUSPENSION MO	3	ST
OCUFLOX 0.3 % DROPS MO	3	
ofloxacin 0.3 % DROPS MO	1	
olopatadine 0.1 %, 0.2 % DROPS MO	1	
OXERVATE 0.002 % DROPS DL	4	PA,QL(112 per 365 days)
PHOSPHOLINE IODIDE 0.125 % DROPS MO	3	
pilocarpine hcl 1 %, 2 %, 4 % DROPS MO	1	
polycin 500-10,000 unit/gram OINTMENT MO	1	
polymyxin b sulf-trimethoprim 10,000 unit- 1 mg/ml DROPS MO	1	
PRED FORTE 1 % DROPS, SUSPENSION MO	3	ST
PRED MILD 0.12 % DROPS, SUSPENSION MO	3	ST
PRED-G 0.3-1 % DROPS, SUSPENSION MO	3	
prednisolone acetate 1 % DROPS, SUSPENSION MO	1	
prednisolone sodium phosphate 1 % DROPS MO	1	
PROLENSA 0.07 % DROPS MO	3	ST,QL(3 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>proparacaine 0.5 % DROPS</i> MO	1	
RESTASIS 0.05 % DROPPERETTE MO	3	PA,QL(60 per 30 days)
RESTASIS MULTIDOSE 0.05 % DROPS MO	3	PA,QL(5.5 per 25 days)
RHOPRESSA 0.02 % DROPS MO	2	ST,QL(2.5 per 25 days)
ROCKLATAN 0.02-0.005 % DROPS MO	2	ST,QL(2.5 per 25 days)
SIMBRINZA 1-0.2 % DROPS, SUSPENSION MO	3	QL(16 per 30 days)
<i>sulfacetamide sodium 10 % DROPS</i> MO	1	
<i>sulfacetamide-prednisolone 10 %-0.23 % (0.25 %) DROPS</i> MO	1	
<i>tafluprost (pf) 0.0015 % DROPPERETTE</i> MO	3	ST,QL(30 per 30 days)
<i>timolol maleate 0.25 % DROPS</i> MO	1	
<i>timolol maleate 0.25 %, 0.5 % GEL FORMING SOLUTION</i> MO	1	
<i>timolol maleate 0.5 % DROPS</i> MO	1	
<i>timolol maleate 0.5 % DROPS, ONCE DAILY</i> MO	1	
<i>timolol maleate (pf) 0.25 %, 0.5 % DROPPERETTE</i> MO	1	
TIMOPTIC 0.25 %, 0.5 % DROPS MO	3	ST
TIMOPTIC OCUDOSE (PF) 0.25 %, 0.5 % DROPPERETTE MO	3	ST
TIMOPTIC-XE 0.25 %, 0.5 % GEL FORMING SOLUTION MO	3	PA
TOBRADEX 0.3-0.1 % DROPS, SUSPENSION MO	3	
TOBRADEX 0.3-0.1 % OINTMENT MO	3	
TOBRADEX ST 0.3-0.05 % DROPS, SUSPENSION MO	3	
<i>tobramycin 0.3 % DROPS</i> MO	1	
<i>tobramycin-dexamethasone 0.3-0.1 % DROPS, SUSPENSION</i> MO	1	
TOBREX 0.3 % OINTMENT MO	3	
TRAVATAN Z 0.004 % DROPS MO	3	ST,QL(2.5 per 25 days)
<i>travoprost 0.004 % DROPS</i> MO	1	QL(2.5 per 25 days)
<i>trifluridine 1 % DROPS</i> MO	1	
TRUSOPT 2 % DROPS MO	3	
TYRVAYA 0.03 MG/SPRAY SPRAY, METERED, NON-AEROSOL MO	3	PA,QL(8.4 per 30 days)
VERKAZIA 0.1 % DROPPERETTE DL	4	PA,QL(120 per 30 days)
VEVYE 0.1 % DROPS MO	3	PA,QL(2 per 30 days)
VIGAMOX 0.5 % DROPS MO	3	PA
VUITY 1.25 % DROPS MO	3	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VYZULTA 0.024 % DROPS MO	3	QL(2.5 per 25 days)
XALATAN 0.005 % DROPS MO	3	PA,QL(5 per 25 days)
XELPROS 0.005 % DROPS, EMULSION MO	3	ST,QL(2.5 per 25 days)
XIIDRA 5 % DROPPERETTE MO	3	PA,QL(60 per 30 days)
ZERVIATE 0.24 % DROPPERETTE MO	3	QL(60 per 30 days)
ZIOPTAN (PF) 0.0015 % DROPPERETTE MO	3	ST,QL(30 per 30 days)
ZYLET 0.3-0.5 % DROPS, SUSPENSION MO	3	
ZYMAXID 0.5 % DROPS MO	3	ST,QL(2.5 per 25 days)
OTIC AGENTS		
CIPRO HC 0.2-1 % DROPS, SUSPENSION MO	3	
CIPRODEX 0.3-0.1 % DROPS, SUSPENSION MO	3	QL(7.5 per 30 days)
<i>ciprofloxacin hcl 0.2 % DROPPERETTE MO</i>	1	
<i>ciprofloxacin-dexamethasone 0.3-0.1 % DROPS, SUSPENSION MO</i>	3	QL(7.5 per 30 days)
<i>ciprofloxacin-fluocinolone 0.3-0.025 % (0.25 ml) SOLUTION MO</i>	3	
CORTISPORIN-TC 3.3-3-10-0.5 MG/ML DROPS, SUSPENSION MO	3	
DERMOTIC OIL 0.01 % DROPS MO	3	
<i>flac otic oil 0.01 % DROPS MO</i>	1	
<i>fluocinolone acetonide oil 0.01 % DROPS MO</i>	1	
<i>hydrocortisone-acetic acid 1-2 % DROPS MO</i>	1	
<i>neomycin-polymyxin-hc 3.5-10,000-1 mg/ml-unit/ml-% DROPS, SUSPENSION MO</i>	1	
<i>neomycin-polymyxin-hc 3.5-10,000-1 mg/ml-unit/ml-% SOLUTION MO</i>	1	
<i>ofloxacin 0.3 % DROPS MO</i>	1	
OTOVEL 0.3-0.025 % (0.25 ML) SOLUTION MO	3	
RESPIRATORY TRACT/PULMONARY AGENTS		
ACCOLATE 10 MG, 20 MG TABLET MO	3	PA,QL(60 per 30 days)
<i>acetylcysteine 100 mg/ml (10 %), 200 mg/ml (20 %) SOLUTION MO</i>	1	BvsD
ADCIRCA 20 MG TABLET DL	4	PA,QL(60 per 30 days)
ADEMPAS 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG TABLET DL,LA	4	PA,QL(90 per 30 days)
ADRENALIN 1 MG/ML, 1 MG/ML (1 ML) SOLUTION MO	3	
ADVAIR DISKUS 100-50 MCG/DOSE, 250-50 MCG/DOSE, 500-50 MCG/DOSE BLISTER WITH DEVICE MO	3	PA,QL(60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ADVAIR HFA 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL(12 per 30 days)
AIRDUO DIGIHALER 113 MCG-14 MCG/ACTUATION, 232-14 MCG/ACTUATION, 55-14 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(1 per 30 days)
AIRDUO RESPICLICK 113-14 MCG/ACTUATION, 232-14 MCG/ACTUATION, 55-14 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(1 per 30 days)
AIRSUPRA 90-80 MCG/ACTUATION HFA AEROSOL INHALER DL	4	PA,QL(32.1 per 30 days)
albuterol sulfate 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg/0.5 ml, 5 mg/ml SOLUTION FOR NEBULIZATION MO	1	BvsD
albuterol sulfate 2 mg, 4 mg TABLET MO	1	
albuterol sulfate 2 mg/5 ml SYRUP MO	1	
albuterol sulfate 2.5 mg /3 ml (0.083 %) SOLUTION FOR NEBULIZATION MO	1	BvsD
albuterol sulfate 4 mg, 8 mg TABLET, ER 12 HR. MO	1	
albuterol sulfate 90 mcg/actuation HFA AEROSOL INHALER MO	1	QL(36 per 30 days)
ALVESCO 160 MCG/ACTUATION, 80 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(18.3 per 28 days)
alyq 20 mg TABLET MO	1	PA,QL(60 per 30 days)
ambrisentan 10 mg, 5 mg TABLET DL	4	PA,QL(30 per 30 days)
aminophylline 250 mg/10 ml, 500 mg/20 ml SOLUTION MO	1	
ANORO ELLIPTA 62.5-25 MCG/ACTUATION BLISTER WITH DEVICE MO	3	PA,QL(60 per 30 days)
arformoterol 15 mcg/2 ml SOLUTION FOR NEBULIZATION MO	1	BvsD,QL(120 per 30 days)
ARMONAIR DIGIHALER 113 MCG/ACTUATION, 232 MCG/ACTUATION, 55 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(1 per 30 days)
ARNUITY ELLIPTA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION BLISTER WITH DEVICE MO	2	QL(30 per 30 days)
ASMANEX HFA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(13 per 30 days)
ASMANEX TWISTHALER 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (14), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60) AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(1 per 28 days)
ATROVENT HFA 17 MCG/ACTUATION HFA AEROSOL INHALER MO	3	PA,QL(25.8 per 30 days)
AUVI-Q 0.1 MG/0.1 ML, 0.15 MG/0.15 ML, 0.3 MG/0.3 ML AUTO-INJECTOR MO	2	QL(4 per 30 days)
azelastine 137 mcg (0.1 %) SPRAY, NON-AEROSOL MO	1	QL(30 per 25 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
azelastine 205.5 mcg (0.15 %) SPRAY, NON-AEROSOL MO	1	QL(30 per 25 days)
azelastine-fluticasone 137-50 mcg/spray SPRAY, NON-AEROSOL MO	1	ST,QL(23 per 28 days)
BECONASE AQ 42 MCG (0.042 %) SPRAY, NON-AEROSOL MO	3	ST,QL(50 per 30 days)
BEVESPI AEROSPHERE 9-4.8 MCG HFA AEROSOL INHALER MO	3	PA,QL(10.7 per 30 days)
bosentan 125 mg, 62.5 mg TABLET DL	4	PA,QL(60 per 30 days)
BREO ELLIPTA 100-25 MCG/DOSE, 200-25 MCG/DOSE, 50-25 MCG/DOSE BLISTER WITH DEVICE MO	2	QL(60 per 30 days)
BREZTRI AEROSPHERE 160-9-4.8 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL(10.7 per 30 days)
BRONCHITOL 40 MG CAPSULE, W/INHALATION DEVICE DL	4	PA,QL(560 per 28 days)
BROVANA 15 MCG/2 ML SOLUTION FOR NEBULIZATION	4	BvsD,QL(120 per 30 days)
budesonide 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml SUSPENSION FOR NEBULIZATION MO	1	BvsD
carbinoxamine maleate 4 mg TABLET MO	1	
carbinoxamine maleate 4 mg/5 ml LIQUID MO	1	
carbinoxamine maleate 6 mg TABLET DL	4	QL(120 per 30 days)
CAYSTON 75 MG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL(84 per 28 days)
cetirizine 1 mg/ml SOLUTION MO	1	QL(300 per 30 days)
CINQAIR 10 MG/ML SOLUTION DL	4	PA
CLARINEX 5 MG TABLET MO	3	PA,QL(30 per 30 days)
clemastine 0.5 mg/5 ml SYRUP DL	4	PA,QL(1800 per 30 days)
clemastine 2.68 mg TABLET MO	1	
COMBIVENT RESPIMAT 20-100 MCG/ACTUATION MIST MO	3	QL(4 per 20 days)
cromolyn 100 mg/5 ml CONCENTRATE MO	1	
cromolyn 20 mg/2 ml SOLUTION FOR NEBULIZATION MO	1	BvsD
cyproheptadine 2 mg/5 ml SYRUP MO	1	
cyproheptadine 4 mg TABLET MO	1	
DALIRESP 250 MCG TABLET MO	3	PA,QL(28 per 365 days)
DALIRESP 500 MCG TABLET MO	3	PA,QL(30 per 30 days)
desloratadine 2.5 mg, 5 mg TABLET, DISINTEGRATING MO	1	ST,QL(30 per 30 days)
desloratadine 5 mg TABLET MO	1	QL(30 per 30 days)
dexchlorpheniramine maleate 2 mg/5 ml SOLUTION MO	1	PA
DIPHEN 12.5 MG/5 ML ELIXIR MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
diphen 12.5 mg/5 ml ELIXIR MO	1	
diphenhydramine hcl 12.5 mg/5 ml ELIXIR MO	1	
diphenhydramine hcl 50 mg/ml SOLUTION MO	1	
diphenhydramine hcl 50 mg/ml SYRINGE MO	1	
DOPRAM 20 MG/ML SOLUTION MO	3	
DUAKLIR PRESSAIR 400-12 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	PA,QL(1 per 30 days)
DULERA 100-5 MCG/ACTUATION, 200-5 MCG/ACTUATION, 50-5 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(13 per 30 days)
DYMISTA 137-50 MCG/SPRAY SPRAY, NON-AEROSOL MO	3	ST,QL(23 per 28 days)
ELIXOPHYLLIN 80 MG/15 ML ELIXIR MO	1	
epinephrine 0.15 mg/0.15 ml, 0.15 mg/0.3 ml, 0.3 mg/0.3 ml AUTO-INJECTOR MO	1	QL(4 per 30 days)
EPIPEN 0.3 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(4 per 30 days)
EPIPEN 2-PAK 0.3 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(4 per 30 days)
EPIPEN JR 0.15 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(4 per 30 days)
EPIPEN JR 2-PAK 0.15 MG/0.3 ML AUTO-INJECTOR MO	3	PA,QL(4 per 30 days)
epoprostenol 0.5 mg, 1.5 mg RECON SOLUTION DL	4	PA
ESBRIET 267 MG CAPSULE DL	4	PA,QL(270 per 30 days)
ESBRIET 267 MG TABLET DL	4	PA,QL(270 per 30 days)
ESBRIET 801 MG TABLET DL	4	PA,QL(90 per 30 days)
FASENRA 10 MG/0.5 ML SYRINGE DL	4	PA,QL(0.5 per 28 days)
FASENRA 30 MG/ML SYRINGE DL	4	PA,QL(1 per 28 days)
FASENRA PEN 30 MG/ML AUTO-INJECTOR DL	4	PA,QL(1 per 28 days)
flunisolide 25 mcg (0.025 %) SPRAY, NON-AEROSOL MO	1	QL(50 per 30 days)
fluticasone propion-salmeterol 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose BLISTER WITH DEVICE MO	1	QL(60 per 30 days)
fluticasone propion-salmeterol 113-14 mcg/actuation, 232-14 mcg/actuation, 55-14 mcg/actuation AEROSOL POWDER BREATH ACTIV. MO	2	QL(1 per 30 days)
fluticasone propionate 100 mcg/actuation, 250 mcg/actuation, 50 mcg/actuation BLISTER WITH DEVICE MO	3	ST,QL(60 per 30 days)
fluticasone propionate 110 mcg/actuation, 220 mcg/actuation HFA AEROSOL INHALER MO	3	ST,QL(24 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>fluticasone propionate 44 mcg/actuation HFA AEROSOL INHALER</i> MO	3	ST,QL(10.6 per 30 days)
<i>fluticasone propionate 50 mcg/actuation SPRAY, SUSPENSION</i> MO	1	QL(16 per 30 days)
<i>formoterol fumarate 20 mcg/2 ml SOLUTION FOR NEBULIZATION</i> MO	1	BvsD,QL(120 per 30 days)
GASTROCROM 100 MG/5 ML CONCENTRATE MO	3	
GRASTEK 2,800 BAU SUBLINGUAL TABLET MO	3	PA,QL(30 per 30 days)
<i>hydroxyzine pamoate 100 mg, 25 mg, 50 mg CAPSULE</i> MO	1	
INCRUSE ELLIPTA 62.5 MCG/ACTUATION BLISTER WITH DEVICE MO	3	PA,QL(30 per 30 days)
<i>ipratropium bromide 0.02 % SOLUTION</i> MO	1	BvsD
<i>ipratropium bromide 21 mcg (0.03 %) SPRAY, NON-AEROSOL</i> MO	1	QL(30 per 30 days)
<i>ipratropium bromide 42 mcg (0.06 %) SPRAY, NON-AEROSOL</i> MO	1	QL(45 per 30 days)
<i>ipratropium-albuterol 0.5 mg-3 mg(2.5 mg base)/3 ml SOLUTION FOR NEBULIZATION</i> MO	1	BvsD
KALYDECO 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG GRANULES IN PACKET DL	4	PA,QL(56 per 28 days)
KALYDECO 150 MG TABLET DL	4	PA,QL(60 per 30 days)
LETAIRIS 10 MG, 5 MG TABLET DL	4	PA,QL(30 per 30 days)
<i>levalbuterol hcl 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml SOLUTION FOR NEBULIZATION</i> MO	1	BvsD
<i>levalbuterol tartrate 45 mcg/actuation HFA AEROSOL INHALER</i> MO	1	ST,QL(30 per 30 days)
<i>levocetirizine 2.5 mg/5 ml SOLUTION</i> MO	1	QL(300 per 30 days)
<i>levocetirizine 5 mg TABLET</i> MO	1	QL(30 per 30 days)
LIQREV 10 MG/ML SUSPENSION DL	4	PA,QL(180 per 30 days)
LONHALA MAGNAIR REFILL 25 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL(60 per 30 days)
LONHALA MAGNAIR STARTER 25 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL(60 per 365 days)
<i>mometasone 50 mcg/actuation SPRAY, NON-AEROSOL</i> MO	1	QL(34 per 30 days)
<i>montelukast 10 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>montelukast 4 mg GRANULES IN PACKET</i> MO	1	QL(30 per 30 days)
<i>montelukast 4 mg, 5 mg CHEWABLE TABLET</i> MO	1	QL(30 per 30 days)
NEFFY 2 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL DL	4	PA,QL(4 per 30 days)
NUCALA 100 MG RECON SOLUTION DL	4	PA,QL(3 per 28 days)
NUCALA 100 MG/ML AUTO-INJECTOR DL	4	PA,QL(3 per 28 days)
NUCALA 100 MG/ML SYRINGE DL	4	PA,QL(3 per 28 days)
NUCALA 40 MG/0.4 ML SYRINGE DL	4	PA,QL(0.4 per 28 days)
ODACTRA 12 SQ-HDM SUBLINGUAL TABLET MO	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OFEV 100 MG, 150 MG CAPSULE DL,LA	4	PA,QL(60 per 30 days)
OHTUVAYRE 3 MG/2.5 ML SUSPENSION FOR NEBULIZATION DL	4	PA,QL(150 per 30 days)
<i>olopatadine</i> 0.6 % SPRAY, NON-AEROSOL MO	1	ST,QL(30.5 per 30 days)
OMNARIS 50 MCG SPRAY, NON-AEROSOL MO	3	ST,QL(12.5 per 30 days)
OPSUMIT 10 MG TABLET DL	4	PA,QL(30 per 30 days)
OPSYNVI 10-20 MG, 10-40 MG TABLET DL	4	PA,QL(30 per 30 days)
ORALAIR 300 INDX REACTIVITY SUBLINGUAL TABLET MO	3	PA,QL(30 per 30 days)
ORENITRAM 0.125 MG TABLET ER DL	4	PA,QL(1000 per 30 days)
ORENITRAM 0.25 MG TABLET ER DL	4	PA,QL(500 per 30 days)
ORENITRAM 1 MG TABLET ER DL	4	PA,QL(720 per 30 days)
ORENITRAM 2.5 MG TABLET ER DL	4	PA,QL(300 per 30 days)
ORENITRAM 5 MG TABLET ER DL	4	PA,QL(150 per 30 days)
ORENITRAM MONTH 1 TITRATION KT 0.125 MG (126)- 0.25 MG (42) TABLET, ER, DOSE PACK DL	4	PA,QL(168 per 28 days)
ORENITRAM MONTH 2 TITRATION KT 0.125 MG (126)- 0.25 MG (210) TABLET, ER, DOSE PACK DL	4	PA,QL(336 per 28 days)
ORENITRAM MONTH 3 TITRATION KT 0.125 MG (126)- 0.25 MG(42)-1MG TABLET, ER, DOSE PACK DL	4	PA,QL(252 per 28 days)
ORKAMBI 100-125 MG, 150-188 MG, 75-94 MG GRANULES IN PACKET DL	4	PA,QL(56 per 28 days)
ORKAMBI 100-125 MG, 200-125 MG TABLET DL	4	PA,QL(112 per 28 days)
PATANASE 0.6 % SPRAY, NON-AEROSOL MO	3	ST,QL(30.5 per 30 days)
PERFOROMIST 20 MCG/2 ML SOLUTION FOR NEBULIZATION DL	4	BvsD,QL(120 per 30 days)
<i>pirfenidone</i> 267 mg CAPSULE DL	4	PA,QL(270 per 30 days)
<i>pirfenidone</i> 267 mg TABLET DL	4	PA,QL(270 per 30 days)
<i>pirfenidone</i> 534 mg, 801 mg TABLET DL	4	PA,QL(90 per 30 days)
PROAIR DIGIHALER 90 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(2 per 30 days)
PROAIR HFA 90 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(36 per 30 days)
PROAIR RESPICLICK 90 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(2 per 30 days)
PROVENTIL HFA 90 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(36 per 30 days)
PULMICORT 0.25 MG/2 ML, 0.5 MG/2 ML, 1 MG/2 ML SUSPENSION FOR NEBULIZATION MO	3	BvsD

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PULMICORT FLEXHALER 180 MCG/ACTUATION, 90 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	ST,QL(2 per 30 days)
PULMOZYME 1 MG/ML SOLUTION DL	4	BvsD
QNASL 40 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(6.8 per 30 days)
QNASL 80 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(10.6 per 30 days)
QUZYTIR 10 MG/ML SOLUTION MO	3	
QVAR REDHALER 40 MCG/ACTUATION HFA AEROSOL BREATH ACTIVATED MO	3	ST,QL(10.6 per 30 days)
QVAR REDHALER 80 MCG/ACTUATION HFA AEROSOL BREATH ACTIVATED MO	3	ST,QL(21.2 per 30 days)
RAGWITEK 12 AMB A 1 UNIT SUBLINGUAL TABLET MO	3	PA,QL(30 per 30 days)
REMODULIN 1 MG/ML, 10 MG/ML, 2.5 MG/ML, 5 MG/ML SOLUTION DL	4	PA
REVATIO 10 MG/ML SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(180 per 30 days)
REVATIO 20 MG TABLET DL	4	PA,QL(90 per 30 days)
roflumilast 250 mcg TABLET MO	1	QL(28 per 365 days)
roflumilast 500 mcg TABLET MO	1	QL(30 per 30 days)
RYALTRIS 665-25 MCG/SPRAY SPRAY, NON-AEROSOL MO	3	ST,QL(29 per 30 days)
RYCLORA 2 MG/5 ML SOLUTION MO	1	
RYVENT 6 MG TABLET MO	1	QL(120 per 30 days)
SEREVENT DISKUS 50 MCG/DOSE BLISTER WITH DEVICE MO	3	PA,QL(60 per 30 days)
sildenafil (pulm.hypertension) 10 mg/ml SUSPENSION FOR RECONSTITUTION DL	4	PA,QL(180 per 30 days)
sildenafil (pulm.hypertension) 20 mg TABLET MO	1	PA,QL(90 per 30 days)
SINGULAIR 10 MG TABLET MO	3	PA,QL(30 per 30 days)
SINGULAIR 4 MG GRANULES IN PACKET MO	3	PA,QL(30 per 30 days)
SINGULAIR 4 MG, 5 MG CHEWABLE TABLET MO	3	PA,QL(30 per 30 days)
SPIRIVA RESPIMAT 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION MIST MO	2	QL(4 per 28 days)
SPIRIVA WITH HANDHALER 18 MCG CAPSULE, W/INHALATION DEVICE MO	2	QL(30 per 30 days)
STIOLTO RESPIMAT 2.5-2.5 MCG/ACTUATION MIST MO	2	QL(4 per 28 days)
STRIVERDI RESPIMAT 2.5 MCG/ACTUATION MIST MO	2	QL(4 per 30 days)
SYMBICORT 160-4.5 MCG/ACTUATION, 80-4.5 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL(10.2 per 30 days)
SYMDEKO 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) TABLET, SEQUENTIAL DL	4	PA,QL(56 per 28 days)
tadalafil (pulm. hypertension) 20 mg TABLET MO	1	PA,QL(60 per 30 days)
TADLIQ 20 MG/5 ML (4 MG/ML) SUSPENSION DL	4	PA,QL(300 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
terbutaline 1 mg/ml SOLUTION MO	1	
terbutaline 2.5 mg, 5 mg TABLET MO	1	
THEO-24 100 MG, 200 MG, 300 MG, 400 MG CAPSULE, ER 24 HR. MO	1	
theophylline 100 mg, 200 mg, 300 mg, 450 mg TABLET, ER 12 HR. MO	1	
theophylline 400 mg, 600 mg TABLET, ER 24 HR. MO	1	
theophylline 80 mg/15 ml ELIXIR MO	1	
theophylline 80 mg/15 ml SOLUTION MO	1	
theophylline in dextrose 5 % 200 mg/100 ml, 200 mg/50 ml, 400 mg/250 ml, 800 mg/250 ml PARENTERAL SOLUTION MO	1	
TOBI PODHALER 28 MG CAPSULE, W/INHALATION DEVICE DL	4	PA,QL(224 per 28 days)
TRACLEER 125 MG, 62.5 MG TABLET DL	4	PA,QL(60 per 30 days)
TRACLEER 32 MG TABLET FOR SUSPENSION DL	4	PA,QL(120 per 30 days)
TRELEGY ELLIPTA 100-62.5-25 MCG, 200-62.5-25 MCG BLISTER WITH DEVICE MO	2	QL(60 per 30 days)
treprostinil sodium 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml SOLUTION DL	4	PA
TRIKAFTA 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) TABLET, SEQUENTIAL DL	4	PA,QL(84 per 28 days)
TRIKAFTA 100-50-75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) GRANULES IN PACKET, SEQUENTIAL DL	4	PA,QL(56 per 28 days)
TUDORZA PRESSAIR 400 MCG/ACTUATION AEROSOL POWDER BREATH ACTIV. MO	3	PA,QL(1 per 30 days)
TYVASO 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION DL	4	PA
TYVASO DPI 16 MCG (112)- 32 MCG (84) CARTRIDGE WITH INHALER DL	4	PA,QL(196 per 28 days)
TYVASO DPI 16 MCG, 32 MCG, 48 MCG, 64 MCG CARTRIDGE WITH INHALER DL	4	PA,QL(112 per 28 days)
TYVASO DPI 16(112)-32(112) -48(28) MCG CARTRIDGE WITH INHALER DL	4	PA,QL(252 per 28 days)
TYVASO DPI 32-48 MCG CARTRIDGE WITH INHALER DL	4	PA,QL(224 per 28 days)
TYVASO INSTITUTIONAL START KIT 1.74 MG/2.9 ML SOLUTION FOR NEBULIZATION DL	4	PA
TYVASO REFILL KIT 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION DL	4	PA
TYVASO STARTER KIT 1.74 MG/2.9 ML SOLUTION FOR NEBULIZATION DL	4	PA
UPTRAVI 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG TABLET DL	4	PA,QL(60 per 30 days)
UPTRAVI 1,800 MCG RECON SOLUTION DL	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
UPTRAVI 200 MCG (140)- 800 MCG (60) TABLET, DOSE PACK DL	4	PA,QL(200 per 30 days)
VELETRI 0.5 MG, 1.5 MG RECON SOLUTION DL	4	PA
VENTAVIS 10 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL(150 per 30 days)
VENTAVIS 20 MCG/ML SOLUTION FOR NEBULIZATION DL	4	PA,QL(90 per 30 days)
VENTOLIN HFA 90 MCG/ACTUATION HFA AEROSOL INHALER MO	2	QL(36 per 30 days)
VISTARIL 25 MG, 50 MG CAPSULE MO	3	
WINREVAIR 45 MG, 60 MG KIT DL	4	PA
wixela inhub 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose BLISTER WITH DEVICE MO	1	QL(60 per 30 days)
XHANCE 93 MCG/ACTUATION AEROSOL BREATH ACTIVATED MO	3	PA,QL(32 per 30 days)
XOPENEX HFA 45 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(30 per 30 days)
YUPELRI 175 MCG/3 ML SOLUTION FOR NEBULIZATION	4	PA,QL(90 per 30 days)
zafirlukast 10 mg, 20 mg TABLET MO	1	QL(60 per 30 days)
ZETONNA 37 MCG/ACTUATION HFA AEROSOL INHALER MO	3	ST,QL(6.1 per 28 days)
zileuton 600 mg TABLET, ER 12 HR., MULTIPHASE	4	ST,QL(120 per 30 days)
ZYFLO 600 MG TABLET DL	4	ST,QL(120 per 30 days)
SKELETAL MUSCLE RELAXANTS		
AMRIX 15 MG, 30 MG CAPSULE, ER 24 HR. DL	4	ST,QL(21 per 30 days)
carisoprodol 250 mg TABLET MO	1	ST,QL(120 per 30 days)
carisoprodol 350 mg TABLET MO	1	QL(120 per 30 days)
chlorzoxazone 250 mg TABLET DL	4	ST,QL(360 per 30 days)
chlorzoxazone 375 mg, 750 mg TABLET MO	1	ST,QL(120 per 30 days)
chlorzoxazone 500 mg TABLET MO	1	ST
cyclobenzaprine 10 mg, 5 mg TABLET MO	1	
cyclobenzaprine 15 mg, 30 mg CAPSULE, ER 24 HR. MO	1	ST,QL(21 per 30 days)
cyclobenzaprine 7.5 mg TABLET MO	1	QL(90 per 30 days)
FEXMID 7.5 MG TABLET MO	1	ST,QL(90 per 30 days)
LORZONE 375 MG TABLET MO	1	ST,QL(120 per 30 days)
LORZONE 750 MG TABLET DL	4	ST,QL(120 per 30 days)
metaxalone 400 mg, 800 mg TABLET MO	1	ST,QL(120 per 30 days)
methocarbamol 1,000 mg TABLET DL	4	PA
methocarbamol 100 mg/ml SOLUTION MO	1	

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
methocarbamol 500 mg, 750 mg TABLET MO	1	
norgesic 25-385-30 mg TABLET DL	4	PA,QL(240 per 30 days)
NORGESIC FORTE 50-770-60 MG TABLET DL	4	PA,QL(120 per 30 days)
orphenadrine citrate 100 mg TABLET ER MO	1	
orphenadrine citrate 30 mg/ml SOLUTION MO	1	ST
orphenadrine-asa-caffeine 25-385-30 mg TABLET DL	4	PA,QL(240 per 30 days)
orphenadrine-asa-caffeine 50-770-60 mg TABLET DL	4	PA,QL(120 per 30 days)
orphengestic forte 50-770-60 mg TABLET DL	4	PA,QL(120 per 30 days)
ROBAXIN 100 MG/ML SOLUTION DL	4	
SOMA 250 MG, 350 MG TABLET DL	4	ST,QL(120 per 30 days)
tanlor 1,000 mg TABLET DL	4	PA
SLEEP DISORDER AGENTS		
AMBIEN 10 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
AMBIEN CR 12.5 MG, 6.25 MG TABLET, ER MULTIPHASE MO	3	PA,QL(30 per 30 days)
armodafinil 150 mg, 200 mg, 250 mg TABLET MO	1	PA,QL(30 per 30 days)
armodafinil 50 mg TABLET MO	1	PA,QL(60 per 30 days)
BELSOMRA 10 MG TABLET MO	2	QL(60 per 30 days)
BELSOMRA 15 MG, 20 MG TABLET MO	2	QL(30 per 30 days)
BELSOMRA 5 MG TABLET MO	2	QL(120 per 30 days)
DAYVIGO 10 MG, 5 MG TABLET MO	3	PA,QL(30 per 30 days)
doxepin 3 mg, 6 mg TABLET MO	1	QL(30 per 30 days)
EDLUAR 10 MG SUBLINGUAL TABLET MO	3	
EDLUAR 5 MG SUBLINGUAL TABLET MO	3	QL(30 per 30 days)
estazolam 1 mg, 2 mg TABLET DL	1	QL(30 per 30 days)
eszopiclone 1 mg, 2 mg, 3 mg TABLET MO	1	QL(30 per 30 days)
flurazepam 15 mg CAPSULE DL	1	QL(60 per 30 days)
flurazepam 30 mg CAPSULE DL	1	QL(30 per 30 days)
HALCION 0.25 MG TABLET DL	3	PA,QL(30 per 30 days)
HETLIOZ 20 MG CAPSULE DL	4	PA,QL(30 per 30 days)
HETLIOZ LQ 4 MG/ML SUSPENSION DL	4	PA,QL(158 per 30 days)
LUMRYZ 4.5 GRAM, 6 GRAM, 7.5 GRAM, 9 GRAM ER GRANULES, PACKET DL	4	PA,QL(30 per 30 days)
LUNESTA 1 MG, 2 MG, 3 MG TABLET MO	3	PA,QL(30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL-Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>modafinil 100 mg, 200 mg TABLET</i> MO	1	PA,QL(60 per 30 days)
NUVIGIL 150 MG, 200 MG, 250 MG TABLET	4	PA,QL(30 per 30 days)
NUVIGIL 50 MG TABLET	4	PA,QL(60 per 30 days)
PROVIGIL 100 MG, 200 MG TABLET	4	PA,QL(60 per 30 days)
QUVIVIQ 25 MG, 50 MG TABLET MO	3	ST,QL(30 per 30 days)
<i>ramelteon 8 mg TABLET</i> MO	1	ST,QL(30 per 30 days)
RESTORIL 15 MG, 22.5 MG, 30 MG, 7.5 MG CAPSULE DL	4	PA,QL(30 per 30 days)
ROZEREM 8 MG TABLET MO	3	ST,QL(30 per 30 days)
SILENOR 3 MG, 6 MG TABLET MO	3	QL(30 per 30 days)
<i>sodium oxybate 500 mg/ml SOLUTION</i> DL	4	PA,QL(540 per 30 days)
SUNOSI 150 MG, 75 MG TABLET MO	3	PA,QL(30 per 30 days)
<i>tasimelteon 20 mg CAPSULE</i> DL	4	PA,QL(30 per 30 days)
<i>temazepam 15 mg, 30 mg CAPSULE</i> DL	1	QL(30 per 30 days)
<i>temazepam 22.5 mg, 7.5 mg CAPSULE</i> DL	1	QL(30 per 30 days)
<i>triazolam 0.125 mg, 0.25 mg TABLET</i> DL	1	QL(30 per 30 days)
WAKIX 17.8 MG, 4.45 MG TABLET DL	4	PA,QL(60 per 30 days)
XYREM 500 MG/ML SOLUTION DL	4	PA,QL(540 per 30 days)
XYWAV 0.5 GRAM/ML SOLUTION DL	4	PA,QL(540 per 30 days)
<i>zaleplon 10 mg, 5 mg CAPSULE</i> MO	1	QL(30 per 30 days)
<i>zolpidem 1.75 mg, 3.5 mg SUBLINGUAL TABLET</i> MO	1	QL(30 per 30 days)
<i>zolpidem 10 mg, 5 mg TABLET</i> MO	1	QL(30 per 30 days)
<i>zolpidem 12.5 mg, 6.25 mg TABLET, ER MULTIPHASE</i> MO	1	QL(30 per 30 days)
ZOLPIDEM 7.5 MG CAPSULE MO	3	QL(30 per 30 days)
ZOLPIMIST 5 MG/SPRAY (0.1 ML) SPRAY, NON-AEROSOL MO	3	QL(23.1 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 10. Need more information about the utilization management requirements? Please go to page 6.

BvsD – Part B vs Part D • CI – Covered Insulin Products • DL – Dispensing Limit • LA – Limited Access • MO – Mail Order • PA – Prior Authorization • PDS – BD/HTL–Droplet are the Preferred Diabetic Supplies • QL – Quantity Limit • \$0 – Vaccine/Diabetic • ST – Step Therapy

Humana Group Medicare Plan Coverage of Additional Prescription Drugs

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
Cough/Cold - Mail Order Available		
<i>benzonatate 100 mg, 150 mg, 200 mg CAPSULE</i>	1	
<i>bromfed dm 2-30-10 mg/5 ml SYRUP</i>	1	
<i>brompheniramine-pseudoeph-dm 2-30-10 mg/5 ml SYRUP</i>	1	
<i>HYCODAN 5-1.5 MG/5 ML (5 ML) SYRUP</i>	1	
<i>HYCODAN (WITH HOMATROPINE) 5-1.5 MG TABLET</i>	1	
<i>HYCODAN (WITH HOMATROPINE) 5-1.5 MG/5 ML SYRUP</i>	1	
<i>hydrocodone-chlorpheniramine 10-8 mg/5 ml SUSPENSION, ER 12 HR.</i>	1	
<i>hydrocodone-homatropine 5-1.5 mg TABLET</i>	1	
<i>hydrocodone-homatropine 5-1.5 mg/5 ml, 5-1.5 mg/5 ml (5 ml) SYRUP</i>	1	
<i>hydromet 5-1.5 mg/5 ml SYRUP</i>	1	
<i>OBREDON 2.5-200 MG/5 ML SOLUTION</i>	3	
<i>promethazine vc-codeine 6.25-5-10 mg/5 ml SYRUP</i>	1	
<i>promethazine-codeine 6.25-10 mg/5 ml SYRUP</i>	1	
<i>promethazine-dm 6.25-15 mg/5 ml SYRUP</i>	1	
<i>promethazine-phenyleph-codeine 6.25-5-10 mg/5 ml SYRUP</i>	1	
<i>RESPA-AR 8-90-0.24 MG TABLET, ER 12 HR.</i>	3	
<i>TUXARIN ER 8-54.3 MG TABLET, ER 12 HR.</i>	3	
<i>TUZISTRA XR 14.7-2.8 MG/5 ML SUSPENSION, ER 12 HR.</i>	3	

Your Humana Group Medicare Plan has additional coverage for some drugs that are not normally covered under Medicare Part D. Guidelines that apply to these drugs include: they are not subject to the Medicare appeals process and your member cost share does not apply to your annual maximum out-of-pocket (MOOP) spend.

BvsD - Part B vs Part D • CI - Covered Insulin Products • DL - Dispensing Limit • LA - Limited Access • MO - Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 - Vaccine/Diabetic • ST - Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
Fertility - Mail Order Available		
<i>cetorelix 0.25 mg KIT</i>	1	
CETROTIDE 0.25 MG KIT	3	
<i>clomid 50 mg TABLET</i>	1	
<i>clomiphene citrate 50 mg TABLET</i>	1	
FOLLISTIM AQ 300 UNIT/0.36 ML, 600 UNIT/0.72 ML, 900 UNIT/1.08 ML CARTRIDGE	3	
<i>fyremadel 250 mcg/0.5 ml SYRINGE</i>	1	
GANIRELIX 250 MCG/0.5 ML SYRINGE	3	
<i>ganirelix 250 mcg/0.5 ml SYRINGE</i>	3	
GONAL-F 1,050 UNIT, 450 UNIT RECON SOLUTION	3	
GONAL-F RFF 75 UNIT RECON SOLUTION	3	
GONAL-F RFF REDI-JECT 300/0.5 UNIT/ML, 450/0.75 UNIT/ML, 900/1.5 UNIT/ML PEN INJECTOR	3	
MENOPUR 75 UNIT RECON SOLUTION	3	
OVIDREL 250 MCG/0.5 ML SYRINGE	3	
Vitamins/Minerals - Mail Order Available		
<i>ascorbic acid (vitamin c) 500 mg/ml SOLUTION</i>	1	
<i>b complex 100 100-2-100-2-2 mg/ml SOLUTION</i>	1	
<i>b-complex injection 100-2-100-2-2 mg/ml SOLUTION</i>	1	
<i>cyanocobalamin (vitamin b-12) 1,000 mcg/ml SOLUTION</i>	1	

Your Humana Group Medicare Plan has additional coverage for some drugs that are not normally covered under Medicare Part D. Guidelines that apply to these drugs include: they are not subject to the Medicare appeals process and your member cost share does not apply to your annual maximum out-of-pocket (MOOP) spend.

BvsD - Part B vs Part D • CI - Covered Insulin Products • DL - Dispensing Limit • LA - Limited Access • MO - Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 - Vaccine/Diabetic • ST - Step Therapy

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
Vitamins/Minerals - Mail Order Available		
<i>cyanocobalamin (vitamin b-12) 500 mcg/spray SPRAY, NON-AEROSOL</i>	1	
<i>dodex 1,000 mcg/ml SOLUTION</i>	1	
DRISDOL 1,250 MCG (50,000 UNIT) CAPSULE	3	
<i>ergocalciferol (vitamin d2) 1,250 mcg (50,000 unit) CAPSULE</i>	1	
<i>folic acid 1 mg TABLET</i>	1	
<i>folic acid 5 mg/ml SOLUTION</i>	1	
<i>hydroxocobalamin 1,000 mcg/ml SOLUTION</i>	1	
INFUVITE ADULT 3,300 UNIT- 150 MCG/10 ML SOLUTION	3	
INFUVITE PEDIATRIC 80 MG-400 UNIT- 200 MCG/5 ML SOLUTION	3	
MEPHYTON 5 MG TABLET	3	
NASCOBAL 500 MCG/SPRAY SPRAY, NON-AEROSOL	3	
<i>phytonadione (vitamin k1) 1 mg/0.5 ml SYRINGE</i>	1	
<i>phytonadione (vitamin k1) 1 mg/0.5 ml, 10 mg/ml SOLUTION</i>	1	
<i>phytonadione (vitamin k1) 5 mg TABLET</i>	1	
<i>pyridoxine (vitamin b6) 100 mg/ml SOLUTION</i>	1	
<i>thiamine hcl (vitamin b1) 100 mg/ml SOLUTION</i>	1	
<i>vitamin d2 1,250 mcg (50,000 unit) CAPSULE</i>	1	
<i>vitamin k 1 mg/0.5 ml SOLUTION</i>	1	
<i>vitamin k1 10 mg/ml SOLUTION</i>	1	

Your Humana Group Medicare Plan has additional coverage for some drugs that are not normally covered under Medicare Part D. Guidelines that apply to these drugs include: they are not subject to the Medicare appeals process and your member cost share does not apply to your annual maximum out-of-pocket (MOOP) spend.

BvsD - Part B vs Part D • CI - Covered Insulin Products • DL - Dispensing Limit • LA - Limited Access • MO - Mail Order • PA - Prior Authorization • PDS - BD/HTL- Droplet are the Preferred Diabetic Supplies • QL - Quantity Limit • \$0 - Vaccine/Diabetic • ST - Step Therapy

Index

A

- abacavir... 74
- abacavir-lamivudine... 74
- ABELCET... 45
- ABILIFY ASIMTUFI... 68
- ABILIFY MAINTENA... 69
- ABILIFY MYCITE MAINTENANCE KIT... 69
- ABILIFY MYCITE STARTER KIT... 69
- ABILIFY... 68
- abiraterone... 51
- ABRAXANE... 51
- ABRILADA(CF) PEN... 156
- ABRILADA(CF)... 156
- ABRYSVO (PF)... 156
- ABSORICA LD... 114
- ABSORICA... 114
- acamprosate... 21
- ACANYA... 114
- acarbose... 81
- ACCOLATE... 182
- ACCUPRIL... 92
- ACCURETIC... 92
- accutane... 114
- acebutolol... 92
- ACETADOTE... 170
- acetaminophen... 170
- acetaminophen-caff-dihydrocod... 11
- acetaminophen-codeine... 11
- acetazolamide sodium... 92
- acetazolamide... 92
- acetic acid... 22, 170
- acetylcysteine... 171, 182
- ACIPHEX... 130
- acitretin... 114
- ACTEMRA ACTPEN... 156
- ACTEMRA... 156
- ACTHAR SELFJECT... 139
- ACTHAR... 139
- ACTHIB (PF)... 156
- ACTICLATE... 22
- ACTIMMUNE... 156
- ACTIQ... 11
- ACTIVELLA... 143
- ACTONEL... 169
- ACTOPLUS MET... 81
- ACTOS... 81
- ACULAR LS... 177
- ACULAR... 177
- ACUVAIL (PF)... 177
- acyclovir sodium... 74
- acyclovir... 74
- ACZONE... 114
- ADACEL(TDAP ADOLESN/ADULT)(PF)... 156
- ADAKVEO... 171
- ADALIMUMAB-AACF... 156
- ADALIMUMAB-AATY... 156
- ADALIMUMAB-ADAZ... 156
- ADALIMUMAB-ADBM... 156
- ADALIMUMAB-ADBM(CF) PEN CROHNS... 156
- ADALIMUMAB-ADBM(CF) PEN PS-UV... 156
- ADALIMUMAB-FKJP... 156
- ADALIMUMAB-RYVK... 156, 157
- adapalene... 114
- adapalene-benzoyl peroxide... 114
- ADBRY... 114
- ADCETRIS... 51
- ADCIRCA... 182
- ADDERALL XR... 107
- ADDERALL... 107
- adefovir... 74
- ADEMPAS... 182
- adenosine... 92
- ADLARITY... 38
- ADLYXIN... 81
- ADMELOG SOLOSTAR U-100 INSULIN... 81

ADMELOG U-100 INSULIN LISPRO... 81	AKLIEF... 115	ALOMIDE... 177
ADRENALIN... 182	AKYNZEO (FOSNETUPITANT)... 43	ALOPRIM... 48
ADRIAMYCIN... 51	AKYNZEO (NETUPITANT)... 43	alosetron... 130
adrucil... 51	ALA-CORT... 115	ALPHAGAN P... 177
ADSTILADRIN... 171	ALA-SCALP... 115	alprazolam intensol... 80
ADVAIR DISKUS... 182	albendazole... 65	alprazolam... 80
ADVAIR HFA... 183	albuterol sulfate... 183	ALREX... 177
ADZENYS XR-ODT... 107	ALCAINE... 177	ALTABAX... 115
ADZYNMA... 87	alclometasone... 115	ALTACE... 92
AEMCOLO... 130	ALCOHOL PADS... 171	altavera (28)... 143
AFINITOR DISPERZ... 51	ALCOHOL PREP PADS... 171	ALTOPREV... 92
AFINITOR... 51	ALCOHOL SWABS... 171	ALTRENO... 115
afirmelle... 143	ALCOHOL WIPES... 171	ALUNBRIG... 51
AFREZZA... 81, 82	ALDACTAZIDE... 92	ALVAIZ... 88
AGAMREE... 139	ALDACTONE... 92	ALVESCO... 183
AGGRASTAT CONCENTRATE... 87	ALDURAZYME... 135	alyacen 1/35 (28)... 143
AGGRASTAT IN SODIUM CHLORIDE... 87	ALECENSA... 51	alyacen 7/7/7 (28)... 143
AGRYLIN... 88	alendronate... 169	ALYGLO... 157
AIMOVIG AUTOINJECTOR... 48	alfuzosin... 138	ALYMSYS... 51
AIRDUO DIGIHALER... 183	ALIMTA... 51	alyq... 183
AIRDUO RESPICLICK... 183	ALIQOPA... 51	amabelz... 143
AIRSUPRA... 183	aliskiren... 92	amantadine hcl... 66
AJOVY AUTOINJECTOR... 48	ALKINDI SPRINKLE... 139	AMARYL... 82
AJOVY SYRINGE... 48	allopurinol sodium... 48	AMBIEN CR... 191
ak-poly-bac... 177	allopurinol... 48	AMBIEN... 191
AKEEGA... 51	ALLZITAL... 171	AMBISOME... 45
	almotriptan malate... 48	ambrisentan... 183
	ALOCRIL... 177	amcinonide... 115

amethia... 143	amlodipine-olmesartan... 93	ANGELIQ... 143
amethyst (28)... 143	amlodipine-valsartan... 93	ANKTIVA... 51
amikacin... 22	amlodipine-valsartan-hcthiazyd... 93	ANNOVERA... 143
amiloride... 92	ammonium lactate... 115	ANORO ELLIPTA... 183
amiloride-hydrochlorothiazide... 92	AMMONUL... 171	ANTIVERT... 43
aminocaproic acid... 88	amnesteem... 115	anusol-hc... 115
aminophylline... 183	amoxapine... 39	ANZEMET... 43
AMINOSYN II 10 %... 124	amoxicil-clarithromy-lansopraz... 130	APADAZ... 11
AMINOSYN II 7 %... 124	amoxicillin... 22	apexicon e... 115
AMINOSYN II 8.5 %... 124	amoxicillin-pot clavulanate... 22	APIDRA SOLOSTAR U-100 INSULIN... 82
AMINOSYN II 8.5 %-ELECTROLYTES... 124	amphetamine sulfate... 107	APIDRA U-100 INSULIN... 82
AMINOSYN M 3.5 %... 124	amphetamine... 107	APLENZIN... 39
AMINOSYN 10 %... 123	amphotericin b liposome... 45	APOKYN... 66
AMINOSYN 7 % WITH ELECTROLYTES... 123	amphotericin b... 45	apomorphine... 67
AMINOSYN 8.5 %... 123	ampicillin sodium... 22	APONVIE... 43
AMINOSYN 8.5 %-ELECTROLYTES... 124	ampicillin... 22	apraclonidine... 177
AMINOSYN-RF 5.2 %... 124	ampicillin-sulbactam... 22	aprepitant... 43
amiodarone... 92	AMPYRA... 107	APRETUDE... 74
AMITIZA... 130	AMRIX... 190	apri... 144
amitriptyline... 39	AMVUTTRA... 135	APRISO... 168
amitriptyline-chlordiazepoxide... 39	AMZEEQ... 115	APTENSIO XR... 107
AMJEVITA(CF) AUTOINJECTOR... 157	ANAFRANIL... 39	APTIOM... 32
AMJEVITA(CF)... 157	anagrelide... 88	APTIVUS... 74
amlodipine... 92	anastrozole... 51	ARALAST NP... 135
amlodipine-atorvastatin... 92	ANCOBON... 45	aranelle (28)... 144
amlodipine-benazepril... 92, 93	ANDRODERM... 143	ARANESP (IN POLYSORBATE)... 88
	ANDROGEL... 143	ARAVA... 157

ARAZLO... 115	ASPARLAS... 52	AUGTYRO... 52
ARCALYST... 157	aspirin-dipyridamole... 88	aurovela fe 1.5/30 (28)... 144
AREXVY (PF)... 157	ASPRUZYO SPRINKLE... 93	aurovela fe 1-20 (28)... 144
arformoterol... 183	ASTAGRAF XL... 157	aurovela 1.5/30 (21)... 144
ARICEPT... 38	ATACAND HCT... 93	aurovela 1/20 (21)... 144
ARIKAYCE... 23	ATACAND... 93	aurovela 24 fe... 144
ARIMIDEX... 51	atazanavir... 74	AUSTEDO XR TITRATION KT(WK1-4)... 107
aripiprazole... 69	ATELVIA... 169	AUSTEDO XR... 107
ARISTADA INITIO... 69	atenolol... 93	AUSTEDO... 107
ARISTADA... 69	atenolol-chlorthalidone... 93	AUTOJECT 2 INJECTION DEVICE... 171
ARIXTRA... 88	ATGAM... 157	AUTOPEN 1 TO 21 UNITS... 171
armodafinil... 191	ATIVAN... 80	AUTOPEN 2 TO 42 UNITS... 171
ARMONAIR DIGIHALER... 183	atomoxetine... 107	AUVELITY... 39
ARMOUR THYROID... 153	ATORVALIQ... 93	AUVI-Q... 183
ARNUITY ELLIPTA... 183	atorvastatin... 93	AVALIDE... 93
AROMASIN... 52	atovaquone... 65	AVAPRO... 93
ARRANON... 52	atovaquone-proguanil... 65	AVASTIN... 52
arsenic trioxide... 52	ATRALIN... 115	AVEED... 144
ARTHROTEC 50... 11	ATRIPLA... 74	AVELOX IN NAACL (ISO-OSMOTIC)... 23
ARTHROTEC 75... 11	ATROPINE SULFATE (PF)... 177	aviane... 144
ASACOL HD... 168	atropine... 130, 177	avidoxy... 23
ASCENIV... 157	ATROVENT HFA... 183	AVITA... 115
ascomp with codeine... 11	AUBAGIO... 107	AVODART... 138
ascorbic acid (vitamin c)... 194	aubra eq... 144	AVONEX... 107
asenapine maleate... 69	aubra... 144	AVSOLA... 157
ashlyna... 144	AUGMENTIN ES-600... 23	AVYCAZ... 23
ASMANEX HFA... 183	AUGMENTIN XR... 23	
ASMANEX TWISTHALER... 183	AUGMENTIN... 23	

AYGESTIN... 144	BACTRIM DS... 23	BD INSULIN SYRINGE ULTRA-FINE... 171
ayuna... 144	BACTRIM... 23	BD INSULIN SYRINGE... 171
AYVAKIT... 52	BAFIERTAM... 108	BD LO-DOSE MICRO-FINE IV... 171
azacitidine... 52	bal-care dha... 124	BD NANO 2ND GEN PEN NEEDLE... 171
AZACTAM... 23	balanced salt... 177	BD SAFETYGLIDE INSULIN SYRINGE... 171
AZASAN... 157	BALCOLTRA... 144	BD SAFETYGLIDE SYRINGE... 171
AZASITE... 177	balsalazide... 168	BD SAFETYGLIDE SYRINGE... 171
azathioprine sodium... 157	BALVERSA... 52	BD ULTRA-FINE MICRO PEN NEEDLE... 171
azathioprine... 157	balziva (28)... 144	BD ULTRA-FINE MINI PEN NEEDLE... 172
azelaic acid... 115	BAND-AID GAUZE PADS... 171	BD ULTRA-FINE NANO PEN NEEDLE... 172
azelastine... 177, 183, 184	BANZEL... 32	BD ULTRA-FINE ORIG PEN NEEDLE... 172
azelastine-fluticasone... 184	BAQSIMI... 82	BD ULTRA-FINE SHORT PEN NEEDLE... 172
AZELEX... 115	BARACLUDE... 74	BD VEO INSULIN SYR (HALF UNIT)... 172
AZILECT... 67	BASAGLAR KWIKPEN U-100 INSULIN... 82	BD VEO INSULIN SYRINGE UF... 172
azithromycin... 23	BASAGLAR TEMPO PEN(U-100)INSLN... 82	BECONASE AQ... 184
AZOPT... 177	BAVENCIO... 52	BELBUCA... 11
AZOR... 93	BAXDELA... 23	BELEODAQ... 52
AZSTARYS... 107	BCG VACCINE, LIVE (PF)... 157	BELSOMRA... 191
aztreonam... 23	BD ALCOHOL SWABS... 171	benazepril... 93
AZULFIDINE EN-TABS... 168	BD AUTOSHIELD DUO PEN NEEDLE... 171	benazepril-hydrochlorothiazide... 93
AZULFIDINE... 168	BD ECLIPSE LUER-LOK... 171	bendamustine... 52
azurette (28)... 144	BD INSULIN SYRINGE (HALF UNIT)... 171	BENDEKA... 52
B	BD INSULIN SYRINGE MICRO-FINE... 171	
b complex 100... 194	BD INSULIN SYRINGE U-500... 171	
b-complex injection... 194		
bacitracin... 23, 177		
bacitracin-polymyxin b... 177		
baclofen... 73		

BENICAR HCT... 93	bethanechol chloride... 138	blisovi fe 1.5/30 (28)... 144
BENICAR... 93	BETHKIS... 23	blisovi fe 1/20 (28)... 144
BENLYSTA... 157	BETIMOL... 178	blisovi 24 fe... 144
BENTYL... 130	BETOPTIC S... 178	BONIVA... 169
BENZAMYCIN... 115	BEVESPI AEROSPHERE... 184	BONJESTA... 43
benzhydrocodone-acetaminophen... 11	bexarotene... 52	BOOSTRIX TDAP... 157
benznidazole... 65	BEXSERO... 157	BORDERED GAUZE... 172
benzonatate... 193	BEYAZ... 144	BORTEZOMIB... 52
benztropine... 67	BEYFORTUS... 172	bosentan... 184
bepotastine besilate... 177	bicalutamide... 52	BOSULIF... 52
BEPREVE... 177	BICILLIN C-R... 23	BRAFTOVI... 52
BERINERT... 157	BICILLIN L-A... 23	BREO ELLIPTA... 184
beser... 115	BICNU... 52	bretylium tosylate... 93
BESIVANCE... 177	BIDIL... 93	BREVIBLOC IN NACL (ISO-OSM)... 94
BESPONSA... 52	BIJUVA... 144	BREVIBLOC... 93
BESREMI... 157	BIKTARVY... 74	BREZTRI AEROSPHERE... 184
BETADINE OPHTHALMIC PREP... 178	BILTRICIDE... 65	briellyn... 144
betaine... 135	bimatoprost... 178	BRILINTA... 88
betamethasone acet,sod phos... 139	BIMZELX AUTOINJECTOR... 157	brimonidine... 116, 178
betamethasone dipropionate... 115	BIMZELX... 157	brinzolamide... 178
betamethasone valerate... 115	BINOSTO... 169	BRIUMVI... 108
betamethasone, augmented... 115, 116	BIORPHEN... 93	BRIVIACT... 32
BETAPACE AF... 93	bismuth subcit k-metronidz-tcn... 130	bromfed dm... 193
BETAPACE... 93	bisoprolol fumarate... 93	bromfenac... 178
BETASERON... 108	bisoprolol-hydrochlorothiazide... 93	bromocriptine... 67
betaxolol... 93, 178	BIVIGAM... 157	brompheniramine-pseudoeph-dm... 193
	bleomycin... 52	BROMSITE... 178

BRONCHITOL... 184	butalbital-acetaminophen... 172	CALDOLOR... 11
BROVANA... 184	butalbital-acetaminophen-caff... 172	CALQUENCE (ACALABRUTINIB MAL)... 53
BRUKINSA... 52	butalbital-aspirin-caffeine... 172	CALQUENCE... 53
BRYHALI... 116	butorphanol... 11	CAMBIA... 11
BSS PLUS... 178	BUTRANS... 11	camila... 144
BSS... 178	BYDUREON BCISE... 82	CAMPTOSAR... 53
budesonide... 168, 184	BYETTA... 82	camrese lo... 144
bumetanide... 94	BYLVAY... 172	camrese... 144
bupap... 172	BYSTOLIC... 94	CAMZYOS... 94
BUPHENYL... 135		CANASA... 168
bupivacaine (pf)... 19	C	CANCIDAS... 45
bupivacaine hcl... 19	c-nate dha... 124	candesartan... 94
bupivacaine-dextrose-water(pf)... 19	CABENUVA... 74	candesartan-hydrochlorothiazid... 94
bupivacaine-epinephrine (pf)... 19	cabergoline... 154	CAPEX... 116
bupivacaine-epinephrine... 19	CABLIVI... 88	CAPLYTA... 69
BUPRENEX... 11	CABOMETYX... 53	CAPRELSA... 53
buprenorphine hcl... 11, 21	CABTREO... 116	captopril... 94
buprenorphine... 11	CADUET... 94	captopril-hydrochlorothiazide... 94
buprenorphine-naloxone... 21	CAFCIT... 172	CARAC... 116
bupropion hcl (smoking deter)... 21	caffeine citrate... 172	CARAFATE... 130
bupropion hcl... 39	CALAN SR... 94	CARBAGLU... 124
bupirone... 80	calcipotriene... 116	carbamazepine... 32
busulfan... 52	calcipotriene-betamethasone... 116	CARBATROL... 32
BUSULFEX... 52	calcitonin (salmon)... 169	carbidopa... 67
butalbital compound w/codeine... 11	calcitriol... 116, 169	carbidopa-levodopa... 67
butalbital-acetaminop-caf-cod... 172	calcium chloride... 124	carbidopa-levodopa-entacapone... 67
	calcium disodium versenate... 172	
	calcium gluconate... 124	

carbinoxamine maleate... 184	cefazolin in dextrose (iso-os)... 24	CEQR SIMPLICITY INSERTER... 172
CARBOCAINE WITH NEO-COBEFRIN... 19	cefazolin... 24	CEQR SIMPLICITY... 172
carboplatin... 53	cefdinir... 24	CERDELGA... 135
carboprost tromethamine... 143	cefepime in dextrose 5 %... 24	CEREBYX... 32
CARDIZEM CD... 94	cefepime in dextrose,iso-osm... 24	CEREZYME... 135
CARDIZEM LA... 94	cefepime... 24	CERVIDIL... 172
CARDIZEM... 94	cefixime... 24	cetirizine... 184
CARDURA XL... 94	cefotetan... 24	cetrotelix... 194
CARDURA... 94	cefoxitin in dextrose, iso-osm... 24	CETROTIDE... 194
CARETOUCH ALCOHOL PREP PAD... 172	cefoxitin... 24	cevimeline... 114
carglumic acid... 124	cefepodoxime... 24	CHANTIX CONTINUING MONTH BOX... 21
carisoprodol... 190	cefprozil... 24	CHANTIX STARTING MONTH BOX... 21
carmustine... 53	ceftazidime in d5w... 24	CHANTIX... 21
CARNITOR (SUGAR-FREE)... 124	ceftazidime... 24	charlotte 24 fe... 144
CARNITOR... 124	ceftriaxone in dextrose,iso-os... 24	chateal eq (28)... 144
CAROSPIR... 94	ceftriaxone... 24	CHEMET... 124
carteolol... 178	cefuroxime axetil... 24	CHENODAL... 130
cartia xt... 94	cefuroxime sodium... 24	chloramphenicol sod succinate... 24
carvedilol phosphate... 94	CELEBREX... 11	chlordiazepoxide hcl... 80
carvedilol... 94	celecoxib... 11	chlorhexidine gluconate... 114
CASODEX... 53	CELESTONE SOLUSPAN... 139	chloroprocaine (pf)... 19
caspofungin... 45	CELEXA... 39	chloroquine phosphate... 65
cataflam... 11	CELLCEPT INTRAVENOUS... 158	chlorothiazide sodium... 94
CAYSTON... 184	CELLCEPT... 158	chlorpromazine... 69
cefaclor... 23	CELONTIN... 32	chlorthalidone... 94, 95
cefadroxil... 23, 24	CENTANY... 116	chlorzoxazone... 190
	cephalexin... 24	
	CEQUA... 178	

CHOLBAM... 135
 cholestyramine (with sugar)... 95
 cholestyramine light... 95
 cholestyramine-aspartame... 95
 CHORIONIC GONADOTROPIN,
 HUMAN... 142
 CIALIS... 138
 CIBINQO... 158
 ciclodan... 45
 ciclopirox... 45
 cidofovir... 74
 cilostazol... 88
 CILOXAN... 178
 CIMDUO... 74
 cimetidine hcl... 130
 cimetidine... 130
 CIMZIA POWDER FOR RECONST...
 158
 CIMZIA STARTER KIT... 158
 CIMZIA... 158
 cinacalcet... 169
 CINQAIR... 184
 CINRYZE... 158
 CINVANTI... 43
 CIPRO HC... 182
 CIPRO... 24, 25
 CIPRODEX... 182
 ciprofloxacin hcl... 25, 178, 182
 ciprofloxacin in 5 % dextrose... 25
 ciprofloxacin... 25
 ciprofloxacin-dexamethasone...
 182
 ciprofloxacin-fluocinolone... 182
 cisplatin... 53
 citalopram... 39, 40
 CITRANATAL B-CALM (FE GLUC)...
 124
 cladribine... 53
 CLAFORAN... 25
 claravis... 116
 CLARINEX... 184
 CLARINEX-D 12 HOUR... 172
 clarithromycin... 25
 clemastine... 184
 CLENPIQ... 131
 CLEOCIN HCL... 25
 CLEOCIN PEDIATRIC... 25
 CLEOCIN T... 116
 CLEOCIN... 25
 CLEVIPREX... 95
 CLIMARA PRO... 144
 CLIMARA... 144
 clindacin etz... 116
 clindacin p... 116
 clindacin... 116
 CLINDAGEL... 116
 clindamycin hcl... 25
 clindamycin in 0.9 % sod chlor... 25
 clindamycin in 5 % dextrose... 25
 clindamycin palmitate hcl... 25
 clindamycin pediatric... 25
 clindamycin phosphate... 25, 116
 clindamycin-benzoyl peroxide... 116
 clindamycin-tretinoin... 116
 CLINDESSE... 25
 CLINIMIX E 2.75%/D5W SULF
 FREE... 124
 CLINIMIX E 4.25%/D10W SUL
 FREE... 124
 CLINIMIX E 4.25%/D5W SULF
 FREE... 124
 CLINIMIX E 5%/D15W SULFIT
 FREE... 124
 CLINIMIX E 5%/D20W SULFIT
 FREE... 124
 CLINIMIX E 8%-D10W
 SULFITEFREE... 125
 CLINIMIX E 8%-D14W
 SULFITEFREE... 125
 CLINIMIX 4.25%/D10W SULF FREE...
 124
 CLINIMIX 4.25%/D5W SULFIT
 FREE... 124
 CLINIMIX
 5%-D20W(SULFITE-FREE)... 124
 CLINIMIX 5%/D15W SULFITE
 FREE... 124

CLINIMIX 6%-D5W (SULFITE-FREE)... 124	COARTEM... 66	COPAXONE... 108
CLINIMIX 8%-D10W(SULFITE-FREE)... 124	codeine sulfate... 11, 12	COPIKTRA... 53
CLINIMIX 8%-D14W(SULFITE-FREE)... 124	codeine-butalbital-asa-caff... 12	CORDRAN TAPE LARGE ROLL... 117
CLINISOL SF 15 %... 125	COLAZAL... 168	CORDRAN... 117
CLINOLIPID... 125	colchicine... 48	COREG CR... 95
clobazam... 32	COLCRYS... 48	COREG... 95
clobetasol... 117	colesevelam... 95	coremino... 25
clobetasol-emollient... 117	COLESTID FLAVORED... 95	CORGARD... 95
CLOBEX... 117	COLESTID... 95	CORLANOR... 95
clocortolone pivalate... 117	colestipol... 95	CORLOPAM... 95
clodan... 117	colistin (colistimethate na)... 25	CORTEF... 117
clofarabine... 53	COLUMVI... 53	CORTENEMA... 168
CLOLAR... 53	COLY-MYCIN M PARENTERAL... 25	CORTIFOAM... 168
clomid... 194	COMBIGAN... 178	CORTISPORIN-TC... 182
clomiphene citrate... 194	COMBIPATCH... 144	CORTROPHIN GEL... 139
clomipramine... 40	COMBIVENT RESPIMAT... 184	CORVERT... 95
clonazepam... 80	COMBIVIR... 74	COSENTYX (2 SYRINGES)... 158
clonidine hcl... 95, 108	COMBOGESIC IV... 172	COSENTYX PEN (2 PENS)... 158
clonidine... 95	COMETRIQ... 53	COSENTYX PEN... 158
clopidogrel... 88	COMPAZINE... 43	COSENTYX UNOREADY PEN... 158
clorazepate dipotassium... 80	COMPLERA... 74	COSENTYX... 158
CLOROTEKAL (PF)... 19	complete natal dha... 125	COSMEGEN... 53
clotrimazole... 45	compro... 43	COSOPT (PF)... 178
clotrimazole-betamethasone... 45	COMTAN... 67	COSOPT... 178
clozapine... 69	CONCERTA... 108	COTELLIC... 53
CLOZARIL... 70	CONDYLOX... 117	COTEMPLA XR-ODT... 108
	constulose... 131	COZAAR... 95
	CONZIP... 12	CREON... 135

CRESEMBA... 45	CYLTEZO(CF)... 158	DAPTACEL (DTAP PEDIATRIC) (PF)... 158
CRESTOR... 95	CYMBALTA... 108	daptomycin in 0.9 % sod chlor... 26
CREXONT... 67	cyproheptadine... 184	daptomycin... 25
CRINONE... 145	CYRAMZA... 53	DARAPRIM... 66
cromolyn... 178, 184	cyred eq... 145	darifenacin... 138
crotan... 117	cyred... 145	DARTISLA... 131
cryselle (28)... 145	CYSTADANE... 135	darunavir... 74
CRYSVITA... 135	CYSTADROPS... 178	DARZALEX FASPRO... 54
CUBICIN RF... 25	CYSTAGON... 135	DARZALEX... 54
CUPRIMINE... 125	CYSTARAN... 178	dasetta 1/35 (28)... 145
CURITY ALCOHOL SWABS... 172	cytarabine (pf)... 53	dasetta 7/7/7 (28)... 145
CURITY GAUZE... 173	cytarabine... 53	daunorubicin... 54
CUTAQUIG... 158	CYTOGAM... 158	DAURISMO... 54
CUVPOSA... 131	CYTOMEL... 153	DAYBUE... 135
CUVRIOR... 125	CYTOTEC... 131	DAYPRO... 12
cyanocobalamin (vitamin b-12)... 194, 195	D	daysee... 145
cyclobenzaprine... 190	dabigatran etexilate... 88	DAYTRANA... 108
cyclophosphamide... 53	dacarbazine... 53	DAYVIGO... 191
cycloserine... 50	DACOGEN... 53	DDAVP... 142
CYCLOSET... 82	dactinomycin... 53	deblitane... 145
cyclosporine modified... 158	dalfampridine... 108	decitabine... 54
cyclosporine... 158, 178	DALIRESP... 184	deferasirox... 125
CYKLOKAPRON... 88	DALVANCE... 25	deferiprone... 125
CYLTEZO(CF) PEN CROHN'S-UC-HS... 158	danazol... 145	deferoxamine... 125
CYLTEZO(CF) PEN PSORIASIS-UV... 158	DANTRIUM... 73	DEFITELIO... 173
CYLTEZO(CF) PEN... 158	dantrolene... 73	deflazacort... 140
	DANYELZA... 54	DELESTROGEN... 145
	dapsone... 50, 117	

DELSTRIGO... 74	desmopressin... 142	dextroamphetamine-amphetamine... 108, 109
DELZICOL... 168	desog-e.estradiol/e.estradiol... 145	dextrose 10 % and 0.2 % nacl... 125
demeclocycline... 26	desogestrel-ethinyl estradiol... 145	dextrose 10 % in water (d10w)... 125
DEMEROL (PF)... 12	desonide... 117	dextrose 25 % in water (d25w)... 125
DEMEROL... 12	DESOWEN... 117	dextrose 5 % in water (d5w)... 125
DEMSER... 95	desoximetasone... 118	dextrose 5 %-lactated ringers... 125
DENAVIR... 74	DESOXYN... 108	dextrose 5%-0.2 % sod chloride... 125
DENGVAXIA (PF)... 158	desrx... 118	dextrose 5%-0.3 % sod.chloride... 125
DEPAKOTE ER... 32	desvenlafaxine succinate... 40	dextrose 50 % in water (d50w)... 125
DEPAKOTE SPRINKLES... 33	desvenlafaxine... 40	dextrose 70 % in water (d70w)... 125
DEPAKOTE... 32	DETROL LA... 138	DHIVY... 67
DEPEN TITRATABS... 125	DETROL... 138	DIACOMIT... 33
DEPO-ESTRADIOL... 145	dexabliss... 140	DIASTAT ACUDIAL... 33
DEPO-MEDROL... 140	dexamethasone intensol... 140	DIASTAT... 33
DEPO-PROVERA... 145	dexamethasone sodium phos (pf)... 140	diazepam intensol... 80
DEPO-SUBQ PROVERA 104... 145	dexamethasone sodium phosphate... 140, 178	diazepam... 33, 80
DEPO-TESTOSTERONE... 145	dexamethasone... 140	diazoxide... 82
DERMA-SMOOTH/FS BODY OIL... 117	dexchlorpheniramine maleate... 184	DIBENZYLINE... 95
DERMA-SMOOTH/FS SCALP OIL... 117	DEXEDRINE SPANSULE... 108	dichlorphenamide... 135
DERMACEA... 173	DEXILANT... 131	DICLEGIS... 43
dermacinrx lidocan... 19	dexlansoprazole... 131	diclofenac epolamine... 12
DERMOTIC OIL... 182	dexmethylphenidate... 108	diclofenac potassium... 12
DESCOVY... 74	dexrazoxane hcl... 54	diclofenac sodium... 12, 118, 178
DESFERAL... 125	DEXTENZA... 178	
desipramine... 40	dextroamphetamine sulfate... 108	
desloratadine... 184		

diclofenac-misoprostol... 12	diphenoxylate-atropine... 131	dorzolamide-timolol... 178
dicloxacillin... 26	DIPROLENE (AUGMENTED)... 118	dotti... 145
dicyclomine... 131	dipyridamole... 88	DOVATO... 74
didanosine... 74	disopyramide phosphate... 96	DOVONEX... 118
DIFFERIN... 118	disulfiram... 21	doxazosin... 96
DIFICID... 26	DITROPAN XL... 138	doxepin... 80, 118, 191
diflorasone... 118	DIURIL... 96	doxercalciferol... 169
DIFLUCAN... 45	divalproex... 33	DOXIL... 54
diflunisal... 12	DIVIGEL... 145	doxorubicin... 54
difluprednate... 178	dobutamine in d5w... 96	doxorubicin, peg-liposomal... 54
digitek... 96	dobutamine... 96	doxy-100... 26
digox... 96	DOCEFREZ... 54	doxycycline hyclate... 26
digoxin... 96	docetaxel... 54	doxycycline monohydrate... 26
dihydroergotamine... 48	dodex... 195	doxylamine-pyridoxine (vit b6)... 43
DILANTIN EXTENDED... 33	dofetilide... 96	DRISDOL... 195
DILANTIN INFATABS... 33	DOJOLVI... 135	DRIZALMA SPRINKLE... 109
DILANTIN... 33	dolishale... 145	dronabinol... 43
DILANTIN-125... 33	donepezil... 38	droperidol... 70
DILAUDID... 12	dopamine in 5 % dextrose... 96	DROPLET INSULIN SYR(HALF UNIT)... 173
dilt-xr... 96	dopamine... 96	DROPLET INSULIN SYRINGE... 173
diltiazem hcl... 96	DOPRAM... 185	DROPLET MICRON PEN NEEDLE... 173
dimenhydrinate... 43	DOPTELET (10 TAB PACK)... 88	DROPLET PEN NEEDLE... 173
dimethyl fumarate... 109	DOPTELET (15 TAB PACK)... 89	DROPSAFE ALCOHOL PREP PADS... 173
DIOVAN HCT... 96	DOPTELET (30 TAB PACK)... 89	DROPSAFE PEN NEEDLE... 173
DIOVAN... 96	DORYX MPC... 26	drospirenone-e.estradiol-lm.fa... 145
DIPENTUM... 168	DORYX... 26	
DIPHEN... 184, 185	dorzolamide... 178	
diphenhydramine hcl... 185	dorzolamide-timolol (pf)... 178	

drosiprenone-ethinyl estradiol... 145	d5 % and 0.9 % sodium chloride... 125	electrolyte-148... 125
DROXIA... 173		electrolyte-48 in d5w... 126
droxidopa... 96	d5 %-0.45 % sodium chloride... 125	ELELYSO... 135
DUAKLIR PRESSAIR... 185	E	ELESTRIN... 145
DUAVEE... 145	E.E.S. GRANULES... 27	eletriptan... 48
DUET DHA WITH OMEGA-3... 125	E.E.S. 400... 26	ELEVIDYS... 135
DUETACT... 82	EASY COMFORT ALCOHOL PAD... 173	ELFABRIO... 135
DUEXIS... 12	EASY TOUCH ALCOHOL PREP PADS... 173	ELIDEL... 118
DULERA... 185	ec-naproxen... 12	ELIGARD (3 MONTH)... 154
duloxetine... 109	econazole... 45	ELIGARD (4 MONTH)... 154
DUOBRII... 118	edaravone... 109	ELIGARD (6 MONTH)... 154
DUOPA... 67	EDARBI... 97	ELIGARD... 154
DUPIXENT PEN... 158	EDARBYCLOR... 97	ELIMITE... 118
DUPIXENT SYRINGE... 159	EDECRIN... 97	elinest... 145
DURAMORPH (PF)... 12	edetate calcium disodium... 173	ELIQUIS DVT-PE TREAT 30D START... 89
DUREZOL... 179	EDLUAR... 191	ELIQUIS... 89
DURYSTA... 179	EDURANT... 75	ELITEK... 54
dutasteride... 138	efavirenz... 75	ELIXOPHYLLIN... 185
dutasteride-tamsulosin... 138	efavirenz-emtricitabin-tenofov... 75	ELLENCE... 54
DUVYZAT... 135	efavirenz-lamivu-tenofov disop... 75	ELMIRON... 138
DUZALLO... 48	EFFEXOR XR... 40	ELREXFIO... 54
DYANAVEL XR... 109	EFFIENT... 89	eluryng... 145
DYMISTA... 185	EFUDEX... 118	ELYXYB... 173
DYRENIUM... 96	EGATEN... 66	ELZONRIS... 54
d10 %-0.45 % sodium chloride... 125	EGRIFTA SV... 142	EMCYT... 54
d2.5 %-0.45 % sodium chloride... 125	ELAPRASE... 135	EMEND (FOSAPREPITANT)... 43
	electrolyte-a... 126	EMEND... 43

EMFLAZA... 140	ENSPRYNG... 179	EPKINLY... 54
EMGALITY PEN... 48	ENSTILAR... 118	eplerenone... 97
EMGALITY SYRINGE... 49	entacapone... 67	EPOGEN... 89
EMPAVELI... 173	ENTADFI... 138	epoprostenol... 185
EMPLICITI... 54	entecavir... 75	EPRONTIA... 33
EMSAM... 40	ENTRESTO SPRINKLE... 97	eprosartan... 97
emtricitabine... 75	ENTRESTO... 97	EPSOLAY... 118
emtricitabine-tenofovir (tdf)... 75	ENTYVIO PEN... 159	eptifibatide... 89
EMTRIVA... 75	ENTYVIO... 159	EPZICOM... 75
emverm... 66	enulose... 131	EQUETRO... 33
emzahh... 145	ENVARUS XR... 159	ERAXIS(WATER DILUENT)... 45
enalapril maleate... 97	EOHILIA... 173	ERBITUX... 54
enalapril-hydrochlorothiazide... 97	EPANED... 97	ergocalciferol (vitamin d2)... 195
enalaprilat... 97	EPCLUSA... 75	ergoloid... 38
ENBREL MINI... 159	EPIDIOLEX... 33	ERGOMAR... 49
ENBREL SURECLICK... 159	EPIDUO FORTE... 118	ergotamine-caffeine... 49
ENBREL... 159	EPIDUO... 118	eribulin... 54
ENDARI... 131	EPIFOAM... 118	ERIVEDGE... 54
endocet... 12	epinastine... 179	ERLEADA... 54
ENDOMETRIN... 145	epinephrine... 185	erlotinib... 54
ENGERIX-B (PF)... 159	EPIPEN JR 2-PAK... 185	ERMEZA... 153
ENGERIX-B PEDIATRIC (PF)... 159	EPIPEN JR... 185	errin... 146
ENHERTU... 54	EPIPEN 2-PAK... 185	ERTACZO... 45
enilloring... 145	EPIPEN... 185	ertapenem... 27
ENJAYMO... 159	epirubicin... 54	ery pads... 118
enoxaparin... 89	epitol... 33	ERY-TAB... 27
enpresse... 146	EPIVIR HBV... 75	ERYGEL... 118
enskyce... 146	EPIVIR... 75	ERYPED 200... 27

ERYPED 400... 27	ethosuximide... 33	EXFORGE HCT... 97
ERYTHROCIN (AS STEARATE)... 27	ethynodiol diac-eth estradiol... 146	EXFORGE... 97
ERYTHROCIN... 27	etodolac... 12, 13	EXJADE... 126
erythromycin ethylsuccinate... 27	etonogestrel-ethinyl estradiol... 146	EXKIVITY... 55
erythromycin lactobionate... 27	ETOPOPHOS... 55	EXPAREL (PF)... 19
erythromycin with ethanol... 118	etoposide... 55	EXSERVAN... 109
erythromycin... 27, 179	etravirine... 75	EXTAVIA... 109
erythromycin-benzoyl peroxide... 118	EUCRISA... 118	EXTINA... 45
ESBRIET... 185	EULEXIN... 55	EYSUVIS... 179
escitalopram oxalate... 40	EURAX... 118, 119	EZALLOR SPRINKLE... 97
ESGIC... 173	EUTHYROX... 153	ezetimibe... 97
esmolol in nacl (iso-osm)... 97	EVAMIST... 146	ezetimibe-atorvastatin... 97
esmolol... 97	EVEKEO ODT... 109	ezetimibe-rosuvastatin... 97
esomeprazole magnesium... 131	EVEKEO... 109	ezetimibe-simvastatin... 97
esomeprazole sodium... 131	EVENTITY... 169	F
estarylla... 146	everolimus (antineoplastic)... 55	FABHALTA... 159
estazolam... 191	everolimus (immunosuppressive)... 159	FABIOR... 119
ESTRACE... 146	EVISTA... 146	FABRAZYME... 135
estradiol valerate... 146	EVKEEZA... 97	falmina (28)... 146
estradiol... 146	EVOCLIN... 119	famciclovir... 75
estradiol-norethindrone acet... 146	EVOMELA... 55	famotidine (pf)... 131
ESTRING... 146	EVOTAZ... 75	famotidine (pf)-nacl (iso-os)... 131
ESTROGEL... 146	EVOXAC... 114	famotidine... 131
eszopiclone... 191	EVRYSDI... 135	FANAPT... 70
ethacrynate sodium... 97	EXELDERM... 45	FARESTON... 55
ethacrynic acid... 97	EXELON PATCH... 38	FARXIGA... 82
ethambutol... 50	exemestane... 55	FASENRA PEN... 185
		FASENRA... 185

FASLODEX... 55	FIASP FLEXTOUCH U-100 INSULIN... 82	FLOLIPID... 98
febuxostat... 48	FIASP PENFILL U-100 INSULIN... 82	FLOMAX... 138
felbamate... 33	FIASP U-100 INSULIN... 82	floxuridine... 55
FELBATOL... 33	FIBRICOR... 98	fluconazole in nacl (iso-osm)... 46
FELDENE... 13	FILSPARI... 173	fluconazole... 45
felodipine... 97	FILSUVEZ... 173	flucytosine... 46
FEMARA... 55	FINACEA... 119	fludarabine... 55
FEMRING... 146	finasteride... 138	fludrocortisone... 140
femynor... 146	fingolimod... 109	FLUMADINE... 75
fenofibrate micronized... 97, 98	FINTEPLA... 33	flumazenil... 173
fenofibrate nanocrystallized... 98	finzala... 146	flunisolide... 185
fenofibrate... 97	FIORICET WITH CODEINE... 173	fluocinolone acetonide oil... 182
fenofibric acid (choline)... 98	fioricet... 173	fluocinolone and shower cap... 119
fenofibric acid... 98	FIRAZYR... 159	fluocinolone... 119
FENOGLIDE... 98	FIRDAPSE... 109	fluocinonide... 119
fenoprofen... 13	FIRMAGON KIT W DILUENT SYRINGE... 154	fluocinonide-e... 119
FENSOLVI... 154	FIRMAGON... 154	fluocinonide-emollient... 119
fentanyl citrate (pf)... 13	FIRVANQ... 27	fluorometholone... 179
fentanyl citrate... 13	flac otic oil... 182	FLUOROPLEX... 119
fentanyl... 13	FLAGYL... 27	fluorouracil... 55, 119
FENTORA... 13	FLAREX... 179	fluoxetine... 40
FERRIPROX (2 TIMES A DAY)... 126	flavoxate... 138	fluphenazine decanoate... 70
FERRIPROX... 126	FLEBOGAMMA DIF... 159	fluphenazine hcl... 70
fesoterodine... 138	flecainide... 98	flurandrenolide... 119
FETROJA... 27	FLECTOR... 13	flurazepam... 191
FETZIMA... 40	FLEQSUVY... 73	flurbiprofen sodium... 179
FEXMID... 190		flurbiprofen... 13

fluticasone propion-salmeterol... 185	fosphenytoin... 33	GAMMAKED... 159
fluticasone propionate... 119, 185, 186	FOTIVDA... 55	GAMMAPLEX (WITH SORBITOL)... 159
fluvastatin... 98	FRAGMIN... 89	GAMMAPLEX... 159
fluvoxamine... 40	FROVA... 49	GAMUNEX-C... 159, 160
FML FORTE... 179	frovatriptan... 49	ganciclovir sodium... 75
FML LIQUIFILM... 179	FRUZAQLA... 55	GANIRELIX... 194
FOCALIN XR... 109	FULPHILA... 89	GARDASIL 9 (PF)... 160
FOCALIN... 109	fulvestrant... 55	GASTROCROM... 186
FOCINVEZ... 43	FURADANTIN... 27	gatifloxacin... 179
folic acid... 195	FUROSCIX... 98	GATTEX ONE-VIAL... 131
FOLLISTIM AQ... 194	furosemide... 98	GATTEX 30-VIAL... 131
FOLOTYN... 55	FUSILEV... 55	GAUZE BANDAGE... 174
fomepizole... 173	FUZEON... 75	GAUZE PAD... 174
fondaparinux... 89	FYARRO... 55	gavilyte-c... 131
FORFIVO XL... 40	fyavolv... 146	gavilyte-g... 131
formoterol fumarate... 186	FYCOMPA... 33	gavilyte-n... 131
FORTEO... 169	FYLNETRA... 89	GAVRETO... 55
FORTESTA... 146	fyremadel... 194	GAZYVA... 55
FOSAMAX PLUS D... 169	G	gefitinib... 55
FOSAMAX... 169	gabapentin... 33, 109	GELNIQUE... 138
fosamprenavir... 75	GABITRIL... 34	gemcitabine... 55
fosaprepitant... 43	GALAFOLD... 135	gemfibrozil... 98
foscarnet... 75	galantamine... 38	gemmily... 146
fosfomycin tromethamine... 27	GAMASTAN... 159	GEMTESA... 138
fosinopril... 98	GAMIFANT... 159	GENERESS FE... 146
fosinopril-hydrochlorothiazide... 98	GAMMAGARD LIQUID... 159	generlac... 131
	GAMMAGARD S-D (IGA < 1 MCG/ML)... 159	gengraf... 160

GENOTROPIN MINIQUICK... 142	GLUMETZA... 82	GVOKE HYPOPEN 2-PACK... 83
GENOTROPIN... 142	glutamine (sickle cell)... 131	GVOKE PFS 1-PACK SYRINGE... 83
gentak... 179	glyburide micronized... 83	GVOKE PFS 2-PACK SYRINGE... 83
gentamicin in nacl (iso-osm)... 27	glyburide... 82	GVOKE... 83
gentamicin sulfate (ped) (pf)... 27	glyburide-metformin... 83	gynazole-1... 46
gentamicin sulfate (pf)... 27	GLYCATE... 131	H
gentamicin... 27, 179	GLYCOPHOS... 126	HADLIMA PUSHTOUCH... 160
GENVOYA... 75	glycopyrrolate (pf) in water... 132	HADLIMA... 160
GEODON... 70	glycopyrrolate (pf)... 132	HADLIMA(CF) PUSHTOUCH... 160
GILENYA... 109	glycopyrrolate... 132	HADLIMA(CF)... 160
GILOTRIF... 55	glydo... 19	HAEGARDA... 160
GIMOTI... 43	GLYNASE... 83	hailey fe 1.5/30 (28)... 147
GIVLAARI... 174	GLYXAMBI... 83	hailey fe 1/20 (28)... 147
GLASSIA... 135	GOCOVRI... 67	hailey 24 fe... 146
glatiramer... 109, 110	GOLYTELY... 132	hailey... 146
glatopa... 110	GONAL-F RFF REDI-JECT... 194	HALAVEN... 56
GLEEVEC... 55	GONAL-F RFF... 194	halcinonide... 119
GLEOSTINE... 55, 56	GONAL-F... 194	HALCION... 191
glimepiride... 82	GONITRO... 98	HALDOL DECANOATE... 70
glipizide... 82	GRALISE... 110	halobetasol propionate... 119, 120
glipizide-metformin... 82	granisetron (pf)... 43	haloette... 147
GLOPERBA... 48	granisetron hcl... 43	HALOG... 120
GLUCAGEN HYPOKIT... 82	GRANIX... 89	haloperidol decanoate... 70
GLUCAGON (HCL) EMERGENCY KIT... 82	GRASTEK... 186	haloperidol lactate... 70
GLUCAGON EMERGENCY KIT (HUMAN)... 82	griseofulvin microsize... 46	haloperidol... 70
GLUCOTROL XL... 82	griseofulvin ultramicrosize... 46	HARVONI... 76
	guanfacine... 98, 110	HAVRIX (PF)... 160
	GVOKE HYPOPEN 1-PACK... 83	heather... 147

HECTOROL... 169	HUMALOG TEMPO PEN(U-100)INSULN... 83	HUMULIN 70/30 U-100 INSULIN... 83
HEMABATE... 143	HUMALOG U-100 INSULIN... 83	HUMULIN 70/30 U-100 KWIKPEN... 83
HEMADY... 140	HUMATIN... 27	HYCAMTIN... 56
HEMANGEOL... 98	HUMATROPE... 142	HYCODAN (WITH HOMATROPINE)... 193
heparin (porcine)... 90	HUMIRA PEN CROHNS-UC-HS START... 160	HYCODAN... 193
heparin, porcine (pf)... 90	HUMIRA PEN PSOR-UVEITS-ADOL HS... 160	hydralazine... 98
HEPLISAV-B (PF)... 160	HUMIRA PEN... 160	HYDREA... 56
HEPSERA... 76	HUMIRA... 160	hydrochlorothiazide... 98
HERCEPTIN HYLECTA... 56	HUMIRA(CF) PEDI CROHNS STARTER... 160	hydrocodone bitartrate... 13
HERCEPTIN... 56	HUMIRA(CF) PEN CROHNS-UC-HS... 160	hydrocodone-acetaminophen... 13
HERZUMA... 56	HUMIRA(CF) PEN PEDIATRIC UC... 161	hydrocodone-chlorpheniramine... 193
HETLIOZ LQ... 191	HUMIRA(CF) PEN PSOR-UV-ADOL HS... 161	hydrocodone-homatropine... 193
HETLIOZ... 191	HUMIRA(CF) PEN... 160	hydrocodone-ibuprofen... 13
HIBERIX (PF)... 160	HUMIRA(CF)... 160	hydrocortisone butyr-emollient... 120
HIPREX... 27	HUMULIN N NPH INSULIN KWIKPEN... 83	hydrocortisone butyrate... 120
HIZENTRA... 160	HUMALOG JUNIOR KWIKPEN U-100... 83	hydrocortisone valerate... 120
HORIZANT... 110	HUMALOG KWIKPEN INSULIN... 83	hydrocortisone... 120, 168
HULIO(CF) PEN... 160	HUMALOG MIX 50-50 INSULN U-100... 83	hydrocortisone-acetic acid... 182
HULIO(CF)... 160	HUMALOG MIX 50-50 KWIKPEN... 83	hydromet... 193
HUMALOG JUNIOR KWIKPEN U-100... 83	HUMALOG MIX 75-25 KWIKPEN... 83	hydromorphone (pf)... 14
HUMALOG KWIKPEN INSULIN... 83	HUMALOG MIX 75-25 KWIKPEN... 83	HYDROMORPHONE... 13, 14
HUMALOG MIX 50-50 INSULN U-100... 83	HUMALOG MIX 75-25(U-100)INSULN... 83	hydroxocobalamin... 195
HUMALOG MIX 50-50 KWIKPEN... 83		hydroxychloroquine... 66
HUMALOG MIX 75-25 KWIKPEN... 83		hydroxyurea... 56
HUMALOG MIX 75-25(U-100)INSULN... 83		

hydroxyzine hcl... 80	IDACIO(CF) PEN CROHN-UC STARTR... 161	IMOGAM RABIES-HT (PF)... 161
hydroxyzine pamoate... 186	IDACIO(CF) PEN PSORIASIS START... 161	IMOVAX RABIES VACCINE (PF)... 161
HYFTOR... 120	IDACIO(CF) PEN... 161	IMPAVIDO... 66
HYPERRAB (PF)... 161	IDACIO(CF)... 161	IMPEKLO... 120
HYPERTET (PF)... 161	IDAMYCIN PFS... 56	IMURAN... 161
HYRIMOZ PEN CROHN'S-UC STARTER... 161	idarubicin... 56	IMVEXXY MAINTENANCE PACK... 147
HYRIMOZ PEN PSORIASIS STARTER... 161	IDHIFA... 56	IMVEXXY STARTER PACK... 147
HYRIMOZ PEN... 161	IFEX... 56	INBRIJA... 67
HYRIMOZ... 161	ifosfamide... 56	incassia... 147
HYRIMOZ(CF) PEDI CROHN STARTER... 161	IGALMI... 174	INCONTROL ALCOHOL PADS... 174
HYRIMOZ(CF) PEN... 161	ILEVRO... 179	INCRELEX... 142
HYRIMOZ(CF)... 161	ILUMYA... 161	INCRUSE ELLIPTA... 186
HYSINGLA ER... 14	imatinib... 56	indapamide... 99
HYZAAR... 98	IMBRUVICA... 56	INDERAL LA... 99
I	IMDELLTRA... 56	INDOCIN... 14
ibandronate... 169	IMFINZI... 56	indomethacin sodium... 14
IBRANCE... 56	imipenem-cilastatin... 27	indomethacin... 14
IBSRELA... 132	imipramine hcl... 40	INFANRIX (DTAP) (PF)... 161
ibu... 14	imipramine pamoate... 40	INFLECTRA... 161
ibuprofen... 14	imiquimod... 120	INFUGEM... 57
ibuprofen-famotidine... 14	IMITREX STATDOSE PEN... 49	INFUMORPH P/F... 14
ibutilide fumarate... 99	IMITREX STATDOSE REFILL... 49	INFUVITE ADULT... 195
icatibant... 161	IMITREX... 49	INFUVITE PEDIATRIC... 195
iclevia... 147	IMJUDO... 56	INGREZZA INITIATION PK(TARDIV)... 110
ICLUSIG... 56	IMLYGIC... 56	INGREZZA SPRINKLE... 110
	IMMPHENTIV... 99	INGREZZA... 110

INLYTA... 57	INVEGA TRINZA... 70, 71	isosorbide-hydralazine... 99
INNOPRAN XL... 99	INVEGA... 70	isotretinoin... 120
INPEFA... 99	INVELTYS... 179	isradipine... 99
INQOVI... 57	INVOKAMET XR... 84	ISTALOL... 179
INREBIC... 57	INVOKAMET... 84	ISTODAX... 57
INSPIRA... 99	INVOKANA... 84	ISTURISA... 142
INSULIN ASP PRT-INSULIN ASPART... 83	IONOSOL-B IN D5W... 126	ISUPREL... 99
INSULIN ASPART U-100... 83, 84	IONOSOL-MB IN D5W... 126	itraconazole... 46
INSULIN DEGLUDEC... 84	IOPIDINE... 179	IV PREP WIPES... 174
INSULIN GLARGINE U-300 CONC... 84	IPOL... 161	ivabradine... 99
INSULIN GLARGINE... 84	ipratropium bromide... 186	ivermectin... 66, 120
INSULIN GLARGINE-YFGN... 84	ipratropium-albuterol... 186	IWILFIN... 57
INSULIN LISPRO PROTAMIN-LISPRO... 84	IQIRVO... 132	IXCHIQ (PF)... 162
INSULIN LISPRO... 84	irbesartan... 99	IXEMPRA... 57
INSULIN SYRINGE MICROFINE... 174	irbesartan-hydrochlorothiazide... 99	IXIARO (PF)... 162
INSULIN SYRINGE... 174	IRESSA... 57	IYUZEH (PF)... 179
INSULIN SYRINGE-NEEDLE U-100... 174	irinotecan... 57	J
INTELENCE... 76	ISENTRESS HD... 76	JADENU SPRINKLE... 126
INTRALIPID... 126	ISENTRESS... 76	JADENU... 126
INTRAROSA... 147	isibloom... 147	jaimiess... 147
INTRON A... 161	ISOLYTE S PH 7.4... 126	JAKAFI... 57
INTUNIVER... 110	ISOLYTE-P IN 5 % DEXTROSE... 126	JALYN... 138
INVANZ... 27	ISOLYTE-S... 126	jantoven... 90
INVEGA HAFYERA... 70	isoniazid... 50, 51	JANUMET XR... 84
INVEGA SUSTENNA... 70	ISORDIL TITRADOSE... 99	JANUMET... 84
	ISORDIL... 99	JANUVIA... 84
	isosorbide dinitrate... 99	JARDIANCE... 84
	isosorbide mononitrate... 99	jasmiel (28)... 147

JATENZO... 147	kaitlib fe... 147	KEVZARA... 162
javygtor... 135, 136	KALETRA... 76	KEYTRUDA... 57
JAYPIRCA... 57	kalliga... 147	KHAPZORY... 57
JEMPERLI... 57	KALYDECO... 186	KIMMTRAK... 57
jencycla... 147	KANJINTI... 57	KIMYRSA... 27
JENTADUETO XR... 84	KANUMA... 136	KINERET... 162
JENTADUETO... 84	KAPSPARGO SPRINKLE... 99	KINRIX (PF)... 162
JEVTANA... 57	KAPVAY... 110	kionex (with sorbitol)... 126
jinteli... 147	kariva (28)... 147	kiprofen... 15
JOENJA... 136	KATERZIA... 99	KISQALI FEMARA CO-PACK... 57
jolessa... 147	KAZANO... 84	KISQALI... 57
JORNAY PM... 110	KEDRAB (PF)... 162	KITABIS PAK... 27
joyeaux... 147	kelnor 1/35 (28)... 147	KLARON... 28
JUBLIA... 46	kelnor 1/50 (28)... 147	klayesta... 46
juleber... 147	KENALOG... 140	KLISYRI... 120
JULUCA... 76	KENALOG-80... 140	KLONOPIN... 80
junel fe 1.5/30 (28)... 147	KENGREAL... 90	klor-con m10... 126
junel fe 1/20 (28)... 147	KEPIVANCE... 114	KLOR-CON M15... 126
junel fe 24... 147	KEPPRA XR... 34	klor-con m20... 126
junel 1.5/30 (21)... 147	KEPPRA... 34	KLOR-CON 10... 126
junel 1/20 (21)... 147	KERENDIA... 99	KLOR-CON 8... 126
JUXTAPID... 99	KERYDIN... 46	klor-con... 126
JYLAMVO... 162	KESIMPTA PEN... 110	KLOXXADO... 21
JYNARQUE... 126	ketoconazole... 46	KONVOMEF... 132
JYNNEOS (PF)... 162	ketodan... 46	KORLYM... 174
K	ketoprofen... 14	KOSELUGO... 57
KABIVEN... 126	ketorolac... 14, 15, 179	KOSHER PRENATAL PLUS IRON... 126
KADCYLA... 57	KEVEYIS... 136	

kourzeq... 114	LAMICTAL XR STARTER (BLUE)... 34	LAZCLUZE... 58
KRAZATI... 57	LAMICTAL XR STARTER (GREEN)... 34	ledipasvir-sofosbuvir... 76
KRINTAFEL... 66	LAMICTAL XR STARTER (ORANGE)... 34	leena 28... 148
KRISTALOSE... 132	LAMICTAL XR... 34	leflunomide... 162
kurvelo (28)... 147	LAMICTAL... 34	LEMTRADA... 110
KUVAN... 136	lamivudine... 76	lenalidomide... 58
KYPROLIS... 58	lamivudine-zidovudine... 76	LENVIMA... 58
L	lamotrigine... 34, 35	LEQVIO... 100
l norgest/e.estradiol-e.estrad... 147	LAMPIT... 66	LESCOL XL... 100
LABETALOL IN DEXTROSE,ISO-OSM... 99	LAMZEDE... 136	lessina... 148
LABETALOL IN NACL (ISO-OSMOT)... 99	LANOXIN PEDIATRIC... 100	LETAIRIS... 186
labetalol... 99	LANOXIN... 99, 100	letrozole... 58
lacosamide... 34	lanreotide... 154	leucovorin calcium... 58
LACRISERT... 179	lansoprazole... 132	LEUKERAN... 58
lactated ringers... 126, 174	LANTUS SOLOSTAR U-100 INSULIN... 84	LEUKINE... 90
lactulose... 132	LANTUS U-100 INSULIN... 84	leuprolide (3 month)... 154
LAGEVRIO (EUA)... 76	lapatinib... 58	leuprolide... 154
LAMICTAL ODT STARTER (BLUE)... 34	larin fe 1.5/30 (28)... 148	levalbuterol hcl... 186
LAMICTAL ODT STARTER (GREEN)... 34	larin fe 1/20 (28)... 148	levalbuterol tartrate... 186
LAMICTAL ODT STARTER (ORANGE)... 34	larin 1.5/30 (21)... 148	levamlodipine... 100
LAMICTAL ODT... 34	larin 1/20 (21)... 148	LEVEMIR FLEXPEN... 85
LAMICTAL STARTER (BLUE) KIT... 34	larin 24 fe... 148	LEVEMIR FLEXTOUCH U100 INSULIN... 85
LAMICTAL STARTER (GREEN) KIT... 34	LASIX... 100	LEVEMIR U-100 INSULIN... 85
LAMICTAL STARTER (ORANGE) KIT... 34	latanoprost... 179	levetiracetam in nacl (iso-os)... 35
	LATUDA... 71	levetiracetam... 35
	LAYOLIS FE... 148	LEVO-T... 153
		levobunolol... 179

levocarnitine (with sugar)... 126	lidocaine-epinephrine bit... 20	LIVALO... 100
levocarnitine... 126	lidocaine-epinephrine... 20	LIVDELZI... 132
levocetirizine... 186	lidocaine-prilocaine... 20	LIVMARLI... 132
levofloxacin in d5w... 28	lidocan iii... 20	LIVTENCITY... 76
levofloxacin... 28, 179	lidocan iv... 20	LO LOESTRIN FE... 148
levoleucovorin calcium... 58	lidocan v... 20	lo-zumandimine (28)... 148
levonest (28)... 148	LIDODERM... 20	LOCOID LIPOCREAM... 120
levonorg-eth estrad triphasic... 148	lignospan standard... 20	LOCOID... 120
levonorgest-eth.estradiol-iron... 148	LINCOCIN... 28	LODINE... 15
levonorgestrel-ethinyl estrad... 148	lincomycin... 28	LODOCO... 100
LEVOPHED (BITARTRATE)... 100	lindane... 120	LODOSYN... 67
levora-28... 148	linezolid in dextrose 5%... 28	LOESTRIN FE 1.5/30 (28-DAY)... 148
levorphanol tartrate... 15	linezolid... 28	LOESTRIN FE 1/20 (28-DAY)... 148
levothyroxine... 153	linezolid-0.9% sodium chloride... 28	LOESTRIN 1.5/30 (21)... 148
LEVOXYL... 153	LINZESS... 132	LOESTRIN 1/20 (21)... 148
LEVULAN... 58	liothyronine... 153	lofena... 15
LEXAPRO... 40	LIPITOR... 100	lofexidine... 21
LEXETTE... 120	LIPOFEN... 100	lojaimiess... 148
LEXIVA... 76	LIQREV... 186	LOKELMA... 127
LIALDA... 168	liraglutide... 85	LOMOTIL... 132
LIBERVANT... 35	lisdexamfetamine... 110	LONHALA MAGNAIR REFILL... 186
LIBTAYO... 58	lisinopril... 100	LONHALA MAGNAIR STARTER... 186
LICART... 15	lisinopril-hydrochlorothiazide... 100	LONSURF... 58
lidocaine (pf)... 19, 100	LITFULO... 162	loperamide... 132
lidocaine hcl... 19, 20	lithium carbonate... 81	LOPID... 100
lidocaine in 5 % dextrose (pf)... 100	lithium citrate... 81	lopinavir-ritonavir... 76
lidocaine viscous... 20	LITHOBID... 81	LOPRESSOR... 100
lidocaine... 19	LITHOSTAT... 174	LOPROX (AS OLAMINE)... 46

LOPROX... 46	LUMIZYME... 136	LYUMJEV TEMPO
LOQTORZI... 58	LUMRYZ... 191	PEN(U-100)INSULN... 85
lorazepam intensol... 81	LUNESTA... 191	LYUMJEV U-100 INSULIN... 85
lorazepam... 80, 81	LUNSUMIO... 58	LYVISPAN... 73
LORBRENA... 58	LUPKYNIS... 162	lyza... 148
LOREEV XR... 81	LUPRON DEPOT (3 MONTH)... 154	M
lortab elixir... 15	LUPRON DEPOT (4 MONTH)... 154	M-M-R II (PF)... 162
loryna (28)... 148	LUPRON DEPOT (6 MONTH)... 155	m-natal plus... 127
LORZONE... 190	LUPRON DEPOT... 154	MACROBID... 28
losartan... 100	LUPRON DEPOT-PED (3 MONTH)... 155	MACRODANTIN... 28
losartan-hydrochlorothiazide... 100	LUPRON DEPOT-PED... 155	mafenide acetate... 121
LOTEMAX SM... 179	lurasidone... 71	magnesium sulfate in d5w... 127
LOTEMAX... 179	lutra (28)... 148	magnesium sulfate in water... 127
LOTENSIN HCT... 100	LUXIQ... 120	magnesium sulfate... 127
LOTENSIN... 100	LUZU... 46	MALARONE PEDIATRIC... 66
loteprednol etabonate... 179	LYBALVI... 71	MALARONE... 66
LOTREL... 100	lyleq... 148	malathion... 121
LOTRONEX... 132	lyllana... 148	mannitol 10 %... 100
lovastatin... 100	LYNPARZA... 58	mannitol 20 %... 100
LOVAZA... 100	LYRICA CR... 110	mannitol 25 %... 100
LOVENOX... 90	LYRICA... 110	mannitol 5 %... 100
low-ogestrel (28)... 148	LYSODREN... 58	maraviroc... 76
loxapine succinate... 71	LYSTEDA... 90	MARCAINE (PF)... 20
lubiprostone... 132	LYTGOBI... 59	MARCAINE SPINAL (PF)... 20
LUCEMYRA... 21	LYUMJEV KWIKPEN U-100	MARCAINE... 20
luliconazole... 46	INSULIN... 85	MARCAINE-EPINEPHRINE (PF)... 20
LUMAKRAS... 58	LYUMJEV KWIKPEN U-200	MARCAINE-EPINEPHRINE... 20
LUMIGAN... 179	INSULIN... 85	MARGENZA... 59

MARINOL... 43	medroxyprogesterone... 148, 149	meropenem-0.9% sodium chloride... 28
marlissa (28)... 148	mefenamic acid... 15	merzee... 149
MARPLAN... 40	mefloquine... 66	mesalamine... 168
MATULANE... 59	megestrol... 149	mesna... 59
matzim la... 101	MEKINIST... 59	MESNEX... 59
MAVENCLAD (10 TABLET PACK)... 110	MEKTOVI... 59	MESTINON TIMESPAN... 50
MAVENCLAD (4 TABLET PACK)... 110	meloxicam submicronized... 15	MESTINON... 50
MAVENCLAD (5 TABLET PACK)... 110	meloxicam... 15	METADATE CD... 111
MAVENCLAD (6 TABLET PACK)... 110	melphalan hcl... 59	metadate er... 111
MAVENCLAD (7 TABLET PACK)... 110	melphalan... 59	metaxalone... 190
MAVENCLAD (8 TABLET PACK)... 110	memantine... 38, 39	metformin... 85
MAVENCLAD (9 TABLET PACK)... 111	MENACTRA (PF)... 162	methadone intensol... 15
MAVYRET... 76, 77	MENEST... 149	methadone... 15
MAXALT... 49	MENOPUR... 194	METHADOSE... 15
MAXALT-MLT... 49	MENOSTAR... 149	methamphetamine... 111
MAXIDEX... 179	MENQUADFI (PF)... 162	methazolamide... 180
MAXITROL... 180	MENTAX... 46	methenamine hippurate... 28
MAXZIDE... 101	MENVEO A-C-Y-W-135-DIP (PF)... 162	methimazole... 156
MAXZIDE-25MG... 101	mepерidine (pf)... 15	METHITEST... 149
MAYZENT STARTER(FOR 1MG MAINT)... 111	mepерidine... 15	methocarbamol... 190, 191
MAYZENT STARTER(FOR 2MG MAINT)... 111	MEPHYTON... 195	methotrexate sodium (pf)... 162
MAYZENT... 111	meprobamate... 81	methotrexate sodium... 162
meclizine... 44	MEPRON... 66	methoxsalen... 121
meclofenamate... 15	MEPSEVII... 136	methscopolamine... 132
MEDROL (PAK)... 140	mercaptopurine... 59	methsuximide... 35
MEDROL... 140	meropenem... 28	methyl dopa... 101

methyldopa-hydrochlorothiazide... 101	MICAFUNGIN IN 0.9 % SODIUM CHL... 46	MINOCIN... 28
methyldopate... 101	micafungin... 46	minocycline... 28, 29
methylergonovine... 174	MICARDIS HCT... 101	minoxidil... 101
METHYLIN... 111	MICARDIS... 101	MIOSTAT... 180
methylphenidate hcl... 111	miconazole nitrate-zinc ox-pet... 46	MIRAPEX ER... 67
methylphenidate... 111	miconazole-3... 46	MIRENA... 174
methylprednisolone acetate... 140	microgestin fe 1.5/30 (28)... 149	mirtazapine... 40, 41
methylprednisolone sodium succ... 140	microgestin fe 1/20 (28)... 149	MIRVASO... 121
methylprednisolone... 140	microgestin 1.5/30 (21)... 149	misoprostol... 132
methyltestosterone... 149	microgestin 1/20 (21)... 149	MITIGARE... 48
metoclopramide hcl... 44	microgestin 24 fe... 149	mitigo (pf)... 15
metolazone... 101	midodrine... 101	mitomycin... 59
metoprolol succinate... 101	MIEBO (PF)... 180	mitoxantrone... 59
metoprolol ta-hydrochlorothiaz... 101	mifepristone... 174	modafinil... 192
metoprolol tartrate... 101	migergot... 49	moexipril... 101
METRO I.V.... 28	miglitol... 85	molindone... 71
METROCREAM... 28	miglustat... 136	mometasone... 121, 186
METROGEL... 28	MIGRANAL... 49	mondoxynel... 29
METROLOTION... 28	mili... 149	MONJUVI... 162
metronidazole in nacl (iso-os)... 28	millipred dp... 140	mono-lynyah... 149
metronidazole... 28	millipred... 140	MONODOX... 29
metyrosine... 101	milrinone in 5 % dextrose... 101	montelukast... 186
mexiletine... 101	milrinone... 101	MONUROL... 29
MIACALCIN... 169	mimvey... 149	morgidox... 29
mibelas 24 fe... 149	MINASTRIN 24 FE... 149	morphine (pf)... 16
	MINIPRESS... 101	morphine concentrate... 16
	MINIVELLE... 149	morphine... 15, 16
		MOTTEGRITY... 132

MOTOFEN... 132	MYFORTIC... 162	naproxen... 17
MOTPOLY XR... 35	MYHIBBIN... 162	naproxen-esomeprazole... 17
MOUNJARO... 85	MYLOTARG... 59	naratriptan... 49
MOVANTIK... 132	myorisan... 121	NARCAN... 21
MOVIPREP... 132	MYRBETRIQ... 138	NARDIL... 41
moxifloxacin... 29, 180	MYSOLINE... 35	NAROPIN (PF)... 20
moxifloxacin-sod.ace,sul-water... 29	MYTESI... 132	NASCOBAL... 195
	N	NATACHEW (FE BIS-GLYCINATE)... 127
moxifloxacin-sod.chloride(iso)... 29	nabumetone... 16	NATACYN... 180
MOZOBIL... 90	nadolol... 101	NATAZIA... 149
MRESVIA (PF)... 162	nafcillin in dextrose iso-osm... 29	nateglinide... 85
MS CONTIN... 16	nafcillin... 29	NATESTO... 149
MULPLETA... 90	naftifine... 46	NATPARA... 169
MULTAQ... 101	NAFTIN... 46, 47	NATROBA... 121
mupirocin calcium... 121	NAGLAZYME... 136	NAYZILAM... 35
mupirocin... 121	nalbuphine... 16	nebivolol... 101
MUTAMYCIN... 59	NALFON... 16	NEBUPENT... 66
MVASI... 59	nalmefene... 21	necon 0.5/35 (28)... 149
MYALEPT... 132	nalocet... 16	nefazodone... 41
MYAMBUTOL... 51	naloxone... 21	NEFFY... 186
MYCAMINE... 46	naltrexone... 21	nelarabine... 59
MYCAPSSA... 155	NAMENDA TITRATION PAK... 39	NEMBUTAL SODIUM... 35
MYCOBUTIN... 51	NAMENDA XR... 39	NEMLUVIO... 162
mycophenolate mofetil (hcl)... 162	NAMENDA... 39	neo-polycin hc... 180
mycophenolate mofetil... 162	NAMZARIC... 39	neo-polycin... 180
mycophenolate sodium... 162	NAPRELAN CR... 16, 17	NEO-SYNALAR... 121
MYDAYIS... 111	NAPROSYN... 17	neomycin... 29
MYFEMBREE... 155	naproxen sodium... 17	

neomycin-bacitracin-poly-hc... 180	NEXIUM... 132	nitrofurantoin... 29
neomycin-bacitracin-polymyxin... 180	NEXLETOL... 102	nitroglycerin in 5 % dextrose... 102
neomycin-polymyxin b gu... 174	NEXLIZET... 102	nitroglycerin... 102, 174
neomycin-polymyxin b-dexameth... 180	NEXPLANON... 149	NITROLINGUAL... 102
neomycin-polymyxin-gramicidin... 180	NEXTERONE... 102	NITROSTAT... 102
neomycin-polymyxin-hc... 180, 182	NEXTSTELLIS... 149	NITYR... 136
NEONATAL COMPLETE... 127	NEXVIAZYME... 136	NIVESTYM... 90
NEONATAL PLUS VITAMIN... 127	NGENLA... 142	nizatidine... 133
NEONATAL-DHA... 127	niacin... 102	NOCDURNA (MEN)... 142
NEORAL... 163	niacor... 102	NOCDURNA (WOMEN)... 142
NERLYNX... 59	nicardipine... 102	NORA-BE... 149
NESACAINE... 20	NICOTROL NS... 21	NORDITROPIN FLEXP... 142
NESACAINE-MPF... 20	NICOTROL... 21	norelgestromin-ethin.estradiol... 149
NESINA... 85	nifedipine... 102	norepinephrine bitartrate... 102
neuac... 121	nikki (28)... 149	noreth-ethinyl estradiol-iron... 149
NEULASTA ONPRO... 90	NILANDRON... 59	norethindrone (contraceptive)... 149
NEULASTA... 90	nilutamide... 59	norethindrone ac-eth estradiol... 150
NEUPOGEN... 90	nimodipine... 102	norethindrone acetate... 150
NEUPRO... 67	NINLARO... 59	norethindrone-e.estradiol-iron... 150
NEURONTIN... 35	NIPENT... 59	NORGESIC FORTE... 191
NEVANAC... 180	nisoldipine... 102	norgesic... 191
nevirapine... 77	nitazoxanide... 66	norgestimate-ethinyl estradiol... 150
NEXAVAR... 59	nitisinone... 136	NORITATE... 29
NEXICLON XR... 102	NITRO-BID... 102	NORLIQVA... 102
NEXIUM IV... 132	NITRO-DUR... 102	
NEXIUM PACKET... 133	nitrofurantoin macrocrystal... 29	
	nitrofurantoin monohyd/m-cryst... 29	

NORMOSOL-M IN 5 % DEXTROSE... 127	NOVOLOG MIX 70-30FLEXPEN U-100... 86	nystatin-triamcinolone... 47
NORPACE CR... 102	NOVOLOG PENFILL U-100 INSULIN... 86	nystop... 47
NORPACE... 102		NYVEPRIA... 90
NORPRAMIN... 41	NOVOLOG U-100 INSULIN ASPART... 86	O
NORTHERA... 102, 103	NOVOPEN ECHO... 174	OB COMPLETE ONE... 127
nortrel 0.5/35 (28)... 150	NOXAFIL... 47	OB COMPLETE PETITE... 127
nortrel 1/35 (21)... 150	np thyroid... 154	OB COMPLETE PREMIER... 127
nortrel 1/35 (28)... 150	NUBEQA... 59	OBREDON... 193
nortrel 7/7/7 (28)... 150	NUCALA... 186	OCALIVA... 133
nortriptyline... 41	NUCYNTA ER... 17	ocella... 150
NORVASC... 103	NUCYNTA... 17	OCREVUS... 111
NORVIR... 77	NUEDEXTA... 111	OCTAGAM... 163
NOURIANZ... 67	NULIBRY... 136	octreotide acetate... 155
NOVAREL... 142	NUPLAZID... 71	OCUFLOX... 180
NOVOLIN N FLEXPEN... 85	NURTEC ODT... 49	ODACTRA... 186
NOVOLIN N NPH U-100 INSULIN... 85	NUTRILIPID... 127	ODEFSEY... 77
NOVOLIN R FLEXPEN... 85	NUTROPIN AQ NUSPIN... 142	ODOMZO... 59
NOVOLIN R REGULAR U100 INSULIN... 85	NUVARING... 150	OFEV... 187
NOVOLIN 70-30 FLEXPEN U-100... 85	NUVESSA... 29	ofloxacin... 29, 180, 182
NOVOLIN 70/30 U-100 INSULIN... 85	NUVIGIL... 192	OGIVRI... 59
NOVOLOG FLEXPEN U-100 INSULIN... 85	NUZYRA... 29	OGSIVEO... 59
NOVOLOG MIX 70-30 U-100 INSULN... 85	nyamyc... 47	OHTUVAYRE... 187
	nylia 1/35 (28)... 150	OJEMDA... 59, 60
	nylia 7/7/7 (28)... 150	OJJAARA... 60
	NYMALIZE... 103	olanzapine... 71
	nymyo... 150	olanzapine-fluoxetine... 41
	nystatin... 47	OLINVYK... 17
		olmesartan... 103

olmesartan-amlodipin-hcthiazyd... 103	OMNIPOD GO PODS 40 UNITS/DAY... 175	OPSUMIT... 187
olmesartan-hydrochlorothiazide... 103	OMNIPOD GO PODS... 174	OPSYNVI... 187
olopatadine... 180, 187	OMNIPOD 5 G6 INTRO KIT (GEN 5)... 174	OPVEE... 22
OLPRUVA... 136	OMNIPOD 5 G6 PODS (GEN 5)... 174	OPZELURA... 121
OLUMIANT... 163	OMNIPOD 5 G6-G7 INTRO KT(GEN5)... 174	ORACEA... 29
OLUX... 121	OMNIPOD 5 G6-G7 PODS (GEN 5)... 174	ORALAIR... 187
OLUX-E... 121	OMNITROPE... 142	oralone... 114
OMECLAMOX-PAK... 133	OMVOH PEN... 163	ORAPRED ODT... 140
omega-3 acid ethyl esters... 103	OMVOH... 163	ORBACTIV... 29
MEGAVEN... 127	ONCASPAR... 60	ORENCIA CLICKJECT... 163
omeprazole... 133	ondansetron hcl (pf)... 44	ORENCIA... 163
omeprazole-sodium bicarbonate... 133	ondansetron hcl... 44	ORENITRAM MONTH 1 TITRATION KT... 187
OMNARIS... 187	ondansetron... 44	ORENITRAM MONTH 2 TITRATION KT... 187
OMNIPOD CLASSIC PODS (GEN 3)... 174	ONEXTON... 121	ORENITRAM MONTH 3 TITRATION KT... 187
OMNIPOD DASH INTRO KIT (GEN 4)... 174	ONFI... 35	ORENITRAM... 187
OMNIPOD DASH PODS (GEN 4)... 174	ONGENTYS... 67	ORFADIN... 136
OMNIPOD GO PODS 10 UNITS/DAY... 174	ONIVYDE... 60	ORGOVYX... 60
OMNIPOD GO PODS 15 UNITS/DAY... 174	ONPATTRO... 136	ORIAHNN... 155
OMNIPOD GO PODS 20 UNITS/DAY... 174	ONTRUZANT... 60	ORILISSA... 155
OMNIPOD GO PODS 25 UNITS/DAY... 174	ONUREG... 60	ORKAMBI... 187
OMNIPOD GO PODS 30 UNITS/DAY... 175	ONZETRA XSAIL... 49	ORLADEYO... 163
	OPDIVO... 60	orlistat... 175
	OPDUALAG... 60	ormalvi... 136
	OPFOLDA... 136	orphenadrine citrate... 191
	opium tincture... 133	orphenadrine-asa-caffeine... 191
		orphengesic forte... 191

ORSERDU... 60	OXISTAT... 47	PALFORZIA (LEVEL 8)... 175
ORTIKOS... 168	OXLUMO... 175	PALFORZIA (LEVEL 9)... 175
oseltamivir... 77	OXTELLAR XR... 35	PALFORZIA INITIAL DOSE... 175
OSENI... 86	oxybutynin chloride... 139	PALFORZIA LEVEL 11 MAINTENANCE... 175
OSMITROL 10 %... 103	oxycodone... 17	paliperidone... 71
OSMITROL 15 %... 103	oxycodone-acetaminophen... 17	PALYNZIQ... 136
OSMITROL 20 %... 103	OXYCONTIN... 18	PAMELOR... 41
OSMITROL 5 %... 103	oxymorphone... 18	pamidronate... 170
OSMOLEX ER... 67, 68	oxytocin... 175	PANCREAZE... 136
OSMOPREP... 133	OXYTROL... 139	PANDEL... 121
OSPHENA... 150	OZEMPIC... 86	PANRETIN... 60
OTEZLA STARTER... 121	OZOBAX DS... 73	pantoprazole in 0.9% sod chlor... 133
OTEZLA... 121	OZOBAX... 73	pantoprazole... 133
OTOVEL... 182	P	PANZYGA... 163
OTREXUP (PF)... 163	PACERONE... 103	paraplatin... 60
OVIDE... 121	paclitaxel protein-bound... 60	paricalcitol... 170
OVIDREL... 194	paclitaxel... 60	PARLODEL... 68
oxacillin in dextrose(iso-osm)... 29	PADCEV... 60	PARNATE... 41
oxacillin... 29	PALFORZIA (LEVEL 1)... 175	paromomycin... 29
oxaliplatin... 60	PALFORZIA (LEVEL 10)... 175	paroxetine hcl... 41
oxandrolone... 150	PALFORZIA (LEVEL 11 UP-DOSE)... 175	paroxetine mesylate(menop.sym)... 41
oxaprozin... 17	PALFORZIA (LEVEL 2)... 175	PATANASE... 187
OXAYDO... 17	PALFORZIA (LEVEL 3)... 175	PAXIL CR... 41
oxazepam... 81	PALFORZIA (LEVEL 4)... 175	PAXIL... 41
OXBRYTA... 136	PALFORZIA (LEVEL 5)... 175	PAXLOVID... 77
oxcarbazepine... 35	PALFORZIA (LEVEL 6)... 175	pazopanib... 60
OXERVATE... 180	PALFORZIA (LEVEL 7)... 175	
oxiconazole... 47		

PEDIAPRED... 140	pentazocine-naloxone... 18	phenytoin... 36
PEDIARIX (PF)... 163	pentobarbital sodium... 35	PHESGO... 61
PEDMARK... 60	pentoxifylline... 103	PHEXXI... 175
PEDVAX HIB (PF)... 163	pepcid... 133	philith... 150
peg 3350-electrolytes... 133	PERCOCET... 18	PHOSPHOLINE IODIDE... 180
peg-electrolyte soln... 133	PERFOROMIST... 187	PHYSIOLYTE... 175
peg-prep... 133	PERIKABIVEN... 127	PHYSIOSOL IRRIGATION... 175
PEGASYS... 163	perindopril erbumine... 103	phytonadione (vitamin k1)... 195
peg3350-sod sul-nacl-kcl-asb-c... 133	periogard... 114	PIASKY... 163
PEMAZYRE... 60	PERJETA... 61	PIFELTRO... 77
pemetrexed disodium... 60	permethrin... 121	pilocarpine hcl... 114, 180
pemetrexed... 60	perphenazine... 71	pimecrolimus... 121
PEMRYDI RTU... 60	perphenazine-amitriptyline... 41	pimozide... 71
PEN NEEDLE, DIABETIC... 175	PERSERIS... 71	pimtree (28)... 150
PENBRAYA (PF)... 163	PERTZYE... 137	pindolol... 103
penciclovir... 77	PEXEVA... 41	pioglitazone... 86
penicillamine... 127	pfizerpen-g... 30	pioglitazone-glimepiride... 86
penicillin g pot in dextrose... 29	PHEBURANE... 137	pioglitazone-metformin... 86
penicillin g potassium... 29	phenazopyridine... 175	piperacillin-tazobactam... 30
penicillin g procaine... 29	phenelzine... 41	PIQRAY... 61
penicillin g sodium... 29	PHENERGAN... 44	pirfenidone... 187
penicillin v potassium... 29, 30	phenobarbital sodium... 36	piroxicam... 18
PENNSAID... 18	phenobarbital... 35, 36	pitavastatin calcium... 103
PENTACEL (PF)... 163	phenoxybenzamine... 103	PITOCIN... 175
PENTAM... 66	phenylephrine hcl... 103	PLAQUENIL... 66
pentamidine... 66	PHENYTEK... 36	PLASMA-LYTE A... 127
PENTASA... 168	phenytoin sodium extended... 36	PLASMA-LYTE 148... 127
	phenytoin sodium... 36	PLAVIX... 90

PLEGRIDY... 112	potassium chloride in 0.9%nacl... 128	PRED-G... 180
PLENAMINE... 127	potassium chloride in 5 % dex... 128	prednicarbate... 121
PLENVU... 133	potassium chloride... 127, 128	prednisolone acetate... 180
plerixafor... 90	potassium chloride-d5-0.2%nacl... 128	prednisolone sodium phosphate... 141, 180
PLIAGLIS... 20	potassium chloride-d5-0.3%nacl... 128	prednisolone... 140, 141
pnv-dha... 127	potassium chloride-d5-0.9%nacl... 128	prednisone intensol... 141
pnv-omega... 127	potassium chloride-0.45 % nacl... 128	prednisone... 141
podofilox... 121	potassium citrate... 128	PREFEST... 150
POLIVY... 61	POTELIGEO... 61	pregabalin... 112
polocaine... 20	pr natal 400 ec... 128	PREGNYL... 143
polocaine-mpf... 20	pr natal 400... 128	PREHEVBRIO (PF)... 163
polycin... 180	pr natal 430 ec... 128	PREMARIN... 150
polymyxin b sulf-trimethoprim... 180	pr natal 430... 128	PREMASOL 10 %... 128
polymyxin b sulfate... 30	PRADAXA... 90	PREMPHASE... 150
POMALYST... 61	pralatrexate... 61	PREMPRO... 150
POMBILITI... 137	PRALUENT PEN... 103	PRENATA... 128
PONVORY 14-DAY STARTER PACK... 112	pramipexole... 68	PRENATABS FA... 128
PONVORY... 112	prasugrel... 90	prenatal plus (calcium carb)... 128
portia 28... 150	pravastatin... 103	prenatal plus dha... 128
PORTRAZZA... 61	praziquantel... 66	prenatal plus vitamin-mineral... 128
posaconazole... 47	prazosin... 103	prenatal vitamin plus low iron... 128
potassium acetate... 127	PRECOSE... 86	prenatal-u... 128
potassium chlorid-d5-0.45%nacl... 127	PRED FORTE... 180	PRENATE ELITE... 128
potassium chloride in lr-d5... 128	PRED MILD... 180	PRETOMANID... 51
potassium chloride in water... 128		PREVACID SOLUTAB... 133
		PREVACID... 133
		prevalite... 103

PREVDUO... 175	procto-med hc... 121	propranolol-hydrochlorothiazid... 104
PREVYMIS... 77	PROCTOFOAM HC... 168	propylthiouracil... 156
PREZCOBIX... 77	proctosol hc... 121	PROQUAD (PF)... 163
PREZISTA... 77	proctozone-hc... 122	PROSCAR... 139
PRIALT... 175	PROCYSBI... 137	PROSOL 20 %... 128
PRIFTIN... 51	progesterone micronized... 150	protamine... 176
PRILOSEC... 133	progesterone... 150	PROTONIX... 133
primaquine... 66	PROGLYCEM... 86	PROTOPIC... 122
PRIMAXIN IV... 30	PROGRAF... 163	protriptyline... 41
primidone... 36	PROLASTIN-C... 137	PROVENTIL HFA... 187
primlev... 18	prolate... 18	PROVERA... 151
PRIMSOL... 30	PROLENSA... 180	PROVIGIL... 192
PRIORIX (PF)... 163	PROLIA... 170	PROZAC... 41
PRISTIQ... 41	PROMACTA... 91	PRUDOXIN... 122
PRIVIGEN... 163	promethazine vc... 175	PULMICORT FLEXHALER... 188
PRO COMFORT ALCOHOL PADS... 175	promethazine vc-codeine... 193	PULMICORT... 187
PROAIR DIGIHALER... 187	promethazine... 44	PULMOZYME... 188
PROAIR HFA... 187	promethazine-codeine... 193	PURE COMFORT ALCOHOL PADS... 176
PROAIR RESPICLICK... 187	promethazine-dm... 193	PURIXAN... 61
probenecid... 48	promethazine-phenyleph-codeine... 193	PYLERA... 133
probenecid-colchicine... 48	promethazine-phenylephrine... 176	pyrazinamide... 51
procainamide... 103	promethegan... 44	PYRIDIDIUM... 176
PROCARDIA XL... 103	PROMETRIUM... 151	pyridostigmine bromide... 50
procentra... 112	propafenone... 104	pyridoxine (vitamin b6)... 195
prochlorperazine edisylate... 44	proparacaine... 181	pyrimethamine... 66
prochlorperazine maleate... 44	propranolol... 104	PYRUKYND... 137
prochlorperazine... 44		
PROCRIT... 91		

Q

QALSODY... 112
 QBRELIS... 104
 QBREXZA... 122
 QDOLO... 18
 QELBREE... 112
 QINLOCK... 61
 QNASL... 188
 QTERN... 86
 QUADRACEL (PF)... 163
 QUALAQUIN... 66
 QUARTETTE... 151
 QUDEXY XR... 36
 QUESTRAN LIGHT... 104
 QUESTRAN... 104
 quetiapine... 71
 QUILLICHEW ER... 112
 QUILLIVANT XR... 112
 quinapril... 104
 quinapril-hydrochlorothiazide... 104
 quinidine gluconate... 104
 quinidine sulfate... 104
 quinine sulfate... 66
 QULIPTA... 49
 QUTENZA... 176
 QUVIVIQ... 192
 QUZYTIR... 188
 QVAR REDIHALER... 188

R

RABAVERT (PF)... 164
 rabeprazole... 133
 RADICAVA ORS STARTER KIT SUSP...
 112
 RADICAVA ORS... 112
 RADICAVA... 112
 RAGWITEK... 188
 raloxifene... 151
 ramelteon... 192
 ramipril... 104
 RANEXA... 104
 ranolazine... 104
 RAPAFLO... 139
 RAPAMUNE... 164
 rasagiline... 68
 RASUVO (PF)... 164
 RAVICTI... 137
 RAYALDEE... 170
 RAYOS... 141
 RAZADYNE ER... 39
 REBIF (WITH ALBUMIN)... 112
 REBIF REBIDOSE... 112
 REBIF TITRATION PACK... 112
 REBLOZYL... 91
 REBYOTA... 133
 RECARBRIO... 30
 RECLAST... 170

reclusen (28)... 151
 RECOMBIVAX HB (PF)... 164
 RECORLEV... 155
 RECTIV... 176
 REDITREX (PF)... 164
 REGLAN... 44
 REGONOL... 50
 REGRANEX... 122
 RELAFEN DS... 18
 RELAFEN... 18
 RELENZA DISKHALER... 77
 RELEUKO... 91
 RELEXXII... 112
 RELISTOR... 133, 134
 RELPAX... 49
 RELTONE... 134
 REMERON SOLTAB... 41
 REMERON... 41
 REMICADE... 164
 REMODULIN... 188
 RENACIDIN... 176
 RENFLEXIS... 164
 repaglinide... 86
 REPATHA PUSHTRONEX... 104
 REPATHA SURECLICK... 104
 REPATHA SYRINGE... 104
 RESPA-AR... 193
 RESTASIS MULTIDOSE... 181

RESTASIS... 181	RILUTEK... 112	ROLVEDON... 91
RESTORIL... 192	riluzole... 112	romidepsin... 61
RETACRIT... 91	rimantadine... 78	ropinirole... 68
RETEVMO... 61	RIMSO-50... 176	ropivacaine (pf)... 20
RETIN-A MICRO PUMP... 122	ringer's... 128, 176	rosadan... 30
RETIN-A MICRO... 122	RINVOQ LQ... 164	rosuvastatin... 104
RETIN-A... 122	RINVOQ... 164	ROTARIX... 164, 165
RETROVIR... 77	RIOMET... 86	ROTATEQ VACCINE... 165
REVATIO... 188	risedronate... 170	ROWASA... 168
REVCOVI... 137	RISPERDAL CONSTA... 72	roweepra xr... 36
revonto... 73	RISPERDAL... 71, 72	roweepra... 36
REXULTI... 71	risperidone... 72	ROXICODONE... 18
REYATAZ... 77, 78	RITALIN LA... 112	ROXYBOND... 18
REYVOW... 49	RITALIN... 112	ROZEREM... 192
REZDIFFRA... 176	ritonavir... 78	ROZLYTREK... 61
REZLIDHIA... 61	RITUXAN HYCELA... 61	RUBRACA... 61
REZUROCK... 164	RITUXAN... 61	RUCONEST... 165
REZVOGLAR KWIKPEN... 86	rivastigmine tartrate... 39	rufinamide... 36
REZZAYO... 47	rivastigmine... 39	RUKOBIA... 78
RHOPHYLAC... 164	rivelsa... 151	RUXIENCE... 61
RHOPRESSA... 181	RIVFLOZA... 176	RYALTRIS... 188
RIABNI... 61	rizatriptan... 49	RYBELSUS... 86
RIASTAP... 91	ROBAXIN... 191	RYBREVANT... 61
ribavirin... 78, 176	ROBINUL FORTE... 134	RYCLORA... 188
RIDAURA... 164	ROBINUL... 134	RYDAPT... 61
rifabutin... 51	ROCALTROL... 170	RYLAZE... 62
RIFADIN... 51	ROCKLATAN... 181	RYSTIGGO... 165
rifampin... 51	roflumilast... 188	RYTARY... 68

RYTELO... 62	SECUADO... 72	sharobel... 151
RYTHMOL SR... 104	SEGLENTIS... 18	SHINGRIX (PF)... 165
RYVENT... 188	SEGLUROMET... 86	SIGNIFOR LAR... 155
S	SELECT-OB (FOLIC ACID)... 129	SIGNIFOR... 155
SABRIL... 36	SELECT-OB + DHA... 129	SIKLOS... 176
SAFYRAL... 151	SELECT-OB... 129	sildenafil (pulm.hypertension)... 188
SAIZEN SAIZENPREP... 143	selegiline hcl... 68	SILENOR... 192
SAIZEN... 143	selenium sulfide... 122	SILIQ... 165
sajazir... 165	SELZENTRY... 78	silodosin... 139
SALAGEN (PILOCARPINE)... 114	SEMGLEE(INSULIN GLARG-YFGN)PEN... 86	SILVADENE... 122
SAMSCA... 128	SEMGLEE(INSULIN GLARGINE-YFGN)... 86	silver sulfadiazine... 122
SANCUSO... 44	SENSIPAR... 170	SIMBRINZA... 181
SANDIMMUNE... 165	SENSORCAINE... 20	SIMLANDI(CF) AUTOINJECTOR... 165
SANDOSTATIN LAR DEPOT... 155	sensorcaine-epinephrine... 20	simliya (28)... 151
SANDOSTATIN... 155	sensorcaine-mpf spinal... 21	simpesse... 151
SANTYL... 122	SENSORCAINE-MPF... 20, 21	SIMPONI ARIA... 165
SAPHNELO... 165	sensorcaine-mpf/epinephrine... 21	SIMPONI... 165
SAPHRIS... 72	SEREVENT DISKUS... 188	SIMULECT... 165
sapropterin... 137	SEROQUEL XR... 72	simvastatin... 104
SARCLISA... 62	SEROQUEL... 72	SINEMET... 68
SAVAYSA... 91	SEROSTIM... 143	SINGULAIR... 188
SAVELLA... 113	sertraline... 42	sirolimus... 165
saxagliptin... 86	setlakin... 151	SIRTURO... 51
saxagliptin-metformin... 86	SEYSARA... 30	sitagliptin... 86
SCEMBLIX... 62	SEZABY... 36	sitagliptin-metformin... 86
scopolamine base... 44	SFROWASA... 168	SIVEXTRO... 30
se-natal 19 chewable... 129		SKYCLARYS... 113
SEASONIQUE... 151		

SKYRIZI... 165	SOLTAMOX... 62	sprintec (28)... 151
SKYTROFA... 143	SOLU-CORTEF ACT-O-VIAL (PF)... 141	SPRITAM... 36
SLYND... 151	SOLU-CORTEF... 141	SPRIX... 18
SMOFLIPID... 129	SOLU-MEDROL (PF)... 141	SPRYCEL... 62
SOAANZ... 104	SOLU-MEDROL... 141	SPS (WITH SORBITOL)... 129
sodium benzoate-sod phenylacet... 176	SOMA... 191	sronyx... 151
sodium bicarbonate... 129	SOMATULINE DEPOT... 155	SSD... 122
sodium chloride 0.45 %... 129	SOMAVERT... 155	STALEVO 100... 68
sodium chloride 0.9 %... 129	SOOLANTRA... 122	STALEVO 125... 68
sodium chloride 3 % hypertonic... 129	sorafenib... 62	STALEVO 150... 68
sodium chloride 5 % hypertonic... 129	SORILUX... 122	STALEVO 200... 68
sodium chloride... 129, 176	sorine... 104	STALEVO 50... 68
SODIUM EDECRIN... 104	sotalol af... 104	STALEVO 75... 68
sodium oxybate... 192	sotalol... 104	stavudine... 78
sodium phenylbutyrate... 137	SOTYKTU... 165	STEGLATRO... 86
sodium phosphate... 129	SOTYLIZE... 104	STEGLUJAN... 86
sodium polystyrene sulfonate... 129	SOVALDI... 78	STELARA... 165
sodium,potassium,mag sulfates... 134	SOVUNA... 66	STIMUFEND... 91
SOGROYA... 143	SPEVIGO... 165	STIOLTO RESPIMAT... 188
SOHONOS... 176	spinosad... 122	STIVARGA... 62
solifenacin... 139	SPIRIVA RESPIMAT... 188	STRATTERA... 113
SOLIQUA 100/33... 86	SPIRIVA WITH HANDIHALER... 188	STRENSIQ... 137
SOLIRIS... 165	spironolacton-hydrochlorothiaz... 104	streptomycin... 30
SOLODYN... 30	spironolactone... 105	STRIBILD... 78
SOLOSEC... 30	SPORANOX PULSEPAK... 47	STRIVERDI RESPIMAT... 188
	SPORANOX... 47	STROMECTOL... 66
		SUBOXONE... 22
		subvenite starter (blue) kit... 36

subvenite starter (green) kit... 36	SUTENT... 62	TADLIQ... 188
subvenite starter (orange) kit... 36	syeda... 151	TAFINLAR... 62
subvenite... 36	SYLVANT... 166	tafluprost (pf)... 181
SUCRAID... 137	SYMBICORT... 188	TAGRISSE... 62
sucralfate... 134	SYMBYAX... 42	TAKHZYRO... 166
SUFLAVE... 134	SYMDEKO... 188	TALICIA... 134
SULAR... 105	SYMFI LO... 78	TALTZ AUTOINJECTOR (2 PACK)... 166
sulfacetamide sodium (acne)... 30	SYMFI... 78	TALTZ AUTOINJECTOR (3 PACK)... 166
sulfacetamide sodium... 30, 181	SYMLINPEN 120... 87	TALTZ AUTOINJECTOR... 166
sulfacetamide-prednisolone... 181	SYMLINPEN 60... 87	TALTZ SYRINGE... 166
sulfadiazine... 30	SYMPAZAN... 36	TALVEY... 62
sulfamethoxazole-trimethoprim... 30	SYMPROIC... 134	TALZENNA... 62
SULFAMYLON... 122	SYMTUZA... 78	TAMIFLU... 78
sulfasalazine... 168	SYNAGIS... 176	tamoxifen... 62
sulindac... 18	SYNALAR... 122	tamsulosin... 139
sumatriptan succinate... 49	SYNAREL... 155	tanlor... 191
sumatriptan... 49	SYNJARDY XR... 87	taperdex... 141
sumatriptan-naproxen... 49	SYNJARDY... 87	TARCEVA... 62
sunitinib malate... 62	SYNRIBO... 62	TARGADOX... 30
SUNLENCA... 78	SYNTHROID... 154	TARGRETIN... 62
SUNOSI... 192	SYPRINE... 129	tarina fe 1-20 eq (28)... 151
SUPREP BOWEL PREP KIT... 134		tarina fe 1/20 (28)... 151
SURE COMFORT ALCOHOL PREP PADS... 176	T	tarina 24 fe... 151
SURE-PREP ALCOHOL PREP PADS... 176	TABLOID... 62	TARPEYO... 169
SUSTIVA... 78	TABRECTA... 62	TASCENSO ODT... 113
SUTAB... 134	TACLONEX... 122	TASIGNA... 62
	tacrolimus... 122, 166	
	tadalafil (pulm. hypertension)... 188	
	tadalafil... 139	

tasimelteon... 192	TEMODAR... 63	THALITONE... 105
TASMAR... 68	TEMOVATE... 122	THALOMID... 63
tavaborole... 47	temsirolimus... 63	THAM... 129
TAVALISSE... 91	tencon... 176	THEO-24... 189
TAVNEOS... 166	TENIVAC (PF)... 166	theophylline in dextrose 5 %... 189
taysofy... 151	tenofovir disoproxil fumarate... 78	theophylline... 189
TAYTULLA... 151	TENORETIC 100... 105	thiamine hcl (vitamin b1)... 195
tazarotene... 122	TENORETIC 50... 105	THIOLA EC... 139
tazicef... 30	TENORMIN... 105	THIOLA... 139
TAZORAC... 122	TEPADINA... 63	thioridazine... 72
taztia xt... 105	TEPEZZA... 176	thiotepa... 63
TAZVERIK... 62	TEPMETKO... 63	thiothixene... 72
TDVAX... 166	terazosin... 105	THYMOGLOBULIN... 166
TECENTRIQ... 62, 63	terbinafine hcl... 47	THYQUIDITY... 154
TECFIDERA... 113	terbutaline... 189	tiadylt er... 105
TECVAYLI... 63	terconazole... 47	tiagabine... 37
TEFLARO... 30	teriflunomide... 113	TIAZAC... 105
TEGLUTIK... 113	TESTIM... 151	TIBSOVO... 63
TEGRETOL XR... 37	testosterone cypionate... 151	TICOVAC... 166
TEGRETOL... 36	testosterone enanthate... 152	TIGAN... 44
TEGSEDI... 137	testosterone... 151	tigecycline... 30
TEKTURNA HCT... 105	TETANUS,DIPHTHERIA TOX PED(PF)... 166	TIGLUTIK... 113
TEKTURNA... 105	tetrabenazine... 113	TIKOSYN... 105
telmisartan... 105	tetracycline... 30	tilia fe... 152
telmisartan-amlodipine... 105	TEVIMBRA... 63	timolol maleate (pf)... 181
telmisartan-hydrochlorothiazid... 105	TEXACORT... 122	timolol maleate... 105, 181
temazepam... 192	TEZSPIRE... 166	TIMOPTIC OCUDOSE (PF)... 181
		TIMOPTIC... 181

TIMOPTIC-XE... 181	topiramate... 37	TRAZIMERA... 63
tinidazole... 30	toposar... 63	trazodone... 42
tiopronin... 139	topotecan... 63	TREANDA... 63
tirofiban-0.9% sodium chloride... 91	TOPROL XL... 105	TRECATOR... 51
TIROSINT... 154	toremifene... 63	TRELEGY ELLIPTA... 189
TIROSINT-SOL... 154	TORISEL... 63	TRELSTAR... 155
TIVDAK... 63	torpenz... 63	TREMFYA... 166
TIVICAY PD... 78	toremide... 105	treprostinil sodium... 189
TIVICAY... 78	TOSYMRA... 50	TRESIBA FLEXTOUCH U-100... 87
tizanidine... 73	TOUJEO MAX U-300 SOLOSTAR... 87	TRESIBA FLEXTOUCH U-200... 87
TLANDO... 152	TOUJEO SOLOSTAR U-300 INSULIN... 87	TRESIBA U-100 INSULIN... 87
TOBI PODHALER... 189	tovet emollient... 123	tretinoin (antineoplastic)... 63
TOBI... 30	TOVIAZ... 139	tretinoin microspheres... 123
TOBRADEX ST... 181	TPN ELECTROLYTES... 129	tretinoin... 123
TOBRADEX... 181	TRACLEER... 189	TREXALL... 166
tobramycin in 0.225 % nacl... 31	TRADJENTA... 87	TREXIMET... 50
tobramycin sulfate... 31	tramadol... 18, 19	TREZIX... 19
tobramycin... 30, 181	tramadol-acetaminophen... 19	tri-estarylla... 152
tobramycin-dexamethasone... 181	trandolapril... 105	tri-legest fe... 152
TOBEX... 181	trandolapril-verapamil... 105	tri-linyah... 152
tolcapone... 68	tranexamic acid... 91	tri-lo-estarylla... 152
tolectin 600... 18	TRANSDERM-SCOP... 44	tri-lo-marzia... 152
tolmetin... 18	TRANXENE T-TAB... 81	tri-lo-mili... 152
TOLSURA... 47	tranylcypromine... 42	tri-lo-sprintec... 152
tolterodine... 139	TRAVASOL 10 %... 129	tri-mili... 152
tolvaptan... 129	TRAVATAN Z... 181	tri-nymyo... 152
TOPAMAX... 37	travoprost... 181	tri-sprintec (28)... 152
TOPICORT... 123		tri-vylibra lo... 152

tri-vylibra... 152	TRISENOX... 63	TURALIO... 63
triamcinolone acetonide... 114, 141	TRISTART DHA... 129	turqoz (28)... 152
triamterene... 105	tritocin... 141	TUXARIN ER... 193
triamterene-hydrochlorothiazid... 105, 106	TRIUMEQ PD... 79	TUZISTRA XR... 193
trianex... 141	TRIUMEQ... 79	TWINRIX (PF)... 166
triazolam... 192	trivora (28)... 152	TWYNEO... 123
TRIBENZOR... 106	TRIZIVIR... 79	TYBLUME... 152
TRICARE... 129	TRODELVY... 63	TYBOST... 79
TRICOR... 106	TROGARZO... 79	tydemy... 152
tridacaine ii... 21	TROKENDI XR... 37	TYENNE AUTOINJECTOR... 166
tridacaine iii... 21	TROPHAMINE 10 %... 129	TYENNE... 166
triderm... 141	trospium... 139	TYGACIL... 31
trientine... 129	TRUDHESA... 50	TYKERB... 63
trifluoperazine... 72	TRUE COMFORT ALCOHOL PADS... 176	TYMLOS... 170
trifluridine... 181	TRUE COMFORT PRO ALCOHOL PADS... 176	TYPHIM VI... 166
trihexyphenidyl... 68	TRULANCE... 134	TYRVAYA... 181
TRIJARDY XR... 87	TRULICITY... 87	TYSABRI... 113
TRIKAFTA... 189	TRUMENBA... 166	TYVASO DPI... 189
TRILEPTAL... 37	TRUQAP... 63	TYVASO INSTITUTIONAL START KIT... 189
TRILIPIX... 106	TRUSOPT... 181	TYVASO REFILL KIT... 189
trimethobenzamide... 44	TRUVADA... 79	TYVASO STARTER KIT... 189
trimethoprim... 31	TRUXIMA... 63	TYVASO... 189
trimipramine... 42	TRYVIO... 106	U
trinatal rx 1... 129	TUDORZA PRESSAIR... 189	UBRELVY... 50
TRINTELLIX... 42	TUKYSA... 63	UCERIS... 169
TRIOSTAT... 154	tulana... 152	UDENYCA AUTOINJECTOR... 91
TRIPTODUR... 155		UDENYCA ONBODY... 91

UDENYCA... 91	VALCYTE... 79	VASCEPA... 106
ULORIC... 48	valganciclovir... 79	VASERETIC... 106
ULTILET ALCOHOL SWAB... 176	VALIUM... 81	VASOTEC... 106
ULTOMIRIS... 166	valproate sodium... 37	vecamyl... 106
ULTRACET... 19	valproic acid (as sodium salt)... 37	VECTIBIX... 64
ULTRAM... 19	valproic acid... 37	VECTICAL... 123
ULTRAVATE... 123	valrubicin... 64	VEGZELMA... 64
UNASYN... 31	valsartan... 106	VELCADE... 64
UNITHROID... 154	valsartan-hydrochlorothiazide... 106	VELETRI... 190
UNITUXIN... 63	VALSTAR... 64	velivet triphasic regimen (28)... 152
UPLIZNA... 166	VALTOCO... 37	VELSIPITY... 167
UPTRAVI... 189, 190	VALTrex... 79	VELTASSA... 130
UROCIT-K 10... 129	VANCOGIN... 31	VELTIN... 123
UROCIT-K 15... 129	vancomycin in dextrose 5 %... 31	VEMLIDY... 79
UROCIT-K 5... 129	vancomycin in 0.9 % sodium chl... 31	VENCLEXTA STARTING PACK... 64
UROXATRAL... 139	vancomycin... 31	VENCLEXTA... 64
URSO FORTE... 134	vancomycin-diluent combo no.1... 31	VENLAFAXINE BESYLATE... 42
URSO 250... 134	VANDAZOLE... 31	venlafaxine... 42
ursodiol... 134	VANFLYTA... 64	VENTAVIS... 190
UZEDY... 72	VANOS... 123	VENTOLIN HFA... 190
V	VAPRISOL IN 5 % DEXTROSE... 129	VEOPOZ... 167
V-GO 20... 176	VAQTA (PF)... 167	VEOZAH... 113
V-GO 30... 176	varenicline... 22	verapamil... 106
V-GO 40... 176	VARIVAX (PF)... 167	VERDESO... 123
VABOMERE... 31	VARIZIG... 167	VEREGEN... 123
VAGIFEM... 152	VARUBI... 44	VERELAN PM... 106
valacyclovir... 79		VERIPRED 20... 141
VALCHLOR... 64		VERKAZIA... 181

VERQUVO... 106	vincasar pfs... 64	VOCABRIA... 79
VERSACLOZ... 72	vincristine... 64	VOGELXO... 152
VERZENIO... 64	vinorelbine... 64	volnea (28)... 152
VESICARE LS... 139	VIOKACE... 137	VONJO... 64
VESICARE... 139	viorele (28)... 152	VOQUEZNA DUAL PAK... 134
vestura (28)... 152	VIRACEPT... 79	VOQUEZNA TRIPLE PAK... 134
VEVYE... 181	VIRAZOLE... 176	VOQUEZNA... 134
VFEND IV... 47	VIREAD... 79	VORANIGO... 64
VFEND... 47	virt-nate dha... 130	voriconazole... 48
VIBATIV... 31	virt-pn dha... 130	VOSEVI... 79
VIBERZI... 134	VISTARIL... 190	VOTRIENT... 64
VIBRAMYCIN (CALCIUM)... 31	VITAFOL FE PLUS... 130	VOWST... 134
VIBRAMYCIN... 31	VITAFOL GUMMIES... 130	VOXZOGO... 137
VICTOZA 2-PAK... 87	VITAFOL ULTRA... 130	VOYDEYA... 167
VICTOZA 3-PAK... 87	VITAFOL-OB... 130	VPRIV... 137
VIDAZA... 64	VITAFOL-OB+DHA... 130	VRAYLAR... 73
vienva... 152	VITAFOL-ONE... 130	VTAMA... 123
vigabatrin... 37	VITAMEDMD ONE RX... 130	vtol lq... 176
vigadrone... 37	vitamin d2... 195	VUITY... 181
VIGAFYDE... 37	vitamin k... 195	VUMERITY... 113
VIGAMOX... 181	vitamin k1... 195	VUSION... 48
vigpoder... 37	VITRAKVI... 64	VYEPTI... 50
VIIBRYD... 42	vivacaine... 21	vyfemla (28)... 152
VIJOICE... 137	VIVELLE-DOT... 152	VYJUVEK... 176
vilazodone... 42	VIVITROL... 22	vylibra... 153
VIMOVO... 19	VIVJOA... 48	VYNDAMAX... 137
VIMPAT... 38	VIVLODEX... 19	VYNDAQEL... 137
vinblastine... 64	VIZIMPRO... 64	VYTORIN 10-10... 106

YUFLYMA(CF) AI CROHN'S-UC-HS... 167	ZELBORAF... 65	ZILBRYSQ... 167
YUFLYMA(CF) AUTOINJECTOR... 167	ZEMAIRA... 138	zileuton... 190
YUFLYMA(CF)... 167	ZEMBRACE SYMTOUCH... 50	ZILRETTA... 141
YUPELRI... 190	ZEMDRI... 31	ZILXI... 123
YUSIMRY(CF) PEN... 167	ZEMPLAR... 170	ZIMHI... 22
yuvaferm... 153	zenatane... 123	zingiber... 177
Z	ZENPEP... 138	ZINPLAVA... 135
zafemy... 153	zenzedi... 113	ZIOPTAN (PF)... 182
zafirlukast... 190	ZEPATIER... 79	ziprasidone hcl... 73
zaleplon... 192	ZEPOSIA STARTER KIT (28-DAY)... 113	ziprasidone mesylate... 73
ZALTRAP... 65	ZEPOSIA STARTER KIT (37-DAY)... 114	ZIPSOR... 19
ZANAFLEX... 73	ZEPOSIA STARTER PACK (7-DAY)... 114	ZIRABEV... 65
ZANOSAR... 65	ZEPOSIA... 113	ZIRGAN... 79
zarah... 153	ZEPZELCA... 65	ZITHROMAX TRI-PAK... 32
ZARONTIN... 38	ZERBAXA... 31	ZITHROMAX Z-PAK... 32
ZARXIO... 92	ZERVIATE... 182	ZITHROMAX... 31, 32
zatean-pn dha... 130	ZESTORETIC... 107	ZITUVIO... 87
zatean-pn plus... 130	ZESTRIL... 107	ZOCOR... 107
ZAVESCA... 138	ZETIA... 107	ZOKINVY... 138
ZAVZPRET... 50	ZETONNA... 190	ZOLADEX... 155
ZCORT... 141	ZEVALIN (Y-90)... 177	zoledronic ac-mannitol-0.9nacl... 170
ZEBUTAL... 177	ZIAC... 107	zoledronic acid... 170
ZEGALOGUE AUTOINJECTOR... 87	ZIAGEN... 79	zoledronic acid-mannitol-water... 170
ZEGALOGUE SYRINGE... 87	ZIANA... 123	ZOLINZA... 65
ZEGERID... 134, 135	zidovudine... 79	zolmitriptan... 50
ZEJULA... 65	ZIEXTENZO... 92	ZOLOFT... 42
ZELAPAR... 68		

zolpidem... 192	ZYMFENTRA... 167
ZOLPIMIST... 192	ZYNLONTA... 65
ZOMACTON... 143	ZYNRELEF... 177
ZOMIG... 50	ZYNYZ... 65
ZONALON... 123	ZYPITAMAG... 107
ZONEGRAN... 38	ZYPREXA RELPREV... 73
ZONISADE... 38	ZYPREXA ZYDIS... 73
zonisamide... 38	ZYPREXA... 73
ZONTIVITY... 92	ZYTIGA... 65
ZORTRESS... 167	ZYVOX... 32
ZORVOLEX... 19	
ZORYVE... 123	
ZOSYN IN DEXTROSE (ISO-OSM)... 32	
zovia 1-35 (28)... 153	
ZOVIRAX... 79	
ZTALMY... 38	
ZTLIDO... 21	
ZUBSOLV... 22	
ZULRESSO... 42	
zumandimine (28)... 153	
ZURZUVAE... 42	
ZYCLARA... 123	
ZYDELIG... 65	
ZYFLO... 190	
ZYKADIA... 65	
ZYLET... 182	
ZYLOPRIM... 48	
ZYMAXID... 182	

Multi-Language Insert

Multi-language Interpreter Services

English: We have free interpreter services to answer any questions you may have about our health or drug plan. To get an interpreter, just call us at 1-877-320-1235 (TTY: 711). Someone who speaks English can help you. This is a free service.

Spanish: Tenemos servicios de intérprete sin costo alguno para responder cualquier pregunta que pueda tener sobre nuestro plan de salud o medicamentos. Para hablar con un intérprete, por favor llame al 1-877-320-1235 (TTY: 711). Alguien que hable español le podrá ayudar. Este es un servicio gratuito.

Chinese Mandarin: 我们提供免费的翻译服务，帮助您解答关于健康或药物保险的任何疑问。如果您需要此翻译服务，请致电 1-877-320-1235 (听障专线：711)。我们的中文工作人员很乐意帮助您。这是一项免费服务。

Chinese Cantonese: 您對我們的健康或藥物保險可能存有疑問，為此我們提供免費的翻譯服務。如需翻譯服務，請致電 1-877-320-1235 (聽障專線：711)。我們講中文的人員將樂意為您提供幫助。這是一項免費服務。

Tagalog: Mayroon kaming libreng serbisyo sa pagsasaling-wika upang masagot ang anumang mga katanungan ninyo hinggil sa aming planong pangkalusugan o panggagamot. Upang makakuha ng tagasaling-wika, tawagan lamang kami sa 1-877-320-1235 (TTY: 711). Maaari kayong tulungan ng isang nakakapagsalita ng Tagalog. Ito ay libreng serbisyo.

French: Nous proposons des services gratuits d'interprétation pour répondre à toutes vos questions relatives à notre régime de santé ou d'assurance-médicaments. Pour accéder au service d'interprétation, il vous suffit de nous appeler au 1-877-320-1235 (TTY: 711). Un interlocuteur parlant Français pourra vous aider. Ce service est gratuit.

Vietnamese: Chúng tôi có dịch vụ thông dịch miễn phí để trả lời các câu hỏi về chương sức khỏe và chương trình thuốc men. Nếu quý vị cần thông dịch viên xin gọi 1-877-320-1235 (TTY: 711) sẽ có nhân viên nói tiếng Việt giúp đỡ quý vị. Đây là dịch vụ miễn phí.

German: Unser kostenloser Dolmetscherservice beantwortet Ihren Fragen zu unserem Gesundheits- und Arzneimittelplan. Unsere Dolmetscher erreichen Sie unter 1-877-320-1235 (TTY: 711). Man wird Ihnen dort auf Deutsch weiterhelfen. Dieser Service ist kostenlos.

Korean: 당사는 의료 보험 또는 약품 보험에 관한 질문에 대해 드리고자 무료 통역 서비스를 제공하고 있습니다. 통역 서비스를 이용하려면 전화 1-877-320-1235 (TTY: 711) 번으로 문의해 주십시오. 한국어를 하는 담당자가 도와 드릴 것입니다. 이 서비스는 무료로 운영됩니다.

Russian: Если у вас возникнут вопросы относительно страхового или медикаментного плана, вы можете воспользоваться нашими бесплатными услугами переводчиков. Чтобы воспользоваться услугами переводчика, позвоните нам по телефону 1-877-320-1235 (TTY: 711). Вам окажет помощь сотрудник, который говорит по-русски. Данная услуга бесплатная.

Arabic: إننا نقدم خدمات المترجم الفوري المجانية للإجابة عن أي أسئلة تتعلق بخططنا الصحية أو خطة الأدوية الموصوفة لدينا. للحصول على مترجم فوري، ليس عليك سوى الاتصال بنا على 1-877-320-1235 (TTY: 711). سيقوم شخص ما يتحدث العربية بمساعدتك. هذه خدمة مجانية.

Hindi: हमारे स्वास्थ्य या दवा की योजना के बारे में आपके किसी भी प्रश्न के जवाब देने के लिए हमारे पास मुफ्त दुभाषिया सेवाएँ उपलब्ध हैं। एक दुभाषिया प्राप्त करने के लिए, बस हमें 1-877-320-1235 (TTY: 711) पर फोन करें। कोई व्यक्ति जो हिन्दी बोलता है आपकी मदद कर सकता है। यह एक मुफ्त सेवा है।

Italian: È disponibile un servizio di interpretariato gratuito per rispondere a eventuali domande sul nostro piano sanitario e farmaceutico. Per un interprete, contattare il numero 1-877-320-1235 (TTY: 711). Un nostro incaricato che parla Italianovi fornirà l'assistenza necessaria. È un servizio gratuito.

Portuguese: Dispomos de serviços de interpretação gratuitos para responder a qualquer questão que tenha acerca do nosso plano de saúde ou de medicação. Para obter um intérprete, contacte-nos através do número 1-877-320-1235 (TTY: 711). Irá encontrar alguém que fale o idioma Português para o ajudar. Este serviço é gratuito.

French Creole: Nou genyen sèvis entèprèt gratis pou reponn tout kesyon ou ta genyen konsènan plan medikal oswa dwòg nou an. Pou jwenn yon entèprèt, jis rele nou nan 1-877-320-1235 (TTY: 711). Yon moun ki pale Kreyòl kapab ede w. Sa a se yon sèvis ki gratis.

Polish: Umożliwiamy bezpłatne skorzystanie z usług tłumacza ustnego, który pomoże w uzyskaniu odpowiedzi na temat planu zdrowotnego lub dawkowania leków. Aby skorzystać z pomocy tłumacza znającego język polski, należy zadzwonić pod numer 1-877-320-1235 (TTY: 711). Ta usługa jest bezpłatna.

Japanese: 当社の健康保険と処方薬プランに関するご質問にお答えするために、無料の通訳サービスをご用意しています。通訳をご用命になるには、1-877-320-1235 (TTY:711) にお電話ください。日本語を話す者が支援いたします。これは無料のサービスです。



This formulary was updated on 09/04/2024. For more recent information or other questions, please contact the NC State Health Plan Humana Customer Care Team with any questions at 1-888-700-2263 or, for TTY users, 711, or visit your.humana.com/ncshp.



Dale R. Folwell, CPA
STATE TREASURER OF NORTH CAROLINA
DALE R. FOLWELL, CPA

GRP042PDG2580025C_v1